Novel Kinases

ABSTRACT

The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK&#39;s and STK&#39;s have been identified and their protein structure predicted.

[0001] This application claims priority to U.S. Provisional Application No. 60/395,632, which was filed on Jul. 15, 2002.

FIELD OF THE INVENTION

[0002] The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions.

BACKGROUND OF THE INVENTION

[0003] The following description of the background of the invention is provided to aid in understanding the invention, but is not admitted to be or to describe prior art to the invention.

[0004] Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of proteins, which enables regulation of the activity of mature proteins by altering their structure and function.

[0005] Protein phosphorylation plays a pivotal role in cellular signal transduction. Among the biological functions controlled by this type of postranslational modification are: cell division, differentiation and death (apoptosis); cell motility and cytoskeletal structure; control of DNA replication, transcription, splicing and translation; protein translocation events from the endoplasmic reticulum and Golgi apparatus to the membrane and extracellular space; protein nuclear import and export; regulation of metabolic reactions, etc. Abnormal protein phosphorylation is widely recognized to be causally linked to the etiology of many diseases including cancer as well as immunologic, neuronal and metabolic disorders.

[0006] The following abbreviations are used for kinases throughout this application:

[0007] ASK Apoptosis signal-regulating kinase

[0008] CaMK Ca2+/calmodulin-dependent protein kinase

[0009] CCRK Cell cycle-related kinase

[0010] CDK Cyclin-dependent kinase

[0011] CK Casein kinase

[0012] DAPK Death-associated protein kinase

[0013] DM myotonic dystrophy kinase

[0014] Dyrk dual-specificity-tyrosine phosphorylating-regulated kinase

[0015] GAK Cyclin G-associated kinase

[0016] GRK G-protein coupled receptor

[0017] GuC Guanylate cyclase

[0018] HIPK Homeodomain-interacting protein kinase

[0019] IRAK Interleukin-1 receptor-associated kinase

[0020] MAPK Mitogen activated protein kinase

[0021] MAST Microtubule-associated STK

[0022] MLCK Myosin-light chain kinase

[0023] MLK Mixed lineage kinase

[0024] NEK NimA-related protein kinase (=NEK)

[0025] PKA cAMP-dependent protein kinase

[0026] RSK Ribosomal protein S6 kinase

[0027] RTK Receptor tyrosine kinase

[0028] SGK Serum and glucocorticoid-regulated kinase

[0029] STK serine threonine kinase

[0030] ULK UNC-51-like kinase

[0031] Protein kinases in eukaryotes phosphorylate proteins on the hydroxyl substituent of serine, threonine and tyrosine residues, which are the most common phospho-acceptor amino acid residues. However, phosphorylation on histidine has also been observed in bacteria.

[0032] The presence of a phosphate moiety modulates protein function in multiple ways. A common mechanism includes changes in the catalytic properties (Vmax and Km) of an enzyme, leading to its activation or inactivation.

[0033] A second widely recognized mechanism involves promoting protein-protein interactions. An example of this is the tyrosine autophosphorylation of the ligand-activated EGF receptor tyrosine kinase. This event triggers the high-affinity binding to the phosphotyrosine residue on the receptor's C-terminal intracellular domain of the SH2 motif of the adaptor molecule Grb2. Grb2, in turn, binds through its SH3 motif to a second adaptor molecule, such as SHC. The formation of this ternary complex activates the signaling events that are responsible for the biological effects of EGF. Serine and threonine phosphorylation events also have been recently recognized to exert their biological function through protein-protein interaction events that are mediated by the high-affinity binding of phosphoserine and phosphothreonine to WW motifs present in a large variety of proteins (Lu, P. J. et al (1999) Science 283: 1325-1328).

[0034] A third important outcome of protein phosphorylation is changes in the subcellular localization of the substrate. As an example, nuclear import and export events in a large diversity of proteins are regulated by protein phosphorylation (Drier E. A. et al (1999) Genes Dev 13: 556-568).

[0035] Protein kinases are one of the largest families of eukaryotic proteins with several hundred known members. These proteins share a 250-300 amino acid domain that can be subdivided into 12 distinct subdomains that comprise the common catalytic core structure. These conserved protein motifs have recently been exploited using PCR-based and bioinformatic strategies leading to a significant expansion of the known kinases.

[0036] Kinases largely fall into two groups: those specific for phosphorylating serines and threonines, and those specific for phosphorylating tyrosines. Some kinases, referred to as “dual specificity” kinases, are able to phosphorylate tyrosine as well as serine/threonine residues.

[0037] Protein kinases can also be characterized by their location within the cell. Some kinases are transmembrane receptor-type proteins capable of directly altering their catalytic activity in response to the external environment such as the binding of a ligand. Others are non-receptor-type proteins lacking any transmembrane domain. They can be found in a variety of cellular compartments from the inner surface of the cell membrane to the nucleus.

[0038] Many kinases are involved in regulatory cascades wherein their substrates may include other kinases whose activities are regulated by their phosphorylation state. Ultimately the activity of some downstream effector is modulated by phosphorylation resulting from activation of such a pathway. The conserved protein motifs of these kinases have recently been exploited using PCR-based cloning strategies leading to a significant expansion of the known kinases.

[0039] Multiple alignment of the sequences in the catalytic domain of protein kinases and subsequent parsimony analysis permits the segregation of related kinases into distinct branches of subfamilies including: tyrosine kinases (PTK's), dual-specificity kinases, and serine/threonine kinases (STK's). The latter subfamily includes cyclic-nucleotide-dependent kinases, calcium/calmodulin kinases, cyclin-dependent kinases (CDK's), MAP-kinases, serine-threonine kinase receptors, and several other less defined subfamilies.

[0040] The protein kinases may be classified into several major groups including AGC, CAMK, Casein kinase 1, CMGC, STE, tyrosine kinases, and atypical kinases (Plowman, GD et al., Proceedings of the National Academy of Sciences, USA, Vol. 96, Issue 24, 13603-13610, Nov. 23, 1999; see also www.kinase.com). Within each group are several distinct families of more closely related kinases. In addition, there is a group designated “other” to represent several smaller families. In addition, an “atypical” family represents those protein kinases whose catalytic domain has little or no primary sequence homology to conventional kinases, including the alpha kinases, pyruvate dehydrogenase kinases, A6 kinases and PI3 kinases.

[0041] AGC Group

[0042] The AGC kinases are basic amino acid-directed enzymes that phosphorylate residues found proximal to Arg and Lys. Examples of this group are the G protein-coupled receptor kinases (GRKs), the cyclic nucleotide-dependent kinases (PKA, PKC, PKG), NDR or DBF2 kinases, ribosomal S6 kinases, AKT kinases, myotonic dystrophy kinases (DMPKs), MAPK interacting kinases (MNKs), MAST kinases, and the YANK family.

[0043] GRKs regulate signaling from heterotrimeric guanine protein coupled receptors (GPCRs). Mutations in GPCRs cause a number of human diseases, including retinitis pigmentosa, stationary night blindness, color blindness, hyperfunctioning thyroid adenomas, familial precocious puberty, familial hypocalciuric hypercalcemia and neonatal severe hyperparathroidism (OMIM, http: //www.ncbi.nlm.nih.gov/Omim/). The regulation of GPCRs by GRKs indirectly implicates GRKs in these diseases.

[0044] The cAMP-dependent protein kinases (PKA) consist of heterotetramers comprised of 2 catalytic (C) and 2 regulatory (R) subunits, in which the R subunits bind to the second messenger cAMP, leading to dissociation of the active C subunits from the complex. Many of these kinases respond to second messengers such as cAMP resulting in a wide range of cellular responses to hormones and neurotransmitters.

[0045] AKT is a mammalian proto-oncoprotein regulated by phosphatidylinositol 3-kinase (PI3-K), which appears to function as a cell survival signal to protect cells from apoptosis. Insulin receptor, RAS, PI3-K, and PDK1 all act as upstream activators of AKT, whereas the lipid phosphatase PTEN functions as a negative regulator of the PI3-K/AKT pathway. Downstream targets for AKT-mediated cell survival include the pro-apoptotic factors BAD and Caspase9, and transcription factors in the forkhead family, such as DAF-16 in the worm. AKT is also an essential mediator in insulin signaling, in part due to its use of GSK-3 as another downstream target.

[0046] The S6 kinases (RSK) regulate a wide array of cellular processes involved in mitogenic response including protein synthesis, translation of specific mRNA species, and cell cycle progression from G1 to S phase. One of the RSK genes has been localized to chromosomal region 17q23 and is amplified in breast cancer (Couch, et al., Cancer Res. 1999 April 1;59(7): 1408-11).

[0047] CAMK Group

[0048] The CAMK kinases are also basic amino acid-directed kinases. They include the Ca2+/calmodulin-regulated and AMP-dependent protein kinases (AMPK), myosin light chain kinases (MLCK), MAP kinase activating protein kinases (MAPKAPKs), checkpoint 2 kinases (CHK2), death-associated protein kinases (DAPKs), phosphorylase kinase (PHK), Rac and Rho-binding Trio kinases, a “unique” family of CAMKs, and the MARK family of protein kinases.

[0049] The MARK family of STKs are involved in the control of cell polarity, microtubule stability and cancer. One member of the MARK family, C-TAK1, has been reported to control entry into mitosis by activating Cdc25C which in turn dephosphorylates Cdc2.

[0050] CMGC Group

[0051] The CMGC kinases are “proline-directed” enzymes phosphorylating residues that exist in a proline-rich context. They include the cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAPKs), GSK3s, RCKs, (dual-specific tyrosine kinases) DYRKs, (SR-protein specific kinase) SRPKs, and CLKs. Most CMGC kinases have larger-than-average kinase domains owing to the presence of insertions within subdomains X and XI.

[0052] CDKs play a pivotal role in the regulation of mitosis during cell division. The process of cell division occurs in four stages: S phase, the period during which chromosomes duplicate, G2, mitosis and G1 or interphase. During mitosis the duplicated chromosomes are evenly segregated allowing each daughter cell to receive a complete copy of the genome. A key mitotic regulator in all eukaryotic cells is the STK cdc2, a CDK regulated by cyclin B. However some CDK-like kinases, such as CDK5 are not cyclin associated nor are they cell cycle regulated.

[0053] MAPKs play a pivotal role in many cellular signaling pathways, including stress response and mitogenesis (Lewis, T. S., Shapiro, P. S., and Ahn, N. G. (1998) Adv. Cancer Res. 74, 49-139). MAP kinases can be activated by growth factors such as EGF, and cytokines such as TNF-alpha. In response to EGF, Ras becomes activated and recruits Raf1 to the membrane where Raf1 is activated by mechanisms that may involve phosphorylation and conformational changes (Morrison, D. K., and Cutler, R. E. (1997) Curr. Opin. Cell Biol. 9, 174-179). Active Raf1 phosphorylates MEK1 which in turn phosphorylates and activates the ERKs subfamily of MAPKs. DYRKS are dual-specificity tyrosine kinases.

[0054] Tyrosine Protein Kinase Group

[0055] The tyrosine kinase group encompass both cytoplasmic (e.g. src) as well as transmembrane receptor tyrosine kinases (e.g. EGF receptor). These kinases play a pivotal role in the signal transduction processes that mediate cell proliferation, differentiation and apoptosis.

[0056] STE Group

[0057] The STE family refers to the 3 classes of protein kinases that lie sequentially upstream of the MAPKs. This group includes STE7 (MEK or MAP2K) kinases, STE11 (MEKK or MAP2K) kinases and STE20 (MEKKK or MAP4K) kinases. In humans, several protein kinase families that bear only distant homology with the STE11 family also operate at the level of MAP3Ks including RAF, MLK, TAK1, and COT. Since crosstalk takes place between protein kinases functioning at different levels of the MAPK cascade, the large number of STE family kinases could translate into an enormous potential for upstream signal specificity. This also includes homologues of the yeast sterile family kinases (STE), which refers to 3 classes of kinases which lie sequentially upstream of the MAPKs;

[0058] The prototype STE20 from baker's yeast is regulated by a hormone receptor, signaling to directly affect cell cycle progression through modulation of CDK activity. It also coordinately regulates changes in the cytoskeleton and in transcriptional programs in a bifurcating pathway. In a similar way, the homologous kinases in humans are likely to play a role in extracellular regulation of growth, cell adhesion and migration, and changes in transcriptional programs, all three of which have critical roles in tumorigenesis. Mammalian STE20-related protein kinases have been implicated in response to growth factors or cytokines, oxidative-, UV-, or irradiation-related stress pathways, inflammatory signals (e.g. TNFα), apoptotic stimuli (e.g. Fas), T and B cell costimulation, the control of cytoskeletal architecture, and cellular transformation. Typically the STE20-related kinases serve as upstream regulators of MAPK cascades. Examples include: HPK1, a protein-serine/threonine kinase (STK) that possesses a STE20-like kinase domain that activates a protein kinase pathway leading to the stress-activated protein kinase SAPK/JNK; PAK1, an STK with an upstream GTPase-binding domain that interacts with Rac and plays a role in cellular transformation through the Ras-MAPK pathway; and murine NIK, which interacts with upstream receptor tyrosine kinases and connects with downstream STE11-family kinases.

[0059] NEK kinases are related to NIMA, which is required for entry into mitosis in the filamentous fungus A. nidulans. Mutations in the nimA gene cause the nim (never in mitosis) G2 arrest phenotype in this fungus (Fry, A. M. and Nigg, E. A. (1995) Current Biology 5: 1122-1125). Several observations suggest that higher eukaryotes may have a NIMA functional counterpart(s): (1) expression of a dominant-negative form of NIMA in HeLa cells causes a G2 arrest; (2) overexpression of NIMA causes chromatin condensation, not only in A. nidulans, but also in yeast, Xenopus oocytes and HeLa cells (Lu, K. P. and Hunter, T. (1995) Prog. Cell Cycle Res. 1, 187-205); (3) NIMA when expressed in mammalian cells interacts with pinl, a prolyl-prolyl isomerase that functions in cell cycle regulation (Lu, K. P. et al. (1996) Nature 380, 544-547); (4) okadaic acid inhibitor studies suggests the presence of cdc2-independent mechanism to induce mitosis (Ghosh, S. et al.(1998) Exp. Cell Res. 242, 1-9) and (5) a NIMA-like kinase (fin1) exists in another eukaryote besides Aspergillus, Saccharomyces pombe (Krien, M. J. E. et al.(1998) J. Cell Sci. 111, 967-976). Eleven mammalian NIMA-like kinases have been identified—NEK1-11. Despite the similarity of the NIMA-related kinases to NIMA over the catalytic region, the mammalian kinases are structurally different to NIMA over the extracatalytic regions. In addition several of the mammalian kinases are unable to complement the nim phenotype in Aspergillus nimA mutants.

[0060] Casein Kinase 1 Group

[0061] The CK1 family represents a distant branch of the protein kinase family. The hallmarks of protein kinase subdomains VIII and IX are difficult to identify. One or more forms are ubiquitously distributed in mammalian tissues and cell lines. CK1 kinases are found in cytoplasm, in nuclei, membrane-bound, and associated with the cytoskeleton. Splice variants differ in their subcellular distribution. VRK is in this group.

[0062] TKL Group

[0063] This group includes integrin receptor kinase (RAK); endoribonuclease-associated kinases (IRE); Mixed lineage kinase (MLK); LIM-domain containing kinase (LIMK); MOS; PIM; Receptor interacting kinase (RIP); SR-protein specific kinase (SRPK); RAF; Serine-threonine kinase receptors (STKR).

[0064] RIP2 is a serine-threonine kinase associated with the tumor necrosis factor (TNF) receptor complex and is implicated in the activation of NF-kappa B and cell death in mammalian cells. It has recently been demonstrated that RIP2 activates the MAPK pathway (Navas, et al., J Biol. Chem. 1999 November 19;274(47): 33684-33690). RIP2 activates AP-1 and serum response element regulated expression by inducing the activation of the Elk1 transcription factor. RIP2 directly phosphorylates and activates ERK2 in vivo and in vitro. RIP2 in turn is activated through its interaction with Ras-activated Raf1. These results highlight the integrated nature of kinase signaling pathway.

[0065] “Other” Group

[0066] Several families cluster within a group of unrelated kinases termed “Other.” Group members that define smaller, yet distinct phylogenetic branches conventional kinases include CHK1; Elongation 2 factor kinases (EIFK); Calcium-calmodulin kinase kinases (CAMKK); IkB kinases (IKK); endoribonuclease-associated kinases (IRE); MOS; PIM; TAK1; Testis specific kinase (TSK); tousled-related kinase (TSL); UNC51-related kinase (UNC); WEE; mitotic kinases (BUB1, AURORA, PLK, and NIMA/NEK); several families that are close homologues to worm (C26C2.1, YQ09, ZC581.9, YFL033c, C24A1.3); Drosophila (SLOB), or yeast (YDOD_sp, YGR262_sc) kinases; and others that are “unique,” that is, those which do not cluster into any obvious family. Additional families are even less well defined and first were identified in lower eukaryotes such as yeast or worms (YNL020, YPL236, YQ09, YWY3, SCY1, C01H6.9, C26C2.1)

[0067] The tousled (TSL) kinase was first identified in the plant Arabidopsis thaliana. TSL encodes a serine/threonine kinase that is essential for proper flower development. Human tousled-like kinases (Tlks) are cell-cycle-regulated enzymes, displaying maximal activities during S phase. This regulated activity suggests that Tlk function is linked to ongoing DNA replication (Sillje, et al., EMBO J 1999 October 15;18(20): 5691-5702).

[0068] BRSK Subfamily

[0069] The BRSK subfamily family of kinases includes the human BRSK1 and BRSK2, SAD-1 from C. elegans, CG6114 from Drosophila and the HrPOPK-1 gene from the primitive chordate Halocynthia roretzi. SAD-1 is expressed in neurons and required for presynaptic vesicle function (Crump et al. (2001) Neuron 29: 115-29). BRSK1 and BRSK2 are selectively expressed in brain, and HrPOPK-1 is selectively expressed in the nervous system, indicating that all members of this family have a neural function, specifically related to synaptic vesicle function.

[0070] The NRBP family includes human kinases NRBP1 and NRBP2, as well as homologs in C. elegans (H37N21.1) and D. melanogaster (LD28657). These kinases are most closely related in sequence to the WNK family of kinases, and may fulfill similar functions, including a role in hypertension.

[0071] Additionally, where BRSK2 is classsified as a member of the CAMKL family (p1102), it should be further classified—i.e. “into the CAMK group, the CAMKL family and the BRSK family.”

[0072] Atypical Protein Kinase Group

[0073] There are several proteins with protein kinase activity that appear structurally unrelated to the eukaryotic protein kinases. These include; Dictyostelium myosin heavy chain kinase A (MHCKA), Physarum polycephalum actin-fragmin kinase, the human A6 PTK, human BCR, mitochondrial pyruvate dehydrogenase and branched chain fatty acid dehydrogenase kinase, and the prokaryotic “histidine” protein kinase family. The slime mold, worm, and human eEF-2 kinase homologues have all been demonstrated to have protein kinase activity, yet they bear little resemblance to conventional protein kinases except for the presence of a putative GxGxxG ATP-binding motif.

[0074] The so-called histidine kinases are abundant in prokaryotes, with more than 20 representatives in E. coli, and have also been identified in yeast, molds, and plants. In response to external stimuli, these kinases act as part of two-component systems to regulate DNA replication, cell division, and differentiation through phosphorylation of an aspartate in the target protein. To date, no “histidine” kinases have been identified in metazoans, although mitochondrial pyruvate dehydrogenase (PDK) and branched chain alpha-ketoacid dehydrogenase kinase (BCKD kinase), are related in sequence. PDK and BCKD kinase represent a unique family of atypical protein kinases involved in regulation of glycolysis, the citric acid cycle, and protein synthesis during protein malnutrition. Structurally they conserve only the C-terminal portion of “histidine” kinases including the G box regions. BCKD kinase phosphorylates the E1asubunit of the BCKD complex on Ser-293, proving it to be a functional protein kinase. Although no bona fide “histidine” kinase has yet been identified in humans, they do contain PDK.

[0075] Several other proteins contain protein kinase-like homology including: receptor guanylyl cyclases, diacylglycerol kinases, choline/ethanolamine kinases, and YLK1-related antibiotic resistance kinases. Each of these families contain short motifs that were recognized by our profile searches with low scoring E-values, but a priori would not be expected to function as protein kinases. Instead, the similarity could simply reflect the modular nature of protein evolution and the primal role of ATP binding in diverse phosphotransfer enzymes. However, two recent papers on a bacterial homologue of the YLK1 family suggests that the aminoglycoside phosphotransferases (APHs) are structurally and functionally related to protein kinases. There are over 40 APHs identified from bacteria that are resistant to aminoglycosides such as kanamycin, gentamycin, or amikacin. The crystal structure of one well characterized APH reveals that it shares greater than 40% structural identity with the 2 lobed structure of the catalytic domain of cAMP-dependent protein kinase (PKA), including an N-terminal lobe composed of a 5-stranded antiparallel beta sheet and the core of the C-terminal lobe including several invariant segments found in all protein kinases. APHs lack the GxGxxG normally present in the loop between beta strands 1 and 2 but contain 7 of the 12 strictly conserved residues present in most protein kinases, including the HGDxxxN signature sequence in kinase subdomain VIB. Furthermore, APH also has been shown to exhibit protein-serine/threonine kinase activity, suggesting that other YLK-related molecules may indeed be functional protein kinases.

[0076] The eukaryotic lipid kinases (PI3Ks, PI4Ks, and PIPKs) also contain several short motifs similar to protein kinases, but otherwise share minimal primary sequence similarity. However, once again structural analysis of PIPKII-beta defines a conserved ATP-binding core that is strikingly similar to conventional protein kinases. Three residues are conserved among all of these enzymes including (relative to the PKA sequence) Lys-72 which binds the gamma-phosphate of ATP, Asp-166 which is part of the HRDLK motif and Asp-184 from the conserved Mg⁺⁺ or Mn⁺⁺ binding DFG motif. The worm genome contains 12 phosphatidylinositol kinases, including 3 PI3-kinases, 2 PI4-kinases, 3 PIP5-kinases, and 4 PI3-kinase-related kinases. The latter group has 6 mammalian members (DNA-PK, SMG1, TRRAP, FRAP/TOR, ATM, and ATR), which have been shown to participate in the maintenance of genomic integrity in response to DNA damage, and exhibit true protein kinase activity, raising the possibility that other PI-kinases may also act as protein kinases. Regardless of whether they have true protein kinase activity, PI3-kinases are tightly linked to protein kinase signaling, as evidenced by their involvement downstream of many growth factor receptors and as upstream activators of the cell survival response mediated by the AKT protein kinase.

SUMMARY OF THE INVENTION

[0077] The present invention relates, in part, to human protein kinases and protein kinase-like enzymes identified from genomic and cDNA sequencing.

[0078] Tyrosine and serine/threonine kinases (PTK's and STK's) have been identified and their protein sequence predicted as part of the instant invention. Mammalian members of these families were identified through the use of a bioinformatics strategy. The partial or complete sequences of these kinases are presented here, together with their classification.

[0079] One aspect of the invention features an identified, isolated, enriched, or purified nucleic acid molecule encoding a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132.

[0080] The term “identified” in reference to a nucleic acid means that a sequence was selected from a genomic, EST, or cDNA sequence database based on it being predicted to encode a portion of a previously unknown or novel protein kinase.

[0081] By “isolated,” in reference to nucleic acid, is meant a polymer of 10, 15, or 18 (preferably 21, more preferably 39, most preferably 75) or more nucleotides conjugated to each other, including DNA and RNA that is isolated from a natural source or that is synthesized as the sense or complementary antisense strand. In certain embodiments of the invention, longer nucleic acids are preferred, for example those of 100, 200, 300, 400, 500, 600, 900, 1200, 1500, or more nucleotides and/or those having at least 50%, 60%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to a sequence selected from the group consisting of those set forth in SEQ ID NO: 1 through SEQ ID NO: 66 or encoding for amino acid selected from SEQ ID NO: 67 through 132.

[0082] The isolated nucleic acid of the present invention is unique in the sense that it is not found in a pure or separated state in nature. Use of the term “isolated” indicates that a naturally occurring sequence has been removed from its normal cellular (i.e., chromosomal) environment. Thus, the sequence may be in a cell-free solution or placed in a different cellular environment. The term does not imply that the sequence is the only nucleotide chain present, but that it is essentially free (about 90-95% pure at least) of non-nucleotide material naturally associated with it, and thus is distinguished from isolated chromosomes.

[0083] By the use of the term “enriched” in reference to nucleic acid is meant that the specific DNA or RNA sequence constitutes a significantly higher fraction (2- to 5-fold) of the total DNA or RNA present in the cells or solution of interest than in normal or diseased cells or in the cells from which the sequence was taken. This could be caused by a person by preferential reduction in the amount of other DNA or RNA present, or by a preferential increase in the amount of the specific DNA or RNA sequence, or by a combination of the two. However, it should be noted that enriched does not imply that there are no other DNA or RNA sequences present, just that the relative amount of the sequence of interest has been significantly increased. The term “significant” is used to indicate that the level of increase is useful to the person making such an increase, and generally means an increase relative to other nucleic acids of about at least 2-fold, more preferably at least 5- to 10-fold or even more. The term also does not imply that there is no DNA or RNA from other sources. The DNA from other sources may, for example, comprise DNA from a yeast or bacterial genome, or a cloning vector such as pUC19. This term distinguishes from naturally occurring events, such as viral infection, or tumor-type growths, in which the level of one mRNA may be naturally increased relative to other species of mRNA. That is, the term is meant to cover only those situations in which a person has intervened to elevate the proportion of the desired nucleic acid.

[0084] It is also advantageous for some purposes that a nucleotide sequence be in purified form. The term “purified” in reference to nucleic acid does not require absolute purity (such as a homogeneous preparation). Instead, it represents an indication that the sequence is relatively more pure than in the natural environment (compared to the natural level this level should be at least 2- to 5-fold greater, e.g., in terms of mg/mL). Individual clones isolated from a cDNA library may be purified to electrophoretic homogeneity. The claimed DNA molecules obtained from these clones could be obtained directly from total DNA or from total RNA. The cDNA clones are not naturally occurring, but rather are preferably obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The construction of a cDNA library from mRNA involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection of the cells carrying the cDNA library. Thus, the process which includes the construction of a cDNA library from mRNA and isolation of distinct cDNA clones yields an approximately 10⁶-fold purification of the native message. Thus, purification of at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

[0085] By a “kinase polypeptide” is meant 32 (preferably 40, more preferably 45, most preferably 55) or more contiguous amino acids in a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132. In certain aspects, polypeptides of 75, 100, 200, 300, 400, 450, 500, 550, 600, 700, 800, 900 or more amino acids are preferred. The kinase polypeptide can be encoded by a full-length nucleic acid sequence or any portion (e.g., a “fragment” as defined herein) of the full-length nucleic acid sequence, so long as a functional activity of the polypeptide is retained, including, for example, a catalytic domain, as defined herein, or a portion thereof. One of skill in the art would be able to select those catalytic domains, or portions thereof, which exhibit a kinase or kinase-like activity, e.g., catalytic activity, as defined herein. It is well known in the art that due to the degeneracy of the genetic code numerous different nucleic acid sequences can code for the same amino acid sequence. Equally, it is also well known in the art that conservative changes in amino acid can be made to arrive at a protein or polypeptide which retains the functionality of the original. Such substitutions may include the replacement of an amino acid by a residue having similar physicochemical properties, such as substituting one aliphatic residue (Ile, Val, Leu or Ala) for another, or substitution between basic residues Lys and Arg, acidic residues Glu and Asp, amide residues Gln and Asn, hydroxyl residues Ser and Tyr, or aromatic residues Phe and Tyr. Further information regarding making amino acid exchanges which have only slight, if any, effects on the overall protein can be found in Bowie et al., Science, 1990, 247, 1306-1310, which is incorporated herein by reference in its entirety including any figures, tables, or drawings. In all cases, all permutations are intended to be covered by this disclosure.

[0086] The amino acid sequence of a kinase peptide of the invention will be substantially similar to a sequence having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132, or the corresponding full-length amino acid sequence, or fragments thereof.

[0087] A sequence that is substantially similar to a sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132, will preferably have at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence.

[0088] By “identity” is meant a property of sequences that measures their similarity or relationship. Identity is measured by dividing the number of identical residues by the total number of residues and gaps and multiplying the product by 100. “Gaps” are spaces in an alignment that are the result of additions or deletions of amino acids. Thus, two copies of exactly the same sequence have 100% identity, but sequences that are less highly conserved, and have deletions, additions, or replacements, may have a lower degree of identity. Those skilled in the art will recognize that several computer programs are available for determining sequence identity using standard parameters, for example Gapped BLAST or PSI-BLAST (Altschul, et al. (1997) Nucleic Acids Res. 25: 3389-3402), BLAST (Altschul, et al. (1990) J. Mol. Biol. 215: 403-410), and Smith-Waterman (Smith, et al. (1981) J. Mol. Biol. 147: 195-197). Preferably, the default settings of these programs will be employed, but those skilled in the art recognize whether these settings need to be changed and know how to make the changes.

[0089] “Similarity” is measured by dividing the number of identical residues plus the number of conservatively substituted residues (see Bowie, et al. Science, 1999), 247, 1306-1310, which is incorporated herein by reference in its entirety, including any drawings, figures, or tables) by the total number of residues and gaps and multiplying the product by 100.

[0090] In preferred embodiments, the invention features isolated, enriched, or purified nucleic acid molecules encoding a kinase polypeptide comprising a nucleotide sequence that: (a) encodes a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132 or an amino acid sequence having at least about 90% identical to a sequence selected from the group consisting of SEQ ID NO: 67 through SEQ ID NO: 132; (b) is the complement of the nucleotide sequence of (a); (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally occurring kinase polypeptide; (d) encodes a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132, except that it lacks one or more, but not all, of the domains selected from the group consisting of the protein kinase, CNH, PH, phobol esters/diacylglycerol binding (C1), protein kinase C-terminal, PDZ (also known as DHR or GLGF), kinase associated domain 1, UBA/TS-N, UBA, armadillo/beta-catenin-like repeat, POLO box duplicated region, P21-Rho-binding, immunoglobulin, WIF, leucine rich repeat, SH3, MYND, EF hand, and bromodomain; (e) encodes a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132, except that it lacks one or more, but not all, of the regions selected from the C-terminal region, the N-terminal region, a spacer region, and the catalytic domain; and (f) is the complement of the nucleotide sequence of (d) or (e).

[0091] The invention includes an antibody or antibody fragment having specific binding affinity to a kinase polypeptide or to a domain of said polypeptide, wherein said polypeptide comprises an amino acid sequence selected from those set forth in SEQ ID NO: 67 through 132, a hybridoma which produces the such an antibody or antibody fragment, a kit comprising such an antibody which binds to a polypeptide of the invention a negative control antibody.

[0092] The invention includes a method for identifying a substance that modulates the activity of a kinase polypeptide comprising the steps of: (a)contacting the kinase polypeptide substantially identical to an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132 with a test substance; (b)measuring the activity of said polypeptide; and (c)determining whether said substance modulates the activity of said polypeptide.

[0093] The invention also includes a method for identifying a substance that modulates the activity of a kinase polypeptide in a cell comprising the steps of: expressing a kinase polypeptide having a sequence substantially identical to an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132; adding a test substance to said cell; and monitoring a change in cell phenotype or the interaction between said polypeptide and a natural binding partner.

[0094] The invention includes a method for treating a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase substantially identical to an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132.

[0095] The treatmnet methods of the invention include the disease or disorder is selected from the group consisting of cancers, immune-related diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, metabolic disorders and inflammatory disorders; and the disease or disorder selected from the group consisting of cancers of tissues; cancers of blood or hematopoietic origin; cancers of the breast, colon, lung, prostate, cervix, brain, ovaries, bladder or kidney. The treatment methods also include the disease or disorder is selected from the group consisting of disorders of the central or peripheral nervous system; migraines; pain; sexual dysfunction; mood disorders; attention disorders; cognition disorders; hypotension; hypertension; psychotic disorders; neurological disorders and dyskinesias. Treatment methods also include disease or disorder selected from the group consisting of inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity and organ transplant rejection.

[0096] The methods of the invention contemplate use of a substance that modulates kinase activity in vitro, including kinase inhibitors.

[0097] The invention includes a method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein said method comprises:

[0098] (a) contacting said sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, said probe comprising the nucleic acid sequence, fragments thereof, or the complements of said sequences and fragments; and

[0099] (b) detecting the presence or amount of the target region: probe hybrid, as an indication of said disease or disorder.

[0100] Such a detection method includes a disease or disorder selected from the group consisting of cancers, immune-related diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, metabolic disorders and inflammatory disorders; a disease or disorder selected from the group consisting of cancers of tissues; cancers of blood or hematopoietic origin; cancers of the breast, colon, lung, prostate, cervix, brain, ovary, bladder or kidney; a disease or disorder is selected from the group consisting of central or peripheral nervious system disease, migraines, pain; sexual dysfunction; mood disorders; attention disorders; cognition disorders; hypotension; hypertension; psychotic disorders; neurological disorders and dyskinesias; a disease or disorder is selected from the group consisting of inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplant rejection.

[0101] The invention includes an isolated, enriched or purified nucleic acid molecule that comprises a nucleic molecule encoding a domain of a kinase polypeptide having a sequence of SEQ ID NO: 67-132.

[0102] The invention includes an isolated, enriched or purified nucleic acid molecule encoding a kinase polypeptide which comprises a nucleotide sequence that encodes a polypeptide having an amino acid sequence that has at least 90% identity to a polypeptide set forth in SEQ ID NO: 67-132.

[0103] The invention includes an isolated, enriched or purified nucleic acid molecule according wherein the molecule comprises a nucleotide sequence substantially identical to a sequence of SEQ ID NO: 1-66.

[0104] The invention includes an isolated, enriched or purified nucleic acid molecule consisting essentially of about 10-30 contiguous nucleotide bases of a nucleic acid sequence that encodes a polypeptide selected from the group consisting of SEQ ID NO: 67 through 132. The invention also includes an isolated, enriched or purified nucleic acid molecule of about 10-30 contiguous nucleotide bases of a nucleic acid sequence that encodes a polypeptide selected from the group consisting of SEQ ID NO: 67 through 132, consisting essentially of about 10-30 contiguous nucleotide bases of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through 66.

[0105] The term “complement” refers to two nucleotides that can form multiple favorable interactions with one another. For example, adenine is complementary to thymine as they can form two hydrogen bonds. Similarly, guanine and cytosine are complementary since they can form three hydrogen bonds. A nucleotide sequence is the complement of another nucleotide sequence if all of the nucleotides of the first sequence are complementary to all of the nucleotides of the second sequence.

[0106] Various low or high stringency hybridization conditions may be used depending upon the specificity and selectivity desired. These conditions are well known to those skilled in the art. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 20 contiguous nucleotides, more preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 50 contiguous nucleotides, most preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 100 contiguous nucleotides. In some instances, the conditions may prevent hybridization of nucleic acids having more than 5 mismatches in the full-length sequence.

[0107] By stringent hybridization assay conditions is meant hybridization assay conditions at least as stringent as the following: hybridization in 50% formamide, 5×SSC, 50 mM NaH2PO4, pH 6.8, 0.5% SDS, 0.1 mg/mL sonicated salmon sperm DNA, and 5× Denhardt's solution at 42° C. overnight; washing with 2×SSC, 0.1% SDS at 45° C.; and washing with 0.2×SSC, 0.1% SDS at 45° C. Under some of the most stringent hybridization assay conditions, the second wash can be done with 0.1×SSC at a temperature up to 70° C. (Berger et al. (1987) Guide to Molecular Cloning Techniques pg 421, hereby incorporated by reference herein in its entirety including any figures, tables, or drawings.). However, other applications may require the use of conditions falling between these sets of conditions. Methods of determining the conditions required to achieve desired hybridizations are well known to those with ordinary skill in the art, and are based on several factors, including but not limited to, the sequences to be hybridized and the samples to be tested. Washing conditions of lower stringency frequently utilize a lower temperature during the washing steps, such as 65° C., 60° C., 55° C., 50° C., or 42° C.

[0108] The term “domain” refers to a region of a polypeptide whose sequence or structure is conserved between several homologs of the polypoeptide and which serves a particular function. Many domains may be identified by searching the Pfam database of domain models (http: //pfam.wustl.edu) which provides coordinates on the polypeptide delimiting the start and end of the domain, as well as a score giving the likelihood that the domain is present in the polypeptide. Other domains may be identified by specialized programs, such as the COILS program to detect colied-coil regions (http: //www.ch.embnet.org/software/COILS_form.html), the SignalP program to detect signal peptides (http: //www.ebs.dtu.dk/services/TMIIMM), by visual inspection of the amino acid sequence (e.g., determination of cysteine-rich or proline-rich domains), or by Smith-Waterman alignment shows a high level of sequence similarity in the region containing the domain, it may be concluded that the domain is present in both proteins within that region which serves a particular function.

[0109] Domains of signal transduction proteins can serve functions including, but not limited to, binding molecules that localize the signal transduction molecule to different regions of the cell, binding other signaling molecules directly responsible for propagating a particular cellular signal or binding molecules that influence the function of the protein. Some domains can be expressed separately from the rest of the protein and function by themselves

[0110] The term “N-terminal region” refers to the extracatalytic region located between the initiator methionine and the catalytic domain of the protein kinase. Depending on its length, the N-terminal region may or may not play a regulatory role in kinase function. An example of a protein kinase whose N-terminal domain has been shown to play a regulatory role is PAK6 or PAK5, which contains a CRIB motif used for Cdc42 and rac binding (Burbelo, P. D. et al. (1995) J. Biol. Chem. 270, 29071-29074). Such an N-terminal region is also termed a N-terminal functional domain or N-terminal domain.

[0111] The term “catalytic domain” or protein kinase domain refers to a region of the protein kinase that is typically 25-300 amino acids long and is responsible for carrying out the phosphate transfer reaction from a high-energy phosphate donor molecule such as ATP or GTP to itself (autophosphorylation) or to other proteins (exogenous phosphorylation). The catalytic domain of protein kinases is made up of 12 subdomains that contain highly conserved amino acid residues, and are responsible for proper polypeptide folding and for catalysis. The catalytic dmoain can be defined with reference to the parameters described in a “Pfam” database: http: //pfam.wustl.edu. In particular, it can be defined with reference to a HMMer search of the Pfam database. In the N-terminal extremity of the catalytic domain there is a glycine rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. In the central part of the catalytic domain there is a conserved aspartic acid residue which is important for the catalytic activity of the enzyme. See Accession number PF00069 of http: //pfam.wustl.edu.

[0112] The term “catalytic activity,” as used herein, defines the rate at which a kinase catalytic domain phosphorylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a phosphorylated product as a function of time. Catalytic activity can be measured by methods of the invention by determining the concentration of a phosphorylated substrate after a fixed period of time. Phosphorylation of a substrate occurs at the active site of a protein kinase. The active site is normally a cavity in which the substrate binds to the protein kinase and is phosphorylated.

[0113] The term “substrate” as used herein refers to a molecule phosphorylated by a kinase of the invention. Kinases phosphorylate substrates on serine/threonine or tyrosine amino acids. The molecule may be another protein or a polypeptide.

[0114] The term “C-terminal region” refers to the region located between the catalytic domain or the last (located closest to the C-terminus) functional domain and the carboxy-terminal amino acid residue of the protein kinase. See Accession number PF00433 of http: //pfam.wustl.edu. Depending on its length and amino acid composition, the C-terminal region may or may not play a regulatory role in kinase function. An example of a protein kinase whose C-terminal region may play a regulatory role is PAK3 which contains a heterotrimeric Gb subunit-binding site near its C-terminus (Leeuw, T. et al. (1998) Nature, 391, 191-195). Such a C-terminal region is also termed a C-terminal functional domain or C-terminal domain.

[0115] By “functional” domain is meant any region of the polypeptide that may play a regulatory or catalytic role as predicted from amino acid sequence homology to other proteins or by the presence of amino acid sequences that may give rise to specific structural conformations.

[0116] The “CNH domain” is the citron homology domain, and is often found after cysteine rich and pleckstrin homology (PH) domains at the C-terminal end of the proteins [MEDLINE: 99321922]. It acts as a regulatory domain and could be involved in macromolecular interactions [MEDLINE: 99321922], [MEDLINE: 97280817]. See Accession number PF00780 of http: //pfam.wustl.edu.

[0117] The “PH domain” is the ‘pleckstrin homology’ (PH) domain and is a domain of about 100 residues that occurs in a wide range of proteins involved in intracellular signaling or as constituents of the cytoskeleton [MEDLINE: 93272305], [MEDLINE: 93268380], [MEDLINE: 94054654], [MEDLINE: 95076505], [MEDLINE: 95157628], [MEDLINE: 95197706], [MEDLINE: 96082954]. See Accession number PF00169 of http: //pfam.wustl.edu.

[0118] The “Phorbol esters/diacylglycerol binding domain” is also known as the Protein kinase C conserved region 1 (C1) domain. The N-terminal region of PKC, known as C1, has been shown [MEDLINE: 89296905] to bind PE and DAG in a phospholipid and zinc-dependent fashion. The C1 region contains one or two copies (depending on the isozyme of PKC) of a cysteine-rich domain about 50 amino-acid residues long and essential for DAG/PE-binding. The DAG/PE-binding domain binds two zinc ions; the ligands of these metal ions are probably the six cysteines and two histidines that are conserved in this domain. See Accession number PF00130 of http: //pfam.wustl.edu.

[0119] The “PDZ domain” is also known as the DHR or GLGF domain. PDZ domains are found in diverse signaling proteins and may function in targeting signalling molecules to sub-membranous sites [MEDLINE: 97348826]. See Accession number PF00595 of http: //pfam.wustl.edu.

[0120] The “kinase associated domain 1” (KA1) domain is found in the C-terminal extremity of various serine/threonine-protein kinases from fungi, plants and animals. See Accession number PF02149 of http: //pfam.wustl.edu.

[0121] The UBA/TS-N domain is composed of three alpha helices. This family includes the previously defined UBA and TS-N domains. The UBA-domain (ubiquitin associated domain) is a sequence motif found in several proteins having connections to ubiquitin and the ubiquitination pathway. The structure of the UBA domain consists of a compact three helix bundle. This domain is found at the N terminus of EF-TS hence the name TS-N. The structure of EF-TS is known and this domain is implicated in its interaction with EF-TU. The domain has been found in non EF-TS proteins such as alpha-NAC P70670 and MJ0280 Q57728 [1]. See Accession number PF00627 of http: //pfam.wustl.edu.

[0122] The “UBA domain” The UBA-domain (ubiquitin associated domain) is a novel sequence motif found in several proteins having connections to ubiquitin and the ubiquitination pathway [MEDLINE: 97025177]. The UBA domain is probably a non-covalent ubiquitin binding domain consisting of a compact three helix bundle [MEDLINE: 99061330]. See Accession number PF00627 of http://pfam.wustl.edu.

[0123] The “armadillo/beta-catenin-like repeat” is an approximately 40 amino acid long tandemly repeated sequence motif first identified in the Drosophila segment polarity gene armadillo. Similar repeats were later found in the mammalian armadillo homolog beta-catenin, the junctional plaque protein plakoglobin, the adenomatous polyposis coli (APC) tumor suppressor protein, and a number of other proteins [MEDLINE: 94170379]. The 3 dimensional fold of an armadillo repeat is known from the crystal structure of beta-catenin [MEDLINE: 98449700]. There, the 12 repeats form a superhelix of alpha-helices, with three helices per unit. The cylindrical structure features a positively charged grove which presumably interacts with the acidic surfaces of the known interaction partners of beta-catenin. See Accession number PF00514 of http: //pfam.wustl.edu.

[0124] The “POLO box duplicated region” (POLO_box) is described as follows. A subgroup of serine/threonine protein kinases (IPR002290) playing multiple roles during cell cycle, especially in M phase progression and cytokinesis, contain a duplicated domain in their C terminal part, the polo box [MEDLINE: 99116035]. The domain is named after its founding member encoded by the polo gene of Drosophila [MEDLINE: 92084090]. This domain of around 70 amino acids has been found in species ranging from yeast to mammals. Point mutations in the Polo box of the budding yeast Cdc5 protein abolish the ability of overexpressed Cdc5 to interact with the spindle poles and to organize cytokinetic structures [MEDLINE: 20063188]. See Accession number PF00659 of http: //pfam.wustl.edu.

[0125] The “P21-Rho-binding domain” is one of a group of small domains that bind Cdc42p- and/or Rho-like small GTPases. These are also known as the Cdc42/Rac interactive binding (CRIB). See Accession number PF00786 of http: //pfam.wustl.edu.

[0126] The “immunoglobulin domain” is a domain that is under the umbrella of the immunoglobulin superfamily. Examples of the superfamily include antibodies, the giant muscle kinase titin and receptor tyrosine kinases. Immunoglobulin-like domains may be involved in protein-protein and protein-ligand interactions. The Pfam alignments do not include the first and last strand of the immunoglobulin-like domain. See Accession number PF00047 of http: //pfam.wustl.edu.

[0127] The “WIF domain” is found in the RYK tyrosine kinase receptors and WIF the Wnt-inhibitory-factor. The domain is extracellular and and contains two conserved cysteines that may form a disulphide bridge. This domain is Wnt binding in WIF, and it has been suggested that RYK may also bind to Wnt [MEDLINE: 20105592]. See Accession number PF02019 of http: //pfam.wustl.edu.

[0128] The “leucine rich repeat”—Leucine-rich repeats (LRRs) are relatively short motifs (22-28 residues in length) found in a variety of cytoplasmic, membrane and extracellular proteins [MEDLINE: 91099665]. Although these proteins are associated with widely different functions, a common property involves protein-protein interaction. Other functions of LRR-containing proteins include, for example, binding to enzymes [MEDLINE: 90094386] and vascular repair [MEDLINE: 89367331]. See Accession number PF00560 of http: //pfam.wustl.edu.

[0129] The “SH3 domain” SH3 (src Homology-3) domains are small protein modules containing approximately 50 amino acid residues [PUB00001025]. They are found in a variety of of proteins with enzymatic activity. The SH3 domain has a characteristic fold which consists of five or six beta-strands arranged as two tightly packed anti-parallel beta sheets. The linker regions may contain short helices [PUB 00001083]. See Accession number PF00018 of http: //pfam.wustl.edu.

[0130] The “MYND finger” is a domain found in some suppressors of cell cycle entry [MEDLINE: 96203118], [MEDLINE: 98079069]. The MYND zinc finger (ZnF) domain is one of two domains in AML/ETO fusion protein required for repression of basal transcription from the multidrug resistance 1 (MDR-1) promoter. The other domain is a hydrophobic heptad repeat (HHR) motif [MEDLINE: 98252948]. The AML-1/ETO fusion protein is created by the (8;21) translocation, the second most frequent chromosomal abnormality associated with acute myeloid leukemia. In the fusion protein the AML-1 runt homology domain, which is responsible for DNA binding and CBF beta interaction, is linked to ETO, a gene of unknown function [MEDLINE: 96068903]. See Accession number PF01753 of http: //pfam.wustl.edu.

[0131] The “EF hand” domain is described as follows: many calcium-binding proteins belong to the same evolutionary family and share a type of calcium-binding domain known as the EF-hand. This type of domain consists of a twelve residue loop flanked on both side by a twelve residue alpha-helical domain. In an EF-hand loop the calcium ion is coordinated in a pentagonal bipyramidal configuration. The six residues involved in the binding are in positions 1, 3, 5, 7, 9 and 12; these residues are denoted by X, Y, Z, -Y, -X and -Z. The invariant Glu or Asp at position 12 provides two oxygens for liganding Ca (bidentate ligand). See Accession number PF00036 of http: //pfam.wustl.edu.

[0132] A “bromodomain” is a 110 amino acid long domain, found in many chromatin associated proteins. Bromodomains can interact specifically with acetylated lysine. [MEDLINE: 97318593] Bromodomains are found in a variety of mammalian, invertebrate and yeast DNA-binding proteins [MEDLINE: 92285152]. The bromodomain may occur as a single copy, or in duplicate. The bromodomain may be involved in protein-protein interactions and may play a role in assembly or activity of multi-component complexes involved in transcriptional activation [MEDLINE: 96022440]. See Accession number PF00439 of http: //pfam.wustl.edu.

[0133] The term “coiled-coil structure region” as used herein, refers to a polypeptide sequence that has a high probability of adopting a coiled-coil structure as predicted by computer algorithms such as COILS (Lupas, A. (1996) Meth. Enzymology 266: 513-525). Coiled-coils are formed by two or three amphipathic α-helices in parallel. Coiled-coils can bind to coiled-coil domains of other polypeptides resulting in homo- or heterodimers (Lupas, A. (1991) Science 252: 1162-1164). Coiled-coil-dependent oligomerization has been shown to be necessary for protein function including catalytic activity of serine/threonine kinases (Roe, J. et al. (1997) J. Biol. Chem. 272: 5838-5845).

[0134] The term “proline-rich region” as used herein, refers to a region of a protein kinase whose proline content over a given amino acid length is higher than the average content of this amino acid found in proteins(i.e., >10%). Proline-rich regions are easily discernable by visual inspection of amino acid sequences and quantitated by standard computer sequence analysis programs such as the DNAStar program EditSeq. Proline-rich regions have been demonstrated to participate in regulatory protein -protein interactions. Among these interactions, those that are most relevant to this invention involve the “PxxP” proline rich motif found in certain protein kinases (i.e., human PAK1) and the SH3 domain of the adaptor molecule Nck (Galisteo, M. L. et al. (1996) J. Biol. Chem. 271: 20997-21000). Other regulatory interactions involving “PxxP” proline-rich motifs include the WW domain (Sudol, M. (1996) Prog. Biochys. Mol. Bio. 65: 113-132).

[0135] The term “spacer region” as used herein, refers to a region of the protein kinase located between predicted functional domains. The spacer region has little conservation when compared with any any amino acid sequence in the database, and can be identified by using a Smith-Waterman alignment of the protein sequence against the non-redundant protein of Pfam database to define the C- and N-terminal boundaries of the flanking functional domains. Spacer regions may or may not play a fundamental role in protein kinase function. Precedence for the regulatory role of spacer regions in kinase function is provided by the role of the src kinase spacer in inter-domain interactions (Xu, W. et al. (1997) Nature 385: 595-602).

[0136] The term “insert” as used herein refers to a portion of a protein kinase that is absent from a close homolog. Inserts may or may not by the product alternative splicing of exons. Inserts can be identified by using a Smith-Waterman sequence alignment of the protein sequence against the non-redundant protein database, or by means of a multiple sequence alignment of homologous sequences using the DNAStar program Megalign. Inserts may play a functional role by presenting a new interface for protein-protein interactions, or by interfering with such interactions.

[0137] The term “signal transduction pathway” refers to the molecules that propagate an extracellular signal through the cell membrane to become an intracellular signal. This signal can then stimulate a cellular response. The polypeptide molecules involved in signal transduction processes are typically receptor and non-receptor protein kinases, receptor and non-receptor protein phosphatases, polypeptides containing SRC homology 2 and 3 domains, phosphotyrosine binding proteins (SRC homology 2 (SH2) and phosphotyrosine binding (PTB and PH) domain containing proteins), proline-rich binding proteins (SH3 domain containing proteins), GTPases, phosphodiesterases, phospholipases, prolyl isomerases, proteases, Ca2+ binding proteins, cAMP binding proteins, guanyl cyclases, adenylyl cyclases, NO generating proteins, nucleotide exchange factors, and transcription factors.

[0138] In other preferred embodiments, the invention features isolated, enriched, or purified nucleic acid molecules encoding kinase polypeptides, further comprising a vector or promoter effective to initiate transcription in a host cell. The nucleic acid may encode a polypeptide of SEQ ID NO: 67-132 and a vector or promoter effective to initiate transcription in a host cell. The invention includes such nucleic acid molecules that are isolated, enriched, or purified from a mammal and in a preferred embodiment, the mammal is a human. The invention also features recombinant nucleic acid, preferably in a cell or an organism. The recombinant nucleic acid may contain a sequence selected from the group consisting of those set forth in SEQ ID NO: 1 through SEQ ID NO: 66, or a functional derivative thereof and a vector or a promoter effective to initiate transcription in a host cell. The recombinant nucleic acid can alternatively contain a transcriptional initiation region functional in a cell, a sequence complementary to an RNA sequence encoding a kinase polypeptide and a transcriptional termination region functional in a cell. Specific vectors and host cell combinations are discussed herein.

[0139] The term “vector” relates to a single or double-stranded circular nucleic acid molecule that can be transfected into cells and replicated within or independently of a cell genome. A circular double-stranded nucleic acid molecule can be cut and thereby linearized upon treatment with restriction enzymes. An assortment of nucleic acid vectors, restriction enzymes, and the knowledge of the nucleotide sequences cut by restriction enzymes are readily available to those skilled in the art. A nucleic acid molecule encoding a kinase can be inserted into a vector by cutting the vector with restriction enzymes and ligating the two pieces together.

[0140] The term “transfecting” defines a number of methods to insert a nucleic acid vector or other nucleic acid molecules into a cellular organism. These methods involve a variety of techniques, such as treating the cells with high concentrations of salt, an electric field, detergent, or DMSO to render the outer membrane or wall of the cells permeable to nucleic acid molecules of interest or use of various viral transduction strategies.

[0141] The term “promoter” as used herein, refers to nucleic acid sequence needed for gene sequence expression. Promoter regions vary from organism to organism, but are well known to persons skilled in the art for different organisms. For example, in prokaryotes, the promoter region contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5′-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

[0142] In preferred embodiments, the isolated nucleic acid comprises, consists essentially of, or consists of a nucleic acid sequence selected from the group consisting of those set forth in SEQ ID NO: 1 through SEQ ID NO: 66, which encodes an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132, a functional derivative thereof, or at least 35, 40, 45, 50, 60, 75, 100, 200, or 300 contiguous amino acids selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132, the catalytic region of SEQ ID NO: 67-132 or catalytic domains, functional domains, or spacer regions of SEQ ID NO: 67 through 132. The nucleic acid may be isolated from a natural source by cDNA cloning or by subtractive hybridization. The natural source may be mammalian, preferably human, preferably blood, semen or tissue, and the nucleic acid may be synthesized by the triester method or by using an automated DNA synthesizer.

[0143] The term “mammal” refers preferably to such organisms as mice, rats, rabbits, guinea pigs, sheep, and goats, more preferably to cats, dogs, monkeys, and apes, and most preferably to humans.

[0144] In yet other preferred embodiments, the nucleic acid is a conserved or unique region, for example those useful for: the design of hybridization probes to facilitate identification and cloning of additional polypeptides, the design of PCR probes to facilitate cloning of additional polypeptides, obtaining antibodies to polypeptide regions, and designing antisense oligonucleotides.

[0145] By “conserved nucleic acid regions,” are meant regions present on two or more nucleic acids encoding a kinase polypeptide, to which a particular nucleic acid sequence can hybridize under lower stringency conditions. Examples of lower stringency conditions suitable for screening for nucleic acid encoding kinase polypeptides are provided in Wahl et al. Meth. Enzym. 152: 399-407 (1987) and in Wahl et al. Meth. Enzym. 152: 415-423 (1987), which are hereby incorporated by reference herein in its entirety, including any drawings, figures, or tables. Preferably, conserved regions differ by no more than 5 out of 20 nucleotides, even more preferably 2 out of 20 nucleotides or most preferably 1 out of 20 nucleotides.

[0146] By “unique nucleic acid region” is meant a sequence present in a nucleic acid coding for a kinase polypeptide that is not present in a sequence coding for any other naturally occurring polypeptide. Such regions preferably encode 32 (preferably 40, more preferably 45, most preferably 55) or more contiguous amino acids, for example, an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132. In particular, a unique nucleic acid region is preferably of manmmalian origin.

[0147] Another aspect of the invention features a nucleic acid probe for the detection of nucleic acid encoding a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132, catalytic domains, functional domains, or spacer regions of SEQ ID NO: 67 through 132, in a sample. The nucleic acid probe contains a nucleotide base sequence that will hybridize to the sequence selected from the group consisting of those set forth in SEQ ID NO: 1 through SEQ ID NO: 66, a sequence encoding catalytic domains, functional domains, or spacer regions of SEQ ID NO: 67 through 132, or a functional derivative thereof.

[0148] In preferred embodiments, the nucleic acid probe hybridizes to nucleic acid encoding at least 12, 32, 75, 90, 105, 120, 150, 200, 250, 300 or 350 contiguous amino acids, wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 66, or a functional derivative thereof.

[0149] Methods for using the probes include detecting the presence or amount of kinase RNA in a sample by contacting the sample with a nucleic acid probe under conditions such that hybridization occurs and detecting the presence or amount of the probe bound to kinase RNA. The nucleic acid duplex formed between the probe and a nucleic acid sequence coding for a kinase polypeptide may be used in the identification of the sequence of the nucleic acid detected (Nelson et al., in Nonisotopic DNA Probe Techniques, Academic Press, San Diego, Kricka, ed., p. 275, 1992, hereby incorporated by reference herein in its entirety, including any drawings, figures, or tables). Kits for performing such methods may be constructed to include a container means having disposed therein a nucleic acid probe.

[0150] Methods for using the probes also include using these probes to find, for example, the full-length clone of each of the predicted kinases by techniques known to one skilled in the art. These clones will be useful for screening for small molecule compounds that inhibit the catalytic activity of the encoded kinase with potential utility in treating cancers, immune-related diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, and metabolic disorders. More specifically disorders including cancers of tissues or blood, or hematopoietic origin, particularly those involving breast, colon, lung, prostate, cervix, skin, brain, ovary, bladder, or kidney; central or peripheral nervous system diseases and conditions including migraine, pain, sexual dysfunction, mood disorders, attention disorders, cognition disorders, hypotension, and hypertension; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome; neurodegenerative diseases including Alzheimer's, Parkinson's, multiple sclerosis, and amyotrophic lateral sclerosis; viral or non-viral infections caused by HIV-1, HIV-2 or other viral- or prion-agents or fungal- or bacterial-organisms; metabolic disorders including Diabetes and obesity and their related syndromes, among others; cardiovascular disorders including reperfusion restenosis, hypertension, coronary thrombosis, clotting disorders, unregulated cell growth disorders, atherosclerosis; ocular disease including glaucoma, retinopathy, and macular degeneration; inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, bone disorder, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplant rejection.

[0151] In another aspect, the invention describes a recombinant cell or tissue comprising a nucleic acid molecule encoding a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132. In such cells, the nucleic acid may be under the control of the genomic regulatory elements, or may be under the control of exogenous regulatory elements including an exogenous promoter. By “exogenous” it is meant a promoter that is not normally coupled in vivo transcriptionally to the coding sequence for the kinase polypeptides.

[0152] The polypeptide is preferably a fragment of the protein encoded by an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132. By “fragment,” is meant an amino acid sequence present in a kinase polypeptide. Preferably, such a sequence comprises at least 32, 45, 50, 60, 100, 200, or 300 contiguous amino acids of a sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132.

[0153] In another aspect, the invention features an isolated, enriched, or purified kinase polypeptide having the amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132.

[0154] By “isolated” in reference to a polypeptide is meant a polymer of 6 (preferably 12, more preferably 18, or 21, most preferably 25, 32, 40, or 50) or more amino acids conjugated to each other, including polypeptides that are isolated from a natural source or that are synthesized. In certain aspects longer polypeptides are preferred, such as those comprising 100, 200, 300, 400, 450, 500, 550, 600, 700, 800, 900 or more contiguous amino acids, including an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132; other longer polypeptides also preferred are those having sequence that is substantially similar to a sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through SEQ ID NO: 132(which preferably has at least 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence).

[0155] The isolated polypeptides of the present invention are unique in the sense that they are not found in a pure or separated state in nature. Use of the term “isolated” indicates that a naturally occurring sequence has been removed from its normal cellular environment. Thus, the sequence may be in a cell-free solution or placed in a different cellular environment. The term does not imply that the sequence is the only amino acid chain present, but that it is essentially free (about 90-95% pure at least) of non-amino acid-based material naturally associated with it.

[0156] By the use of the term “enriched” in reference to a polypeptide is meant that the specific amino acid sequence constitutes a significantly higher fraction (2- to 5-fold) of the total amino acid sequences present in the cells or solution of interest than in normal or diseased cells or in the cells from which the sequence was taken. This could be caused by a person by preferential reduction in the amount of other amino acid sequences present, or by a preferential increase in the amount of the specific amino acid sequence of interest, or by a combination of the two. However, it should be noted that enriched does not imply that there are no other amino acid sequences present, just that the relative amount of the sequence of interest has been significantly increased. The term “significantly” here is used to indicate that the level of increase is useful to the person making such an increase, and generally means an increase relative to other amino acid sequences of about at least 2-fold, more preferably at least 5- to 10-fold or even more. The term also does not imply that there is no amino acid sequence from other sources. The other source of amino acid sequences may, for example, comprise amino acid sequence encoded by a yeast or bacterial genome, or a cloning vector such as pUC19. The term is meant to cover only those situations in which man has intervened to increase the proportion of the desired amino acid sequence.

[0157] It is also advantageous for some purposes that an amino acid sequence be in purified form. The term “purified” in reference to a polypeptide does not require absolute purity (such as a homogeneous preparation); instead, it represents an indication that the sequence is relatively purer than in the natural environment. Compared to the natural level this level should be at least 2- to 5-fold greater (e.g., in terms of mg/mL). Purification of at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. The substance is preferably free of contamination at a functionally significant level, for example 90%, 95%, or 99% pure.

[0158] In preferred embodiments, the kinase polypeptide is a fragment of the protein encoded by an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132. Preferably, the kinase polypeptide contains at least 32, 45, 50, 60, 100, 200, or 300 contiguous amino acids of a sequence selected from the group consisting of those set forth in SEQ ID NO: 3 and 4, or a functional derivative thereof.

[0159] In preferred embodiments, the kinase polypeptide comprises an amino acid sequence having (a) an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132; and (b) an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, except that it lacks one or more of the domains selected from the group consisting of the catalytic domain, the C-terminal region, the N-terminal region, and the spacer region.

[0160] The polypeptide can be isolated from a natural source by methods well-known in the art. The natural source may be mammalian, preferably human, preferably blood, semen or tissue, and the polypeptide may be synthesized using an automated polypeptide synthesizer.

[0161] In some embodiments the invention includes a recombinant kinase polypeptide having (a) an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132. By “recombinant kinase polypeptide” is meant a polypeptide produced by recombinant DNA techniques such that it is distinct from a naturally occurring polypeptide either in its location (e.g., present in a different cell or tissue than found in nature), purity or structure. Generally, such a recombinant polypeptide will be present in a cell in an amount different from that normally observed in nature.

[0162] The polypeptides to be expressed in host cells may also be fusion proteins which include regions from heterologous proteins. Such regions may be included to allow, e.g., secretion, improved stability, or facilitated purification of the polypeptide. For example, a sequence encoding an appropriate signal peptide can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused in-frame to the polynucleotide sequence so that the polypeptide is translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cell promotes extracellular secretion of the polypeptide. Preferably, the signal sequence will be cleaved from the polypeptide upon secretion of the polypeptide from the cell. Thus, preferred fusion proteins can be produced in which the N-terminus of a kinase polypeptide is fused to a carrier peptide.

[0163] In one embodiment, the polypeptide comprises a fusion protein which includes a heterologous region used to facilitate purification of the polypeptide. Many of the available peptides used for such a function allow selective binding of the fusion protein to a binding partner. A preferred binding partner includes one or more of the IgG binding domains of protein A are easily purified to homogeneity by affinity chromatography on, for example, IgG-coupled Sepharose. Alternatively, many vectors have the advantage of carrying a stretch of histidine residues that can be expressed at the N-terminal or C-terminal end of the target protein, and thus the protein of interest can be recovered by metal chelation chromatography. A nucleotide sequence encoding a recognition site for a proteolytic enzyme such as enterokinase, factor X procollagenase or thrombine may immediately precede the sequence for a kinase polypeptide to permit cleavage of the fusion protein to obtain the mature kinase polypeptide. Additional examples of fusion-protein binding partners include, but are not limited to, the yeast I-factor, the honeybee melatin leader in sf9 insect cells, 6-His tag, thioredoxin tag, hemaglutinin tag, GST tag, and OmpA signal sequence tag. As will be understood by one of skill in the art, the binding partner which recognizes and binds to the peptide may be any ion, molecule or compound including metal ions (e.g., metal affinity columns), antibodies, or fragments thereof, and any protein or peptide which binds the peptide, such as the FLAG tag.

[0164] In another aspect, the invention features an antibody (e.g., a monoclonal or polyclonal antibody) having specific binding affinity to a kinase polypeptide or a kinase polypeptide domain or fragment where the polypeptide is selected from the group having a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence set forth in SEQ ID NO: 67 through 132. By “specific binding affinity” is meant that the antibody binds to the target kinase polypeptide with greater affinity than it binds to other polypeptides under specified conditions. Antibodies or antibody fragments are polypeptides that contain regions that can bind other polypeptides. Antibodies can be used to identify an endogenous source of kinase polypeptides, to monitor cell cycle regulation, and for immuno-localization of kinase polypeptides within the cell.

[0165] The term “polyclonal” refers to antibodies that are heterogenous populations of antibody molecules derived from the sera of animals immunized with an antigen or an antigenic functional derivative thereof. For the production of polyclonal antibodies, various host animals may be immunized by injection with the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species.

[0166] “Monoclonal antibodies” are substantially homogenous populations of antibodies to a particular antigen. They may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. Monoclonal antibodies may be obtained by methods known to those skilled in the art (Kohler et al., Nature 256: 495-497, 1975, and U.S. Pat. No. 4,376,110, both of which are hereby incorporated by reference herein in their entirety including any figures, tables, or drawings).

[0167] An antibody of the present invention includes “humanized” monoclonal and polyclonal antibodies. Humanized antibodies are recombinant proteins in which non-human (typically murine) complementarity determining regions of an antibody have been transferred from heavy and light variable chains of the non-human (e.g. murine) immunoglobulin into a human variable domain, followed by the replacement of some human residues in the framework regions of their murine counterparts. Humanized antibodies in accordance with this invention are suitable for use in therapeutic methods. General techniques for cloning murine immunoglobulin variable domains are described, for example, by the publication of Orlandi et al., Proc. Nat'l Acad. Sci. USA 86: 3833 (1989). Techniques for producing humanized monoclonal antibodies are described, for example, by Jones et al., Nature 321: 522 (1986), Riechmann et al., Nature 332: 323 (1988), Verhoeyen et al., Science 239: 1534 (1988), Carter et al., Proc. Nat'l Acad. Sci. USA 89: 4285 (1992), Sandhu, Crit. Rev. Biotech. 12: 437 (1992), and Singer et al., J. Immun. 150: 2844 (1993).

[0168] The term “antibody fragment” refers to a portion of an antibody, often the hypervariable region and portions of the surrounding heavy and light chains, that displays specific binding affinity for a particular molecule. A hypervariable region is a portion of an antibody that physically binds to the polypeptide target.

[0169] An antibody fragment of the present invention includes a “single-chain antibody,” a phrase used in this description to denote a linear polypeptide that binds antigen with specificity and that comprises variable or hypervariable regions from the heavy and light chains of an antibody. Such single chain antibodies can be produced by conventional methodology. The Vh and Vl regions of the Fv fragment can be covalentlyjoined and stabilized by the insertion of a disulfide bond. See Glockshuber, et al., Biochemistry 1362 (1990). Alternatively, the Vh and Vl regions can be joined by the insertion of a peptide linker. A gene encoding the Vh, Vl and peptide linker sequences can be constructed and expressed using a recombinant expression vector. See Colcher, et al., J. Nat'l Cancer Inst. 82: 1191 (1990). Amino acid sequences comprising hypervariable regions from the Vh and Vl antibody chains can also be constructed using disulfide bonds or peptide linkers.

[0170] Antibodies or antibody fragments having specific binding affinity to a polypeptide of the invention may be used in methods for detecting the presence and/or amount of kinase polypeptide in a sample by probing the sample with the antibody under conditions suitable for kinase antibody immunocomplex formation and detecting the presence and/or amount of the antibody conjugated to the kinase polypeptide. Diagnostic kits for performing such methods may be constructed to include antibodies or antibody fragments specific for the kinase as well as a conjugate of a binding partner of the antibodies or the antibodies themselves.

[0171] An antibody or antibody fragment with specific binding affinity to a kinase polypeptide of the invention can be isolated, enriched, or purified from a prokaryotic or eukaryotic organism. Routine methods known to those skilled in the art enable production of antibodies or antibody fragments, in both prokaryotic and eukaryotic organisms. Purification, enrichment, and isolation of antibodies, which are polypeptide molecules, are described above. The antibody may be directly labelled with a fluorescent or radioactive label.

[0172] Antibodies having specific binding affinity to a kinase polypeptide of the invention may be used in methods for detecting the presence and/or amount of kinase polypeptide in a sample by contacting the sample with the antibody under conditions such that an immunocomplex forms and detecting the presence and/or amount of the antibody conjugated to the kinase polypeptide. Diagnostic kits for performing such methods may be constructed to include a first container containing the antibody and a second container having a conjugate of a binding partner of the antibody and a label, such as, for example, a radioisotope or fluorescent label. The diagnostic kit may also include notification of an FDA approved use and instructions therefor. Antibodies may identify phosphorylated regions of a kinase polypeptide when a protein is phosphorylated.

[0173] In another aspect, the invention features a hybridoma which produces an antibody having specific binding affinity to a kinase polypeptide or a kinase polypeptide domain, where the polypeptide is selected from the group having an amino acid sequence set forth in SEQ ID NO: 67 through 132. By hybridoma is meant an immortalized cell line that is capable of secreting an antibody, for example an antibody to a kinase of the invention. In preferred embodiments, the antibody to the kinase comprises a sequence of amino acids that is able to specifically bind a kinase polypeptide of the invention.

[0174] In another aspect, the present invention is also directed to kits comprising antibodies that bind to a polypeptide encoded by any of the nucleic acid molecules described above, and a negative control antibody.

[0175] The term “negative control antibody” refers to an antibody derived from similar source as the antibody having specific binding affinity, but where it displays no binding affinity to a polypeptide of the invention.

[0176] In another aspect, the invention features a kinase polypeptide binding agent able to bind to a kinase polypeptide selected from the group having (a) an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132. The binding agent is preferably a purified antibody that recognizes an epitope present on a kinase polypeptide of the invention. Other binding agents include molecules that bind to kinase polypeptides and analogous molecules that bind to a kinase polypeptide. Such binding agents may be identified by using assays that measure kinase binding partner activity, such as those that measure PDGFR activity.

[0177] The invention also features a method for screening for human cells containing a kinase polypeptide of the invention or an equivalent sequence. The method involves identifying the novel polypeptide in human cells using techniques that are routine and standard in the art, such as those described herein for identifying the kinases of the invention (e.g., cloning, Southern or Northern blot analysis, in situ hybridization, PCR amplification, etc.).

[0178] In another aspect, the invention features methods for identifying a substance that modulates kinase activity comprising the steps of: (a) contacting a kinase polypeptide selected from the group having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132 with a test substance; (b) measuring the activity of said polypeptide; and (c) determining whether said substance modulates the activity of said polypeptide. The skilled artisan will appreciate that the kinase polypeptides of the invention, including, for example, a portion of a full-length sequence such as a catalytic domain or a portion thereof, are useful for the identification of a substance which modulates kinase activity. Those kinase polypeptides having a functional activity (e.g., catalytic activity as defined herein) are useful for identifying a substance that modulates kinase activity.

[0179] The term “modulates” refers to the ability of a compound to alter the function of a kinase of the invention. A modulator preferably activates or inhibits the activity of a kinase of the invention depending on the concentration of the compound (modulator) exposed to the kinase.

[0180] The term “modulates” also refers to altering the function of kinases of the invention by increasing or decreasing the probability that a complex forms between the kinase and a natural binding partner. A modulator preferably increases the probability that such a complex forms between the kinase and the natural binding partner, more preferably increases or decreases the probability that a complex forms between the kinase and the natural binding partner depending on the concentration of the compound (modulator) exposed to the kinase, and most preferably decreases the probability that a complex forms between the kinase and the natural binding partner.

[0181] The term “activates” refers to increasing the cellular activity of the kinase. The term inhibit refers to decreasing the cellular activity of the kinase. Kinase activity is the phosphorylation of a substrate or the binding with a natural binding partner.

[0182] The term “complex” refers to an assembly of at least two molecules bound to one another. Signal transduction complexes often contain at least two protein molecules bound to one another. For instance, a tyrosine receptor protein kinase, GRB2, SOS, RAF, and RAS assemble to form a signal transduction complex in response to a mitogenic ligand.

[0183] The term “natural binding partner” refers to polypeptides, lipids, small molecules, or nucleic acids that bind to kinases in cells. A change in the interaction between a kinase and a natural binding partner can manifest itself as an increased or decreased probability that the interaction forms, or an increased or decreased concentration of kinase/natural binding partner complex.

[0184] The term “contacting” as used herein refers to mixing a solution comprising the test compound with a liquid medium bathing the cells of the methods. The solution comprising the compound may also comprise another component, such as dimethyl sulfoxide (DMSO), which facilitates the uptake of the test compound or compounds into the cells of the methods. The solution comprising the test compound may be added to the medium bathing the cells by utilizing a delivery apparatus, such as a pipette-based device or syringe-based device.

[0185] In another aspect, the invention features methods for identifying a substance that modulates kinase activity in a cell comprising the steps of: (a) expressing a kinase polypeptide in a cell, wherein said polypeptide is selected from the group having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132; (b) adding a test substance to said cell; and (c) monitoring a change in kinase activity or a change in cell phenotype or the interaction between said polypeptide and a natural binding partner. The skilled artisan will appreciate that the kinase polypeptides of the invention, including, for example, a portion of a full-length sequence such as a catalytic domain or a portion thereof, and are useful for the identification of a substance which modulates kinase activity. Those kinase polypeptides having a functional activity (e.g., catalytic activity as defined herein) are useful for identifying a substance that modulates kinase activity.

[0186] The term “expressing” as used herein refers to the production of kinases of the invention from a nucleic acid vector containing kinase genes within a cell. The nucleic acid vector is transfected into cells using well known techniques in the art as described herein.

[0187] Another aspect of the instant invention is directed to methods of identifying compounds that bind to kinase polypeptides of the present invention, comprising contacting the kinase polypeptides with a compound, and determining whether the compound binds the kinase polypeptides. Binding can be determined by binding assays which are well known to the skilled artisan, including, but not limited to, gel-shift assays, Western blots, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross linking, interaction trap/two-hybrid analysis, southwestern analysis, ELISA, and the like, which are described in, for example, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, NY, which is incorporated herein by reference in its entirety. The compounds to be screened include, but are not limited to, compounds of extracellular, intracellular, biological or chemical origin.

[0188] The methods of the invention also embrace compounds that are attached to a label, such as a radiolabel (e.g., ¹²⁵I, ³⁵S, ³²P, ³³P, ³H), a fluorescence label, a chemiluminescent label, an enzymic label and an immunogenic label. The kinase polypeptides employed in such a test may either be free in solution, attached to a solid support, borne on a cell surface, located intracellularly or associated with a portion of a cell. One skilled in the art can, for example, measure the formation of complexes between a kinase polypeptide and the compound being tested. Alternatively, one skilled in the art can examine the diminution in complex formation between a kinase polypeptide and its substrate caused by the compound being tested.

[0189] Other assays can be used to examine enzymatic activity including, but not limited to, photometric, radiometric, HPLC, electrochemical, and the like, which are described in, for example, Enzyme Assays: A Practical Approach, eds. R. Eisenthal and M. J. Danson, 1992, Oxford University Press, which is incorporated herein by reference in its entirety.

[0190] Another aspect of the present invention is directed to methods of identifying compounds which modulate (i.e., increase or decrease) activity of a kinase polypeptide comprising contacting the kinase polypeptide with a compound, and determining whether the compound modifies activity of the kinase polypeptide. As described herein, the kinase polypeptides of the invention include a portion of a full-length sequence, such as a catalytic domain, as defined herein. In some instances, the kinase polypeptides of the invention comprise less than the entire catalytic domain, yet exhibit kinase or kinase-like activity. These compounds are also referred to as “modulators of protein kinases.” The activity in the presence of the test compound is compared to the activity in the absence of the test compound. Where the activity of a sample containing the test compound is higher than the activity in a sample lacking the test compound, the compound will have increased the activity. Similarly, where the activity of a sample containing the test compound is lower than the activity in the sample lacking the test compound, the compound will have inhibited the activity.

[0191] The present invention is particularly useful for screening compounds by using a kinase polypeptide in any of a variety of drug screening techniques. The compounds to be screened include, but are not limited to, extracellular, intracellular, biological or chemical origin. The kinase polypeptide employed in such a test may be in any form, preferably, free in solution, attached to a solid support, borne on a cell surface or located intracellularly. One skilled in the art can, for example, measure the formation of complexes between a kinase polypeptide and the compound being tested. Alternatively, one skilled in the art can examine the diminution in complex formation between a kinase polypeptide and its substrate caused by the compound being tested.

[0192] The activity of kinase polypeptides of the invention can be determined by, for example, examining the ability to bind or be activated by chemically synthesised peptide ligands. Alternatively, the activity of the kinase polypeptides can be assayed by examining their ability to bind metal ions such as calcium, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, and odorants. Thus, modulators of the kinase polypeptide's activity may alter a kinase function, such as a binding property of a kinase or an activity such as signal transduction or membrane localization.

[0193] In various embodiments of the method, the assay may take the form of a yeast growth assay, an Aequorin assay, a Luciferase assay, a mitogenesis assay, a MAP Kinase activity assay, as well as other binding or function-based assays of kinase activity that are generally known in the art. In several of these embodiments, the invention includes any of the receptor and non-receptor protein tyrosine kinases, receptor and non-receptor protein phosphatases, polypeptides containing SRC homology 2 and 3 domains, phosphotyrosine binding proteins (SRC homology 2 (SH2) and phosphotyrosine binding (PTB and PH) domain containing proteins), proline-rich binding proteins (SH3 domain containing proteins), GTPases, phosphodiesterases, phospholipases, prolyl isomerases, proteases, Ca2+ binding proteins, cAMP binding proteins, guanyl cyclases, adenylyl cyclases, NO generating proteins, nucleotide exchange factors, and transcription factors. Biological activities of kinases according to the invention include, but are not limited to, the binding of a natural or a synthetic ligand, as well as any one of the functional activities of kinases known in the art. Non-limiting examples of kinase activities include transmembrane signaling of various forms, which may involve kinase binding interactions and/or the exertion of an influence over signal transduction.

[0194] The modulators of the invention exhibit a variety of chemical structures, which can be generally grouped into mimetics of natural kinase ligands, and peptide and non-peptide allosteric effectors of kinases. The invention does not restrict the sources for suitable modulators, which may be obtained from natural sources such as plant, animal or mineral extracts, or non-natural sources such as small molecule libraries, including the products of combinatorial chemical approaches to library construction, and peptide libraries.

[0195] The use of cDNAs encoding kinases in drug discovery programs is well-known; assays capable of testing thousands of unknown compounds per day in high-throughput screens (HTSs) are thoroughly documented. The literature is replete with examples of the use of radiolabelled ligands in HTS binding assays for drug discovery (see Williams, Medicinal Research Reviews, 1991, 11, 147-184.; Sweetnam, et al., J. Natural Products, 1993, 56, 441-455 for review). Recombinant proteins are preferred for binding assay HTS because they allow for better specificity (higher relative purity), provide the ability to generate large amounts of material, and can be used in a broad variety of formats (see Hodgson, Bio/Technology, 1992, 10, 973-980; each of which is incorporated herein by reference in its entirety).

[0196] A variety of heterologous systems is available for functional expression of recombinant proteins that are well known to those skilled in the art. Such systems include bacteria (Strosberg, et al., Trends in Pharmacological Sciences, 1992, 13, 95-98), yeast (Pausch, Trends in Biotechnology, 1997, 15, 487-494), several kinds of insect cells (Vanden Broeck, Int. Rev. Cytology, 1996, 164, 189-268), amphibian cells (Jayawickreme et al., Current Opinion in Biotechnology, 1997, 8, 629-634) and several mammalian cell lines (CHO, HEK293, COS, etc.; see Gerhardt, et al., Eur. J. Pharmacology, 1997, 334, 1-23). These examples do not preclude the use of other possible cell expression systems, including cell lines obtained from nematodes (PCT application WO 98/37177).

[0197] An expressed kinase can be used for HTS binding assays in conjunction with its defined ligand, in this case the corresponding peptide that activates it. The identified peptide is labeled with a suitable radioisotope, including, but not limited to, ¹²⁵I, ³H, ³⁵S or ³²P, by methods that are well known to those skilled in the art. Alternatively, the peptides may be labeled by well-known methods with a suitable fluorescent derivative (Baindur, et al., Drug Dev. Res., 1994, 33, 373-398; Rogers, Drug Discovery Today, 1997, 2, 156-160). Radioactive ligand specifically bound to the receptor in membrane preparations made from the cell line expressing the recombinant protein can be detected in HTS assays in one of several standard ways, including filtration of the receptor-ligand complex to separate bound ligand from unbound ligand (Williams, Med. Res. Rev., 1991, 11, 147-184.; Sweetnam, et al., J. Natural Products, 1993, 56, 441-455). Alternative methods include a scintillation proximity assay (SPA) or a FlashPlate format in which such separation is unnecessary (Nakayama, Cur. Opinion Drug Disc. Dev., 1998, 1, 85-91 Bossé, et al., J. Biomolecular Screening, 1998, 3, 285-292.). Binding of fluorescent ligands can be detected in various ways, including fluorescence energy transfer (FRET), direct spectrophotofluorometric analysis of bound ligand, or fluorescence polarization (Rogers, Drug Discovery Today, 1997, 2, 156-160; Hill, Cur. Opinion Drug Disc. Dev., 1998, 1, 92-97).

[0198] The kinases and natural binding partners required for functional expression of heterologous kinase polypeptides can be native constituents of the host cell or can be introduced through well-known recombinant technology. The kinase polypeptides can be intact or chimeric. The kinase activation results in the stimulation or inhibition of other native proteins, events that can be linked to a measurable response.

[0199] Examples of such biological responses include, but are not limited to, the following: the ability to survive in the absence of a limiting nutrient in specifically engineered yeast cells (Pausch, Trends in Biotechnology, 1997, 15, 487-494); changes in intracellular Ca²⁺ concentration as measured by fluorescent dyes (Murphy, et al., Cur. Opinion Drug Disc. Dev., 1998, 1, 192-199), cell cycle, apoptosis, and growth. Fluorescence changes can also be used to monitor ligand-induced changes in membrane potential or intracellular pH; an automated system suitable for HTS has been described for these purposes (Schroeder, et al., J. Biomolecular Screening, 1996, 1, 75-80).

[0200] The invention contemplates a multitude of assays to screen and identify inhibitors of ligand binding to kinase polypeptides. In one example, the kinase polypeptide is immobilized and interaction with a binding partner is assessed in the presence and absence of a candidate modulator such as an inhibitor compound. In another example, interaction between the kinase polypeptide and its binding partner is assessed in a solution assay, both in the presence and absence of a candidate inhibitor compound. In either assay, an inhibitor is identified as a compound that decreases binding between the kinase polypeptide and its natural binding partner. Another contemplated assay involves a variation of the di-hybrid assay wherein an inhibitor of protein/protein interactions is identified by detection of a positive signal in a transformed or transfected host cell, as described in PCT publication number WO 95/20652, published Aug. 3, 1995 and is included by reference herein including any figures, tables, or drawings.

[0201] Candidate modulators contemplated by the invention include compounds selected from libraries of either potential activators or potential inhibitors. There are a number of different libraries used for the identification of small molecule modulators, including: (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules. Chemical libraries consist of random chemical structures, some of which are analogs of known compounds or analogs of compounds that have been identified as “hits” or “leads” in other drug discovery screens, while others are derived from natural products, and still others arise from non-directed synthetic organic chemistry. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) thereof. For a review, see Science 282: 63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture. These libraries are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning, or proprietary synthetic methods. Of particular interest are non-peptide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, Curr. Opin. Biotechnol. 8: 701-707 (1997). Identification of modulators through use of the various libraries described herein permits modification of the candidate “hit” (or “lead”) to optimize the capacity of the “hit” to modulate activity.

[0202] Still other candidate inhibitors contemplated by the invention can be designed and include soluble forms of binding partners, as well as such binding partners as chimeric, or fusion, proteins. A “binding partner” as used herein broadly encompasses both natural binding partners as described above as well as chimeric polypeptides, peptide modulators other than natural ligands, antibodies, antibody fragments, and modified compounds comprising antibody domains that are immunospecific for the expression product of the identified kinase gene.

[0203] Other assays may be used to identify specific peptide ligands of a kinase polypeptide, including assays that identify ligands of the target protein through measuring direct binding of test ligands to the target protein, as well as assays that identify ligands of target proteins through affinity ultrafiltration with ion spray mass spectroscopy/HPLC methods or other physical and analytical methods. Alternatively, such binding interactions are evaluated indirectly using the yeast two-hybrid system described in Fields et al., Nature, 340: 245-246 (1989), and Fields et al., Trends in Genetics, 10: 286-292 (1994), both of which are incorporated herein by reference. The two-hybrid system is a genetic assay for detecting interactions between two proteins or polypeptides. It can be used to identify proteins that bind to a known protein of interest, or to delineate domains or residues critical for an interaction. Variations on this methodology have been developed to clone genes that encode DNA binding proteins, to identify peptides that bind to a protein, and to screen for drugs. The two-hybrid system exploits the ability of a pair of interacting proteins to bring a transcription activation domain into close proximity with a DNA binding domain that binds to an upstream activation sequence (UAS) of a reporter gene, and is generally performed in yeast. The assay requires the construction of two hybrid genes encoding (1) a DNA-binding domain that is fused to a first protein and (2) an activation domain fused to a second protein. The DNA-binding domain targets the first hybrid protein to the UAS of the reporter gene; however, because most proteins lack an activation domain, this DNA-binding hybrid protein does not activate transcription of the reporter gene. The second hybrid protein, which contains the activation domain, cannot by itself activate expression of the reporter gene because it does not bind the UAS. However, when both hybrid proteins are present, the noncovalent interaction of the first and second proteins tethers the activation domain to the UAS, activating transcription of the reporter gene. For example, when the first protein is a kinase gene product, or fragment thereof, that is known to interact with another protein or nucleic acid, this assay can be used to detect agents that interfere with the binding interaction. Expression of the reporter gene is monitored as different test agents are added to the system. The presence of an inhibitory agent results in lack of a reporter signal.

[0204] When the function of the kinase polypeptide gene product is unknown and no ligands are known to bind the gene product, the yeast two-hybrid assay can also be used to identify proteins that bind to the gene product. In an assay to identify proteins that bind to a kinase polypeptide, or fragment thereof, a fusion polynucleotide encoding both a kinase polypeptide (or fragment) and a UAS binding domain (i.e., a first protein) may be used. In addition, a large number of hybrid genes each encoding a different second protein fused to an activation domain are produced and screened in the assay. Typically, the second protein is encoded by one or more members of a total CDNA or genomic DNA fusion library, with each second protein coding region being fused to the activation domain. This system is applicable to a wide variety of proteins, and it is not even necessary to know the identity or function of the second binding protein. The system is highly sensitive and can detect interactions not revealed by other methods; even transient interactions may trigger transcription to produce a stable mRNA that can be repeatedly translated to yield the reporter protein.

[0205] Other assays may be used to search for agents that bind to the target protein. One such screening method to identify direct binding of test ligands to a target protein is described in U.S. Pat. No. 5,585,277, incorporated herein by reference. This method relies on the principle that proteins generally exist as a mixture of folded and unfolded states, and continually alternate between the two states. When a test ligand binds to the folded form of a target protein (i.e., when the test ligand is a ligand of the target protein), the target protein molecule bound by the ligand remains in its folded state. Thus, the folded target protein is present to a greater extent in the presence of a test ligand which binds the target protein, than in the absence of a ligand. Binding of the ligand to the target protein can be determined by any method which distinguishes between the folded and unfolded states of the target protein. The function of the target protein need not be known in order for this assay to be performed. Virtually any agent can be assessed by this method as a test ligand, including, but not limited to, metals, polypeptides, proteins, lipids, polysaccharides, polynucleotides and small organic molecules.

[0206] Another method for identifying ligands of a target protein is described in Wieboldt et al., Anal. Chem., 69: 1683-1691 (1997), incorporated herein by reference. This technique screens combinatorial libraries of 20-30 agents at a time in solution phase for binding to the target protein. Agents that bind to the target protein are separated from other library components by simple membrane washing. The specifically selected molecules that are retained on the filter are subsequently liberated from the target protein and analyzed by HPLC and pneumatically assisted electrospray (ion spray) ionization mass spectroscopy. This procedure selects library components with the greatest affinity for the target protein, and is particularly useful for small molecule libraries.

[0207] In preferred embodiments of the invention, methods of screening for compounds which modulate kinase activity comprise contacting test compounds with kinase polypeptides and assaying for the presence of a complex between the compound and the kinase polypeptide. In such assays, the ligand is typically labelled. After suitable incubation, free ligand is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular compound to bind to the kinase polypeptide.

[0208] In another embodiment of the invention, high throughput screening for compounds having suitable binding affinity to kinase polypeptides is employed. Briefly, large numbers of different small peptide test compounds are synthesised on a solid substrate. The peptide test compounds are contacted with the kinase polypeptide and washed. Bound kinase polypeptide is then detected by methods well known in the art. Purified polypeptides of the invention can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the protein and immobilize it on the solid support.

[0209] Other embodiments of the invention comprise using competitive screening assays in which neutralizing antibodies capable of binding a polypeptide of the invention specifically compete with a test compound for binding to the polypeptide. In this manner, the antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with a kinase polypeptide. Radiolabeled competitive binding studies are described in A. H. Lin et al. Antimicrobial Agents and Chemotherapy, 1997, vol. 41, no. 10. pp. 2127-2131, the disclosure of which is incorporated herein by reference in its entirety.

[0210] In another aspect, the invention provides methods for treating a disease by administering to a patient in need of such treatment a substance that modulates the activity of a kinase polypeptide selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, as well as the full-length polypeptide thereof, or a portion of any of these sequences that retains functional activity, as described herein. Preferably the disease is selected from the group consisting of cancers, immune-elated diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, and metabolic disorders. More specifically these diseases include cancer of tissues, blood, or hematopoietic origin, particularly those involving breast, colon, lung, prostate, cervical, brain, ovarian, bladder, skin or kidney; central or peripheral nervous system diseases and conditions including migraine, pain, sexual dysfunction, mood disorders, attention disorders, cognition disorders, hypotension, and hypertension; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome; neurodegenerative diseases including Alzheimer's, Parkinson's, Multiple sclerosis, and Amyotrophic lateral sclerosis; viral or non-viral infections caused by HIV-1, HIV-2 or other viral- or prion-agents or fungal- or bacterial-organisms; metabolic disorders including Diabetes and obesity and their related syndromes, among others; cardiovascular disorders including reperfusion restenosis, hypertension, coronary thrombosis, clotting disorders, unregulated cell growth disorders, atherosclerosis; ocular disease including glaucoma, retinopathy, and macular degeneration; inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, bone disorders, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplant rejection.

[0211] In preferred embodiments, the invention provides methods for treating or preventing a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, as well as the full-length polypeptide thereof, or a portion of any of these sequences that retains functional activity, as described herein. Preferably, the disease is selected from the group consisting of cancers, immune-related diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, and metabolic disorders. More specifically these diseases include cancer of tissues, blood, or hematopoietic origin, particularly those involving breast, colon, lung, prostate, cervical, brain, ovarian, bladder, or kidney; central or peripheral nervous system diseases and conditions including migraine, pain, sexual dysfunction, mood disorders, attention disorders, cognition disorders, hypotension, and hypertension; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome; neurodegenerative diseases including Alzheimer's, Parkinson's, Multiple sclerosis, and Amyotrophic lateral sclerosis; viral or non-viral infections caused by HIV-1, HIV-2 or other viral- or prion-agents or fungal- or bacterial-organisms; metabolic disorders including Diabetes and obesity and their related syndromes, among others; cardiovascular disorders including reperfusion restenosis, coronary thrombosis, clotting disorders, unregulated cell growth disorders, atherosclerosis; ocular disease including glaucoma, retinopathy, and macular degeneration; inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplant rejection.

[0212] Substances useful for treatment of kinase-related disorders or diseases preferably show positive results in one or more in vitro assays for an activity corresponding to treatment of the disease or disorder in question (Examples of such assays are provided in the references in section VI, below; and in Example 7, herein). Examples of substances that can be screened for favorable activity are provided and referenced in section VI, below. The substances that modulate the activity of the kinases preferably include, but are not limited to, antisense oligonucleotides and inhibitors of protein kinases, as determined by methods and screens referenced in section VI and Example 7, below.

[0213] The term “preventing” refers to decreasing the probability that an organism contracts or develops an abnormal condition.

[0214] The term “treating” refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism.

[0215] The term “therapeutic effect” refers to the inhibition or activation factors causing or contributing to the abnormal condition. A therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition. In reference to the treatment of abnormal conditions, a therapeutic effect can refer to one or more of the following: (a) an decrease in the proliferation, growth, and/or differentiation of cells; (b) inhibition (i.e., slowing or stopping) of cell death; (c) inhibition of degeneration; (d) relieving to some extent one or more of the symptoms associated with the abnormal condition; and (e) enhancing the function of the affected population of cells. Compounds demonstrating efficacy against abnormal conditions can be identified as described herein.

[0216] The term “abnormal condition” refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation, or cell survival.

[0217] Abnormal cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

[0218] Abnormal differentiation conditions include, but are not limited to neurodegenerative disorders, slow wound healing rates, and slow tissue grafting healing rates.

[0219] Abnormal cell survival conditions relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the protein kinases could lead to cell immortality or premature cell death.

[0220] The term “aberration,” in conjunction with the function of a kinase in a signal transduction process, refers to a kinase that is over- or under-expressed in an organism, mutated such that its catalytic activity is lower or higher than wild-type protein kinase activity, mutated such that it can no longer interact with a natural binding partner, is no longer modified by another protein kinase or protein phosphatase, or no longer interacts with a natural binding partner.

[0221] The term “administering” relates to a method of incorporating a compound into cells or tissues of an organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism. Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the organism, many techniques exist in the art to administer compounds, including (but not limited to) oral, parenteral, dermal, injection, and aerosol applications. For cells outside of the organism, multiple techniques exist in the art to administer the compounds, including (but not limited to) cell microinjection techniques, transformation techniques, and carrier techniques.

[0222] The abnormal condition can also be prevented or treated by administering a compound to a group of cells having an aberration in a signal transduction pathway to an organism. The effect of administering a compound on organism function can then be monitored. The organism is preferably a mammal. The organism also is preferably a mouse, rat, rabbit, guinea pig, dog, cat, horse, pig, sheep, or goat, more preferably a monkey or ape, and most preferably a human.

[0223] In another aspect, the invention features methods for detection of a kinase polypeptide in a sample as a diagnostic tool for diseases or disorders, wherein the method comprises the steps of: (a) contacting the sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, said probe comprising the nucleic acid sequence encoding the polypeptide, fragments thereof, and the complements of the sequences and fragments; and (b) detecting the presence or amount of the probe: target region hybrid as an indication of the disease.

[0224] In preferred embodiments of the invention, the disease or disorder is selected from the group consisting of Preferably the disease is selected from the group consisting of cancers, immune-elated diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, and metabolic disorders. More specifically these diseases include cancer of tissues, blood, or hematopoietic origin, particularly those involving breast, colon, lung, prostate, cervical, brain, ovarian, bladder, skin or kidney; central or peripheral nervous system diseases and conditions including migraine, pain, sexual dysfunction, mood disorders, attention disorders, cognition disorders, hypotension, and hypertension; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome; neurodegenerative diseases including Alzheimer's, Parkinson's, Multiple sclerosis, and Amyotrophic lateral sclerosis; viral or non-viral infections caused by HIV-1, HIV-2 or other viral- or prion-agents or fungal- or bacterial-organisms; metabolic disorders including Diabetes and obesity and their related syndromes, among others; cardiovascular disorders including reperfusion restenosis, hypertension, coronary thrombosis, clotting disorders, unregulated cell growth disorders, atherosclerosis; ocular disease including glaucoma, retinopathy, and macular degeneration; inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, bone disorders, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplant rejection.

[0225] The kinase “target region” is the nucleotide base sequence selected from the group consisting of those set forth in SEQ ID NO: 1 through SEQ ID NO: 66, or the corresponding full-length sequences, a functional derivative thereof, or a fragment thereof, to which the nucleic acid probe will specifically hybridize. Specific hybridization indicates that in the presence of other nucleic acids the probe only hybridizes detectably with the kinase of the invention's target region. Putative target regions can be identified by methods well known in the art consisting of alignment and comparison of the most closely related sequences in the database.

[0226] In preferred embodiments the nucleic acid probe hybridizes to a kinase target region encoding at least 6, 12, 75, 90, 105, 120, 150, 200, 250, 300 or 350 contiguous amino acids of a sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, or the corresponding full-length amino acid sequence, a portion of any of these sequences that retains functional activity, as described herein, or a functional derivative thereof. Hybridization conditions should be such that hybridization occurs only with the kinase genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having more than 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined supra.

[0227] The diseases for which detection of kinase genes in a sample could be diagnostic include diseases in which kinase nucleic acid (DNA and/or RNA) is amplified in comparison to normal cells. By “amplification” is meant increased numbers of kinase DNA or RNA in a cell compared with normal cells. In normal cells, kinases are typically found as single copy genes. In selected diseases, the chromosomal location of the kinase genes may be amplified, resulting in multiple copies of the gene, or amplification. Gene amplification can lead to amplification of kinase RNA, or kinase RNA can be amplified in the absence of kinase DNA amplification.

[0228] “Amplification” as it refers to RNA can be the detectable presence of kinase RNA in cells, since in some normal cells there is no basal expression of kinase RNA. In other normal cells, a basal level of expression of kinase exists, therefore in these cases amplification is the detection of at least 1-2-fold, and preferably more, kinase RNA, compared to the basal level.

[0229] The diseases that could be diagnosed by detection of kinase nucleic acid in a sample preferably include cancers or other diseases described herein. The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample that is compatible with the method utilized.

[0230] The invention also features a method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein the method comprises: (a) comparing a nucleic acid target region encoding the kinase polypeptide in a sample, where the kinase polypeptide has an amino acid sequence selected from the group consisting those set forth in SEQ ID NO: 67 through SEQ ID NO: 132, or one or more fragments thereof, with a control nucleic acid target region encoding the kinase polypeptide, or one or more fragments thereof; and (b) detecting differences in sequence or amount between the target region and the control target region, as an indication of the disease or disorder. Preferably the disease is selected from the group consisting of cancers, immune-related diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, and metabolic disorders. More specifically these diseases include cancer of tissues, blood, or hematopoietic origin, particularly those involving breast, colon, lung, prostate, cervical, brain, ovarian, bladder, or kidney; central or peripheral nervous system diseases and conditions including migraine, pain, sexual dysfunction, mood disorders, attention disorders, cognition disorders, hypotension, and hypertension; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Tourette's Syndrome; neurodegenerative diseases including Alzheimer's, Parkinson's, Multiple sclerosis, and Amyotrophic lateral sclerosis; viral or non-viral infections caused by HIV-1, HIV-2 or other viral- or prion-agents or fungal- or bacterial-organisms; metabolic disorders including Diabetes and obesity and their related syndromes, among others; cardiovascular disorders including reperfusion restenosis, coronary thrombosis, clotting disorders, unregulated cell growth disorders, atherosclerosis; ocular disease including glaucoma, retinopathy, and macular degeneration; inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplant rejection.

[0231] The term “comparing” as used herein refers to identifying discrepancies between the nucleic acid target region isolated from a sample, and the control nucleic acid target region. The discrepancies can be in the nucleotide sequences, e.g. insertions, deletions, or point mutations, or in the amount of a given nucleotide sequence. Methods to determine these discrepancies in sequences are well-known to one of ordinary skill in the art. The “control” nucleic acid target region refers to the sequence or amount of the sequence found in normal cells, e.g. cells that are not diseased as discussed previously.

[0232] The summary of the invention described above is not limiting and other features and advantages of the invention will be apparent from the following detailed description of the invention, and from the claims.

BRIEF DESCRIPTION OF THE FIGURES

[0233]FIG. 1 shows the nucleotide sequences for human protein kinases oriented in a 5′ to 3′ direction (SEQ ID NO: 1-66).

[0234]FIG. 2 shows the amino acid sequences for the human protein kinases encoded by SEQ ID No. 1 and 2 in the direction of translation (SEQ ID NO: 67 through 132). If a predicted stop codons is within the coding region, it is indicated by an ‘x.’

DETAILED DESCRIPTION OF THE INVENTION

[0235] The invention provides, inter alia, protein kinase and kinase-like genes, as well as fragments thereof, which have been identified in genomic databases. In part, the invention provides nucleic acid molecules that are capable of encoding polypeptides having a kinase or kinase-like activity. By reference to Tables 1 though 6, below, genes of the invention can be better understood. The invention additionally provides a number of different embodiments, such as those described below.

Nucleic Acids

[0236] Associations of chromosomal localizations for mapped genes with amplicons implicated in cancer are based on literature searches (PubMed http: //www.ncbi.nlm.nih.gov/entrez/query.fcgi), OMIM searches (Online Mendelian Inheritance in Man, http: //www.ncbi.nlm.nih.gov/Omim/searchomim.html) and the comprehensive database of cancer amplicons maintained by Knuutila, et al. (Knuutila, et al., DNA copy number amplifications in human neoplasms. Review of comparative genomic hybridization studies. Am J Pathol 152: 1107-1123, 1998. http: //www.helsinki.fi/˜lgl_www/CMG.html).

[0237] For single nucleotide polymorphisms, an accession number is given if the SNP is documented in dbSNP (the database of single nucleotide polymorphisms) maintained at NCBI (http: //www.ncbi.nlm.nih.gov/SNP/index.html). The accession number for SNP can be used to retrieve the full SNP-containing sequence from this site.

[0238] All of the sequences are derived from human DNA, with the exception of Pak4, which is from Mus musculus.

NUCLEIC ACID PROBES, METHODS, AND KITS FOR DETECTION OF KINASES

[0239] The invention additionally provides nucleic acid probes and uses therefor. A nucleic acid probe of the present invention may be used to probe an appropriate chromosomal or cDNA library by usual hybridization methods to obtain other nucleic acid molecules of the present invention. A chromosomal DNA or cDNA library may be prepared from appropriate cells according to recognized methods in the art (cf. “Molecular Cloning: A Laboratory Manual,” second edition, Cold Spring Harbor Laboratory, Sambrook, Fritsch, & Maniatis, eds., 1989).

[0240] In the alternative, chemical synthesis can be carried out in order to obtain nucleic acid probes having nucleotide sequences which correspond to N-terminal and C-terminal portions of the amino acid sequence of the polypeptide of interest. The synthesized nucleic acid probes may be used as primers in a polymerase chain reaction (PCR) carried out in accordance with recognized PCR techniques, essentially according to PCR Protocols, “A Guide to Methods and Applications,” Academic Press, Michael, et al., eds., 1990, utilizing the appropriate chromosomal or cDNA library to obtain the fragmentof the present invention.

[0241] One skilled in the art can readily design such probes based on the sequence disclosed herein using methods of computer alignment and sequence analysis known in the art (“Molecular Cloning: A Laboratory Manual,” 1989, supra). The hybridization probes of the present invention can be labeled by standard labeling techniques such as with a radiolabel, enzyme label, fluorescent label, biotin-avidin label, chemiluminescence, and the like. After hybridization, the probes may be visualized using known methods.

[0242] The nucleic acid probes of the present invention include RNA, as well as DNA probes, such probes being generated using techniques known in the art. The nucleic acid probe may be immobilized on a solid support. Examples of such solid supports include, but are not limited to, plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, and acrylic resins, such as polyacrylamide and latex beads. Techniques for coupling nucleic acid probes to such solid supports are well known in the art.

[0243] The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample which is compatible with the method utilized.

[0244] One method of detecting the presence of nucleic acids of the invention in a sample comprises (a) contacting said sample with the above-described nucleic acid probe under conditions such that hybridization occurs, and (b) detecting the presence of said probe bound to said nucleic acid molecule. One skilled in the art would select the nucleic acid probe according to techniques known in the art as described above. Samples to be tested include but should not be limited to RNA samples of human tissue.

[0245] A kit for detecting the presence of nucleic acids of the invention in a sample comprises at least one container means having disposed therein the above-described nucleic acid probe. The kit may further comprise other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound nucleic acid probe. Examples of detection reagents include, but are not limited to radiolabelled probes, enzymatic labeled probes (horseradish peroxidase, alkaline phosphatase), and affinity labeled probes (biotin, avidin, or steptavidin). Preferably, the kit further comprises instructions for use.

[0246] In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the probe or primers used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, and the like), and containers which contain the reagents used to detect the hybridized probe, bound antibody, amplified product, or the like. One skilled in the art will readily recognize that the nucleic acid probes described in the present invention can readily be incorporated into one of the established kit formats which are well known in the art.

CATEGORIZATION OF THE POLYPEPTIDES ACCORDING TO THE INVENTION

[0247] For a number of protein kinases of the invention, there is provided a classification of the protein class and family to which it belongs, a summary of non-catalytic protein motifs, as well as a chromosomal location, which provides information on function, regulation and/or therapeutic utility for each of the proteins. Amplification of chromosomal region can be associated with various cancers. For amplicons discussed in this application, the source of information was Knuutila, et al (Knuutila S, Björkqvist A-M, Autio K, Tarkkanen M, Wolf M, Monni 0, Szymanska J, Larramendy M L, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius V-M, Vidgren V & Zhu Y: DNA copy number amplifications in human neoplasms. Review of comparative genomic hybridization studies. Am J Pathol 152: 1107-1123, 1998. http: //www.helsinki.fi/˜lgl_www/CMG.html).

[0248] The kinase classification and protein domains often reflect pathways, cellular roles, or mechanisms of up- or down-stream regulation. Also disease-relevant genes often occur in families of related genes. For example, if one member of a kinase family functions as an oncogene, a tumor suppressor, or has been found to be disrupted in an immune, neurologic, cardiovascular, or metabolic disorder, frequently other family members may play a similar role.

[0249] Chromosomal location can identify candidate targets for a tumor amplicon or a tumor-suppressor locus. Summaries of prevalent tumor amplicons are available in the literature, and can identify tumor types to experimentally be confirmed to contain amplified copies of a kinase gene which localizes to an adjacent region.

[0250] As described herein, the polypeptides of the present invention can be classified. The salient features related to the biological and clinical implications of these different groups are described hereafter in more general terms.

[0251] A more specific characterization of the polypeptides of the invention, including potential biological and clinical implications, is provided, e.g., in EXAMPLES 2a and 2b.

CLASSIFICATION OF POLYPEPTIDES EXHIBITING KINASE ACTIVITY

[0252] The classification of the polypeptides described in this application is found in Tables 1 and 2. The present application describes members of the following superfamilies: protein kinase, lipid kinase, atypical protein kinase. The present application also describes members of the following groups: CAMK Group, CKI (or CK1) Group, CMGC Group, STE Group, TK Group, DAG (diacylglycerol) Group, BRD Group. ***

[0253] Potential biological and clinical implications of these novel kinases are described below.

THERAPEUTIC METHODS ACCORDING TO THE INVENTION

[0254] Diagnostics:

[0255] The invention provides methods for detecting a polypeptide in a sample as a diagnostic tool for diseases or disorders, wherein the method comprises the steps of: (a) contacting the sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of a polypeptide selected from the group consisting of SEQ ID NO: 67 through 132, said probe comprising the nucleic acid sequence encoding the polypeptide, fragments thereof, and the complements of the sequences and fragments; and (b) detecting the presence or amount of the probe: target region hybrid as an indication of the disease.

[0256] In preferred embodiments of the invention, the disease or disorder is selected from the group consisting of rheumatoid arthritis, atherosclerosis, autoimmune disorders, organ transplantation, myocardial infarction, cardiomyopathies, stroke, renal failure, oxidative stress-related neurodegenerative disorders, metabolic disorder including diabetes, reproductive disorders including infertility, and cancer.

[0257] Hybridization conditions should be such that hybridization occurs only with the genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions only highly complementary nucleic acid sequences hybridize. Preferably, such conditions prevent hybridization of nucleic acids having 1 or 2 mismatches out of 20 contiguous nucleotides. Such conditions are defined supra.

[0258] The diseases for which detection of genes in a sample could be diagnostic include diseases in which nucleic acid (DNA and/or RNA) is amplified in comparison to normal cells. By “amplification” is meant increased numbers of DNA or RNA in a cell compared with normal cells.

[0259] “Amplification” as it refers to RNA can be the detectable presence of RNA in cells, since in some normal cells there is no basal expression of RNA. In other normal cells, a basal level of expression exists, therefore in these cases amplification is the detection of at least 1-2-fold, and preferably more, compared to the basal level.

[0260] The diseases that could be diagnosed by detection of nucleic acid in a sample preferably include cancers. The test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids. The samples used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample that is compatible with the method utilized.

[0261] Antibodies, Hybridomas, Methods of Use and Kits for Detection of Kinases

[0262] The present invention relates to an antibody having binding affinity to a kinase of the invention. The polypeptide may have the amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, or a functional derivative thereof, or at least 9 contiguous amino acids thereof (preferably, at least 20, 30, 35, or 40 contiguous amino acids thereof).

[0263] The present invention also relates to an antibody having specific binding affinity to a kinase of the invention. Such an antibody may be isolated by comparing its binding affinity to a kinase of the invention with its binding affinity to other polypeptides. Those which bind selectively to a kinase of the invention would be chosen for use in methods requiring a distinction between a kinase of the invention and other polypeptides. Such methods could include, but should not be limited to, the analysis of altered kinase expression in tissue containing other polypeptides.

[0264] The kinases of the present invention can be used in a variety of procedures and methods, such as for the generation of antibodies, for use in identifying pharmaceutical compositions, and for studying DNA/protein interaction.

[0265] The kinases of the present invention can be used to produce antibodies or hybridomas. One skilled in the art will recognize that if an antibody is desired, such a peptide could be generated as described herein and used as an immunogen. The antibodies of the present invention include monoclonal and polyclonal antibodies, as well fragments of these antibodies, and humanized forms. Humanized forms of the antibodies of the present invention may be generated using one of the procedures known in the art such as chimerization or CDR grafting.

[0266] The present invention also relates to a hybridoma which produces the above-described monoclonal antibody, or binding fragment thereof. A hybridoma is an immortalized cell line which is capable of secreting a specific monoclonal antibody.

[0267] In general, techniques for preparing monoclonal antibodies and hybridomas are well known in the art (Campbell, “Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology,” Elsevier Science Publishers, Amsterdam, The Netherlands, 1984; St. Groth et al., J. Immunol. Methods 35: 1-21, 1980). Any animal (mouse, rabbit, and the like) which is known to produce antibodies can be immunized with the selected polypeptide. Methods for immunization are well known in the art. Such methods include subcutaneous or intraperitoneal injection of the polypeptide. One skilled in the art will recognize that the amount of polypeptide used for immunization will vary based on the animal which is immunized, the antigenicity of the polypeptide and the site of injection.

[0268] The polypeptide may be modified or administered in an adjuvant in order to increase the peptide antigenicity. Methods of increasing the antigenicity of a polypeptide are well known in the art. Such procedures include coupling the antigen with a heterologous protein (such as globulin or β-galactosidase) or through the inclusion of an adjuvant during immunization.

[0269] For monoclonal antibodies, spleen cells from the immunized animals are removed, fused with myeloma cells, such as SP2/0-Ag14 myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells. Any one of a number of methods well known in the art can be used to identify the hybridoma cell which produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, western blot analysis, or radioimmunoassay (Lutz et al., Exp. Cell Res. 175: 109-124, 1988). Hybridomas secreting the desired antibodies are cloned and the class and subclass are determined using procedures known in the art (Campbell, “Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology,” supra, 1984).

[0270] For polyclonal antibodies, antibody-containing antisera is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures. The above-described antibodies may be detectably labeled. Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin; avidin, and the like), enzymatic labels (such as horseradish peroxidase, alkaline phosphatase, and the like) fluorescent labels (such as FITC or rhodamine, and the like), paramagnetic atoms, and the like. Procedures for accomplishing such labeling are well-known in the art, for example, see Stemberger et al., J. Histochem. Cytochem. 18: 315, 1970; Bayer et al., Meth. Enzym. 62: 308, 1979; Engval et al., Immunol. 109: 129, 1972; Goding, J. Immunol. Meth. 13: 215, 1976. The labeled antibodies of the present invention can be used for in vitro, in vivo, and in situ assays to identify cells or tissues which express a specific peptide.

[0271] The above-described antibodies may also be immobilized on a solid support. Examples of such solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir et al., “Handbook of Experimental Immunology” 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10, 1986; Jacoby et al., Meth. Enzym. 34, Academic Press, N.Y., 1974). The immobilized antibodies of the present invention can be used for in vitro, in vivo, and in situ assays as well as in immunochromotography.

[0272] Furthermore, one skilled in the art can readily adapt currently available procedures, as well as the techniques, methods and kits disclosed herein with regard to antibodies, to generate peptides capable of binding to a specific peptide sequence in order to generate rationally designed antipeptide peptides (Hurby et al., “Application of Synthetic Peptides: Antisense Peptides,” In Synthetic Peptides, A User's Guide, W. H. Freeman, NY, pp. 289-307, 1992; Kaspczak et al., Biochemistry 28: 9230-9238, 1989).

[0273] Anti-peptide peptides can be generated by replacing the basic amino acid residues found in the peptide sequences of the kinases of the invention with acidic residues, while maintaining hydrophobic and uncharged polar groups. For example, lysine, arginine, and/or histidine residues are replaced with aspartic acid or glutamic acid and glutamic acid residues are replaced by lysine, arginine or histidine.

[0274] The present invention also encompasses a method of detecting a kinase polypeptide in a sample, comprising: (a) contacting the sample with an above-described antibody, under conditions such that immunocomplexes form, and (b) detecting the presence of said antibody bound to the polypeptide. In detail, the methods comprise incubating a test sample with one or more of the antibodies of the present invention and assaying whether the antibody binds to the test sample. Altered levels of a kinase of the invention in a sample as compared to normal levels may indicate disease.

[0275] Conditions for incubating an antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the antibody used in the assay. One skilled in the art will recognize that any one of the commonly available immunological assay formats (such as radioimmunoassays, enzyme-linked immunosorbent assays, diffusion-based Ouchterlony, or rocket immunofluorescent assays) can readily be adapted to employ the antibodies of the present invention. Examples of such assays can be found in Chard (“An Introduction to Radioimmunoassay and Related Techniques” Elsevier Science Publishers, Amsterdam, The Netherlands, 1986), Bullock et al. (“Techniques in Immunocytochemistry,” Academic Press, Orlando, Fla. Vol. 1, 1982; Vol. 2, 1983; Vol. 3, 1985), Tijssen (“Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology,” Elsevier Science Publishers, Amsterdam, The Netherlands, 1985).

[0276] The immunological assay test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as blood, serum, plasma, or urine. The test samples used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can readily be adapted in order to obtain a sample which is testable with the system utilized.

[0277] A kit contains all the necessary reagents to carry out the previously described methods of detection. The kit may comprise: (i) a first container means containing an above-described antibody, and (ii) second container means containing a conjugate comprising a binding partner of the antibody and a label. In another preferred embodiment, the kit further comprises one or more other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound antibodies.

[0278] Examples of detection reagents include, but are not limited to, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the chromophoric, enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody. The compartmentalized kit may be as described above for nucleic acid probe kits. One skilled in the art will readily recognize that the antibodies described in the present invention can readily be incorporated into one of the established kit formats which are well known in the art.

[0279] Isolation of Compounds Capable of Interacting With Kinases

[0280] The present invention also relates to a method of detecting a compound capable of binding to a kinase of the invention comprising incubating the compound with a kinase of the invention and detecting the presence of the compound bound to the kinase. The compound may be present within a complex mixture, for example, serum, body fluid, or cell extracts.

[0281] The present invention also relates to a method of detecting an agonist or antagonist of kinase activity or kinase binding partner activity comprising incubating cells that produce a kinase of the invention in the presence of a compound and detecting changes in the level of kinase activity or kinase binding partner activity. The compounds thus identified would produce a change in activity indicative of the presence of the compound. The compound may be present within a complex mixture, for example, serum, body fluid, or cell extracts. Once the compound is identified it can be isolated using techniques well known in the art.

[0282] Modulating Polypeptide Activity:

[0283] The invention additionally provides methods for treating a disease or abnormal condition by administering to a patient in need of such treatment a substance that modulates the activity of a polypeptide selected from the group consisting of SEQ ID NO: 67 through 132. Preferably, the disease is selected from the group consisting of rheumatoid arthritis, atherosclerosis, autoimmune disorders, organ transplantation, myocardial infarction, cardiomyopathies, stroke, renal failure, oxidative stress-related neurodegenerative disorders, metabolic and reproductive disorders, and cancer.

[0284] Substances useful for treatment of disorders or diseases preferably show positive results in one or more assays for an activity corresponding to treatment of the disease or disorder in question Substances that modulate the activity of the polypeptides preferably include, but are not limited to, antisense oligonucleotides and inhibitors of protein kinases.

[0285] The term “preventing” refers to decreasing the probability that an organism contracts or develops an abnormal condition.

[0286] The term “treating” refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism.

[0287] The term “therapeutic effect” refers to the inhibition or activation factors causing or contributing to the abnormal condition. A therapeutic effect relieves to some extent one or more of the symptoms of the abnormal condition. In reference to the treatment of abnormal conditions, a therapeutic effect can refer to one or more of the following: (a) a decrease in the proliferation, growth, and/or differentiation of cells; (b) inhibition (, slowing or stopping) of cell death; (c) inhibition of degeneration; (d) relieving to some extent one or more of the symptoms associated with the abnormal condition; and (e) enhancing the function of the affected population of cells. Compounds demonstrating efficacy against abnormal conditions can be identified as described herein.

[0288] The term “abnormal condition” refers to a function in the cells or tissues of an organism that deviates from their normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation or cell survival. An abnormal condition may also include irregularities in cell cycle progression, i.e., irregularities in normal cell cycle progression through mitosis and meiosis.

[0289] Abnormal cell proliferative conditions include cancers such as fibrotic and mesangial disorders, abnormal angiogenesis and vasculogenesis, wound healing, psoriasis, diabetes mellitus, and inflammation.

[0290] Abnormal differentiation conditions include, but are not limited to, neurodegenerative disorders, slow wound healing rates, and slow tissue grafting healing rates.

[0291] Abnormal cell survival conditions may also relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the protein kinases could lead to cell immortality or premature cell death.

[0292] The term “aberration,” in conjunction with the function of a kinase in a signal transduction process, refers to a kinase that is over- or under-expressed in an organism, mutated such that its catalytic activity is lower or higher than wild-type protein kinase activity, mutated such that it can no longer interact with a natural binding partner, is no longer modified by another protein kinase or protein phosphatase, or no longer interacts with a natural binding partner.

[0293] The term “administering” relates to a method of incorporating a compound into cells or tissues of an organism. The abnormal condition can be prevented or treated when the cells or tissues of the organism exist within the organism or outside of the organism. Cells existing outside the organism can be maintained or grown in cell culture dishes. For cells harbored within the organism, many techniques exist in the art to administer compounds, including (but not limited to) oral, parenteral, dermal, injection, and aerosol applications. For cells outside of the organism, multiple techniques exist in the art to administer the compounds, including (but not limited to) cell microinjection techniques, transformation techniques and carrier techniques.

[0294] The abnormal condition can also be prevented or treated by administering a compound to a group of cells having an aberration in a signal transduction pathway to an organism. The effect of administering a compound on organism function can then be monitored. The organism is preferably a mouse, rat, rabbit, guinea pig or goat, more preferably a monkey or ape, and most preferably a human.

[0295] The present invention also encompasses a method of agonizing (stimulating) or antagonizing kinase associated activity in a mammal comprising administering to said mammal an agonist or antagonist to a kinase of the invention in an amount sufficient to effect said agonism or antagonism. A method of treating diseases in a mammal with an agonist or antagonist of the activity of one of the kinases of the invention comprising administering the agonist or antagonist to a mammal in an amount sufficient to agonize or antagonize kinase-associated functions is also encompassed in the present application.

[0296] In an effort to discover novel treatments for diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit the function of protein kinases. Some small organic molecules form a class of compounds that modulate the function of protein kinases. Examples of molecules that have been reported to inhibit the function of some protein kinases include, but are not limited to, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642, published November 26, 1992 by Maguire et al.), vinylene-azaindole derivatives (PCT WO 94/14808, published Jul. 7, 1994 by Ballinari et al.), 1-cyclopropyl-4-pyridyl-quinolones (U.S. Pat. No. 5,330,992), styryl compounds (U.S. Pat. No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Pat. No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427, published Feb. 17, 1994 by Denny et al.), tricyclic polyhydroxylic compounds (PCT WO 92/21660, published Dec. 10, 1992 by Dow), and benzylphosphonic acid compounds (PCT WO 91/15495, published Oct. 17, 1991 by Dow et al).

[0297] Compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous as therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein kinase inhibitors only weakly inhibit the function of protein kinases. In addition, many inhibit a variety of protein kinases and will therefore cause multiple side-effects as therapeutics for diseases.

[0298] Some indolinone compounds, however, form classes of acid resistant and membrane permeable organic molecules. WO 96/22976 (published Aug. 1, 1996 by Ballinari et al.) describes hydrosoluble indolinone compounds that harbor tetralin, naphthalene, quinoline, and indole substituents fused to the oxindole ring. These bicyclic substituents are in turn substituted with polar moieties including hydroxylated alkyl, phosphate, and ether moieties. U.S. patent application Ser. Nos. 08/702,232, filed Aug. 23, 1996, entitled “Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease” by Tang et al. (Lyon & Lyon Docket No. 221/187) and 08/485,323, filed Jun. 7, 1995, entitled “Benzylidene-Z-Indoline Compounds for the Treatment of Disease” by Tang et al. (Lyon & Lyon Docket No. 223/298) and International Patent Publications WO 96/40116, published Dec. 19, 1996 by Tang, et al., and WO 96/22976, published Aug. 1, 1996 by Ballinari et al., all of which are incorporated herein by reference in their entirety, including any drawings, figures, or tables, describe indolinone chemical libraries of indolinone compounds harboring other bicyclic moieties as well as monocyclic moieties fused to the oxindole ring. Applications Ser. No. 08/702,232, filed Aug. 23, 1996, entitled “Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease” by Tang et al. (Lyon & Lyon Docket No. 221/187), 08/485,323, filed Jun. 7, 1995, entitled “Benzylidene-Z-Indoline Compounds for the Treatment of Disease” by Tang et al. (Lyon & Lyon Docket No. 223/298), and WO 96/22976, published Aug. 1, 1996 by Ballinari et al. teach methods of indolinone synthesis, methods of testing the biological activity of indolinone compounds in cells, and inhibition patterns of indolinone derivatives.

[0299] Other examples of substances capable of modulating kinase activity include, but are not limited to, tyrphostins, quinazolines, quinoxolines, and quinolines. The quinazolines, tyrphostins, quinolines, and quinoxolines referred to above include well known compounds such as those described in the literature. For example, representative publications describing quinazolines include Barker et al., EPO Publication No. 0 520 722 A1; Jones et al., U.S. Pat. No. 4,447,608; Kabbe et al., U.S. Pat. No. 4,757,072; Kaul and Vougioukas, U.S. Pat. No. 5,316,553; Kreighbaum and Comer, U.S. Pat. No. 4,343,940; Pegg and Wardleworth, EPO Publication No. 0 562 734 A1; Barker et al., (1991) Proc. of Am. Assoc. for Cancer Research 32: 327; Bertino, J. R., (1979) Cancer Research 3: 293-304; Bertino, J. R., (1979) Cancer Research 9(2 part 1): 293-304; Curtin et al., (1986) Br. J. Cancer 53: 361-368; Fernandes et al., (1983) Cancer Research 43: 1117-1123; Ferris et al. J. Org. Chem. 44(2): 173-178; Fry et al., (1994) Science 265: 1093-1095; Jackmnan et al., (1981) Cancer Research 51: 5579-5586; Jones et al. J. Med. Chem. 29(6): 1114-1118; Lee and Skibo, (1987) Biochemistry 26(23): 7355-7362; Lemus et al., (1989) J. Org. Chem. 54: 3511-3518; Ley and Seng, (1975) Synthesis 1975: 415-522; Maxwell et al., (1991) Magnetic Resonance in Medicine 17: 189-196; Mini et al., (1985) Cancer Research 45: 325-330; Phillips and Castle, J. (1980) Heterocyclic Chem. 17(19): 1489-1596; Reece et al., (1977) Cancer Research 47(11): 2996-2999; Sculier et al., (1986) Cancer Immunol. and Immunother. 23, A65; Sikora et al., (1984) Cancer Letters 23: 289-295; Sikora et al., (1988) Analytical Biochem. 172: 344-355; all of which are incorporated herein by reference in their entirety, including any drawings.

[0300] Quinoxaline is described in Kaul and Vougioukas, U.S. Pat. No. 5,316,553, incorporated herein by reference in its entirety, including any drawings.

[0301] Quinolines are described in Dolle et al., (1994) J. Med. Chem. 37: 2627-2629; MaGuire, J. (1994) Med. Chem. 37: 2129-2131; Burke et al., (1993) J. Med. Chem. 36: 425-432; and Burke et al. (1992) BioOrganic Med. Chem. Letters 2: 1771-1774, all of which are incorporated by reference in their entirety, including any drawings.

[0302] Tyrphostins are described in Allen et al., (1993) Clin. Exp. Immunol. 91: 141-156; Anafi et al., (1993) Blood 82: 12, 3524-3529; Baker et al., (1992) J. Cell Sci. 102: 543-555; Bilder et al., (1991) Amer. Physiol. Soc. pp. 6363-6143: C721-C730; Brunton et al., (1992) Proceedings of Amer. Assoc. Cancer Rsch. 33: 558; Bryckaert et al., (1992) Exp. Cell Research 199: 255-261; Dong et al., (1993) J. Leukocyte Biology 53: 53-60; Dong et al., (1993) J. Immunol. 151(5): 2717-2724; Gazit et al., (1989) J. Med. Chem. 32, 2344-2352; Gazit et al., (1993) J. Med. Chem. 36: 3556-3564; Kaur et al., (1994) Anti-Cancer Drugs 5: 213-222; King et al., (1991) Biochem. J. 275: 413-418; Kuo et al., (1993) Cancer Letters 74: 197-202; Levitzki, A., (1992) The FASEB J. 6: 3275-3282; Lyall et al., (1989) J. Biol. Chem. 264: 14503-14509; Peterson et al., (1993) The Prostate 22: 335-345; Pillemer et al., (1992) Int. J. Cancer 50: 80-85; Posner et al., (1993) Molecular Pharmacology 45: 673-683; Rendu et al., (1992) Biol. Pharmacology 44(5): 881-888; Sauro and Thomas, (1993) Life Sciences 53: 371-376; Sauro and Thomas, (1993) J. Pharm. and Experimental Therapeutics 267(3): 119-1125; Wolbring et al., (1994) J. Biol. Chem. 269(36): 22470-22472; and Yoneda et al., (1991) Cancer Research 51: 4430-4435; all of which are incorporated herein by reference in their entirety, including any drawings.

[0303] Other compounds that could be used as modulators include oxindolinones such as those described in U.S. patent application Ser. No. 08/702,232 filed Aug. 23, 1996, incorporated herein by reference in its entirety, including any drawings.

RECOMBINANT DNA TECHNOLOGY

[0304] DNA Constructs Comprising a Kinase Nucleic Acid Molecule and Cells Containing These Constructs:

[0305] The present invention also relates to a recombinant DNA molecule comprising, 5′ to 3′, a promoter effective to initiate transcription in a host cell and the above-described nucleic acid molecules. In addition, the present invention relates to a recombinant DNA molecule comprising a vector and an above-described nucleic acid molecule. The present invention also relates to a nucleic acid molecule comprising a transcriptional region functional in a cell, a sequence complementary to an RNA sequence encoding an amino acid sequence corresponding to the above-described polypeptide, and a transcriptional termination region functional in said cell. The above-described molecules may be isolated and/or purified DNA molecules.

[0306] The present invention also relates to a cell or organism that contains an above-described nucleic acid molecule and thereby is capable of expressing a polypeptide. The polypeptide may be purified from cells which have been altered to express the polypeptide. A cell is said to be “altered to express a desired polypeptide” when the cell, through genetic manipulation, is made to produce a protein which it normally does not produce or which the cell normally produces at lower levels. One skilled in the art can readily adapt procedures for introducing and expressing either genomic, cDNA, or synthetic sequences into either eukaryotic or prokaryotic cells.

[0307] A nucleic acid molecule, such as DNA, is said to be “capable of expressing” a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are “operably linked” to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene sequence expression. The precise nature of the regulatory regions needed for gene sequence expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation. Such regions will normally include those 5′-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

[0308] If desired, the non-coding region 3′ to the sequence encoding a kinase of the invention may be obtained by the above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation. Thus, by retaining the 3′-region naturally contiguous to the DNA sequence encoding a kinase of the invention, the transcriptional termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3′ region functional in the host cell may be substituted.

[0309] Two DNA sequences (such as a promoter region sequence and a sequence encoding a kinase of the invention) are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of a gene sequence encoding a kinase of the invention, or (3) interfere with the ability of the gene sequence of a kinase of the invention to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence. Thus, to express a gene encoding a kinase of the invention, transcriptional and translational signals recognized by an appropriate host are necessary.

[0310] The present invention encompasses the expression of a gene encoding a kinase of the invention (or a functional derivative thereof) in either prokaryotic or eukaryotic cells. Prokaryotic hosts are, generally, very efficient and convenient for the production of recombinant proteins and are, therefore, one type of preferred expression system for kinases of the invention. Prokaryotes most frequently are represented by various strains of E. coli. However, other microbial strains may also be used, including other bacterial strains.

[0311] In prokaryotic systems, plasmid vectors that contain replication sites and control sequences derived from a species compatible with the host may be used. Examples of suitable plasmid vectors may include pBR322, pUC118, pUC119 and the like; suitable phage or bacteriophage vectors may include λgt10, λgt11 and the like; and suitable virus vectors may include pMAM-neo, pKRC and the like. Preferably, the selected vector of the present invention has the capacity to replicate in the selected host cell.

[0312] Recognized prokaryotic hosts include bacteria such as E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, and the like. However, under such conditions, the polypeptide will not be glycosylated. The prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.

[0313] To express a kinase of the invention (or a functional derivative thereof) in a prokaryotic cell, it is necessary to operably link the sequence encoding the kinase of the invention to a functional prokaryotic promoter. Such promoters may be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible). Examples of constitutive promoters include the int promoter of bacteriophage λ, the bla promoter of the β-lactamase gene sequence of pBR322, and the cat promoter of the chloramphenicol acetyl transferase gene sequence of pPR325, and the like. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage λ (P_(L) and P_(R)), the trp, λrecA, acZ, λacI, and gal promoters of E. coli, the α-amylase (Ulmanen et al., J. Bacteriol. 162: 176-182, 1985) and the ζ-28-specific promoters of B. subtilis (Gilman et al., Gene Sequence 32: 11-20, 1984), the promoters of the bacteriophages of Bacillus (Gryczan, in: The Molecular Biology of the Bacilli, Academic Press, Inc., NY, 1982), and Streptomyces promoters (Ward et al., Mol. Gen. Genet. 203: 468-478, 1986). Prokaryotic promoters are reviewed by Glick (Ind. Microbiot. 1: 277-282, 1987), Cenatiempo (Biochimie 68: 505-516, 1986), and Gottesman (Ann. Rev. Genet. 18: 415-442, 1984).

[0314] Proper expression in a prokaryotic cell also requires the presence of a ribosome-binding site upstream of the gene sequence-encoding sequence. Such ribosome-binding sites are disclosed, for example, by Gold et al. (Ann. Rev. Microbiol. 35: 365-404, 1981). The selection of control sequences, expression vectors, transformation methods, and the like, are dependent on the type of host cell used to express the gene. As used herein, “cell,” “cell line,” and “cell culture” may be used interchangeably and all such designations include progeny. Thus, the words “transformants” or “transformed cells” include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. However, as defined, mutant progeny have the same functionality as that of the originally transformed cell.

[0315] Host cells which may be used in the expression systems of the present invention are not strictly limited, provided that they are suitable for use in the expression of the kinase polypeptide of interest. Suitable hosts may often include eukaryotic cells. Preferred eukaryotic hosts include, for example, yeast, fungi, insect cells, mammalian cells either in vivo, or in tissue culture. Mammalian cells which may be useful as hosts include HeLa cells, cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin and their derivatives. Preferred mammalian host cells include SP2/0 and J558L, as well as neuroblastoma cell lines such as IMR 332, which may provide better capacities for correct post-translational processing.

[0316] In addition, plant cells are also available as hosts, and control sequences compatible with plant cells are available, such as the cauliflower mosaic virus 35S and 19S, and nopaline synthase promoter and polyadenylation signal sequences. Another preferred host is an insect cell, for example the Drosophila larvae. Using insect cells as hosts, the Drosophila alcohol dehydrogenase promoter can be used (Rubin, Science 240: 1453-1459, 1988). Alternatively, baculovirus vectors can be engineered to express large amounts of kinases of the invention in insect cells (Jasny, Science 238: 1653, 1987; Miller et al., in: Genetic Engineering, Vol. 8, Plenum, Setlow et al., eds., pp. 277-297, 1986).

[0317] Any of a series of yeast expression systems can be utilized which incorporate promoter and termination elements from the actively expressed sequences coding for glycolytic enzymes that are produced in large quantities when yeast are grown in mediums rich in glucose. Known glycolytic gene sequences can also provide very efficient transcriptional control signals. Yeast provides substantial advantages in that it can also carry out post-translational modifications. A number of recombinant DNA strategies exist utilizing strong promoter sequences and high copy number plasmids which can be utilized for production of the desired proteins in yeast. Yeast recognizes leader sequences on cloned mammalian genes and secretes peptides bearing leader sequences (i.e., pre-peptides). Several possible vector systems are available for the expression of kinases of the invention in a mammalian host.

[0318] A wide variety of transcriptional and translational regulatory sequences may be employed, depending upon the nature of the host. The transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, cytomegalovirus, simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression. Alternatively, promoters from mammalian expression products, such as actin, collagen, myosin, and the like, may be employed. Transcriptional initiation regulatory signals may be selected which allow for repression or activation, so that expression of the gene sequences can be modulated. Of interest are regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical (such as metabolite) regulation.

[0319] Expression of kinases of the invention in eukaryotic hosts requires the use of eukaryotic regulatory regions. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis. Preferred eukaryotic promoters include, for example, the promoter of the mouse metallothionein I gene sequence (Hamer et al., J. Mol. Appl. Gen. 1: 273-288, 1982); the TK promoter of Herpes virus (McKnight, Cell 31: 355-365, 1982); the SV40 early promoter (Benoist et al., Nature (London) 290: 304-31, 1981); and the yeast gal4 gene sequence promoter (Johnston et al., Proc. Natl. Acad. Sci. (USA) 79: 6971-6975, 1982; Silver et al., Proc. Natl. Acad. Sci. (USA) 81: 5951-5955, 1984).

[0320] Translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes a kinase of the invention (or a functional derivative thereof) does not contain any intervening codons which are capable of encoding a methionine (i.e., AUG). The presence of such codons results either in the formation of a fusion protein (if the AUG codon is in the same reading frame as the kinase of the invention coding sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the kinase of the invention coding sequence).

[0321] A nucleic acid molecule encoding a kinase of the invention and an operably linked promoter may be introduced into a recipient prokaryotic or eukaryotic cell either as a nonreplicating DNA or RNA molecule, which may either be a linear molecule or, more preferably, a closed covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the gene may occur through the transient expression of the introduced sequence. Alternatively, permanent expression may occur through the integration of the introduced DNA sequence into the host chromosome.

[0322] A vector may be employed which is capable of integrating the desired gene sequences into the host cell chromosome. Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector. The marker may provide for prototrophy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama (Mol. Cell. Biol. 3: 280-289, 1983).

[0323] The introduced nucleic acid molecule can be incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to “shuttle” the vector between host cells of different species.

[0324] Preferred prokaryotic vectors include plasmids such as those capable of replication in E. coli (such as, for example, pBR322, ColE1, pSC101, pACYC 184, πrVX; “Molecular Cloning: A Laboratory Manual,” 1989, supra). Bacillus plasmids include pC194, pC221, pT127, and the like (Gryczan, In: The Molecular Biology of the Bacilli, Academic Press, NY, pp. 307-329, 1982). Suitable Streptomyces plasmids include p1J101 (Kendall et al., J. Bacteriol. 169: 4177-4183, 1987), and streptomyces bacteriophages such as φC31 (Chater et al., In: Sixth International Symposium on Actinomycetales Biology, Akademiai Kaido, Budapest, Hungary, pp. 45-54, 1986). Pseudomonas plasmids are reviewed by John et al. (Rev. Infect. Dis. 8: 693-704, 1986), and Izaki (Jpn. J. Bacteriol. 33: 729-742, 1978).

[0325] Preferred eukaryotic plasmids include, for example, BPV, vaccinia, SV40, 2-micron circle, and the like, or their derivatives. Such plasmids are well known in the art (Botstein et al., Miami Wntr. Symp. 19: 265-274, 1982; Broach, In: “The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance,” Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., p. 445-470, 1981; Broach, Cell 28: 203-204, 1982; Bollon et al., J. Clin. Hematol. Oncol. 10: 39-48, 1980; Maniatis, In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene Sequence Expression, Academic Press, NY, pp. 563-608, 1980).

[0326] Once the vector or nucleic acid molecule containing the construct(s) has been prepared for expression, the DNA construct(s) may be introduced into an appropriate host cell by any of a variety of suitable means, i.e., transformation, transfection, conjugation, protoplast fusion, electroporation, particle gun technology, calcium phosphate-precipitation, direct microinjection, and the like. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene(s) results in the production of a kinase of the invention, or fragments thereof. This can take place in the transformed cells as such, or following the induction of these cells to differentiate (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like). A variety of incubation conditions can be used to form the peptide of the present invention. The most preferred conditions are those which mimic physiological conditions.

[0327] Transgenic Animals:

[0328] A variety of methods are available for the production of transgenic animals associated with this invention. DNA can be injected into the pronucleus of a fertilized egg before fusion of the male and female pronuclei, or injected into the nucleus of an embryonic cell (e.g., the nucleus of a two-cell embryo) following the initiation of cell division (Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442, 1985). Embryos can be infected with viruses, especially retroviruses, modified to carry inorganic-ion receptor nucleotide sequences of the invention.

[0329] Pluripotent stem cells derived from the inner cell mass of the embryo and stabilized in culture can be manipulated in culture to incorporate nucleotide sequences of the invention. A transgenic animal can be produced from such cells through implantation into a blastocyst that is implanted into a foster mother and allowed to come to term. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, Mass.), Taconic (Germantown, N.Y.), Harlan Sprague Dawley (Indianapolis, Ind.), etc.

[0330] The procedures for manipulation of the rodent embryo and for microinjection of DNA into the pronucleus of the zygote are well known to those of ordinary skill in the art (Hogan et al., supra). Microinjection procedures for fish, amphibian eggs and birds are detailed in Houdebine and Chourrout (Experientia 47: 897-905, 1991). Other procedures for introduction of DNA into tissues of animals are described in U.S. Pat. No. 4,945,050 (Sanford et al., Jul. 30, 1990).

[0331] By way of example only, to prepare a transgenic mouse, female mice are induced to superovulate. Females are placed with males, and the mated females are sacrificed by CO₂ asphyxiation or cervical dislocation and embryos are recovered from excised oviducts. Surrounding cumulus cells are removed. Pronuclear embryos are then washed and stored until the time of injection. Randomly cycling adult female mice are paired with vasectomized males. Recipient females are mated at the same time as donor females. Embryos then are transferred surgically. The procedure for generating transgenic rats is similar to that of mice (Hammer et al., Cell 63: 1099-1112, 1990).

[0332] Methods for the culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection also are well known to those of ordinary skill in the art (Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press, 1987).

[0333] In cases involving random gene integration, a clone containing the sequence(s) of the invention is co-transfected with a gene encoding resistance. Alternatively, the gene encoding neomycin resistance is physically linked to the sequence(s) of the invention. Transfection and isolation of desired clones are carried out by any one of several methods well known to those of ordinary skill in the art (E. J. Robertson, supra).

[0334] DNA molecules introduced into ES cells can also be integrated into the chromosome through the process of homologous recombination (Capecchi, Science 244: 1288-1292, 1989). Methods for positive selection of the recombination event (i.e., neo resistance) and dual positive-negative selection (i.e., neo resistance and gancyclovir resistance) and the subsequent identification of the desired clones by PCR have been described by Capecchi, supra and Joyner et al. (Nature 338: 153-156, 1989), the teachings of which are incorporated herein in their entirety including any drawings. The final phase of the procedure is to inject targeted ES cells into blastocysts and to transfer the blastocysts into pseudopregnant females. The resulting chimeric animals are bred and the offspring are analyzed by Southern blotting to identify individuals that carry the transgene. Procedures for the production of non-rodent mammals and other animals have been discussed by others (Houdebine and Chourrout, supra; Pursel et al., Science 244: 1281-1288, 1989; and Simms et al., Bio/Technology 6: 179-183, 1988).

[0335] Thus, the invention provides transgenic, nonhuman mammals containing a transgene encoding a kinase of the invention or a gene affecting the expression of the kinase. Such transgenic nonhuman mammals are particularly useful as an in vivo test system for studying the effects of introduction of a kinase, or regulating the expression of a kinase (i.e., through the introduction of additional genes, antisense nucleic acids, or ribozymes).

[0336] A “transgenic animal” is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats. The transgenic DNA may encode human kinases. Native expression in an animal may be reduced by providing an amount of antisense RNA or DNA effective to reduce expression of the receptor.

[0337] Gene Therapy:

[0338] Kinases or their genetic sequences will also be useful in gene therapy (reviewed in Miller, Nature 357: 455-460, 1992). Miller states that advances have resulted in practical approaches to human gene therapy that have demonstrated positive initial results. The basic science of gene therapy is described in Mulligan (Science 260: 926-931, 1993).

[0339] In one preferred embodiment, an expression vector containing a kinase coding sequence is inserted into cells, the cells are grown in vitro and then infused in large numbers into patients. In another preferred embodiment, a DNA segment containing a promoter of choice (for example a strong promoter) is transferred into cells containing an endogenous gene encoding kinases of the invention in such a manner that the promoter segment enhances expression of the endogenous kinase gene (for example, the promoter segment is transferred to the cell such that it becomes directly linked to the endogenous kinase gene).

[0340] The gene therapy may involve the use of an adenovirus containing kinase cDNA targeted to a tumor, systemic kinase increase by implantation of engineered cells, injection with kinase-encoding virus, or injection of naked kinase DNA into appropriate tissues.

[0341] Target cell populations may be modified by introducing altered forms of one or more components of the protein complexes in order to modulate the activity of such complexes. For example, by reducing or inhibiting a complex component activity within target cells, an abnormal signal transduction event(s) leading to a condition may be decreased, inhibited, or reversed. Deletion or missense mutants of a component, that retain the ability to interact with other components of the protein complexes but cannot function in signal transduction, may be used to inhibit an abnormal, deleterious signal transduction event.

[0342] Expression vectors derived from viruses such as retroviruses, vaccinia virus, adenovirus, adeno-associated virus, herpes viruses, several RNA viruses, or bovine papilloma virus, may be used for delivery of nucleotide sequences (e.g., cDNA) encod-ing recombinant kinase of the invention protein into the targeted cell population (e.g., tumor cells). Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors containing coding sequences (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989; Ausubel et al., Current Proto-cols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y., 1989). Alter-natively, recombinant nucleic acid molecules encoding protein sequences can be used as naked DNA or in a recon-stituted system e.g., liposomes or other lipid systems for delivery to target cells (e.g., Felgner et al., Nature 337: 387-8, 1989). Several other methods for the direct transfer of plasmid DNA into cells exist for use in human gene therapy and involve targeting the DNA to receptors on cells by complexing the plasmid DNA to proteins (Miller, supra).

[0343] In its simplest form, gene transfer can be performed by simply injecting minute amounts of DNA into the nucleus of a cell, through a process of microinjection (Capecchi, Cell 22: 479-88, 1980). Once recombinant genes are introduced into a cell, they can be recognized by the cell's normal mechanisms for transcription and translation, and a gene product will be expressed. Other methods have also been attempted for introducing DNA into larger numbers of cells. These methods include: transfection, wherein DNA is precipitated with calcium phosphate and taken into cells by pinocytosis (Chen et al., Mol. Cell Biol. 7: 2745-52, 1987); electroporation, wherein cells are exposed to large voltage pulses to introduce holes into the membrane (Chu et al., Nucleic Acids Res. 15: 1311-26, 1987); lipofection/liposome fusion, wherein DNA is packaged into lipophilic vesicles which fuse with a target cell (Felgner et al., Proc. Natl. Acad. Sci. USA. 84: 7413-7417, 1987); and particle bombardment using DNA bound to small projectiles (Yang et al., Proc. Natl. Acad. Sci. 87: 9568-9572, 1990). Another method for introducing DNA into cells is to couple the DNA to chemically modified proteins.

[0344] It has also been shown that adenovirus proteins are capable of destabilizing endosomes and enhancing the uptake of DNA into cells. The admixture of adenovirus to solutions containing DNA complexes, or the binding of DNA to polylysine covalently attached to adenovirus using protein crosslinking agents substantially improves the uptake and expression of the recombinant gene (Curiel et al., Am. J. Respir. Cell. Mol. Biol., 6: 247-52, 1992).

[0345] As used herein “gene transfer” means the process of introducing a foreign nucleic acid molecule into a cell. Gene transfer is commonly performed to enable the expression of a particular product encoded by the gene. The product may include a protein, polypeptide, antisense DNA or RNA, or enzymatically active RNA. Gene transfer can be performed in cultured cells or by direct administration into animals. Generally gene transfer involves the process of nucleic acid contact with a target cell by non-specific or receptor mediated interactions, uptake of nucleic acid into the cell through the membrane or by endocytosis, and release of nucleic acid into the cyto-plasm from the plasma membrane or endosome. Expression may require, in addition, movement of the nucleic acid into the nucleus of the cell and binding to appropriate nuclear factors for transcription.

[0346] As used herein “gene therapy” is a form of gene transfer and is included within the definition of gene transfer as used herein and specifically refers to gene transfer to express a therapeutic product from a cell in vivo or in vitro. Gene transfer can be performed ex vivo on cells which are then transplanted into a patient, or can be performed by direct administration of the nucleic acid or nucleic acid-protein complex into the patient.

[0347] In another preferred embodiment, a vector having nucleic acid sequences encoding a kinase polypeptide is provided in which the nucleic acid sequence is expressed only in specific tissue. Methods of achieving tissue-specific gene expression are set forth in International Publication No. WO 93/09236, filed Nov. 3, 1992 and published May 13, 1993.

[0348] In all of the preceding vectors set forth above, a fuirther aspect of the invention is that the nucleic acid sequence contained in the vector may include additions, deletions or modifications to some or all of the sequence of the nucleic acid, as defined above.

[0349] Expression, including over-expression, of a kinase polypeptide of the invention can be inhibited by administration of an antisense molecule that binds to and inhibits expression of the mRNA encoding the polypeptide. Alternatively, expression can be inhibited in an analogous manner using a ribozyme that cleaves the mRNA. General methods of using antisense and ribozyme technology to control gene expression, or of gene therapy methods for expression of an exogenous gene in this manner are well known in the art. Each of these methods utilizes a system, such as a vector, encoding either an antisense or ribozyme transcript of a kinase polypeptide of the invention.

[0350] The term “ribozyme” refers to an RNA structure of one or more RNAs having catalytic properties. Ribozymes generally exhibit endonuclease, ligase or polymerase activity. Ribozymes are structural RNA molecules which mediate a number of RNA self-cleavage reactions. Various types of trans-acting ribozymes, including “hammerhead” and “hairpin” types, which have different secondary structures, have been identified. A variety of ribozymes have been characterized. See, for example, U.S. Pat. Nos. 5,246,921, 5,225,347, 5,225,337 and 5,149,796. Mixed ribozymes comprising deoxyribo and ribooligonucleotides with catalytic activity have been described. Perreault, et al., Nature, 344: 565-567 (1990).

[0351] As used herein, “antisense” refers of nucleic acid molecules or their derivatives which specifically hybridize, e.g., bind, under cellular conditions, with the genomic DNA and/or cellular mRNA encoding a kinase polypeptide of the invention, so as to inhibit expression of that protein, for example, by inhibiting transcription and/or translation. The binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix.

[0352] In one aspect, the antisense construct is an nucleic acid which is generated ex vivo and that, when introduced into the cell, can inhibit gene expression by, without limitation, hybridizing with the mRNA and/or genomic sequences of a kinase polynucleotide of the invention.

[0353] Antisense approaches can involve the design of oligonucleotides (either DNA or RNA) that are complementary to kinase polypeptide mRNA and are based on the kinase polynucleotides of the invention, including SEQ ID NO: 1 through 66. The antisense oligonucleotides will bind to the kinase polypeptide mRNA transcripts and prevent translation.

[0354] Although absolute complementarity is preferred, it is not required. A sequence “complementary” to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

[0355] In general, oligonucleotides that are complementary to the 5′ end of the message, e.g., the 5′ untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3′ untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. (Wagner, R. (1994) Nature 372: 333). Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5′, 3′ or coding region of the kinase polypeptide mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably less than about 100 and more preferably less than about 50 or 30 nucleotides in length. Typically they should be between 10 and 25 nucleotides in length. Such principles will inform the practitioner in selecting the appropriate oligonucleotides In preferred embodiments, the antisense sequence is selected from an oligonucleotide sequence that comprises, consists of, or consists essentially of about 10-30, and more preferably 15-25, contiguous nucleotide bases of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through 66 or domains thereof.

[0356] In another preferred embodiment, the invention includes an isolated, enriched or purified nucleic acid molecule comprising, consisting of or consisting essentially of about 10-30, and more preferably 15-25 contiguous nucleotide bases of a nucleic acid sequence that encodes a polypeptide of SEQ ID NO: 67 through 132.

[0357] Using the sequences of the present invention, antisense oligonucleotides can be designed. Such antisense oligonucleotides would be administered to cells expressing the target kinase and the levels of the target RNA or protein with that of an internal control RNA or protein would be compared. Results obtained using the antisense oligonucleotide would also be compared with those obtained using a suitable control oligonucleotide. A preferred control oligonucleotide is an oligonucleotide of approximately the same length as the test oligonucleotide. Those antisense oligonucleotides resulting in a reduction in levels of target RNA or protein would be selected.

[0358] The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. USA 84: 648-652; PCT Publication No. WO 88/09810, published Dec. 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134, published Apr. 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al. (1988) BioTechniques 6: 958-976) or intercalating agents. (See, e.g, Zon (1988) Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

[0359] The antisense oligonucleotide may comprise at least one modified base moiety which is selected from moieties such as 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, and 5-(carboxyhydroxyethyl) uracil. The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

[0360] In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof. (see also U.S. Pat. Nos. 5,176,996; 5,264,564; and 5,256,775)

[0361] In yet a further embodiment, the antisense oligonucleotide is an α-anomeric oligonucleotide. An α-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gautier et al. (1987) Nucl. Acids Res. 15: 6625-6641). The oligonucleotide is a 2′-0-methylribonucleotide (Inoue et al. (1987) Nucl. Acids Res. 15: 6131-6148), or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215: 327-330).

[0362] Also suitable are peptidyl nucleic acids, which are polypeptides such as polyserine, polythreonine, etc. including copolymers containing various amino acids, which are substituted at side-chain positions with nucleic acids (T,A,G,C,U). Chains of such polymers are able to hybridize through complementary bases in the same manner as natural DNA/RNA. Alternatively, an antisense construct of the present invention can be delivered, for example, as an expression plasmid or vector that, when transcribed in the cell, produces RNA complementary to at least a unique portion of the cellular mRNA which encodes a kinase polypeptide of the invention.

[0363] While antisense nucleotides complementary to the kinase polypeptide coding region sequence can be used, those complementary to the transcribed untranslated region are most preferred.

[0364] In another preferred embodiment, a method of gene replacement is set forth. “Gene replacement” as used herein means supplying a nucleic acid sequence which is capable of being expressed in vivo in an animal and thereby providing or augmenting the function of an endogenous gene which is missing or defective in the animal.

PHARMACEUTICAL FORMULATIONS AND ROUTES OF ADMINISTRATION

[0365] The compounds described herein, including kinase polypeptides of the invention, antisense molecules, ribozymes, and any other compound that modulates the activity of a kinase polypeptide of the invention, can be administered to a human patient per se, or in pharmaceutical compositions where it is mixed with other active ingredients, as in combination therapy, or suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., latest edition.

[0366] Routes of Administration:

[0367] Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.

[0368] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a solid tumor, often in a depot or sustained release formulation.

[0369] Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

[0370] Composition/Formulation:

[0371] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[0372] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0373] For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0374] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Suitable carriers include excipients such as, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0375] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0376] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

[0377] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0378] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0379] The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[0380] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0381] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0382] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

[0383] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0384] A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD: D5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

[0385] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

[0386] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0387] Many of the tyrosine or serine/threonine kinase modulating compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms.

[0388] Suitable Dosage Regimens:

[0389] Pharmaceutical compositions suitable for use in the present invention include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0390] Methods of determining the dosages of compounds to be administered to a patient and modes of administering compounds to an organism are disclosed in U.S. application Ser. No. 08/702,282, filed Aug. 23, 1996 and International patent publication number WO 96/22976, published Aug. 1, 1996, both of which are incorporated herein by reference in their entirety, including any drawings, figures or tables. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

[0391] The proper dosage depends on various factors such as the type of disease being treated, the particular composition being used and the size and physiological condition of the patient. Therapeutically effective doses for the compounds described herein can be estimated initially from cell culture and animal models. For example, a dose can be formulated in animal models to achieve a circulating concentration range that initially takes into account the IC₅₀ as determined in cell culture assays. The animal model data can be used to more accurately determine useful doses in humans.

[0392] For any compound used in the methods of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC₅₀ as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the tyrosine or serine/threonine kinase activity). Such information can be used to more accurately determine useful doses in humans.

[0393] Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD₅₀ and ED₅₀. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al., 1975, in “The Pharmacological Basis of Therapeutics,” Ch. 1 p.1).

[0394] In another example, toxicity studies can be carried out by measuring the blood cell composition. For example, toxicity studies can be carried out in a suitable animal model as follows: 1) the compound is administered to mice (an untreated control mouse should also be used); 2) blood samples are periodically obtained via the tail vein from one mouse in each treatment group; and 3) the samples are analyzed for red and white blood cell counts, blood cell composition and the percent of lympho-cytes versus polymorphonuclear cells. A comparison of results for each dosing regime with the controls indicates if toxicity is present.

[0395] At the termination of each toxicity study, further studies can be carried out by sacrificing the animals (preferably, in accordance with the American Veterinary Medical Association guidelines Report of the American Veterinary Medical Assoc. Panel on Euthanasia: 229-249, 1993). Representative animals from each treatment group can then be examined by gross necropsy for immediate evidence of metastasis, unusual illness or toxicity. Gross abnormalities in tissue are noted and tissues are examined histologically. Compounds causing a reduction in body weight or blood components are less preferred, as are compounds having an adverse effect on major organs. In general, the greater the adverse effect the less preferred the compound.

[0396] For the treatment of cancers the expected daily dose of a hydrophobic pharmaceutical agent is between 1 to 500 mg/day, preferably 1 to 250 mg/day, and most preferably 1 to 50 mg/day. Drugs can be delivered less frequently provided plasma levels of the active moiety are sufficient to maintain therapeutic effectiveness.

[0397] Plasma levels should reflect the potency of the drug. Generally, the more potent the compound the lower the plasma levels necessary to achieve efficacy.

[0398] Plasma half-life and biodistribution of the drug and metabolites in the plasma, tumors and major organs can also be determined to facilitate the selection of drugs most appropriate to inhibit a disorder. Such measurements can be carried out. For example, HPLC analysis can be performed on the plasma of animals treated with the drug and the location of radiolabeled compounds can be determined using detection methods such as X-ray, CAT scan and MRI. Compounds that show potent inhibitory activity in the screening assays, but have poor pharmacokinetic characteristics, can be optimized by altering the chemical structure and retesting. In this regard, compounds displaying good pharmacokinetic characteristics can be used as a model.

[0399] Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data; e.g., the concentration necessary to achieve 50-90% inhibition of the kinase using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

[0400] Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.

[0401] In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

[0402] The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

[0403] Packaging:

[0404] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the polynucleotide for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a tumor, inhibition of angiogenesis, treatment of fibrosis, diabetes, and the like.

FUNCTIONAL DERIVATIVES

[0405] Also provided herein are functional derivatives of a polypeptide or nucleic acid of the invention. By “functional derivative” is meant a “chemical derivative,” “fragment,” or “variant,” of the polypeptide or nucleic acid of the invention, which terms are defined below. A functional derivative retains at least a portion of the function of the protein, for example reactivity with an antibody specific for the protein, enzymatic activity or binding activity mediated through noncatalytic domains, which permits its utility in accordance with the present invention. It is well known in the art that due to the degeneracy of the genetic code numerous different nucleic acid sequences can code for the same amino acid sequence. Equally, it is also well known in the art that conservative changes in amino acid can be made to arrive at a protein or polypeptide that retains the functionality of the original. In both cases, all permutations are intended to be covered by this disclosure.

[0406] Included within the scope of this invention are the functional equivalents of the herein-described isolated nucleic acid molecules. The degeneracy of the genetic code permits substitution of certain codons by other codons that specify the same amino acid and hence would give rise to the same protein. The nucleic acid sequence can vary substantially since, with the exception of methionine and tryptophan, the known amino acids can be coded for by more than one codon. Thus, portions or all of the genes of the invention could be synthesized to give a nucleic acid sequence significantly different from one selected from the group consisting of those set forth in SEQ ID NO: 1 through SEQ ID NO: 66. The encoded amino acid sequence thereof would, however, be preserved.

[0407] In addition, the nucleic acid sequence may comprise a nucleotide sequence which results from the addition, deletion or substitution of at least one nucleotide to the 5′-end and/or the 3′-end of the nucleic acid formula selected from the group consisting of those set forth in SEQ ID NO: 1 through SEQ ID NO: 66, or a derivative thereof. Any nucleotide or polynucleotide may be used in this regard, provided that its addition, deletion or substitution does not alter the amino acid sequence of selected from the group consisting of those set forth in SEQ ID NO: 1 through 66, which is encoded by the nucleotide sequence. For example, the present invention is intended to include any nucleic acid sequence resulting from the addition of ATG as an initiation codon at the 5′-end of the inventive nucleic acid sequence or its derivative, or from the addition of TTA, TAG or TGA as a termination codon at the 3′-end of the inventive nucleotide sequence or its derivative. Moreover, the nucleic acid molecule of the present invention may, as necessary, have restriction endonuclease recognition sites added to its 5′-end and/or 3′-end.

[0408] Such functional alterations of a given nucleic acid sequence afford an opportunity to promote secretion and/or processing of heterologous proteins encoded by foreign nucleic acid sequences fused thereto. All variations of the nucleotide sequence of the kinase genes of the invention and fragments thereof permitted by the genetic code are, therefore, included in this invention.

[0409] Further, it is possible to delete codons or to substitute one or more codons with codons other than degenerate codons to produce a structurally modified polypeptide, but one which has substantially the same utility or activity as the polypeptide produced by the unmodified nucleic acid molecule. As recognized in the art, the two polypeptides are functionally equivalent, as are the two nucleic acid molecules that give rise to their production, even though the differences between the nucleic acid molecules are not related to the degeneracy of the genetic code.

[0410] A “chemical derivative” of the complex contains additional chemical moieties not normally a part of the protein. Covalent modifications of the protein or peptides are included within the scope of this invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues, as described below.

[0411] Cysteinyl residues most comnnonly are reacted with alpha-haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

[0412] Histidyl residues are derivatized by reaction with diethylprocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain. Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0.

[0413] Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect or reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing primary amine containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.

[0414] Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pK_(a) of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine alpha-amino group.

[0415] Tyrosyl residues are well-known targets of modification for introduction of spectral labels by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizol and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.

[0416] Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimide (R′—N—C—N—R′) such as 1-cyclohexyl-3-(2-morpholinyl(4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

[0417] Glutaminyl and asparaginyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

[0418] Derivatization with bifunctional agents is useful, for example, for cross-linking the component peptides of the protein to each other or to other proteins in a complex to a water-insoluble support matrix or to other macromolecular carriers. Commonly used cross-linking agents include, for example, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3′-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[p-azidophenyl) dithiolpropioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

[0419] Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains (Creighton, T. E., Proteins: Structure and Molecular Properties, W. H. Freeman & Co., San Francisco, pp. 79-86 (1983)), acetylation of the N-terminal amine, and, in some instances, amidation of the C-terminal carboxyl groups.

[0420] Such derivatized moieties may improve the stability, solubility, absorption, biological half life, and the like. The moieties may alternatively eliminate or attenuate any undesirable side effect of the protein complex and the like. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, Pa. (1990).

[0421] The term “fragment” is used to indicate a polypeptide derived from the amino acid sequence of the proteins, of the complexes having a length less than the full-length polypeptide from which it has been derived. Such a fragment may, for example, be produced by proteolytic cleavage of the full-length protein. Preferably, the fragment is obtained recombinantly by appropriately modifying the DNA sequence encoding the proteins to delete one or more amino acids at one or more sites of the C-terminus, N-terminus, and/or within the native sequence. Fragments of a protein are useful for screening for substances that act to modulate signal transduction, as described herein. It is understood that such fragments may retain one or more characterizing portions of the native complex. Examples of such retained characteristics include: catalytic activity; substrate specificity; interaction with other molecules in the intact cell; regulatory functions; or binding with an antibody specific for the native complex, or an epitope thereof.

[0422] Another functional derivative intended to be within the scope of the present invention is a “variant” polypeptide which either lacks one or more amino acids or contains additional or substituted amino acids relative to the native polypeptide. The variant may be derived from a naturally occurring complex component by appropriately modifying the protein DNA coding sequence to add, remove, and/or to modify codons for one or more amino acids at one or more sites of the C-terminus, N-terminus, and/or within the native sequence. It is understood that such variants having added, substituted and/or additional amino acids retain one or more characterizing portions of the native protein, as described above.

[0423] A functional derivative of a protein with deleted, inserted and/or substituted amino acid residues may be prepared using standard techniques well-known to those of ordinary skill in the art. For example, the modified components of the functional derivatives may be produced using site-directed mutagenesis techniques (as exemplified by Adelman et al., 1983, DNA 2: 183) wherein nucleotides in the DNA coding the sequence are modified such that a modified coding sequence is modified, and thereafter expressing this recombinant DNA in a prokaryotic or eukaryotic host cell, using techniques such as those described above. Alternatively, proteins with amino acid deletions, insertions and/or substitutions may be conveniently prepared by direct chemical synthesis, using methods well-known in the art. The functional derivatives of the proteins typically exhibit the same qualitative biological activity as the native proteins.

TABLES AND DESCRIPTION THEREOF

[0424] This patent application describes 66 protein kinase polypeptides identified in genomic and cDNA sequence databases. The results are summarized in six tables, described below. The Tables appear beginning at page 233.

[0425] Table 1 documents the name of each gene, the nucleic acid and amino acid sequence identification numbers, the species (human or mouse), the classifications of each gene (superfamily, family and group), the lengths of the nucleic acid and protein sequences, the positions and lengths of the open reading frames within the sequence, and whether Sugen has cloned a full length version of the gene. From left to right the data presented is as follows: Gene name, Species, ID#na, SEQ ID NO: , Super-family, Group, Family, NA_length, AA_length, ORF Start, ORF End, ORF Length, Physical Status (FL indicates a full-length cDNA version of the gene has been obtained). “Gene name” refers to name given the sequence encoding the kinase or kinase-like enzyme. The “ID#na” and “ID#aa” refer to the SEQ ID NOS given each nucleic acid and amino acid sequence in this patent. “Superfamily” identifies whether the gene is a protein kinase or protein-kinase-like. “Group” and “Family” refer to the protein kinase classification defined by sequence homology and based on previously established phylogenetic analysis [Hardie, G. and Hanks S. The Protein Kinase Book, Academic Press (1995) and Hunter T. and Plowman, G. Trends in Biochemical Sciences (1977) 22: 18-22 and Plowman G. D. et al. (1999) Proc. Natl. Acad. Sci. 96: 13603-13610)]. “NA_length” refers to the length in nucleotides of the corresponding nucleic acid sequence. “AA length” refers to the length in amino acids of the peptide encoded in the corresponding nuclei acid sequence. “ORF start” refers to the beginning nucleotide of the open reading frame. “ORF end” refers to the last nucleotide of the open reading frame, excluding the stop codon. “ORF length” refers to the length in nucleotides of the open reading frame (including the stop codon). In the “Physical Status” column, “FL” indicates a full-length cDNA version of the gene has been obtained.

[0426] Table 2 describes the results of Smith Waterman similarity searches (Matrix: Pam 100; gap open/extension penalties 12/2) of the amino acid sequences against the, NCBI database of non-redundant protein sequences (http: //www.ncbi.nlm.nih.gov/Entrez/protein.html). It is broken into two sections, Tables 2a and 2b. For Table 2a: from left to right the data presented is as follows: Gene_NAME, Species, ID#na, ID#aa, Super-family, Group, Family, AA length, PSCORE, MATCHES, % Identity, % Similarity, ACCESSION, and DESCRIPTION. The first columns (Gene₁₃ NAME, Species, ID#na, ID#aa, Super-family, Group, Family, AA length) are the same as in Table 1. “PSCORE” refers to the Smith Waterman probability score. This number approximates the chance that the alignment occurred by chance. Thus, a very low number, such as 2.10E-64, indicates that there is a very significant match between the query and the database target. “Matches” indicates the number of amino acids that were identical in the alignment. “% Identity” lists the percent of amino acids that were identical over the alignment. “% Similarity” lists the percent of amino acids that were similar over the alignment. ACCESSION refers to the accession number of the most similar protein in the NCBI database of non-redundant proteins. “Description” contains the name and species of origin of the most similar protein in the NCBI database of non-redundant proteins. Table 2b continues the tabulation of the Smith Waterman results. The headings are: Gene_NAME, Species, ID#na, ID#aa, Super-family, Group, Family, QUERYSTART, QUERYEND, TARGETSTART, TARGETEND, % QUERY, % TARGET. The “QUERY” is the patent sequence, and the “TARGET” is the best hit within the NCBI protein database. “QUERYSTART” refers to the amino acid number at which the Query (the patent protein sequence) begins to align with the TARGET (database) sequence. “QUERYEND” refers to the amino acid position within the patent protein sequence (the QUERY) at which the alignment with the database protein (the TARGET) ends. “TARGETSTART” refers to the amino acid position of the database protein (the TARGET) at which the alignment with the patent sequence (the QUERY) begins. “TARGETEND” refers to the amino acid position within the database sequence (the TARGET) at which alignment with the QUERY ends. % QUERY gives the percent of the patent amino acid sequence which is aligned with the database hit (the TARGET). % TARGET gives the percent of the database hit which aligns with the patent sequence.

[0427] Table 3 lists the results of searching the database of single nucleotide polymorphisms (dbSNP) with the patent nucleic acid sequences. The column headings are: Gene, ID#na, ID#aa, Nucleotide #, Polymorphism, Nucleotide in patent sequence, AA Residue #, Silent/Residue Change, AA Residue in Patent, Accession#. “Nucleotide #” refers the to the position within the nucleic acid sequence at which the SNP occurs; “Polymorphism” describes the sequence change at the site of the SNP, for example, a change from C to T; “Nucleotide in patent sequence” lists the nucleotide (A,C,G,T) present in the patent sequence; “AA Residue #” refers to the position within the patent protein of the amino acid affected by the SNP (regions outside the coding sequence are referred to as untranslated regions, or UTRs); “Silent/Residue Change” lists the nature of the change in the protein sequence as a consequence of the SNP: silent (for example “no change,” E/A (a glutamic acid in one form is replace by an alanine in the other form), R/stop (a codon for arginine has been altered to a stop codon); “AA Residue in Patent” lists which of the alternative amino acids is present in the patent protein sequence; “Accession#” lists the dbSNP accession number (http: //www.ncbi.nlm.nih.gov/SNP/index.html).

[0428] Table 4 describes the extent and the boundaries of the kinase catalytic domains, and other protein domains. These domains were identified using PFAM (http: //Dfam.wustl.edu/hmmsearch.shtml) models, a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Version Pfam 7.3 (May 2002) contains alignments and models for 3849 protein families. The PFAM alignments were downloaded from http: //pfam.wustl.edu/hmmsearch.shtml and the HMMr searches were run locally on a Timelogic computer (TimeLogic Corporation, Incline Village, Nev.). The column headings are: “Gene,” “ID#na,” “ID#aa,” “Profile Description,” “Profile Accession,” “Pscore,” “Domain Start,” “Domain End,” “Profile Start,” “Profile End,” “Profile Length,” and “Query Length.” The “Profile Description” column contains the name of the protein domain; “Profile Accession” refers to the PFAM accession number for the domain; “Pscore” lists the probability score, or E-value, and is the number of hits that would be expected to have a score equal or better by chance alone. A good E-value is much less than 1. Around 1 is what is expected just by chance; “Domain Start” lists the amino acid number within the protein sequence at which the domain begins; “Domain End” lists the amino acid number within the protein sequence at which the domain ends; “Profile Start” refers to the position within the profile at which it begins alignment with the patent sequence; “Profile End” lists the position within the profile at which it the alignment with the patent sequence ends; “Profile Length” lists the length in amino acid residues of the PFAM profile; and “Query Length” lists the amino acid length of the patent protein.

[0429] Table 5 lists the chromosomal position of the patent genes. The cytogenetic localization of the kinase genes allows one to compare their map position with databases of “disease loci,” such as the “Online Mendelian Inheritance in Man” (http: //www.ncbi.nlm.nih.gov/Omim/searchomim.html). This database is a catalog of human genes and genetic disorders maintained at the National Center for Biotechnology Information. The database contains textual information, pictures, and reference information. The column headings for table 5 are: “Gene_Name,” “Species,” “ID#na,” “ID#aa,” “Cytogenetic position,” “Cancer Amplicon,” and “Disease Loci.” “Cytogenetic position” lists the cytogenetic band to which the gene has been mapped, “Cancer Amplicon” annotates the observation that the kinase maps to a known cancer amplicon; and “Disease Loci” annotates the observation that the kinase maps to a region implicated in human disease and documented in OMIM.

[0430] Table 6 lists human ESTs representing the patent genes. The column headings are: “RANK” (number of ESTs per gene, 1-10 for most; SGK110 and SGK069 were not represented in dbEST database); “Gene” (Gene name and ID numbers); “Human EST” (derived from BLASTN search of http: //www.ncbi.nlm.nih.gov/dbEST/index.html).

EXAMPLES

[0431] The examples below are not limiting and are merely representative of various aspects and features of the present invention. The examples below demonstrate the isolation and characterization of the nucleic acid molecules according to the invention, as well as the polypeptides they encode.

Example 1 Identification and Characterization of Genomic Fragments Encoding Protein Kinases

[0432] Novel kinases were identified from the Celera human genomic sequence databases, and from the public Human Genome Sequencing project (http: //www.ncbi.nlm.nih.gov/) using a hidden Markov model (HMMR) built with 70 mammalian and yeast kinase catalytic domain sequences. These sequences were chosen from a comprehensive collection of kinases such that no two sequences had more than 50% sequence identity. The genomic database entries were translated in six open reading frames and searched against the model using a Timelogic Decypher box with a Field programmable array (FPGA) accelerated version of HMMR2.1. The DNA sequences encoding the predicted protein sequences aligning to the HMMR profile were extracted from the original genomic database. The nucleic acid sequences were then clustered using the Pangea Clustering tool to eliminated repetitive entries. The putative protein kinase sequences were then sequentially run through a series of queries and filters to identify novel protein kinase sequences. Specifically, the HMMR identified sequences were searched using BLASTN and BLASTX against a nucleotide and amino acid repository containing 634 known human protein kinases and all subsequent new protein kinase sequences as they are identified. The output was parsed into a spreadsheet to facilitate elimination of known genes by manual inspection. Two models were developed, a “complete” model and a “partial” or Smith Waterman model. The partial model was used to identify sub-catalytic kinase domains, whereas the complete model was used to identify complete catalytic domains. The selected hits were then queried using BLASTN against the public nrna and EST databases to confirm they are indeed unique. In some cases the novel genes were judged to be homologues of previously identified rodent or vertebrate protein kinases.

[0433] Extension of partial DNA sequences to encompass the full-length open-reading frame was carried out by several methods. Iterative blastn searching of the cDNA databases listed in Table 9 was used to find cDNAs that extended the genomic sequences. “LifeSeqGold” databases are from Incyte Genomics, Inc (http: //www.incyte.com/). NCBI databases are from the National Center for Biotechnology Information (http: //www.ncbi.nlm.nih.gov/). All blastn searches were conducted using a penalty for a nucleotide mismatch of-3 and reward for a nucleotide match of 1. The gapped blast algorithm is described in: Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res. 25: 3389-3402).

[0434] Extension of partial DNA sequences to encompass the full-length open-reading frame was also carried out by iterative searches of genomic databases. The first method made use of the Smith-Waterman algorithm to carry out protein-protein searches of a close protein homologue to the partial. The target databases consisted of Genscan and open-reading frame (ORF) predictions of all human genomic sequence derived from the human genome project (HGP) as well as from Celera. The complete set of genomic databases searched is shown in Table 7, below. Genomic sequences encoding potential extensions were further assessed by blastx analysis against the NCBI nonredundant database to confirm the novelty of the hit. The extending genomic sequences were incorporated into the cDNA sequence after removal of potential introns using the Seqman program from DNAStar. The default parameters used for Smith-Waterman searches were as shown next. Matrix: blosum 62; gap-opening penalty: 12; gap extension penalty: 2. Genscan predictions were made using the Genscan program as detailed in Chris Burge and Sam Karlin “Prediction of Complete Gene Structures in Human Genomic DNA,” JMB (1997) 268(1): 78-94). ORF predictions from genomic DNA were made using a standard 6-frame translation.

[0435] Another method for defining DNA extensions from genomic sequence used iterative searches of genomic databases through the Genscan program to predict exon splicing. These predicted genes were then assessed to see if they represented “real” extensions of the partial genes based on homology to related kinases.

[0436] Another method involved using the Genewise program (http: //www.sanger.ac.uk/Software/Wise2/) to predict potential ORFs based on homology to the closest orthologue/homologue. Genewise requires two inputs, the homologous protein, and genomic DNA containing the gene of interest. The genomic DNA was identified by blastn searches of Celera and Human Genome Project databases. The orthologs were identified by blastp searches of the NCBI non-redundant protein database (NRAA). Genewise compares the protein sequence to a genomic DNA sequence, allowing for introns and frameshifting errors. TABLE 7 Databases used for cDNA-based sequence extensions Database Database Date LifeGold templates March 2002 LifeGold compseqs March 2002 LifeGold fl March 2002 LifeGold flft March 2002 NCBI human Ests March 2001 NCBI murine Ests March 2002 NCBI nonredundant March 2002

[0437] TABLE 8 Databases used for genomic-based sequence extensions Number of Database Database entries Date Celera Assembly 6 479,986 March 2002 HGP Chromosomal assemblies 2759 March 2002

[0438] Results:

[0439] For genes that were extended using Genewise, the accession numbers of the protein ortholog and the genomic DNA are given. (Genewise uses the ortholog to assemble the coding sequence of the target gene from the genomic sequence). The amino acid sequences for the orthologs were obtained from the NCBI non-redundant database of proteins.(http: //www.ncbi.nlm.nih.gov/Entrez/protein.html). The genomic DNA came from two sources: Celera andHGP (human genome project), as indicated below. cDNA sources are also listed below. All of the genomic sequences were used as input for Genscan predictions to predict splice sites [Burge and Karlin, JMB (1997) 268(1): 78-94)]. Abbreviations: HGP: Human Genome Project; NCBI, National Center for Biotechnology Information.

[0440] The results are detailed in the paragraphs below for each gene.

[0441] Results—Nucleic Acid Sequences

[0442] CRIK, SEQ ID NO: 1, SEQ ID NO: 67, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the DMPK family. The nucleic acid sequence is 8656 nucleotides long, and codes for a protein that is 2055 amino acids long. The open reading frame starts at nucleotide number 51 and ends at nucleotide number 6218. The length of the ORF is 6168 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 12q24.3 1. The CRIK sequence maps to Celera contig 181000000794572. A mouse homolog (Rho/rac interacting citron kinase gi|3599509) of CRIK is 353 AAs longer at the N terminus than the public CRIK. Rho/rac interacting citron kinase from mouse (gi|3599509) was used as a model for a genewise prediction. Incyte template, 233643.1, and Incyte CB1 sequence, 7484498CB1, were used to extend the C-terminus of the genewise prediction. Two additional public ESTs (gi|4534019 and gi|3753446) support a different 3′ end. These two public ESTs (gi|4534019 and gi|3753446) have an earlier poly A site, just after ATTCTTAATAGATTTGAATAGCGACGTA (just following the run of T's), this generates an alternative 3′ end in that form.

[0443] DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the DMPK family. The nucleic acid sequence is 5438 nucleotides long, and codes for a protein that is 1572 amino acids long. The open reading frame starts at nucleotide number 66 and ends at nucleotide number 4784. The length of the ORF is 4719 nucleotides. The gene has been mapped to chromosomal region 11q12-q13.1. This region has been identified as a cancer amplicon (Knuutila, et al). This region has been associated with susceptibility to osteoarthritis (OMIM 165720). DMPK2 maps to Celera assembly 5 contig 92000004065166. A genewise prediction was run with this contig and myotonic dystrophy associated protein kinase from rat (gi|7446379) as the model. The rat sequence is 118 AA longer at the N-term and 1200 AA longer at the C-term.

[0444] MAST3, SEQ ID NO: 3, SEQ ID NO: 69, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the MAST family. The nucleic acid sequence is 5990 nucleotides long, and codes for a protein that is 1332 amino acids long. The open reading frame starts at nucleotide number 36 and ends at nucleotide number 4031. The length of the ORF is 3996 nucleotides. The gene has been mapped to chromosomal region 19p13.1.

[0445] The current MAST3 sequence adds a novel N-terminus of 46 AA to sequences previously published. This region is predicted to be of functional importance due to the high level of similarity seen in an orthologous mouse EST (gi|6631994).

[0446] MAST205, SEQ ID NO: 4, SEQ ID NO: 70, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the MAST family. The nucleic acid sequence is 5516 nucleotides long, and codes for a protein that is 1798 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 5397. The length of the ORF is 5397 nucleotides. The gene has been mapped to chromosomal region 1p34.1. The public MAST205 sequence is partial at the N and C-terminus. The MAST205 sequence maps to Celera assembly 5 contig 92000004111345. The mouse homolog microtubule-associated testis specific S/T protein kinase (gi|6678958) was used as a model for a genewise prediction.

[0447] MASTL, SEQ ID NO: 5, SEQ ID NO: 71, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the MAST family. The nucleic acid sequence is 3882 nucleotides long, and codes for a protein that is 878 amino acids long. The open reading frame starts at nucleotide number 967 and ends at nucleotide number 3603. The length of the ORF is 2637 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 10p11.2-p12.1. This region has been associated with susceptibility to schizophrenia (OMIM 181500).

[0448] PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the PKC family. The nucleic acid sequence is 2392 nucleotides long, and codes for a protein that is 683 amino acids long. The open reading frame starts at nucleotide number 407 and ends at nucleotide number 2458. The length of the ORF is 2052 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 14q23.1.

[0449] H19102, SEQ ID NO: 7, SEQ ID NO: 73, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the RSK family. The nucleic acid sequence is 1564 nucleotides long, and codes for a protein that is 449 amino acids long. The open reading frame starts at nucleotide number 188 and ends at nucleotide number 1537. The length of the ORF is 1350 nucleotides. The gene has been mapped to chromosomal region 17q11.1. This region has been identified as a cancer amplicon (Knuutila, et al).

[0450] Genewise predictions with the nearest homologs (bicoid-interacting protein in fly and a C. elegans predicted protein) as models yielded some downstream sequence, extending the kinase domain.

[0451] MSK1, SEQ ID NO: 8, SEQ ID NO: 74, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the RSK family. The nucleic acid sequence is 3813 nucleotides long, and codes for a protein that is 802 amino acids long. The open reading frame starts at nucleotide number 159 and ends at nucleotide number 2567. The length of the ORF is 2409 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 14q32.11.

[0452] YANK3, SEQ ID NO: 9, SEQ ID NO: 75, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the YANK family. The nucleic acid sequence is 2051 nucleotides long, and codes for a protein that is 486 amino acids long. The open reading frame starts at nucleotide number 70 and ends at nucleotide number 1530. The length of the ORF is 1461 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 10q26.3.

[0453] MARK2, SEQ ID NO: 10, SEQ ID NO: 76, is a member of the Protein Kinase superfamily. It is further classified into the CAMK group, and the CAMKL family. The nucleic acid sequence is 3063 nucleotides long, and codes for a protein that is 787 amino acids long. The open reading frame starts at nucleotide number 399 and ends at nucleotide number 2762. The length of the ORF is 2364 nucleotides. The gene has been mapped to chromosomal region 11q12-11q13. This region has been identified as a cancer amplicon (Knuutila, et al). This region has been associated with susceptibility to osteoarthritis (OMIM 165720).

[0454] The current sequence extends the N-terminus of published sequences by 33 AA. The mouse ortholog (gi|6679643) is identical in these 33 AA, which implies that this terminal region is important for full biological function of the protein and has been highly conserved to preserve that function.

[0455] NuaK2, SEQ ID NO: 11, SEQ ID NO: 77, is a member of the Protein Kinase superfamily. It is further classified into the CAMK group, and the CAMKL family. The nucleic acid sequence is 3463 nucleotides long, and codes for a protein that is 672 amino acids long. The open reading frame starts at nucleotide number 57 and ends at nucleotide number 2075. The length of the ORF is 2019 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 1q31-q32.1.

[0456] BRSK2, SEQ ID NO: 12, SEQ ID NO: 78, is a member of the Protein Kinase superfamily. It is further classified into the CAMK group, and the CAMKL family. The nucleic acid sequence is 3831 nucleotides long, and codes for a protein that is 674 amino acids long. The open reading frame starts at nucleotide number 25 and ends at nucleotide number 2049. The length of the ORF is 2025 nucleotides. The gene has been mapped to chromosomal region 11p15.5.

[0457] MARK4, SEQ ID NO: 13, SEQ ID NO: 79, is a member of the Protein Kinase superfamily. It is further classified into the CAMK group, and the CAMKL family. The nucleic acid sequence is 3249 nucleotides long, and codes for a protein that is 752 amino acids long. The open reading frame starts at nucleotide number 17 and ends at nucleotide number 2275. The length of the ORF is 2259 nucleotides. The gene has been mapped to chromosomal region 19q13.2-q13.33. This region has been identified as a cancer amplicon (Knuutila, et al).

[0458] DCAMKL2, SEQ ID NO: 14, SEQ ID NO: 80, is a member of the Protein Kinase superfamily. It is further classified into the CAMK group, and the DCAMKL family. The nucleic acid sequence is 2827 nucleotides long, and codes for a protein that is 766 amino acids long. The open reading frame starts at nucleotide number 350 and ends at nucleotide number 2650. The length of the ORF is 2301 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 4q31.3.

[0459] PIM2, SEQ ID NO: 15, SEQ ID NO: 81, is a member of the Protein Kinase superfamily. It is further classified into the CAMK group, and the PIM family. The nucleic acid sequence is 2186 nucleotides long, and codes for a protein that is 435 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 1305. The length of the ORF is 1305 nucleotides. The gene has been mapped to chromosomal region Xp11.23. This region has been identified as a cancer amplicon (Knuutila, et al).

[0460] Based on other family members, and rodent orthologs it has been determined that the PIM2 protein starts with an atypical CTG initiation codon, making the first AA an L rather than an M.

[0461] PIM:3, SEQ ID NO: 16, SEQ ID NO: 82, is a member of the Protein Kinase superfamily. It is further classified into the CAMK group, and the PIM family. The nucleic acid sequence is 2405 nucleotides long, and codes for a protein that is 326 amino acids long. The open reading frame starts at nucleotide number 436 and ends at nucleotide number 1416. The length of the ORF is 981 nucleotides. Sugen has cloned the full length cDNA for this gene. The gene has been mapped to chromosomal region 22q13.

[0462] TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, is a member of the Protein Kinase superfamily. It is further classified into the CAMK group, and the TSSK family. The nucleic acid sequence is 1710 nucleotides long, and codes for a protein that is 328 amino acids long. The open reading frame starts at nucleotide number 617 and ends at nucleotide number 1603. The length of the ORF is 987 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 14q11.1.

[0463] The ORF was also extended by documenting an alternative splice variant (7693857.2) which shortened the 5′ end of exon 4 by 72 nucleotides(splicing out an inframe stop codon): >72 alternatively spliced nucleotides GTCCAACTGCTCATTGCCTGTGTGGCACAATGGAGAAAAACTCAGGCAAG ACCTCTCTCTCCCCTGCTCTAG. Canonical splice sites are maintained with both splice variants. The sequence now shares tight similarity to a mouse cDNA from RIKEN (gi|12855865) over its full length.

[0464] CKIL2, SEQ ID NO: 18, SEQ ID NO: 84, is a member of the Protein Kinase superfamily. It is further classified into the CKI group, and the CKIL family. The nucleic acid sequence is 5946 nucleotides long, and codes for a protein that is 1244 amino acids long. The open reading frame starts at nucleotide number 368 and ends at nucleotide number 4102. The length of the ORF is 3735 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 15q14-q15.3. This region has been associated with susceptibility to schizophrenia (OMIM 181500).\

[0465] PCTAIRE3, SEQ ID NO: 19, SEQ ID NO: 85, is a member of the Protein Kinase superfamily. It is further classified into the CMGC group, and the CDK family. The nucleic acid sequence is 3229 nucleotides long, and codes for a protein that is 505 amino acids long. The open reading frame starts at nucleotide number 303 and ends at nucleotide number 1817. The length of the ORF is 1515 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 1q32.

[0466] PFTAIRE2, SEQ ID NO: 20, SEQ ID NO: 86, is a member of the Protein Kinase superfamily. It is further classified into the CMGC group, and the CDK family. The nucleic acid sequence is 2250 nucleotides long, and codes for a protein that is 435 amino acids long. The open reading frame starts at nucleotide number 45 and ends at nucleotide number 1352. The length of the ORF is 1308 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 2q33.2-q34. This region has been identified as a cancer amplicon (Knuutila, et al). This region has been associated with susceptibility to osteoarthritis (OMIM 140600).

[0467] ERK7, SEQ ID NO: 21, SEQ ID NO: 87, is a member of the Protein Kinase superfamily. It is further classified into the CMGC group, and the MAPK family. The nucleic acid sequence is 1906 nucleotides long, and codes for a protein that is 563 amino acids long. The open reading frame starts at nucleotide number 19 and ends at nucleotide number 1710. The length of the ORF is 1692 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 8q24.3. A genewise prediction was run with a rat homolog, extracellular signal-regulated kinase 7 (gi|4220888), as the model. Two splice variants were noted for ERK7: >Nucleotides 967-1098 are alternatively spliced GCACTGCAGCACCCCTACGTGCAGAGGTTCCACTGCCCCAGCGACGAGTG GGCACGAGAGGCAGATGTGCGGCCCCGGGCACACGAAGGGGTCCAGCTC TCTGTGCCTGAGTACCGCAGCCGCGTCTATCAG. >Nucleotides 184-240 are alternatively spliced GACATGGGCTTCCTTCTTGCTCCACCCACCCACACACCTGTGTTTCTGTCTC TTCAG.

[0468] CKIIa-rs, SEQ ID NO: 22, SEQ ID NO: 88, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the CKII family. The nucleic acid sequence is 1494 nucleotides long, and codes for a protein that is 391 amino acids long. The open reading frame starts at nucleotide number 150 and ends at nucleotide number 1325. The length of the ORF is 1176 nucleotides. The gene has been mapped to chromosomal region 11p15.

[0469] DYRK4, SEQ ID NO: 23, SEQ ID NO: 89, is a member of the Protein Kinase superfamily. It is further classified into the CMCG group, and the DYRK family. The nucleic acid sequence is 2886 nucleotides long, and codes for a protein that is 921 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 2766. The length of the ORF is 2766 nucleotides. The full length cDNA for this gene was cloned. The gene has been mapped to chromosomal region 12p13. This region has been associated with susceptibility to essential hypertension (OMIM 145500).

[0470] HIPK1, SEQ ID NO: 24, SEQ ID NO: 90, is a member of the Protein Kinase superfamily. It is further classified into the CMGC group, and the DYRK family. The nucleic acid sequence is 8212 nucleotides long, and codes for a protein that is 1210 amino acids long. The open reading frame starts at nucleotide number 286 and ends at nucleotide number 3918. The length of the ORF is 3633 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 1p11-p12. Contigs from Celera and HGP with homeoedomain interacting protein kinase 1 from mouse were used for genewise predictions.

[0471] HIPK4, SEQ ID NO: 25, SEQ ID NO: 91, is a member of the Protein Kinase superfamily. It is further classified into the CMGC group, and the DYRK family. The nucleic acid sequence is 3142 nucleotides long, and codes for a protein that is 616 amino acids long. The open reading frame starts at nucleotide number 977 and ends at nucleotide number 2827. The length of the ORF is 1851 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 19q13.1. This region has been identified as a cancer amplicon (Knuutila, et al).

[0472] BIKE, SEQ ID NO: 26, SEQ ID NO: 92, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NAK family. The nucleic acid sequence is 3895 nucleotides long, and codes for a protein that is 1161 amino acids long. The open reading frame starts at nucleotide number 203 and ends at nucleotide number 3688. The length of the ORF is 3486 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 4q13-q21.21. This region has been associated with susceptibility to osteoarthritis (OMIM 140600).

[0473] The BIKE sequence is full length, and 89% identical to murine BIKE across the full length of the protein.

[0474] NEK10, SEQ ID NO: 27, SEQ ID NO: 93, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NEK family. The nucleic acid sequence is 3912 nucleotides long, and codes for a protein that is 1125 amino acids long. The open reading frame starts at nucleotide number 176 and ends at nucleotide number 3553. The length of the ORF is 3378 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 3p21.33.

[0475] pNEK5, SEQ ID NO: 28, SEQ ID NO: 94, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NEK family. The nucleic acid sequence is 2816 nucleotides long, and codes for a protein that is 889 amino acids long. The open reading frame starts at nucleotide number 147 and ends at nucleotide number 2816. The length of the ORF is 2670 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 13q14. This region has been identified as a cancer amplicon (Knuutila, et al).

[0476] The current sequence is an extension of our previously filed patent application sequence (gi|14546899, Sequence 45 from Patent WO0138503), incorporated herein by reference, which adds a 57 AA extension to the N terminus, a 127 AA extension to the C-terminus and is alternatively spliced at two regions in the middle of the gene.

[0477] NEK1, SEQ ID NO: 29, SEQ ID NO: 95, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NEK family. The nucleic acid sequence is 5583 nucleotides long, and codes for a protein that is 1286 amino acids long. The open reading frame starts at nucleotide number 493 and ends at nucleotide number 4353. The length of the ORF is 3861 nucleotides. The gene has been mapped to chromosomal region 4q33-q34.

[0478] The revised sequence now contains a complete kinase domain and overlaps completely with the mouse ortholog of Nek1 (gi|1709251). Three alternative splice variants were noted: >Nucleotides 243-320 (canonical splice sites maintained) gtgtggagagtctcagtgccccctttcagtctggactgtgagctgctgctggttagacagtcttggtttctctttcag. >Nucleotides 1923-2054 (canonical splice sites maintained) AGGAATTCTGCCTGGAGTTCGTCCAGGATTTCCTTATGGGGCTGCAGGTCA TCACCATTTTCCTGATGCTGATGATATTAGAAAAACTTTGAAAAGATTGAA GGCGGTGTCTAAACAAGCCAATGCAAACAG. >Nucleotides 2158-2241 (canonical splice sites maintained). GGAATCCTGCAAAACCTGGCAGCTATGTATGGAGGCAGGCCCAGCTCTTC AAGAGGAGGGAAGCCAAGAAACAAAGAGGAAGAG.

[0479] NEK3, SEQ ID NO: 30, SEQ ID NO: 96, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NEK family. The nucleic acid sequence is 2326 nucleotides long, and codes for a protein that is 506 amino acids long. The open reading frame starts at nucleotide number 296 and ends at nucleotide number 1816. The length of the ORF is 1521 nucleotides. The gene has been mapped to chromosomal region 13q14.3. This region has been identified as a cancer amplicon (Knuutila, et al).

[0480] SGK069, SEQ ID NO: 31, SEQ ID NO: 97, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NKF1 family. The nucleic acid sequence is 1156 nucleotides long, and codes for a protein that is 348 amino acids long. The open reading frame starts at nucleotide number 110 and ends at nucleotide number 1156. The length of the ORF is 1047 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 19q13.43.

[0481] SGK110, SEQ ID NO: 32, SEQ ID NO: 98, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NKF1 family. The nucleic acid sequence is 1853 nucleotides long, and codes for a protein that is 414 amino acids long. The open reading frame starts at nucleotide number 299 and ends at nucleotide number 1543. The length of the ORF is 1245 nucleotides. Sugen has cloned the full length cDNA for this gene. The gene has been mapped to chromosomal region 19q13.43.

[0482] NRBP2, SEQ ID NO: 33, SEQ ID NO: 99, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NRBP family. The nucleic acid sequence is 3765 nucleotides long, and codes for a protein that is 507 amino acids long. The open reading frame starts at nucleotide number 282 and ends at nucleotide number 1805. The length of the ORF is 1524 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 8q24.3.

[0483] CNK, SEQ ID NO: 34, SEQ ID NO: 100, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the PLK family. The nucleic acid sequence is 2535 nucleotides long, and codes for a protein that is 646 amino acids long. The open reading frame starts at nucleotide number 534 and ends at nucleotide number 2474. The length of the ORF is 1941 nucleotides. The gene has been mapped to chromosomal region 1p34.1.

[0484] Two alternative splice variants were noted (Incyte template 222139.15): (1) an intron read through over the intron between exons 9 and 10, (2) exon 6 is alternatively spliced: >Nucleotides (insert after nucleotide 1697) GTGAGGCGCTCAGGTGGACACTGTTCCCCTGACTCACCCCCAC CCTAGCA GCTGAGGGAAGCCGGGGATAAAAGAGGCTGCTGAAGCATCCAG CCTCGT GGTGGCCTAATTGGCTGTGTGTCACCAGCCTGGCGGGGCTGAC CTGGGGT GCCCTGGGAGCCAGGGCAGGGCCAGGCCATGGACTCAAGGGTT TGGATTT TGGGGCCTGTGTCACTCCCTTTCCCTGCCCAACCCTCCAG >Nucleotides 2039-2168 GACTGTGCACTACAATCCCACCAGCACAAAGCACTTCTCCTTC TCCGTGGG TGCTGTGCCCCGGGCCCTGCAGCCTCAGCTGGGTATCCTGCGG TACTTCGC CTCCTACATGGAGCAGCACCTCATGAAG

[0485] SCYL2, SEQ ID NO: 35, SEQ ID NO: 101, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the SCY1 family. The nucleic acid sequence is 5525 nucleotides long, and codes for a protein that is 933 amino acids long. The open reading frame starts at nucleotide number 173 and ends at nucleotide number 2974. The length of the ORF is 2802 nucleotides. The gene has been mapped to chromosomal region 12q23-q24.1.

[0486] SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, is a member of the Protein Kinase superfamily. It is further classified into the CMGC group, and the SRPK family. The nucleic acid sequence is 3715 nucleotides long, and codes for a protein that is 688 amino acids long. The open reading frame starts at nucleotide number 179 and ends at nucleotide number 2245. The length of the ORF is 2067 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 7q22.3. This region has been identified as a cancer amplicon (Knuutila, et al).

[0487] TLK1, SEQ ID NO: 37, SEQ ID NO: 103, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the TLK family. The nucleic acid sequence is 4321 nucleotides long, and codes for a protein that is 787 amino acids long. The open reading frame starts at nucleotide number 238 and ends at nucleotide number 2601. The length of the ORF is 2364 nucleotides. The gene has been mapped to chromosomal region 2q31.1. This region has been associated with susceptibility to osteoarthritis (OMIM 140600).

[0488] One alternative splice variant was noted: >Nucleotides 645-707 GTTCCCCAACCTCCCGGTCTTCCAGTCCTTGGCCTATTGGGAA ATGGGTCGTACAGCAGGAGG.

[0489] SGK071, SEQ ID NO: 38, SEQ ID NO: 104, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the Unique family. The nucleic acid sequence is 2285 nucleotides long, and codes for a protein that is 632 amino acids long. The open reading frame starts at nucleotide number 195 and ends at nucleotide number 2093. The length of the ORF is 1899 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 9q34.

[0490] SK516, SEQ ID NO: 39, SEQ ID NO: 105, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the Unique family. The nucleic acid sequence is 7364 nucleotides long, and codes for a protein that is 929 amino acids long. The open reading frame starts at nucleotide number 180 and ends at nucleotide number 2969. The length of the ORF is 2790 nucleotides. The gene has been mapped to chromosomal region 1q31-32.1.

[0491] H85389, SEQ ID NO: 40, SEQ ID NO: 106, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the ULK family. The nucleic acid sequence is 1971 nucleotides long, and codes for a protein that is 401 amino acids long. The open reading frame starts at nucleotide number 134 and ends at nucleotide number 1339. The length of the ORF is 1206 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 20p13.

[0492] Wee1b, SEQ ID NO: 41, SEQ ID NO: 107, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the WEE family. The nucleic acid sequence is 1704 nucleotides long, and codes for a protein that is 567 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 1704. The length of the ORF is 1704 nucleotides. The gene has been mapped to chromosomal region 7q34-36.

[0493] Wnk2, SEQ ID NO: 42, SEQ ID NO: 108, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the Wnk family. The nucleic acid sequence is 7981 nucleotides long, and codes for a protein that is 2245 amino acids long. The open reading frame starts at nucleotide number 67 and ends at nucleotide number 6804. The length of the ORF is 6738 nucleotides. The gene has been mapped to chromosomal region 9q22.31. Other members of this family (Wnk1 and Wnk4) have been strongly implicated in hypertension (Lifton R P, et al, Human hypertension caused by mutations in WNK kinases, Science. 2001 Aug. 10;293(5532): 1107-12), and so Wnk2 may also play a role in this disease.

[0494] Six alternative splice variants are noted: > Wnk2, SEQ ID NO: 42 Nucleotides 2059 and 2214 CCTGGCTTGCCGGTGGGCTCTGTCCCGGCCCCCGCCTGCCCTCCGTCCCT CCAGCAGCACTTCCCGGATCCGGCCATGAGCTTCGCCCCCGTGCTGCCGC CGCCCAGCACCCCCATGCCCACGGGCCCAGGCCAGCCAGCACCCCCCGGC CAGCAG > Wnk2, SEQ ID NO: 42 Nucleotides 5945 and 6136 GTCACTTGGCTGACTCCAGCAGAGGCCCTCCCGCTAAGGACCCTGCCCAA GCCAGTGTGGGGCTCACTGCAGACAGCACGGGCCTGAGCGGGAAGGCAGT GCAGACCCAGCAGCCCTGCTCCGTCCGGGCCTCCCTGTCTTCGGACATCT GCTCCGGCTTAGCCAGTGATGGAGGCGGAGCGCGTGGCCAAG > Wnk2, SEQ ID NO: 42 Nucleotides 6137 and 6280 GCTGGACGGTTTACCACCCAACGTCTGAGAGAGTGACCTATAAGTCTAGT AGCAAACCTCGTGCTCGATTCCTCAGTGGACCCGTATCTGTGTCCATCTG GTCTGCCCTGAAGCGTCTCTGCCTAGGCAAAGAACACAGCAGTA > Wnk2, SEQ ID NO: 42 Nucleotides 5945 and 6280 GTCACTTGGCTGACTCCAGCAGAGGCCCTCCCGCTAAGGACCCTGCCCAA GCCAGTGTGGGGCTCACTGCAGACAGCACGGGCCTGAGCGGGAAGGCAGT GCAGACCCAGCAGCCCTGCTCCGTCCGGGCCTCCCTGTCTTCGGACATCT GCTCCGGCTTAGCCAGTGATGGAGGCGGAGCGCGTGGCCAAGGCTGGACG GTTTACCACCCAACGTCTGAGAGAGTGACCTATAAGTCTAGTAGCAAACC TCGTGCTCGATTCCTCAGTGGACCCGTATCTGTGTCCATCTGGTCTGCCC TGAAGCGTCTCTGCCTAGGCAAAGAACACAGCAGTA > Wnk2, SEQ ID NO: 42 Insert after nucleotide 620 TCTGTGCGGTTGACTCCTTTTCCTCCCCGCCTGGAGATCCCCGTGGTGTC GACTGGAAGCATGGAGGCACCTTGGGGAG > Wnk2, SEQ ID NO: 42 Replaces nucleotides 6650-7981 ATCCTGAGAGTGAGAAGCCTGACTGACCCCGCCTAGACGCCAGGCCCACT TCACGCCGTCTAAGTGGAGAAGTGACGGACCCTCAGGGCCAGCTGCTCCT CCTGTCCAGTTCACGCTGTTTTGTAACCACTTTCTAAGCATTTTTTATTC ACAATTGGAAACACAAATGTAATGCAAGAATAAAAAATATTTTGGGGCAG AAAGGACTTTGGTTTTTCAAACTATTTCCTCTCTGGTGGCCCTCGGCCAG CCAGGTGACTGGGATGTGACAGGGGTGGGGGGACATTCCCAGGACCCTGG CATGCTCAGGATAGCCCTGTTCTCTGCAGGGCCCTGGAGGTGGCGGCCCC GGGGAGGCTGATCTCCAAGTCCCCCCGATGCCAGCTGGC

[0495] MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, is a member of the Protein Kinase superfamily. It is further classified into the STE group, and the STE11 family. The nucleic acid sequence is 7026 nucleotides long, and codes for a protein that is 1511 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 4536. The length of the ORF is 4536 nucleotides. The gene has been mapped to chromosomal region 5q11.2-q13. This region has been associated with susceptibility to schizophrenia (OMIM 181500).

[0496] The sequence has good similarity to the mouse and rat orthologs.

[0497] MAP3K8, SEQ ID NO: 44, SEQ ID NO: 110, is a member of the Protein Kinase superfamily. It is further classified into the STE group, and the STE11 family. The nucleic acid sequence is 2571 nucleotides long, and codes for a protein that is 735 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 2208. The length of the ORF is 2208 nucleotides. The gene has been mapped to chromosomal region 2q21.3.

[0498] One alternative splice variant was noted: >MAP3K8, SEQ ID NO: 44 Replaces nucleotides 1412-2571 GTTCAAGTCCAATGGGAAAGAAATATCTTCCTTCAACAGCTGAATATGTT ACTGGAAGTTTGGAGAATCATTACTAGATGGCAAAAACAAAAGATGTTCC TTCCATTTTGTGAACTGCATAAGAGATCTTGGGGGGTGGGCGATGAAGAG AGGTATACTGTGGTCTCACTAGTCAAGGACAGCTAATAGCTGTAAAACAG GTGGCTTTGGATAACT

[0499] Pak4_m, SEQ ID NO: 45 SEQ ID NO: 111, is the only murine sequence in this application. It is a member of the Protein Kinase superfamily, further classified into the STE group, and the STE20 family. The nucleic acid sequence is 1782 nucleotides long, and codes for a protein that is 593 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 1782. The length of the ORF is 1782 nucleotides. The human ortholog has been mapped to 19q13.2.

[0500] STLK6-rs, SEQ ID NO: 46 SEQ ID NO: 112, is a member of the Protein Kinase superfamily. It is further classified into the STE group, and the STE20 family. The nucleic acid sequence is 2171 nucleotides long, and codes for a protein that is 418 amino acids long. The open reading frame starts at nucleotide number 242 and ends at nucleotide number 1498. The length of the ORF is 1257 nucleotides. The gene has been mapped to chromosomal region 1p33.

[0501] MAP2K2, SEQ ID NO: 47 SEQ ID NO: 113, is a member of the Protein Kinase superfamily. It is further classified into the STE group, and the STE7 family. The nucleic acid sequence is 1724 nucleotides long, and codes for a protein that is 380 amino acids long. The open reading frame starts at nucleotide number 248 and ends at nucleotide number 1390. The length of the ORF is 1143 nucleotides. Sugen has cloned the full length cDNA for this gene. The gene has been mapped to chromosomal region 7q34.

[0502] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, is a member of the Protein Kinase superfamily. It is further classified into the TK group, and the CCK4 family. The nucleic acid sequence is 4232 nucleotides long, and codes for a protein that is 1070 amino acids long. The open reading frame starts at nucleotide number 191 and ends at nucleotide number 3403. The length of the ORF is 3213 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 6p21-p12.

[0503] LMR1, SEQ ID NO: 49 SEQ ID NO: 115, is a member of the Protein Kinase superfamily. It is further classified into the TK group, and the Lmr family. The nucleic acid sequence is 5313 nucleotides long, and codes for a protein that is 1374 amino acids long. The open reading frame starts at nucleotide number 85 and ends at nucleotide number 4209. The length of the ORF is 4125 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 17q25.

[0504] RYK, SEQ ID NO: 50 SEQ ID NO: 116, is a member of the Protein Kinase superfamily. It is further classified into the TK group, and the Ryk family. The nucleic acid sequence is 3663 nucleotides long, and codes for a protein that is 607 amino acids long. The open reading frame starts at nucleotide number 91 and ends at nucleotide number 1914. The length of the ORF is 1824 nucleotides. The gene has been mapped to chromosomal region 3q22.

[0505] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, is a member of the Protein Kinase superfamily. It is further classified into the TKL group, and the LRRK family. The nucleic acid sequence is 9753 nucleotides long, and codes for a protein that is 2534 amino acids long. The open reading frame starts at nucleotide number 633 and ends at nucleotide number 8237. The length of the ORF is 7605 nucleotides. The gene has been mapped to chromosomal region 12q11-q12.

[0506] For LRRK2, the 3′ most 4 nucleotides of the original SGK040 sequence were mispredicted. Correcting the prediction removes the stop and allows for further 3′ extension. The sequence was extended at the 3′ end by three EST/cDNA sequences (Incyte templates 215217.7 and 215217.9 and NCBI_nr cDNA gi|17454342). Two different splice variants were present. Because the Incyte template 215217.7 and the NCBI_nr cDNA gi|17454342 3′ extension yields a longer ORF it was used in the final sequence, extending the sequence in the 3′ direction by 133 AA and through the stop codon. The 5′ most 52 nucleotides of the original sequence were mispredicted and removed from the final revised sequence. The 5′ end of the sequence was extended by an overlapping Incyte flft CB1 sequence (71059650CB1) which is supported in two different stretches by over lapping Incyte templates (1017699.1, 316571.1, 415310.1 and 295385.1). Parts of the 5′ extension are based on the Incyte CB1 sequence and a genscan prediction. The N-terminus was extended by approximately 1500 AA.

[0507] pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, is a member of the Protein Kinase superfamily. It is further classified into the TKL group, and the MLK family. The nucleic acid sequence is 4667 nucleotides long, and codes for a protein that is 1036 amino acids long. The open reading frame starts at nucleotide number 262 and ends at nucleotide number 3372. The length of the ORF is 3111 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 1q42.2.

[0508] KSR, SEQ ID NO: 53 SEQ ID NO: 119, is a member of the Protein Kinase superfamily. It is further classified into the TKL group, and the RAF family. The nucleic acid sequence is 5913 nucleotides long, and codes for a protein that is 901 amino acids long. The open reading frame starts at nucleotide number 165 and ends at nucleotide number 2870. The length of the ORF is 2706 nucleotides. The gene has been mapped to chromosomal region 17q11.1. This region has been identified as a cancer amplicon (Knuutila, et al).

[0509] The patent sequence for KSR, SEQ ID NO: 53 SEQ ID NO: 119 is full length, and aligns across the full length with the mouse ortholog.

[0510] KSR2, SEQ ID NO: 54 SEQ ID NO: 120, is a member of the Protein Kinase superfamily. It is further classified into the TKL group, and the RAF family. The nucleic acid sequence is 2994 nucleotides long, and codes for a protein that is 982 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 2949. The length of the ORF is 2949 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 12q24.3.

[0511] KIAA1646, SEQ ID NO: 55 SEQ ID NO: 121, is a member of the Lipid Kinase superfamily. It is further classified into the DAG kin group, and the DAG kin family. The nucleic acid sequence is 4429 nucleotides long, and codes for a protein that is 537 amino acids long. The open reading frame starts at nucleotide number 92 and ends at nucleotide number 1705. The length of the ORF is 1614 nucleotides. The gene has been mapped to chromosomal region 22q13.31.

[0512] DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122, is a member of the Lipid Kinase superfamily. It is further classified into the DAG kin group, and the DAG kin family. The nucleic acid sequence is 4297 nucleotides long, and codes for a protein that is 804 amino acids long. The open reading frame starts at nucleotide number 372 and ends at nucleotide number 2786. The length of the ORF is 2415 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 7p21.3-p22. This region has been associated with susceptibility to osteoarthritis (OMIM 140600).

[0513] IP6K1, SEQ ID NO: 57 SEQ ID NO: 123, is a member of the Lipid Kinase superfamily. It is further classified into the Inositol kinase group, and the IP6K family. The nucleic acid sequence is 4461 nucleotides long, and codes for a protein that is 441 amino acids long. The open reading frame starts at nucleotide number 309 and ends at nucleotide number 1634. The length of the ORF is 1326 nucleotides. The gene has been mapped to chromosomal region 3p21.31.

[0514] YAB1, SEQ ID NO: 58 SEQ ID NO: 124, is a member of the Atypical PK superfamily. It is further classified into the Atypical group, and the ABCl family. The nucleic acid sequence is 2508 nucleotides long, and codes for a protein that is 647 amino acids long. The open reading frame starts at nucleotide number 99 and ends at nucleotide number 2042. The length of the ORF is 1944 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 1q42. This region has been associated with susceptibility to schizophrenia (OMIM 181500).

[0515] AF052122, SEQ ID NO: 59 SEQ ID NO: 125, is a member of the Atypical PK superfamily. It is further classified into the Atypical group, and the ABC1 family. The nucleic acid sequence is 5237 nucleotides long, and codes for a protein that is 591 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 1776. The length of the ORF is 1776 nucleotides. Sugen has cloned the full length cDNA for this gene. The gene has been mapped to chromosomal region 19q13.1. This region has been identified as a cancer amplicon (Knuutila, et al).

[0516] AAF23326, SEQ ID NO: 60 SEQ ID NO: 126, is a member of the Atypical PK superfamily. It is further classified into the Atypical group, and the ABC1 family. The nucleic acid sequence is 1368 nucleotides long, and codes for a protein that is 455 amino acids long. The open reading frame starts at nucleotide number 1 and ends at nucleotide number 1368. The length of the ORF is 1368 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 14q24.3-q32.

[0517] SGK493, SEQ ID NO: 61 SEQ ID NO: 127, is a member of the Atypical PK superfamily. It is further classified into the Atypical group, and the RIO 1 family. The nucleic acid sequence is 1832 nucleotides long, and codes for a protein that is 552 amino acids long. The open reading frame starts at nucleotide number 50 and ends at nucleotide number 1708. The length of the ORF is 1659 nucleotides. The full length cDNA for this gene has been cloned. The gene has been mapped to chromosomal region 5q14.

[0518] BRD2, SEQ ID NO: 62 SEQ ID NO: 128, is a member of the Atypical PK superfamily. It is further classified into the BRD group, and the BRD family. The nucleic acid sequence is 4693 nucleotides long, and codes for a protein that is 801 amino acids long. The open reading frame starts at nucleotide number 1702 and ends at nucleotide number 4107. The length of the ORF is 2406 nucleotides. The gene has been mapped to chromosomal region 6p21.2.

[0519] BRD3, SEQ ID NO: 63, SEQ ID NO: 129, is a member of the Atypical PK superfamily. It is further classified into the BRD group, and the BRD family. The nucleic acid sequence is 3085 nucleotides long, and codes for a protein that is 726 amino acids long. The open reading frame starts at nucleotide number 140 and ends at nucleotide number 2320. The length of the ORF is 2181 nucleotides. The gene has been mapped to chromosomal region 9q34.

[0520] BRD4, SEQ ID NO: 64, SEQ ID NO: 130, is a member of the Atypical PK superfamily. It is further classified into the BRD group, and the BRD family. The nucleic acid sequence is 3149 nucleotides long, and codes for a protein that is 722 amino acids long. The open reading frame starts at nucleotide number 223 and ends at nucleotide number 2391. The length of the ORF is 2169 nucleotides. The gene has been mapped to chromosomal region 19p13.2.

[0521] BRDT, SEQ ID NO: 65, SEQ ID NO: 131, is a member of the Atypical PK superfamily. It is further classified into the BRD group, and the BRD family. The nucleic acid sequence is 3106 nucleotides long, and codes for a protein that is 947 amino acids long. The open reading frame starts at nucleotide number 108 and ends at nucleotide number 2951. The length of the ORF is 2844 nucleotides. The gene has been mapped to chromosomal region 1p21.

[0522] ZC1, SEQ ID NO: 66, SEQ ID NO: 132 is a member of the protein kinase superfamily, the STE group, and the STE20 family. The nucleic acid sequence is 7986 nucleotides long, and codes for a protein (in its longest form) of 1392 amino acids (see below for splice variants). The open reading frame starts at nucleotide number 366 and ends at nucleotide number 4544. The length of the ORF is 4179 nucleotides. The gene has been mapped to chromosomal region 2q11.1-q11.2.

[0523] PolyA tails are present in ZC1, SEQ ID NO: 66 after position 4791, position 6100 and position 7986. All sites are within the 3 prime untranslated region and do not alter the protein sequence. Differential use of these polyadenylation sites has been seen in ESTs from brain and other tissues, indicating that sequences within the untranslated region may be involved in controlling gene expression in a tissue-specific manner. Alternatively spliced transcripts have been seen in cDNA and EST sequences which lack portions of this sequence. Nine sections (modules) of this sequence are alternatively spliced and it is predicted that transcripts containing all combinations of alternatively spliced modules exist. All alternatively spliced modules are within the open reading frame and contain a multiple of three nucleotides. Therefore, omission of any one module from a transcript results in an inframe deletion of a peptide from the protein. No frameshifts or premature stops are produced by any of these alternatively spliced forms. The positions of the modules on the DNA and protein sequences are as follows: Notes for ZC1, Module DNA range Protein Range SEQ ID NO: 66 M1 1761-1847 466-494 Encodes C-terminal extension of coiled-coil domain. Similar module found in the paralogous gene TNIK. M2 1848-1940 495-525 M3 2070-2231 569-622 Similar module found in TNIK. Contains 2 PxxP motifs, predicted to bind SH3-domain proteins M4 2232-2462 623-694 Contains 2 PxxP motifs. M5 2568-2570 736-736 M6 2821-2829 819-821 M7 3126-3317 921-984 M8 4008-4064 1215-1233 Encodes part of CNH domain. Similar sequence seen in other human GCK-IV kinases M9 4137-4160 1258-1265 Encodes part of CNH domain. Similar sequence not seen in other CNH domains.

Example 2a Expression Analysis of Polypeptides of the Invention

[0524] The gene expression patterns for selected genes were studied using a PCR screen of 96 human tissues. This technique does not yield quantitative expression levels between tissues, but does identify which tissues express the gene at a level detectable by PCR and those which do not.

Example 2b Predicted Proteins II. Predicted Proteins

[0525] Description of the Proteins—Smith-Waterman Comparisons (Table 2, a & b)

[0526] CRIK, SEQ ID NO: 1, SEQ ID NO: 67 encodes a protein that is 2055 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1975; percent identity over the alignment: 96%; percent similarity over the alignment: 98%; accession number for best hit: AAC72823.1; description and species for best hit: Rho/rac-interacting citron kinase [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 2055; target start: 1; target end: 2055. The percent of the query that aligns with the target is: 96%. The percent of the target that aligns with the query is: 96%.

[0527] DMPK2, SEQ ID NO: 2, SEQ ID NO: 68 encodes a protein that is 1572 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.20E-211; number of matches: 731; percent identity over the alignment: 45%; percent similarity over the alignment: 63%; accession number for best hit: NP_(—)446109.1; description and species for best hit: Ser-Thr protein kinase related to the myotonic dystrophy protein kinase [Rattus norvegicus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 2; query end: 1462; target start: 4; target end: 1588. The percent of the query that aligns with the target is: 46%. The percent of the target that aligns with the query is: 42%.

[0528] MAST3, SEQ ID NO: 3, SEQ ID NO: 69 encodes a protein that is 1331 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1287; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: BAA25487.1; description and species for best hit: (AB011133) KIAA0561 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 39; query end: 1331; target start: 16; target end: 1308. The percent of the query that aligns with the target is: 96%. The percent of the target that aligns with the query is: 98%.

[0529] MAST205, SEQ ID NO: 4, SEQ ID NO: 70 encodes a protein that is 1798 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1684; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: NP_(—)055927.1; description and species for best hit: KIAA0807 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 1687; target start: 1; target end: 1687. The percent of the query that aligns with the target is: 93%. The percent of the target that aligns with the query is: 97%.

[0530] MASTL, SEQ ID NO: 5, SEQ ID NO: 71 encodes a protein that is 878 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 876; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: NP_(—)116233.1; description and species for best hit: Hypothetical protein FLJ14813 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 878; target start: 1; target end: 878. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0531] PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72 encodes a protein that is 683 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 679; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: NP_(—)006246.1; description and species for best hit: (NM_(—)006255) protein kinase C, eta [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 683; target start: 1; target end: 682. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0532] H19102, SEQ ID NO: 7, SEQ ID NO: 73 encodes a protein that is 449 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.00E-124; number of matches: 269; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: BAB71555.1; description and species for best hit: Unnamed protein product [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 41; query end: 310; target start: 1; target end: 271. The percent of the query that aligns with the target is: 59%. The percent of the target that aligns with the query is: 98%.

[0533] MSK1, SEQ ID NO: 8, SEQ ID NO: 74 encodes a protein that is 802 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=3.50E-304; number of matches: 787; percent identity over the alignment: 98%; percent similarity over the alignment: 98%; accession number for best hit: NP_(—)004746.1; description and species for best hit: (NM_(—)004755) ribosomal protein S6 kinase, 90 kD, polypeptide 5; mitogen- and stress-activated protein kinase 1 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 800; target start: 1; target end: 800. The percent of the query that aligns with the target is: 98%. The percent of the target that aligns with the query is: 97%.

[0534] YANK3, SEQ ID NO: 9, SEQ ID NO: 75 encodes a protein that is 486 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=8.9e-311; number of matches: 444; percent identity over the alignment: 91%; percent similarity over the alignment: 94%; accession number for best hit: AAH26457; description and species for best hit: (BC026457) hypothetical serine/threonine protein kinase [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 485; target start: 1; target end: 487. The percent of the query that aligns with the target is: 91%. The percent of the target that aligns with the query is: 90%.

[0535] MARK2, SEQ ID NO: 10, SEQ ID NO: 76 encodes a protein that is 787 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.60E-299; number of matches: 752; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: AAH08771.1; description and species for best hit: (BC008771) Similar to ELKL motif kinase [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 34; query end: 787; target start: 1; target end: 755. The percent of the query that aligns with the target is: 95%. The percent of the target that aligns with the query is: 99%.

[0536] NuaK2, SEQ ID NO: 11, SEQ ID NO: 77 encodes a protein that is 672 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=5.10E-269; number of matches: 628; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)112214.1; description and species for best hit: (NM_(—)030952) hypothetical protein DKFZp434J037 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 45; query end: 672; target start: 1; target end: 628. The percent of the query that aligns with the target is: 93%. The percent of the target that aligns with the query is: 100%.

[0537] BRSK2, SEQ ID NO: 12, SEQ ID NO: 78 encodes a protein that is 674 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=4.20E-175; number of matches: 602; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: CAA07196.1; description and species for best hit: Putative serine/threonine protein kinase [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 72; query end: 674; target start: 1; target end: 603. The percent of the query that aligns with the target is: 89%. The percent of the target that aligns with the queryis: 99%.

[0538] MARK4, SEQ ID NO: 13, SEQ ID NO: 79 encodes a protein that is 752 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=4.30E-298; number of matches: 751; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: AAL23683.1; description and species for best hit: MARK4 serine/threonine protein kinase [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 752; target start: 1; target end: 752. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0539] DCAMKL2, SEQ ID NO: 14, SEQ ID NO: 80 encodes a protein that is 766 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=8.10E-159; number of matches: 513; percent identity over the alignment: 67%; percent similarity over the aligrnent: 80%; accession number for best hit: O15075; description and species for best hit: DCAMKL1 (doublecortin-like and CAMK-like 1) [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 741; target start: 1; target end: 739. The percent of the query that aligns with the target is: 66%. The percent of the target that aligns with the query is: 69%.

[0540] PIM2, SEQ ID NO: 15, SEQ ID NO: 81 encodes a protein that is 434 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.40E-145; number of matches: 334; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)006866.1; description and species for best hit: (NM_(—)006875) pim-2 oncogene; proto-oncogene Pim-2 (serine threonine kinase) [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 101; query end: 434; target start: 1; target end: 334. The percent of the query that aligns with the target is: 76%. The percent of the target that aligns with the query is: 100%.

[0541] PIM3, SEQ ID NO: 16, SEQ ID NO: 82 encodes a protein that is 326 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=9.90E-174; number of matches: 311; percent identity over the alignment: 95%; percent similarity over the alignment: 97%; accession number for best hit: AAH17621.1; description and species for best hit: Serine threonine kinase pim3 [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 326; target start: 1; target end: 326. The percent of the query that aligns with the target is: 95%. The percent of the target that aligns with the query is: 95%.

[0542] TSSK4, SEQ ID NO: 17, SEQ ID NO: 83 encodes a protein that is 328 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.60E-69; number of matches: 281; percent identity over the alignment: 85%; percent similarity over the alignment: 94%; accession number for best hit: BAB30483.1; description and species for best hit: Putative [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 328; target start: 1; target end: 328. The percent of the query that aligns with the target is: 85%. The percent of the target that aligns with the query is: 85%.

[0543] CKIL2, SEQ ID NO: 18, SEQ ID NO: 84 encodes a protein that is 1244 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.50E-298; number of matches: 645; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: BAA74870.1; description and species for best hit: KIAA0847 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 600; query end: 1244; target start: 1; target end: 645. The percent of the query that aligns with the target is: 51%. The percent of the target that aligns with the query is: 100%.

[0544] PCTAIRE3, SEQ ID NO: 19, SEQ ID NO: 85 encodes a protein that is 504 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.50E-220; number of matches: 471; percent identity over the alignment: 93%; percent similarity over the alignment: 93%; accession number for best hit: Q07002; description and species for best hit: Serine/threonine protein kinase PCTAIRE-3 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 502; target start: 1; target end: 472. The percent of the query that aligns with the target is: 93%. The percent of the target that aligns with the query is: 99%.

[0545] PFTAIRE2, SEQ ID NO: 20, SEQ ID NO: 86 encodes a protein that is 435 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=8.40E-100; number of matches: 225; percent identity over the alignment: 68%; percent similarity over the alignment: 81%; accession number for best hit: NP_(—)035204.1; description and species for best hit: (NM_(—)011074) PFTAIRE protein kinase 1 [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 97; query end: 426; target start: 129; target end: 458. The percent of the query that aligns with the target is: 51%. The percent of the target that aligns with the query is: 47%.

[0546] ERK7, SEQ ID NO: 21, SEQ ID NO: 87 encodes a protein that is 563 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.90E-128; number of matches: 384; percent identity over the alignment: 67%; percent similarity over the alignment: 75%; accession number for best hit: AAD12719.2; description and species for best hit: Extracellular signal-regulated kinase 7; ERK7 [Rattus norvegicus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 560; target start: 1; target end: 544. The percent of the query that aligns with the target is: 68%. The percent of the target that aligns with the query is: 70%.

[0547] CKIIa-rs, SEQ ID NO: 22, SEQ ID NO: 88 encodes a protein that is 391 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=9.60E-195; number of matches: 390; percent identity over the alignment: 99%; percent similarity over the alignment: 100%; accession number for best hit: CAA49758.1; description and species for best hit: Casein kinase II alpha subunit [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 391; target start: 1; target end: 391. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0548] DYRK4, SEQ ID NO: 23, SEQ ID NO: 89 encodes a protein that is 921 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.20E-304; number of matches: 526; percent identity over the alignment: 99%; percent similarity over the alignment: 100%; accession number for best hit: Q9NR20; description and species for best hit: DYRK44 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 395; query end: 921; target start: 15; target end: 541. The percent of the query that aligns with the target is: 57%. The percent of the target that aligns with the query is: 97%.

[0549] HIPK1, SEQ ID NO: 24, SEQ ID NO: 90 encodes a protein that is 1210 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1181; percent identity over the alignment: 97%; percent similarity over the alignment: 99%; accession number for best hit: AAD41592.1; description and species for best hit: Myak-L [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 1210; target start: 1; target end: 1210. The percent of the query that aligns with the target is: 97%. The percent of the target that aligns with the query is: 97%.

[0550] HIPK4, SEQ ID NO: 25, SEQ ID NO: 91 encodes a protein that is 616 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 598; percent identity over the alignment: 97%; percent similarity over the alignment: 98%; accession number for best hit: BAB72080.1; description and species for best hit: Hypothetical protein [Macaca fascicularis]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 616; target start: 1; target end: 616. The percent of the query that aligns with the target is: 97%. The percent of the target that aligns with the query is: 97%.

[0551] BIKE, SEQ ID NO: 26, SEQ ID NO: 92 encodes a protein that is 1161 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=7.60E-244; number of matches: 960; percent identity over the alignment: 82%; percent similarity over the alignment: 89%; accession number for best hit: NP_(—)542439.1; description and species for best hit: (NM_(—)080708) Bmp2-inducible kinase [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 1161; target start: 1; target end: 1138. The percent of the query that aligns with the target is: 82%. The percent of the target that aligns with the query is: 84%.

[0552] NEK10, SEQ ID NO: 27, SEQ ID NO: 93 encodes a protein that is 1125 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=9.80E-185; number of matches: 428; percent identity over the alignment: 90%; percent similarity over the alignment: 90%; accession number for best hit: BAB71395.1; description and species for best hit: (AK057247) unnamed protein product [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 698; query end: 1125; target start: 10; target end: 484. The percent of the query that aligns with the target is: 38%. The percent of the target that aligns with the query is: 88%.

[0553] pNEK5, SEQ ID NO: 28, SEQ ID NO: 94 encodes a protein that is 889 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.60E-78; number of matches: 180; percent identity over the alignment: 65%; percent similarity over the alignment: 82%; accession number for best hit: P51954; description and species for best hit: Serine/threonine-protein kinase NEKI (NimA-related protein kinase 1) [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 58; query end: 333; target start: 1; target end: 275. The percent of the query that aligns with the target is: 20%. The percent of the target that aligns with the query is: 23%.

[0554] NEK1, SEQ ID NO: 29, SEQ ID NO: 95 encodes a protein that is 1286 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1258; percent identity over the alignment: 97%; percent similarity over the alignment: 97%; accession number for best hit: BAB67794.1; description and species for best hit: KIAA1901 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 1286; target start: 8; target end: 1265. The percent of the query that aligns with the target is: 97%. The percent of the target that aligns with the query is: 99%.

[0555] NEK3, SEQ ID NO: 30, SEQ ID NO: 96 encodes a protein that is 506 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.80E-202; number of matches: 458; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: P51956; description and species for best hit: SERINE/THREONINE-PROTEIN KINASE NEK3 (NIMA-RELATED PROTEIN KINASE 3) (HSPK 36) [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 48; query end: 506; target start: 1; target end: 459. The percent of the query that aligns with the target is: 90%. The percent of the target that aligns with the query is: 99%.

[0556] SGK069, SEQ ID NO: 31, SEQ ID NO: 97 encodes a protein that is 348 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=7.40E-48; number of matches: 122; percent identity over the alignment: 42%; percent similarity over the alignment: 59%; accession number for best hit: AAK52420.1; description and species for best hit: Protein kinase Bsk146 [Danio rerio]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 348; target start: 394; target end: 763. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 41%.

[0557] SGK110, SEQ ID NO: 32, SEQ ID NO: 98 encodes a protein that is 414 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=4.00E-35; number of matches: 110; percent identity over the alignment: 41%; percent similarity over the alignment: 60%; accession number for best hit: S71887; description and species for best hit: serine/threonine-specific kinase (EC 2.7.1.-), pk9.7 gastrula-specific [Xenopus laevis]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 96; query end: 359; target start: 9; target end: 272. The percent of the query that aligns with the target is: 26%. The percent of the target that aligns with the query is: 30%.

[0558] NRBP2, SEQ ID NO: 33, SEQ ID NO: 99 encodes a protein that is 507 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=3.20E-158; number of matches: 300; percent identity over the alignment: 61%; percent similarity over the alignment: 75%; accession number for best hit: NP_(—)037524.1; description and species for best hit: Nuclear receptor binding protein; multiple domain putative nuclear protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 17; query end: 502; target start: 44; target end: 518. The percent of the query that aligns with the target is: 59%. The percent of the target that aligns with the query is: 56%.

[0559] CNK, SEQ ID NO: 34, SEQ ID NO: 100 encodes a protein that is 646 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=8.60E-236; number of matches: 645; percent identity over the alignment: 99%; percent similarity over the alignment: 100%; accession number for best hit: AAH13899.1; description and species for best hit: (BC013899) Unknown (protein for MGC: 14852) [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 646; target start: 1; target end: 646. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0560] SCYL2, SEQ ID NO: 35, SEQ ID NO: 101 encodes a protein that is 933 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 791; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: BAA92598.1; description and species for best hit: KIAA1360 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 140; query end: 933; target start: 3; target end: 796. The percent of the query that aligns with the target is: 84%. The percent of the target that aligns with the query is: 99%.

[0561] SRPK2, SEQ ID NO: 36, SEQ ID NO: 102 encodes a protein that is 688 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=7.80E-183; number of matches: 684; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: NP_(—)003129.1; description and species for best hit: (NM_(—)003138) SFRS protein kinase 2 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 688; target start: 1; target end: 686. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0562] TLK1, SEQ ID NO: 37, SEQ ID NO: 103 encodes a protein that is 787 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 777; percent identity over the alignment: 98%; percent similarity over the alignment: 99%; accession number for best hit: NP_(—)036422.1; description and species for best hit: (NM_(—)012290) tousled-like kinase 1; KIAA0137 gene product; serine threonine protein kinase [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 787; target start: 1; target end: 787. The percent of the query that aligns with the target is: 98%. The percent of the target that aligns with the query is: 98%.

[0563] SGK071, SEQ ID NO: 38, SEQ ID NO: 104 encodes a protein that is 632 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0.000001; number of matches: 63; percent identity over the alignment: 30%; percent similarity over the alignment: 50%; accession number for best hit: NP_(—)175853.1; description and species for best hit: Hypothetical protein [Arabidopsis thaliana]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 25; query end: 228; target start: 1; target end: 197. The percent of the query that aligns with the target is: 9%. The percent of the target that aligns with the query is: 10%.

[0564] SK516, SEQ ID NO: 39, SEQ ID NO: 105 encodes a protein that is 929 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=5.70E-180; number of matches: 365; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: BAA32317.1; description and species for best hit: KIAA0472 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 565; query end: 929; target start: 1; target end: 365. The percent of the query that aligns with the target is: 39%. The percent of the target that aligns with the query is: 100%.

[0565] H85389, SEQ ID NO: 40, SEQ ID NO: 106 encodes a protein that is 401 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.40E-162; number of matches: 400; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: CAC 10518.2; description and species for best hit: Novel protein kinase [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 401; target start: 118; target end: 517. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 77%.

[0566] Wee1b, SEQ ID NO: 41, SEQ ID NO: 107 encodes a protein that is 567 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.00E-287; number of matches: 541; percent identity over the alignment: 96%; percent similarity over the alignment: 96%; accession number for best hit: AAD04726.1; description and species for best hit: Similar to weel-like protein kinase [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 559; target start: 1; target end: 541. The percent of the query that aligns with the target is: 95%. The percent of the target that aligns with the query is: 100%.

[0567] Wnk2, SEQ ID NO: 42, SEQ ID NO: 108 encodes a protein that is 2245 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1385; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: BAB21851.1; description and species for best hit: KIAA1760 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 860; query end: 2245; target start: 1; target end: 1386. The percent of the query that aligns with the target is: 61%. The percent of the target that aligns with the query is: 99%.

[0568] MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109 encodes a protein that is 1511 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1459; percent identity over the alignment: 97%; percent similarity over the alignment: 97%; accession number for best hit: Q13233; description and species for best hit: MEKK 1 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 21; query end: 1511; target start: 2; target end: 1495. The percent of the query that aligns with the target is: 96%. The percent of the target that aligns with the query is: 97%.

[0569] MAP3K8, SEQ ID NO: 44, SEQ ID NO: 110 encodes a protein that is 735 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.80E-82; number of matches: 168; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: XP_(—)017343.1; description and species for best hit: Hypothetical protein fragment FLJ23074 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 547; query end: 714; target start: 1; target end: 168. The percent of the query that aligns with the target is: 22%. The percent of the target that aligns with the query is: 100%.

[0570] Pak5_m, SEQ ID NO: 45 SEQ ID NO: 111 encodes a protein that is 593 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.70E-130; number of matches: 550; percent identity over the alignment: 92%; percent similarity over the alignment: 96%; accession number for best hit: NP_(—)005875.1; description and species for best hit: p21-activated kinase 4; protein kinase related to S. cerevisiae STE20, effector for Cdc42Hs [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 593; target start: 1; target end: 591. The percent of the query that aligns with the target is: 92%. The percent of the target that aligns with the query is: 93%.

[0571] STLK6-rs, SEQ ID NO: 46 SEQ ID NO: 112 encodes a protein that is 418 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=5.90E-222; number of matches: 407; percent identity over the alignment: 97%; percent similarity over the alignment: 98%; accession number for best hit: NP_(—)061041.2; description and species for best hit: Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 418; target start: 1; target end: 418. The percent of the query that aligns with the target is: 97%. The percent of the target that aligns with the query is: 97%.

[0572] MAP2K2, SEQ ID NO: 47 SEQ ID NO: 113 encodes a protein that is 381 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=4.80E-156; number of matches: 353; percent identity over the alignment: 92%; percent similarity over the alignment: 95%; accession number for best hit: NP_(—)109587.1; description and species for best hit: (NM_(—)030662) mitogen-activated protein kinase kinase 2; protein kinase, mitogen-activated, kinase 2, p45 (MAP kinase kinase 2) [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 2; query end: 380; target start: 1; target end: 380. The percent of the query that aligns with the target is: 92%. The percent of the target that aligns with the query is: 88%.

[0573] CCK4, SEQ ID NO: 48 SEQ ID NO: 114 encodes a protein that is 1070 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1069; percent identity over the alignment: 99%; percent similarity over the alignment: 100%; accession number for best hit: JC4593; description and species for best hit: protein-tyrosine kinase-related receptor PTK7 precursor [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 1070; target start: 1; target end: 1070. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0574] LMR1, SEQ ID NO: 49 SEQ ID NO: 115 encodes a protein that is 1374 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1207; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)004911.1; description and species for best hit: (NM_(—)004920) apoptosis-associated tyrosine kinase [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 168; query end: 1374; target start: 1; target end: 1207. The percent of the query that aligns with the target is: 87%. The percent of the target that aligns with the query is: 100%.

[0575] RYK, SEQ ID NO: 50 SEQ ID NO: 116 encodes a protein that is 607 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=3.60E-287; number of matches: 603; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: 137560; description and species for best hit: Protein-tyrosine kinase Ryk -[Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 607; target start: 1; target end: 607. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0576] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117 encodes a protein that is 2534 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=7.90E-189; number of matches: 463; percent identity over the alignment: 84%; percent similarity over the alignment: 92%; accession number for best hit: NP_(—)080006.1; description and species for best hit: RIKEN cDNA 4921513O20 gene [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1990; query end: 2534; target start: 17; target end: 561. The percent of the query that aligns with the target is: 18%. The percent of the target that aligns with the query is: 82%.

[0577] pMLK4, SEQ ID NO: 52 SEQ ID NO: 118 encodes a protein that is 1036 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1027; percent identity over the alignment: 99%; percent similarity over the alignment: 99%; accession number for best hit: CAC84640.1; description and species for best hit: (AJ311798) mixed lineage kinase 4 beta [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 1036; target start: 1; target end: 1036. The percent of the query that aligns with the target is: 99%. The percent of the target that aligns with the query is: 99%.

[0578] KSR, SEQ ID NO: 53 SEQ ID NO: 119 encodes a protein that is 901 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=3.30E-269; number of matches: 797; percent identity over the alignment: 88%; percent similarity over the alignment: 92%; accession number for best hit: NP_(—)038599.1; description and species for best hit: (NM_(—)013571) kinase suppressor of ras [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 901; target start: 1; target end: 873. The percent of the query that aligns with the target is: 88%. The percent of the target that aligns with the query is: 91%.

[0579] KSR2, SEQ ID NO: 54 SEQ ID NO: 120 encodes a protein that is 982 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=9.60E-119; number of matches: 452; percent identity over the alignment: 48%; percent similarity over the alignment: 62%; accession number for best hit: NP_(—)038599.1; description and species for best hit: (NM_(—)013571) kinase suppressor of ras [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 51; query end: 982; target start: 34; target end: 849. The percent of the query that aligns with the target is: 46%. The percent of the target that aligns with the query is: 51%.

[0580] KIAA1646, SEQ ID NO: 55 SEQ ID NO: 121 encodes a protein that is 537 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 481; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: BAB33316.1; description and species for best hit: KIAA1646 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 57; query end: 537; target start: 1; target end: 481. The percent of the query that aligns with the target is: 89%. The percent of the target that aligns with the query is: 100%.

[0581] DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122 encodes a protein that is 804 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 804; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: Q9Y6T7; description and species for best hit: Diacylglycerol kinase, bets (DGK-BETA) [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 804; target start: 1; target end: 804. The percent of the query that aligns with the target is: 100%. The percent of the target that aligns with the query is: 100%.

[0582] IP6K1, SEQ ID NO: 57 SEQ ID NO: 123 encodes a protein that is 441 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.60E-257; number of matches: 441; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: BAA13393.2; description and species for best hit: KIAA0263 protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 441; target start: 22; target end: 462. The percent of the query that aligns with the target is: 100%. The percent of the target that aligns with the query is: 95%.

[0583] YAB1, SEQ ID NO: 58 SEQ ID NO: 124 encodes a protein that is 647 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=3.80E-244; number of matches: 368; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)064632.1; description and species for best hit: (NM 020247) chaperone, ABC1 activity of bc1 complex like [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 280; query end: 647; target start: 1; target end: 368. The percent of the query that aligns with the target is: 56%. The percent of the target that aligns with the query is: 100%.

[0584] AF052122, SEQ ID NO: 59 SEQ ID NO: 125 encodes a protein that is 591 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.20E-246; number of matches: 385; percent identity over the alignment: 99%; percent similarity over the alignment: 100%; accession number for best hit: AAH 13114.1; description and species for best hit: Hypothetical protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 206; query end: 591; target start: 1; target end: 386. The percent of the query that aligns with the target is: 65%. The percent of the target that aligns with the query is: 99%.

[0585] AAF23326, SEQ ID NO: 60 SEQ ID NO: 126 encodes a protein that is 455 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=1.40E-304; number of matches: 455; percent identity over the alignment: 100%; percent similarity over the alignment: 10%; accession number for best hit: NP_(—)065154.1; description and species for best hit: Hypothetical protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 455; target start: 1; target end: 455. The percent of the query that aligns with the target is: 100%. The percent of the target that aligns with the query is: 100%.

[0586] SGK493, SEQ ID NO: 61 SEQ ID NO: 127 encodes a protein that is 552 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 552; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)060813.1; description and species for best hit: Hypothetical protein FLJ. 11159 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 552; target start: 1; target end: 552. The percent of the query that aligns with the target is: 100%. The percent of the target that aligns with the query is: 100%.

[0587] BRD2, SEQ ID NO: 62 SEQ ID NO: 128 encodes a protein that is 801 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.60E-256; number of matches: 801; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)005095.1; description and species for best hit: Bromodomain-containing protein 2; female sterile homeotic-related gene 1 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 801; target start: 1; target end: 801. The percent of the query that aligns with the target is: 100%. The percent of the target that aligns with the query is: 100%.

[0588] BRD3, SEQ ID NO: 63, SEQ ID NO: 129 encodes a protein that is 726 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.20E-243; number of matches: 726; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)031397.1; description and species for best hit: Bromodomain-containing protein 3 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 726; target start: 1; target end: 726. The percent of the query that aligns with the target is: 100%. The percent of the target that aligns with the query is: 100%.

[0589] BRD4, SEQ ID NO: 64, SEQ ID NO: 130 encodes a protein that is 722 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=2.60E-232; number of matches: 722; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)055114.1; description and species for best hit: Bromodomain-containing protein 4 [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 722; target start: 1; target end: 722. The percent of the query that aligns with the target is: 100%. The percent of the target that aligns with the query is: 100%.

[0590] BRDT, SEQ ID NO: 65, SEQ ID NO: 131 encodes a protein that is 947 amino acids long. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 947; percent identity over the alignment: 100%; percent similarity over the alignment: 100%; accession number for best hit: NP_(—)001717.1; description and species for best hit: Testis-specific bromodomain protein [Homo sapiens]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 947; target start: 1; target end: 947. The percent of the query that aligns with the target is: 100%. The percent of the target that aligns with the query is: 100%.

[0591] ZC1, SEQ ID NO: 66, SEQ ID NO: 132 encodes a protein that is 1392 amino acids long. It has multiple splice variants, as described above in the Nucleic Acids description section. The results of a Smith-Waterman search of the NCBI non-redundant protein database with the amino acid sequence for this protein yielded the following results: P score=0; number of matches: 1202; percent identity over the alignment: 86%; percent similarity over the alignment: 87%; accession number for best hit: NP_(—)032722; description and species for best hit: NCK interacting kinase; HPK/GCK-like kinase [Mus musculus]. The boundaries of the alignments for the query and the database (target) amino acid sequences were as follows. Query start: 1; query end: 1392; target start: 1; target end: 12433. The percent of the query that aligns with the target is: 87%. The percent of the target that aligns with the query is: 98%.

[0592] Domains of Predicted Proteins (Table 4)

[0593] Many protein kinases contain modular domains in addition to the protein kinases domain. These extra-catalytic domains may play key roles in regulating the activity, protein-protein interactions, and sub-cellular localization of the protein. The paragraphs below describe in detail the protein domains found within the patent sequences. These domains were identified using PFAM (http: //pfam.wustl.edu/hmmsearch.shtml) models, a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Version Pfam 7.3 (May 2002) contains alignments and models for 3849 protein families. The PFAM alignments were downloaded from http: //pfam.wustl.edu/hmmsearch.shtml and the HMMr searches were run locally on a Timelogic computer (TimeLogic Corporation, Incline Village, Nev.).

[0594] Results:

[0595] CRIK, SEQ ID NO: 1, SEQ ID NO: 67, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 9.20E-67. The domain starts at amino acid 98 and ends at amino acid 361. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0596] CRIK, SEQ ID NO: 1, SEQ ID NO: 67, has a CNH domain, (PFAM profile accession #PF00780), identified with P_score 2.60E-115. The domain starts at amino acid 1620 and ends at amino acid 1917. The profile has a length of 378 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 378.

[0597] CRIK, SEQ ID NO: 1, SEQ ID NO: 67, has a PH domain, (PFAM profile accession #PF00169), identified with P_score 3.00E-16. The domain starts at amino acid 1472 and ends at amino acid 1591. The profile has a length of 85 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 85.

[0598] CRIK, SEQ ID NO: 1, SEQ ID NO: 67, has a Phorbol esters/diacylglycerol binding domain (C1 domain), (PFAM profile accession #PF00130), identified with P_score 1.00E-09. The domain starts at amino acid 1391 and ends at amino acid 1439. The profile has a length of 51 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 51.

[0599] CRIK, SEQ ID NO: 1, SEQ ID NO: 67, has a Protein kinase C terminal domain, (PFAM profile accession #PF00433), identified with P_score 3.00E-08. The domain starts at amino acid 362 and ends at amino acid 391. The profile has a length of 70 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 32.

[0600] DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.10E-70. The domain starts at amino acid 71 and ends at amino acid 337. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0601] DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, has a Phorbol esters/diacylglycerol binding domain (CI domain), (PFAM profile accession # PF00130), identified with P_score 3.10E-17. The domain starts at amino acid 887 and ends at amino acid 935. The profile has a length of 51 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 51.

[0602] DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, has a PH domain, (PFAM profile accession #PF00169), identified with P_score 1.70E-16. The domain starts at amino acid 956 and ends at amino acid 1074. The profile has a length of 85 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 85.

[0603] DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, has a CNH domain, (PFAM profile accession #PF00780), identified with P_score 1.50E-12. The domain starts at amino acid 1100 and ends at amino acid 1380. The profile has a length of 378 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 378.

[0604] DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, has a Protein kinase C terminal domain, (PFAM profile accession #PF00433), identified with P_score 2.00E-08. The domain starts at amino acid 351 and ends at amino acid 366. The profile has a length of 70 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 16 to “profile end” residue number 31.

[0605] MAST3, SEQ ID NO: 3, SEQ ID NO: 69, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 5.50E-74. The domain starts at amino acid 389 and ends at amino acid 535. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 149.

[0606] MAST3, SEQ ID NO: 3, SEQ ID NO: 69, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 5.50E-74. The domain starts at amino acid 560 and ends at amino acid 662. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 158 to “profile end” residue number 294.

[0607] MAST3, SEQ ID NO: 3, SEQ ID NO: 69, has a PDZ domain, (PFAM profile accession #PF00595), identified with P_score 3.70E-09. The domain starts at amino acid 972 and ends at amino acid 1054. The profile has a length of 84 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 79.

[0608] MAST205, SEQ ID NO: 4, SEQ ID NO: 70, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 7.90E-80. The domain starts at amino acid 512 and ends at amino acid 785. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0609] MAST205, SEQ ID NO: 4, SEQ ID NO: 70, has a PDZ domain (Also known as DHR or GLGF)., (PFAM profile accession #PF00595), identified with P_score 2.20E-10. The domain starts at amino acid 1104 and ends at amino acid 1191. The profile has a length of 83 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 83.

[0610] MASTL, SEQ ID NO: 5, SEQ ID NO: 71, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.20E-73. The domain starts at amino acid 35 and ends at amino acid 310. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0611] MASTL, SEQ ID NO: 5, SEQ ID NO: 71, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.20E-73. The domain starts at amino acid 739 and ends at amino acid 834. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 149 to “profile end” residue number 278.

[0612] MASTL, SEQ ID NO: 5, SEQ ID NO: 71, has a Protein kinase C terminal domain, (PFAM profile accession #PF00433), identified with P_score 4.60E-07. The domain starts at amino acid 835 and ends at amino acid 863. The profile has a length of 70 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 31.

[0613] PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 3.60E-82. The domain starts at amino acid 355 and ends at amino acid 614. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 294.

[0614] PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, has a Phorbol esters/diacylglycerol binding domain (C1 domain), (PFAM profile accession # PF00130), identified with P_score 4.40E-46. The domain starts at amino acid 172 and ends at amino acid 222. The profile has a length of 51 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 51.

[0615] PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, has a Phorbol esters/diacylglycerol binding domain (C1 domain), (PFAM profile accession # PF00130), identified with P_score 4.40E-46. The domain starts at amino acid 246 and ends at amino acid 295. The profile has a length of 51 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 51.

[0616] PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, has a Protein kinase C terminal domain, (PFAM profile accession #PF00433), identified with P_score=1.80E-41. The domain starts at amino acid 615 and ends at amino acid 681. The profile has a length of 70 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 70.

[0617] H19102, SEQ ID NO: 7, SEQ ID NO: 73, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 3.20E-64. The domain starts at amino acid 146 and ends at amino acid 398. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0618] MSK1, SEQ ID NO: 8, SEQ ID NO: 74, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.60E-182. The domain starts at amino acid 49 and ends at amino acid 318. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0619] MSK1, SEQ ID NO: 8, SEQ ID NO: 74, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.60E-182. The domain starts at amino acid 427 and ends at amino acid 687. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 2 to “profile end” residue number 278.

[0620] MSK1, SEQ ID NO: 8, SEQ ID NO: 74, has a Protein kinase C terminal domain, (PFAM profile accession #PF00433), identified with P_score 2.40E-21. The domain starts at amino acid 319 and ends at amino acid 382. The profile has a length of 70 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 70.

[0621] YANK3, SEQ ID NO: 9, SEQ ID NO: 75, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 3.80E-71. The domain starts at amino acid 93 and ends at amino acid 345. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 287.

[0622] MARK2, SEQ ID NO: 10, SEQ ID NO: 76, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.30E-100. The domain starts at amino acid 53 and ends at amino acid 304. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 294.

[0623] MARK2, SEQ ID NO: 10, SEQ ID NO: 76, has a Kinase associated domain 1, (PFAM profile accession #PF02149), identified with P_score 3.00E-21. The domain starts at amino acid 738 and ends at amino acid 787. The profile has a length of 50 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 50.

[0624] MARK2, SEQ ID NO: 10, SEQ ID NO: 76, has a UBA/TS-N domain, (PFAM profile accession #PF00627), identified with P_score 0.000003. The domain starts at amino acid 324 and ends at amino acid 363. The profile has a length of 45 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 45.

[0625] NuaK2, SEQ ID NO: 11, SEQ ID NO: 77, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 8.00E-94. The domain starts at amino acid 97 and ends at amino acid 347. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 294.

[0626] BRSK2, SEQ ID NO: 12, SEQ ID NO: 78, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 3.20E-97. The domain starts at amino acid 19 and ends at amino acid 270. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0627] MARK4, SEQ ID NO: 13, SEQ ID NO: 79, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score=7.70E-104. The domain starts at amino acid 59 and ends at amino acid 310. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0628] MARK4, SEQ ID NO: 13, SEQ ID NO: 79, has a Kinase associated domain 1, (PFAM profile accession #PF02149), identified with P_score 1.30E-15. The domain starts at amino acid 703 and ends at amino acid 752. The profile has a length of 50 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 50.

[0629] MARK4, SEQ ID NO: 13, SEQ ID NO: 79, has a UBA domain, (PFAM profile accession #PF00627), identified with P_score 6.30E-11. The domain starts at amino acid 330 and ends at amino acid 368. The profile has a length of 41 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 41.

[0630] DCAMKL2, SEQ ID NO: 14, SEQ ID NO: 80, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.70E-97. The domain starts at amino acid 394 and ends at amino acid 651. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0631] PIM2, SEQ ID NO: 15, SEQ ID NO: 81, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.40E-71. The domain starts at amino acid 132 and ends at amino acid 386. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 294.

[0632] PIM3, SEQ ID NO: 16, SEQ ID NO: 82, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 9.90E-80. The domain starts at amino acid 40 and ends at amino acid 293. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0633] TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.10E-78. The domain starts at amino acid 25 and ends at amino acid 293. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0634] CKIL2, SEQ ID NO: 18, SEQ ID NO: 84, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 8.50E-33. The domain starts at amino acid 21 and ends at amino acid 276. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 265.

[0635] PCTAIRE3, SEQ ID NO: 19, SEQ ID NO: 85, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.20E-87. The domain starts at amino acid 50 and ends at amino acid 331. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0636] PFTAIRE2, SEQ ID NO: 20, SEQ ID NO: 86, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 4.40E-80. The domain starts at amino acid 103 and ends at amino acid 387. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0637] ERK7, SEQ ID NO: 21, SEQ ID NO: 87, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 4.80E-90. The domain starts at amino acid 13 and ends at amino acid 323. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0638] CKIIa-rs, SEQ ID NO: 22, SEQ ID NO: 88, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.20E-89. The domain starts at amino acid 39 and ends at amino acid 324. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0639] DYRK4, SEQ ID NO: 23, SEQ ID NO: 89, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 4.00E-64. The domain starts at amino acid 506 and ends at amino acid 802. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0640] HIPK1, SEQ ID NO: 24, SEQ ID NO: 90, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 6.20E-58. The domain starts at amino acid 190 and ends at amino acid 518. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0641] HIPK4, SEQ ID NO: 25, SEQ ID NO: 91, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.10E-58. The domain starts at amino acid 11 and ends at amino acid 347. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0642] BIKE, SEQ ID NO: 26, SEQ ID NO: 92, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.50E-38. The domain starts at amino acid 51 and ends at amino acid 314. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 294.

[0643] NEK10, SEQ ID NO: 27, SEQ ID NO: 93, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 8.80E-70. The domain starts at amino acid 519 and ends at amino acid 783. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 294.

[0644] NEK10, SEQ ID NO: 27, SEQ ID NO: 93, has a Armadillo/beta-catenin-like repeat, (PFAM profile accession #PF00514), identified with P_score 0.009707. The domain starts at amino acid 198 and ends at amino acid 238. The profile has a length of 40 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 40.

[0645] NEK10, SEQ ID NO: 27, SEQ ID NO: 93, has a Armadillo/beta-catenin-like repeat, (PFAM profile accession #PF00514), identified with P_score 0.009707. The domain starts at amino acid 239 and ends at amino acid 279. The profile has a length of 40 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 40.

[0646] NEK10, SEQ ID NO: 27, SEQ ID NO: 93, has a Armadillo/beta-catenin-like repeat, (PFAM profile accession #PF00514), identified with P_score 0.009707. The domain starts at amino acid 280 and ends at amino acid 320. The profile has a length of 40 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 40.

[0647] pNEK5, SEQ ID,NO: 28, SEQ ID NO: 94, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 9.10E-87. The domain starts at amino acid 61 and ends at amino acid 316. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 294.

[0648] NEK1, SEQ ID NO: 29, SEQ ID NO: 95, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.50E-89. The domain starts at amino acid 4 and ends at amino acid 258. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0649] NEK3, SEQ ID NO: 30, SEQ ID NO: 96, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 5.60E-92. The domain starts at amino acid 4 and ends at amino acid 257. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0650] SGK069, SEQ ID NO: 31, SEQ ID NO: 97, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 3.80E-40. The domain starts at amino acid 62 and ends at amino acid 325. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 263.

[0651] SGK110, SEQ ID NO: 32, SEQ ID NO: 98, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.70E-39. The domain starts at amino acid 98 and ends at amino acid 359. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 273.

[0652] NRBP2, SEQ ID NO: 33, SEQ ID NO: 99, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.00E-24. The domain starts at amino acid 38 and ends at amino acid 313. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0653] CNK, SEQ ID NO: 34, SEQ ID NO: 100, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.60E-91. The domain starts at amino acid 62 and ends at amino acid 314. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0654] CNK, SEQ ID NO: 34, SEQ ID NO: 100, has a POLO box duplicated region., (PFAM profile accession #PF00659), identified with P_score 9.70E-35. The domain starts at amino acid 470 and ends at amino acid 533. The profile has a length of 77 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 77.

[0655] CNK, SEQ ID NO: 34, SEQ ID NO: 100, has a POLO box duplicated region., (PFAM profile accession #PF00659), identified with P_score 9.70E-35. The domain starts at amino acid 567 and ends at amino acid 637. The profile has a length of 77 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 77.

[0656] SCYL2, SEQ ID NO: 35, SEQ ID NO: 101, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 8.00E-13. The domain starts at amino acid 32 and ends at amino acid 327. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0657] SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 7.40E-42. The domain starts at amino acid 81 and ends at amino acid 686. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0658] TLK1, SEQ ID NO: 37, SEQ ID NO: 103, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 4.70E-71. The domain starts at amino acid 477 and ends at amino acid 755. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0659] SGK071, SEQ ID NO: 38, SEQ ID NO: 104, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 7.60E-26. The domain starts at amino acid 28 and ends at amino acid 296. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 27 to “profile end” residue number 278.

[0660] SK516, SEQ ID NO: 39, SEQ ID NO: 105, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.50E-44. The domain starts at amino acid 652 and ends at amino acid 915. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0661] H85389, SEQ ID NO: 40, SEQ ID NO: 106, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 3.90E-60. The domain starts at amino acid 69 and ends at amino acid 397. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0662] Wee1b, SEQ ID NO: 41, SEQ ID NO: 107, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.10E-49. The domain starts at amino acid 212 and ends at amino acid 486. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 272.

[0663] Wnk2, SEQ ID NO: 42, SEQ ID NO: 108, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 6.60E-63. The domain starts at amino acid 181 and ends at amino acid 439. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0664] MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.00E-85. The domain starts at amino acid 1242 and ends at amino acid 1507. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0665] MAP3K8, SEQ ID NO: 44, SEQ ID NO: 110, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.10E-88. The domain starts at amino acid 468 and ends at amino acid 731. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0666] Pak4 (Mus musculus), SEQ ID NO: 45 SEQ ID NO: 111, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 5.00E-86. The domain starts at amino acid 323 and ends at amino acid 574. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0667] Pak4, SEQ ID NO: 45 SEQ ID NO: 111, has a P21-Rho-binding domain, (PFAM profile accession #PF00786), identified with P_score 3.20E-12. The domain starts at amino acid 11 and ends at amino acid 69. The profile has a length of 64 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 64.

[0668] STLK6-rs, SEQ ID NO: 46 SEQ ID NO: 112, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 2.60E-33. The domain starts at amino acid 58 and ends at amino acid 369. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 14 to “profile end” residue number 278.

[0669] MAP2K2, SEQ ID NO: 47 SEQ ID NO: 113, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 3.20E-58. The domain starts at amino acid 72 and ends at amino acid 369. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0670] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 6.70E-63. The domain starts at amino acid 796 and ends at amino acid 1061. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 272.

[0671] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, has a Immunoglobulin domain, (PFAM profile accession #PF00047), identified with P_score 1.00E-61. The domain starts at amino acid 46 and ends at amino acid 103. The profile has a length of 45 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 45.

[0672] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, has a Immunoglobulin domain, (PFAM profile accession #PF00047), identified with P_score 1.00E-61. The domain starts at amino acid 143 and ends at amino acid 202. The profile has a length of 45 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 45.

[0673] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, has a Immunoglobulin domain, (PFAM profile accession #PF00047), identified with P_score 1.00E-61. The domain starts at amino acid 239 and ends at amino acid 303. The profile has a length of 45 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 45.

[0674] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, has a Immunoglobulin domain, (PFAM profile accession #PF00047), identified with P_score 1.00E-61. The domain starts at amino acid 336 and ends at amino acid 393. The profile has a length of 45 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 45.

[0675] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, has a Immunoglobulin domain, (PFAM profile accession #PF00047), identified with P_score 1.00E-61. The domain starts at amino acid 426 and ends at amino acid 483. The profile has a length of 45 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 45.

[0676] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, has a Immunoglobulin domain, (PFAM profile accession #PF00047), identified with P_score 1.00E-61. The domain starts at amino acid 517 and ends at amino acid 572. The profile has a length of 45 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 45.

[0677] CCK4, SEQ ID NO: 48 SEQ ID NO: 114, has a hmmunoglobulin domain, (PFAM profile accession #PF00047), identified with P_score 1.00E-61. The domain starts at amino acid 606 and ends at amino acid 666. The profile has a length of 45 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 45.

[0678] LMR1, SEQ ID NO: 49 SEQ ID NO: 115, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.10E-46. The domain starts at amino acid 125 and ends at amino acid 395. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 294.

[0679] RYK, SEQ ID NO: 50 SEQ ID NO: 116, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 3.10E-81. The domain starts at amino acid 330 and ends at amino acid 596. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 276.

[0680] RYK, SEQ ID NO: 50 SEQ ID NO: 116, has a WIF domain, (PFAM profile accession #PF02019), identified with P_score 3.30E-91. The domain starts at amino acid 66 and ends at amino acid 194. The profile has a length of 132 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 132.

[0681] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.00E-41. The domain starts at amino acid 1886 and ends at amino acid 2138. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 8 to “profile end” residue number 272.

[0682] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 983 and ends at amino acid 1004. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0683] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1012 and ends at amino acid 1035. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0684] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1036 and ends at amino acid 1058. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0685] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1084 and ends at amino acid 1103. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0686] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1108 and ends at amino acid 1129. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0687] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1130 and ends at amino acid 1153. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0688] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1174 and ends at amino acid 1196. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0689] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1197 and ends at amino acid 1218. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0690] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1221 and ends at amino acid 1244. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0691] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1246 and ends at amino acid 1268. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0692] LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, has a Leucine Rich Repeat, (PFAM profile accession #PF00560), identified with P_score 2.10E-34. The domain starts at amino acid 1269 and ends at amino acid 1293. The profile has a length of 23 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 23.

[0693] pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.70E-87. The domain starts at amino acid 124 and ends at amino acid 398. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 292.

[0694] pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, has a SH3 domain, (PFAM profile accession #PF00018), identified with P_score 2.00E-14. The domain starts at amino acid 45 and ends at amino acid 100. The profile has a length of 58 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 5 to “profile end” residue number 58.

[0695] KSR, SEQ ID NO: 53 SEQ ID NO: 119, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.40E-31. The domain starts at amino acid 591 and ends at amino acid 731. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 147.

[0696] KSR, SEQ ID NO: 53 SEQ ID NO: 119, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.40E-31. The domain starts at amino acid 753 and ends at amino acid 792. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 163 to “profile end” residue number 195.

[0697] KSR, SEQ ID NO: 53 SEQ ID NO: 119, has a Phorbol esters/diacylglycerol binding domain (C1 domain), (PFAM profile accession # PF00130), identified with P_score 0.008623. The domain starts at amino acid 348 and ends at amino acid 391. The profile has a length of 51 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 51.

[0698] KSR, SEQ ID NO: 53 SEQ ID NO: 119, has a MYND finger, (PFAM profile accession #PF01753), identified with P_score 1.311685. The domain starts at amino acid 360 and ends at amino acid 377. The profile has a length of 43 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 21.

[0699] KSR2, SEQ ID NO: 54 SEQ ID NO: 120, has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 6.90E-40. The domain starts at amino acid 698 and ends at amino acid 957. The profile has a length of 294 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 289.

[0700] KSR2, SEQ ID NO: 54 SEQ ID NO: 120, has a Phorbol esters/diacylglycerol binding domain (C1 domain), (PFAM profile accession # PF00130), identified with P_score 0.000127. The domain starts at amino acid 445 and ends at amino acid 488. The profile has a length of 51 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 51.

[0701] KIAA1646, SEQ ID NO: 55 SEQ ID NO: 121, has a Diacylglycerol kinase catalytic domain, (PFAM profile accession #PF00781), identified with P_score 2.50E-09. The domain starts at amino acid 132 and ends at amino acid 278. The profile has a length of 159 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 159.

[0702] DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122, has a Diacylglycerol kinase accessory domain, (PFAM profile accession #PF00609), identified with P_score 3.30E-129. The domain starts at amino acid 582 and ends at amino acid 762. The profile has a length of 190 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 190.

[0703] DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122, has a Diacylglycerol kinase catalytic domain, (PFAM profile accession #PF00781), identified with P_score 1.20E-71. The domain starts at amino acid 438 and ends at amino acid 562. The profile has a length of 159 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 159.

[0704] DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122, has a Phorbol esters/diacylglycerol binding domain (C1 domain), (PFAM profile accession # PF00130), identified with P_score 5.00E-28. The domain starts at amino acid 245 and ends at amino acid 294. The profile has a length of 51 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 51.

[0705] DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122, has a Phorbol esters/diacylglycerol binding domain (C1 domain), (PFAM profile accession # PF00130), identified with P_score 5.00E-28. The domain starts at amino acid 310 and ends at amino acid 358. The profile has a length of 51 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 51.

[0706] DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122, has a EF hand, (PFAM profile accession #PF00036), identified with P_score 4.10E-17. The domain starts at amino acid 153 and ends at amino acid 181. The profile has a length of 29 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 29.

[0707] DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122, has a EF hand, (PFAM profile accession #PF00036), identified with P_score 4.10E-17. The domain starts at amino acid 198 and ends at amino acid 226. The profile has a length of 29 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 29.

[0708] IP6K1, SEQ ID NO: 57 SEQ ID NO: 123, did not have a recognizable protein domain.

[0709] YAB1, SEQ ID NO: 58 SEQ ID NO: 124, has a ABC1 family, (PFAM profile accession #PF03109), identified with P_score 1.20E-42. The domain starts at amino acid 318 and ends at amino acid 434. The profile has a length of 124 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 124.

[0710] BRD2, SEQ ID NO: 62 SEQ ID NO: 128, has a Bromodomain, (PFAM profile accession #PF00439), identified with P_score 4.90E-91. The domain starts at amino acid 79 and ends at amino acid 168. The profile has a length of 92 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 92.

[0711] BRD2, SEQ ID NO: 62 SEQ ID NO: 128, has a Bromodomain, (PFAM profile accession #PF00439), identified with P_score 4.90E-91. The domain starts at amino acid 352 and ends at amino acid 441. The profile has a length of 92 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 92.

[0712] BRD3, SEQ ID NO: 63, SEQ ID NO: 129, has a Bromodomain, (PFAM profile accession #PF00439), identified with P_score 6.50E-87. The domain starts at amino acid 39 and ends at amino acid 128. The profile has a length of 92 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 92.

[0713] BRD3, SEQ ID NO: 63, SEQ ID NO: 129, has a Bromodomain, (PFAM profile accession #PF00439), identified with P_score 6.50E-87. The domain starts at amino acid 315 and ends at amino acid 403. The profile has a length of 92 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 92.

[0714] BRD4, SEQ ID NO: 64, SEQ ID NO: 130, has a Bromodomain, (PFAM profile accession #PF00439), identified with P_score 1.80E-90. The domain starts at amino acid 63 and ends at amino acid 152. The profile has a length of 92 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 92.

[0715] BRD4, SEQ ID NO: 64, SEQ ID NO: 130, has a Bromodomain, (PFAM profile accession #PF00439), identified with P_score 1.80E-90. The domain starts at amino acid 356 and ends at amino acid 445. The profile has a length of 92 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 92.

[0716] BRDT, SEQ ID NO: 65, SEQ ID NO: 131, has a Bromodomain, (PFAM profile accession #PF00439), identified with P_score 7.50E-86. The domain starts at amino acid 32 and ends at amino acid 121. The profile has a length of 92 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 92.

[0717] BRDT, SEQ ID NO: 65, SEQ ID NO: 131, has a Bromodomain, (PFAM profile accession #PF00439), identified with P_score 7.50E-86. The domain starts at amino acid 275 and ends at amino acid 364. The profile has a length of 92 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 92.

[0718] ZC1, SEQ ID NO: 66, SEQ ID NO: 132 has a Protein kinase domain, (PFAM profile accession #PF00069), identified with P_score 1.4E-91. The domain starts at amino acid 25 and ends at amino acid 289. The profile has a length of 278 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 278.

[0719] ZC1, SEQ ID NO: 66, SEQ ID NO: 132 also has a CNH domain, (PFAM profile accession #PF00780), identified with P_score 9.2E-131. The domain starts at amino acid 1066 and ends at amino acid 1372. The profile has a length of 378 amino acids. The regions of the profile that recognized the domain within the protein were from “profile start” residue number 1 to “profile end” residue number 378.

IV. Biological Significance, Applications, and Clinical Relevance

[0720] For each protein kinase in this application, we provide a classification of the protein class and family to which it belongs, a summary of non-catalytic protein motifs, and a chromosomal location. This information can be used to suggest potential function, regulation or therapeutic utility for each of the proteins. Amplification of chromosomal region can be associated with various cancers. For amplicons discussed in this application, the source of infonnation was Knuutila, et al (Knuutila S, Björkqvist A-M, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy M L, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius V-M, Vidgren V & Zhu Y: DNA copy number amplifications in human neoplasms. Review of comparative genomic hybridization studies. Am J Pathol 152: 1107-1123, 1998. http: //www.helsinki.fi/˜lgl_www/CMG.html).

[0721] The kinase classification and protein domains often reflect pathways, cellular roles, or mechanisms of up- or down-stream regulation. Also disease-relevant genes often occur in families of related genes. For example if one member of a kinase family functions as an oncogene, a tumor suppressor, or has been found to be disrupted in an immune, neurologic, cardiovascular, or metabolic disorder, frequently other family members may play a related role.

I. Biological and Potential Clinical Implications of the Novel Protein Kinases

[0722] AGC Group

[0723] CRIK, SEQ ID NO: 1, SEQ ID NO: 67, DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, MAST3, SEQ ID NO: 3, SEQ ID NO: 69, MAST205, SEQ ID NO: 4, SEQ ID NO: 70, MASTL, SEQ ID NO: 5, SEQ ID NO: 71, PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, H19102, SEQ ID NO: 7, SEQ ID NO: 73, MSK1, SEQ ID NO: 8, SEQ ID NO: 74, YANK3, SEQ ID NO: 9, SEQ ID NO: 75 are members of the AGC group of protein kinases. The AGC group of protein kinases includes as its major prototypes protein kinase C (PKC), cAMP-dependent protein kinases (PKA), the G protein-coupled receptor kinases [(ARK and rhodopsin kinase (GRK1)] as well as p70S6K and AKT.

[0724] The human CRIK protein and nucleic acid are described in this patent. By PCR of a mouse primary keratinocyte cDNA library, Di Cunto et al. (1998) identified murine CRIK (citron Rho-interacting kinase), belonging to the myotonic dystrophy kinase (see 605377) family. Murine CRIK can be expressed as at least 2 isoforms, one of which encompasses the previously reported form of citron in almost its entirety. The long form of murine CRIK is a 240-kD protein in which the kinase domain is followed by the sequence of citron. The short murine form, CRIK-SK (short kinase), is an approximately 54-kD protein that consists mostly of the kinase domain. CRIK and CRIK-SK proteins are capable of phosphorylating exogenous substrates as well as of autophosphorylation, when tested by in vitro kinase assays after expression into COS-7 cells. Murine CRIK kinase activity is increased several-fold by coexpression of constitutively active Rho, while active Rac has more limited effects. Kinase activity of the endogenous CRIK is indicated by in vitro kinase assays after immunoprecipitation with antibodies recognizing the citron moiety of the protein. When expressed in keratinocytes, fill-length CRIK, but not CRIK-SK, localizes into corpuscular cytoplasmic structures and elicits recruitment of actin into these structures. The CRIK protein contains a kinase domain, a coiled-coil domain, a leucine-rich domain, a Rho-Rac binding domain, a zinc finger region, a pleckstrin homology domain, and a putative SH3-binding domain. Di Cunto, F.; Calautti, E.; Hsiao, J.; Ong, L.; Topley, G.; Turco, E.; Dotto, G. P.: Citron Rho-interacting kinase, a novel tissue-specific ser/thr kinase encompassing the Rho-Rac-binding protein citron. J. Biol. Chem. 273: 29706-29711, 1998.

[0725] The human DMPK2 protein and nucleic acid are described in this patent. The homolog DMPK1 is associated with myotonic dystrophy (DM), is a multisystem disorder and the most common form of muscular dystrophy in adults. One form of the disorder (Dystrophia Myotonica 1, DM1; 160900) is caused by an expanded CTG repeat in the 3-prime untranslated region of the dystrophia myotonica protein kinase gene (DMPK1; 605377) on 19q13. A CTG repeat in DMPK1 is transcribed and is located in the 3-prime untranslated region of an mRNA that is expressed in tissues affected by myotonic dystrophy. The polypeptide encoded by this mRNA is a member of the protein kinase family. Since the triplet repeat sequence is within a gene that has a sequence similar to protein kinases, Fu et al. (1992) suggested that the gene be referred to as myotonin-protein kinase. Jansen et al. (1992) demonstrated that the brain and heart transcripts of the DM-kinase gene are subject to alternative RNA splicing in both human and mouse. Given the homology between DMPK1 and DMPK2, DMPK2 may be involved in diseases similar to myotonic dystrophy. Fu, Y et al. Science 255: 1256-1258, 1992.

[0726] Jansen, G.; et al. Characterization of the Myotonic Dystrophy Region Predicts Multiple Protein Isoform-encoding mRNAs. Nature Genet. 1: 261-266, 1992.

[0727] CRIK, SEQ ID NO: 1, SEQ ID NO: 67, and DMPK2, SEQ ID NO: 2, SEQ ID NO: 68 are a members of the DMPK family. These proteins, Dystrophia myotonica-protein kinases, may play a role in muscle contraction; trinucleotide repeat expansion mutations in the 3′ untranslated region of DMPK are associated with myotonic dystrophy. These genes may be involved in diseases of the muscle or nerves.

[0728] MAST3, SEQ ID NO: 3, SEQ ID NO: 69, MAST205, SEQ ID NO: 4, SEQ ID NO: 70, and MASTL, SEQ ID NO: 5, SEQ ID NO: 71, are a members of the MAST family. Mast protein kinases have strong similarity to microtubule associated testis specific serine/threonine protein kinase (mouse Mtssk), which may act in spermatid maturation and microtubule organization. These kinases may be involved in microtubule-associated disease processes, such as tumor cell invasion.

[0729] PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, is a member of the PKC family. Protein kinase C (PKC) is a family of enzymes that are physiologically activated by 1,2-diacylglycerol (DAG) and other lipids. To date, 11 different isozymes, alpha, betaI, betaII, gamma, delta, epsilon, nu, lambda(iota), mu, theta and zeta, have been identified. On the basis of their structure and activators, they can be divided into three groups, two of which are activated by DAG or its surrogate, phorbol 12-myristate 13-acetate (PMA). PKC isozyrnes are remarkably different in number and prevalence in different cell lines and tissues. When activated, the isozymes bind to membrane phospholipids or to receptors that are located in and anchor the enzymes in a subcellular compartment. Some PKCs may also be activated in their soluble form. These enzymes phosphorylate serine and threonine residues on protein substrates, perhaps the best known of which are the myristoylated, alanine-rich C kinase substrate and nuclear lamins A, B and C. The enzymes clearly play a role in signal transduction, and, because of the importance of PMA as a tumor promoter, they are thought to affect some aspect of cell cycling. (See “The sevenfold way of PKC regulation,” Liu W S, Heckman Calif., Cell Signal, 1998 Sept. 10(8): 529-42).

[0730] H19102, SEQ ID NO: 7, SEQ ID NO: 73, MSK1, SEQ ID NO: 8, SEQ ID NO: 74, are members of the family of S6 kinases with a potential role in cancer, inflammation, as well as other disease conditions. Ribosomal protein S6 protein kinases play important pleotropic functions, among them is a key role in the regulation of mRNA translation during protein biosynthesis (Eur J Biochem 2000 November; 267(21): 6321-30, Exp Cell Res. 1999 Nov. 25;253 (1): 100-9, Mol Cell Endocrinol 1999 May 25;151(1-2): 65-77). The phosphorylation of the S6 ribosomal protein by p70S6 has also been implicated in the regulation of cell motility (Immunol Cell Biol 2000 August;78(4): 447-51) and cell growth (Prog Nucleic Acid Res Mol Biol 2000;65: 101-27), and hence, may be important in tumor metastasis, the immune response and tissue repair.

[0731] YANK3, SEQ ID NO: 9, SEQ ID NO: 75, is a member of the Protein Kinase superfamily. It is further classified into the AGC group, and the YANK family.

[0732] CAMK Group

[0733] MARK2, SEQ ID NO: 10, SEQ ID NO: 76, NuaK2, SEQ ID NO: 11, SEQ ID NO: 77, BRSK2, SEQ ID NO: 12, SEQ ID NO: 78, MARK4, SEQ ID NO: 13, SEQ ID NO: 79, DCAMKL2, SEQ ID NO: 14, SEQ ID NO: 80, PIM2, SEQ ID NO: 15, SEQ ID NO: 81, PIM3, SEQ ID NO: 16, SEQ ID NO: 82, and TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, are classified into the CAMK group. The CAMK group of protein kinases includes as its major prototypes the calmodulin-dependent protein kinases, elongation factor-2 kinases, phosphorylase kinase and the Snfl and cAMP-dependent family of protein kinases.

[0734] CK1 Group

[0735] CKIL2, SEQ ID NO: 18, SEQ ID NO: 84, is a member of the Protein Kinase superfamily, the CKI group, and the CKIL family. The casein kinase (CK) group of protein kinases includes as its major prototype casein kinasel (CKI) and case in kinasell (CKII). Both CKI and CKII are ubiquitous, constitutively-active, second-messenger-independent kinases These highly conserved enzymes exist in multiple isoforms. CKI functions in vesicular trafficking, DNA repair, cell cycle progression and cytokinesis (Cell Signal 1998 Nov.; 10(10): 699-711). CKII functions in cell cycle progression in non-neural cells. CKII has also been implicated in multiple signaling pathways in normal and disease states of the mammalian nervous systems (Prog Neurobiol 2000 February;60(3): 211-46).

[0736] Other Group

[0737] CKIIa-rs, SEQ ID NO: 22, SEQ ID NO: 88, is a member of the Protein Kinase superfamily, the Other group, and the CKII family.

[0738] CMGC Group

[0739] PCTAIRE3, SEQ ID NO: 19, SEQ ID NO: 85 and PFTAIRE2, SEQ ID NO: 20, SEQ ID NO: 86 belong in the CMGC group, and the CDK family. The CMGC group of protein kinases includes as its major prototypes the cyclin-dependent protein kinases as well as the MAPK kinases family member. The CDK family to which these kinases belong regulates the cell cycle, as well as transcription and other basic cellular processes.

[0740] ERK7, SEQ ID NO: 21, SEQ ID NO: 87, is a member of the Protein Kinase superfamily. It is further classified into the CMGC group, and the MAPK family. Member of the MAP kinase family of proteins, which are involved in signal transduction; may interact with MEK family of kinases.

[0741] DYRK4, SEQ ID NO: 23, SEQ ID NO: 89, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the DYRK family.

[0742] HIPK1, SEQ ID NO: 24, SEQ ID NO: 90, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the DYRK family.

[0743] HIPK4, SEQ ID NO: 25, SEQ ID NO: 91, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the DYRK family.

[0744] SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, is a member of the Protein Kinase superfamily. It is further classified into the GMGC group, and the SRPK family. Its role is in mRNA splicing.

[0745] Other Family

[0746] BIKE, SEQ ID NO: 26, SEQ ID NO: 92, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NAK family. Bike (BMP-2-Inducible Kinase) kinase activity impairs osteoblast differentiation in vitro (Kearns A E, et al.,. J Biol Chem 2001 November 9;276(45): 42213-8. Since differentiation of osteoblasts is an important step in the progression of bone diseases such as osteoporosis and cancer associated bone degradation, inhibition of Bike may be an excellent means of treating these diseases, as well as others associated with aberrant bone biology.

[0747] NEK Family

[0748] NEK10, SEQ ID NO: 27, SEQ ID NO: 93, NEK5, SEQ ID NO: 28, SEQ ID NO: 94, NEK1, SEQ ID NO: 29, SEQ ID NO: 95, NEK3, SEQ ID NO: 30, SEQ ID NO: 96, are members of the Protein Kinase superfamily, the Other group, and the NEK family. The prototype for this family, NIMA (never in mitosis, gene A), was originally identified in Aspergillus nidulans as a serine/threonine kinase critical for cell cycle progression. NIMA is specifically required to initiate the cytological aspects of mitosis. Temperature-sensitive mutants of NIMA or overexpression of dominant negative forms of NIMA cause cells to arrest in G2 with uncondensed DNA and interphase microtubules (Osmani, (1991) Cell 67, 283-291). In addition, overexpression of NIMA in fungus as well as in mammalian cells results in the early onset of mitotic events, including chromatin condensation and depolymerization of microtubules (Lu, K. P., and Hunter, T. (1995) Prog. Cell Cycle Res. 1, 187-205). The ability of NIMA to functionally regulate mitosis in higher organisms has suggested the existence of a conserved NIMA-like pathway in eukaryotes. However, only in the filamentous ascomycete, Neurospora crassa, and the fission yeast Schizosaccharomyces pombe have functional homologs been identified. Several mammalian Neks have been identified. These typically contain 40-50% sequence identity, which is confined to the catalytic domain. Positional cloning studies revealed Nekl as the gene that is altered in polycystic kidney disease, although its precise function remains unknown (Upadhya, P.,. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 217-221). Nek2 represents the best characterized mammalian Nek. Nek2 displays cell-cycle dependent expression similar to NIMA, both being most abundant at the onset of mitosis (Fry, A. M., (1995) J. Biol. Chem. 270, 12899-12905). Endogenous Nek2 associates with centrosomes, and overexpression of active Nek2 in cells causes a pronounced splitting of centrosomes, required for G2/M transition. Nek2 phosphorylates a centrosomal coiled-coil protein, c-Nap1, and also associates with protein phosphatase 1 (Helps, N. R., (2000) Biochem. J. 349, 509-518). These findings suggest that Nek2 contributes to proper centrosomal function. Characterization of Nek9 has recently been published (Holland, P M et al, J. Biol. Chem., Vol. 277, Issue 18, 16229-16240, May 3, 2002). The novel NEK genes described in this application may play roles in cell-cycle regulation, protein synthesis, changes in cell morphology and regulation of protein sorting.

[0749] These genes are classified within the NKF1 family: SGK069, SEQ ID NO: 31, SEQ ID NO: 97, and SGK110, SEQ ID NO: 32, SEQ ID NO: 98, are members of the Protein Kinase superfamily, classified into the Other group, and the NKF1 family.

[0750] NRBP2, SEQ ID NO: 33, SEQ ID NO: 99, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the NRBP family. This family is releated to the WNK family of kinases, and like the WNK family, may be involved in hypertension.

[0751] CNK, SEQ ID NO: 34, SEQ ID NO: 100, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the PLK family. CNK seems to be required in a step between RAS and RAF or in parallel to RAF, and its function is required for normal cell proliferation and differentiation (PNAS, Therrien, M., et al, Vol. 96, Issue 23, 13259-13263, Nov. 9, 1999). Its role in Ras signalling may implicate it in aberrant signaling associated with cancer, inflammation or CNS disorders.

[0752] SCYL2, SEQ ID NO: 35, SEQ ID NO: 101, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the SCY1 family.

[0753] TLK1, SEQ ID NO: 37, SEQ ID NO: 103, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the TLK family.

[0754] SGK071, SEQ ID NO: 38, SEQ ID NO: 104, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the Unique family.

[0755] SK516, SEQ ID NO: 39, SEQ ID NO: 105, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the Unique family.

[0756] H85389, SEQ ID NO: 40, SEQ ID NO: 106, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the ULK family. It is related to hedgehog signaling.

[0757] Wee1b, SEQ ID NO: 41, SEQ ID NO: 107, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the WEE family.

[0758] Wnk2, SEQ ID NO: 42, SEQ ID NO: 108, is a member of the Protein Kinase superfamily. It is further classified into the Other group, and the Wnk family. Wnk2 belongs to the same family as Wnk1 and Wnk4, which have been shown to be involved in human hypertension (Wilson F H, et al Science, 2001 Aug. 10;293(5532): 1030). Wnk1 and Wnk4 cause pseudohypoaldosteronism type II, a Mendelian trait featuring hypertension, increased renal salt reabsorption, and impaired K+ and H+ excretion. Disease-causing mutations in WNK1 are large intronic deletions that increase WNK1 expression. The mutations in WNK4 are missense, which cluster in a short, highly conserved segment of the encoded protein. Both proteins localize to the distal nephron, a kidney segment involved in salt, K+, and pH homeostasis. WNK1 is cytoplasmic, whereas WNK4 localizes to tight junctions. The WNK kinases and their associated signaling pathway(s) may offer new targets for the development of antihypertensive drugs. Based on its similarity to Wnk1 and Wnk4, Wnk2 may play a role in human hypertension.

[0759] STE Group

[0760] The STE group of protein kinases represent key regulators of multiple signal transduction pathways important in cell proliferation, survival, differentiation and response to cellular stress. The STE group of protein kinases includes as its major prototypes the NEK kinases as well as the STE11 and STE20 family of sterile protein kinases. MAP3K8, SEQ ID NO: 44, SEQ ID NO: 110, is a member of the STE11 family; Pak5_m, SEQ ID NO: 45 SEQ ID NO: 111, is a member of the STE20 family; STLK6-rs, SEQ ID NO: 46 SEQ ID NO: 112, is a member of the STE20 family; MAP2K2, SEQ ID NO: 47 SEQ ID NO: 113, is a member of the STE7 family. Based on the similarity to STE family members, these novel kinases may participate in cell cycle regulation.

[0761] Tyrosine Kinase Group

[0762] The tyrosine kinase group encompass both cytoplasmic (e.g. src) as well as transmembrane receptor tyrosine kinases (e.g. EGF receptor). These kinases play a pivotal role in the signal transduction processes that mediate cell proliferation, differentiation and apoptosis. Three genes are classified as tyrosine kinases: CCK4, SEQ ID NO: 48 SEQ ID NO: 114, is classified into the TK group, and the CCK4 family; LMR1, SEQ ID NO: 49 SEQ ID NO: 115, classified into the TK group, and the Lmr family; and RYK, SEQ ID NO: 50 SEQ ID NO: 116, is classified into the TK group, and the Ryk family.

[0763] Tyrosine Kinase-Like (TKL) Group

[0764] The TKL family represents protein kinases that are more closely related to tyrosine kinases than to serine-threonine kinases. The TKL family consists of the IRAK, LISK, LRRK, MLK, RAF/KSR and STKR sub-families (Manning, G, et al, The Human Kinome, submitted to Science, June 2002; see also www.kinase.com for kinase classification). LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, is classified into the TKL group, and the LRRK family; MLK4, SEQ ID NO: 52 SEQ ID NO: 118, is classified into the TKL group, and the MLK family; KSR, SEQ ID NO: 53 SEQ ID NO: 119, is classified into the TKL group, and the RAF family; KSR2, SEQ ID NO: 54 SEQ ID NO: 120, is classified into the TKL group, and the RAF family.

[0765] Lipid Kinase Superfamily

[0766] KIAA1646, SEQ ID NO: 55 SEQ ID NO: 121, and DGK-beta, SEQ ID NO: 56 SEQ ID NO: 122, are members of the Lipid Kinase superfamily and the DAG/DGK family. Diacylglycerol kinases (DGKs) phosphorylate the second-messenger diacylglycerol (DAG) to phosphatidic acid (PA). The family of DGKs is well conserved among most species. Nine mammalian isotypes have been identified, and are classified into five subgroups based on their primary structure. DGKs contain a conserved catalytic domain and an array of other conserved motifs that are likely to play a role in lipid-protein and protein-protein interactions in various signalling pathways dependent on DAG and/or PA production. DGK is therefore believed to be activated at the (plasma) membrane where DAG is generated. Some isotypes are found associated with and/or regulated by small GTPases of the Rho family. Others are (also) found in the nucleus, in association with other regulatory enzymes of the phosphoinositide cycle, and have an effect on cell cycle progression. Most DGK isotypes show high expression in the brain, often in distinct brain regions, suggesting that each individual isotype has a unique function. (see “Properties and functions of diacylglycerol kinases,” van Blitterswijk W J; Cell Signal 2000 Oct.;12(9-10): 595-605).

[0767] IP6K1, SEQ ID NO: 57 SEQ ID NO: 123, is a member of the Lipid Kinase superfamily. It is further classified into the Inositol kinase group, and the IP6K family (J. Biol. Chem., Vol. 276, Issue 44, 40998-41004, Nov. 2, 2001). Signaling through the inositol phosphate pathway involves a series of kinases and phosphatases that phosphorylate and dephosphorylate the large number of soluble inositol polyphosphates known to exist in eukaryotic cells (Shears, S. B. (1991) Pharmacol. Ther. 49, 79-104). A branch point in this pathway occurs with the production of inositol 1,3,4-trisphosphate (Ins(1,3,4)P3)1, resulting from the hydrolysis of inositol 1,3,4,5-tetrakisphosphate (Ins(1 ,3,4,5)P4) by one of the numerous inositol polyphosphate 5-phosphatase isozymes. Ins(1,3,4)P3 can be dephosphorylated by specific phosphatases, resulting ultimately in the generation of myo-inositol, or it can be phosphorylated further, resulting in the formation of higher phosphorylated forms of inositol. Inositol 1,3,4-trisphosphate 5/6-kinase (5/6-kinase) phosphorylates Ins(1,3,4)P3 to form both inositol 1,3,4,6-tetrakisphosphate (Ins(1,3,4,6)P4) and Ins(1,3,4,5)P4. Ins(1,3,4,6)P4 is the first intermediate in the pathway leading to the formation of the higher phosphorylated inositols including other inositol tetrakisphosphate isomers, inositol 1,3,4,5,6-pentakisphosphate (InsP5), inositol hexakisphosphate (InsP6), and the pyrophosphate forms of inositol (Safrany, S. T., et al. (1999) Biol. Chem. 380, 945-951). IP6K1, SEQ ID NO: 57 SEQ ID NO: 123 may play a role in signalling pathways mediated by phosphoinositol molecules, such as cancer, inflammation and CNS diseases.

[0768] Atypical Group

[0769] ABCI Family

[0770] YAB1, SEQ ID NO: 58 SEQ ID NO: 124, AF052122, SEQ ID NO: 59 SEQ ID NO: 125, and AAF23326, SEQ ID NO: 60 SEQ ID NO: 126 are members of the ABC1 family. ABC1 is an anciently-conserved family of atypical kinases. The family has four members in human, five in Drosophila, and three each in C. elegans and S. cerevisiae. There is weak sequence and structural similarity between ABC1 family members and eukaryotic protein kinases (see Novel Families of Putative Protein Kinases in Bacteria and Archaea: Evolution of the Eukaryotic Protein Kinase Superfamily, C J. Leonared, et al, Genome Research, 8: 1038-1047, 1998). Some family members are localized to the nucleus or the mitochondrion, and may function as novel chaperonins and in energy metabolism. Human family members may serve as targets for disrupting metabolism of cancer cells, for conditions where folding and turnover of proteins is misregulated, or where disruption of protein folding or turnover may have a therapeutic effect, as has been seen recently with the use of proteasome inhibitors to treat a range of cancers.

[0771] Rio Family

[0772] SGK493, SEQ ID NO: 61 SEQ ID NO: 127, is a member of the atypical PK superfamily, and the RIO1 family. Rio is an anciently-conserved family of atypical kinases. Three Rio genes are present in the human genome, with distinct orthologs in fly and worm, and homologs in fungi, archeal bacteria and plants. Rio kinases have weak protein and structural similarity to eukaryotic protein kinases, and biochemical kinase activity has recently been shown for the Rio1 family member in S. cerevisiae (Angermayr et al, (2002) Molecular Microbiology 44(2): 309-24). Riol is required for proper cell cycle and cell division, and for mRNA processing. Both family members in yeast (Rio1 and Rio2) are essential genes null mutants are lethal. Emericella nidulans sudD is another member of the family and is also involved in cell cycle and chromosome segregation. These conserved functions indicate that human members of this family may play critical roles in cell cycle and constitute tractable targets for cancer therapies.

[0773] BRD Family

[0774] BRD2, SEQ ID NO: 62 SEQ ID NO: 128, BRD3, SEQ ID NO: 63, SEQ ID NO: 129, BRD4, SEQ ID NO: 64, SEQ ID NO: 130, and BRDT, SEQ ID NO: 65, SEQ ID NO: 131, are members of the atypical protein kinase superfamily, belonging to the BRD sub-family This family consists of 4 human members, with a single ortholog in Drosophila and in C. elegans. This phylogenetic footprint indicates that the family plays an essential role in metazoan animals, and has been expanded to serve more specialized or expanded functions in humans. All family members contain two bromodomains, thought to be involved in chromosome biology, and an additional conserved region which bears weak sequence and structural similarity to the eukaryotic protein kinase domain. The Drosophila ortholog, fsh is involved in homeotic gene function and chromosomal imprinting. One of the human family members, BRD2/RING3 has been shown to have protein kinase activity. (Denis G V, et al, RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F.Cell Growth Differ. 2000 August; 11(8): 417-24). BRD2 expression is elevated in certain human leukemias, is localized to the nucleus and is required for induction of expression of a number of cell cycle genes. This data, and the bromodomains found in other family members indicate that all family members may be involved in control of cell cycle, chromosome function and oncogenic transformation.

Example 3 Isolation of cDNAs Encoding Mammalian Protein Kinases

[0775] Materials and Methods

[0776] Identification of Novel Clones

[0777] Total RNAs are isolated using the Guanidine Salts/Phenol extraction protocol of Chomczynski and Sacchi (P. Chomczynski and N. Sacchi, Anal. Biochem. 162, 156 (1987)) from primary human tumors, normal and tumor cell lines, normal human tissues, and sorted human hematopoietic cells. These RNAs are used to generate single-stranded cDNA using the Superscript Preamplification System (GIBCO BRL, Gaithersburg, Md.; Gerard, G F et al. (1989), FOCUS 11, 66) under conditions recommended by the manufacturer. A typical reaction uses 10 μg total RNA with 1.5 μg oligo(dT)₁₂₋₁₈ in a reaction volume of 60 μL. The product is treated with RNaseH and diluted to 100 μL with H₂O. For subsequent PCR amplification, 1-4 μL of this sscDNA is used in each reaction.

[0778] Degenerate oligonucleotides are synthesized on an Applied Biosystems 3948 DNA synthesizer using established phosphoramidite chemistry, precipitated with ethanol and used unpurified for PCR. These primers are derived from the sense and antisense strands of conserved motifs within the catalytic domain of several protein kinases. Degenerate nucleotide residue designations are: N=A, C, G, or T; R=A or G; Y=C or T; H=A, C or T not G; D=A, G or T not C; S=C or G; and W=A or T.

[0779] PCR reactions are performed using degenerate primers applied to multiple single-stranded cDNAs. The primers are added at a final concentration of 5 μM each to a mixture containing 10 mM TrisHCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 200 μM each deoxynucleoside triphosphate, 0.001% gelatin, 1.5 U AmpliTaq DNA Polymerase (Perkin-Elmer/Cetus), and 1-4 μL cDNA. Following 3 min denaturation at 95° C., the cycling conditions are 94° C. for 30 s, 50° C. for 1 min, and 72° C. for 1 min 45 s for 35 cycles. PCR fragments migrating between 300-350 bp are isolated from 2% agarose gels using the GeneClean Kit (Bio101), and T-A cloned into the pCRII vector (Invitrogen Corp. U.S.A.) according to the manufacturer's protocol.

[0780] Colonies are selected for mini plasmid DNA-preparations using Qiagen columns and the plasmid DNA is sequenced using a cycle sequencing dye-terminator kit with AmpliTaq DNA Polymerase, FS (ABI, Foster City, Calif.). Sequencing reaction products are run on an ABI Prism 377 DNA Sequencer, and analyzed using the BLAST alignment algorithm (Altschul, S. F. et al., J.Mol.Biol. 215: 403-10).

[0781] Additional PCR strategies are employed to connect various PCR fragments or ESTs using exact or near exact oligonucleotide primers. PCR conditions are as described above except the annealing temperatures are calculated for each oligo pair using the formula: Tm=4(G+C)+2(A+T).

[0782] Isolation of cDNA Clones

[0783] Human cDNA libraries are probed with PCR or EST fragments corresponding to kinase-related genes. Probes are ³²P-labeled by random priming and used at 2×10⁶ cpm/mL following standard techniques for library screening. Pre-hybridization (3 h) and hybridization (overnight) are conducted at 42° C. in 5×SSC, 5× Denhart's solution, 2.5% dextran sulfate, 50 mM Na₂PO₄/NaHPO₄, pH 7.0, 50% formamide with 100 mg/mL denatured salmon sperm DNA. Stringent washes are performed at 65° C. in 0.1×SSC and 0.1% SDS. DNA sequencing was carried out on both strands using a cycle sequencing dye-terminator kit with AmpliTaq DNA Polymerase, FS (ABI, Foster City, Calif.). Sequencing reaction products are run on an ABI Prism 377 DNA Sequencer.

Example 4 Expression Analysis of Mammalian Protein Kinases

[0784] Materials and Methods

[0785] Northern Blot Analysis

[0786] Northern blots are prepared by running 10 μg total RNA isolated from 60 human tumor cell lines (such as HOP-92, EKVX, NCI-H23, NCI-H226, NCI-H322M, NCI-H460, NCI-H522, A549, HOP-62, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, IGROV1, SK-OV-3, SNB-19, SNB-75, U251, SF-268, SF-295, SF-539, CCRF-CEM, K-562, MOLT-4, HL-60, RPMI 8226, SR, DU-145, PC-3, HT-29, HCC-2998, HCT-116, SW620, Colo 205, HTC15, KM-12, UO-31, SNI2C, A498, CaKil, RXF-393, ACHN, 786-0, TK-10, LOX IMVI, Malme-3M, SK-MEL-2, SK-MEL-5, SK-MEL-28, UACC-62, UACC-257, M14, MCF-7, MCF-7/ADR RES, Hs578T, MDA-MB-231, MDA-MB-435, MDA-N, BT-549, T47D), from human adult tissues (such as thymus, lung, duodenum, colon, testis, brain, cerebellum, cortex, salivary gland, liver, pancreas, kidney, spleen, stomach, uterus, prostate, skeletal muscle, placenta, mammary gland, bladder, lymph node, adipose tissue), and 2 human fetal normal tissues (fetal liver, fetal brain), on a denaturing formaldehyde 1.2% agarose gel and transferring to nylon membranes.

[0787] Filters are hybridized with random primed [α²P]dCTP-labeled probes synthesized from the inserts of several of the kinase genes. Hybridization is performed at 42° C. overnight in 6×SSC, 0.1% SDS, 1× Denhardt's solution, 100 μg/mL denatured herring sperm DNA with 1-2×10⁶ cpm/mL of ³²P-labeled DNA probes. The filters are washed in 0.1×SSC/0.1% SDS, 65° C., and exposed on a Molecular Dynamics phosphorimager.

[0788] Quantitative PCR Analysis

[0789] RNA is isolated from a variety of normal human tissues and cell lines. Single stranded cDNA is synthesized from 10 μg of each RNA as described above using the Superscript Preamplification System (GibcoBRL). These single strand templates are then used in a 25 cycle PCR reaction with primers specific to each clone. Reaction products are electrophoresed on 2% agarose gels, stained with ethidium bromide and photographed on a UV light box. The relative intensity of the STK-specific bands were estimated for each sample.

[0790] DNA Array Based Expression Analysis

[0791] Plasmid DNA array blots are prepared by loading 0.5 μg denatured plasmid for each kinase on a nylon membrane. The [γ³²P]dCTP labeled single stranded DNA probes are synthesized from the total RNA isolated from several human immune tissue sources or tumor cells (such as thymus, dendrocytes, mast cells, monocytes, B cells (primary, Jurkat, RPMI8226, SR), T cells (CD8/CD4+, TH1, TH2, CEM, MOLT4), K562 (megakaryocytes). Hybridization is performed at 42° C. for 16 hours in 6×SSC, 0.1% SDS, 1× Denhardt's solution, 100 μg/mL denatured herring sperm DNA with 10⁶ cpm/mL of [γ³²P]dCTP labeled single stranded probe. The filters are washed in 0.1×SSC/0.1% SDS, 65° C., and exposed for quantitative analysis on a Molecular Dynamics phosphorimager.

Example 5 Protein Kinase Gene Expression

[0792] Vector Construction

[0793] Materials and Methods

[0794] Expression Vector Construction

[0795] Expression constructs are generated for some of the human cDNAs including: a) full-length clones in a pCDNA expression vector; b) a GST-fusion construct containing the catalytic domain of the novel kinase fused to the C-terminal end of a GST expression cassette; and c) a full-length clone containing a Lys to Ala (K to A) mutation at the predicted ATP binding site within the kinase domain, inserted in the pCDNA vector.

[0796] The “K to A” mutants of the kinase might function as dominant negative constructs, and will be used to elucidate the function of these novel STKs.

Example 6 Generation of Specific Immunoreagents to Protein Kinases

[0797] Materials and Methods

[0798] Specific immunoreagents are raised in rabbits against KLH- or MAP-conjugated synthetic peptides corresponding to isolated kinase polypeptides. C-terminal peptides were conjugated to KLH with glutaraldehyde, leaving a free C-terminus. Internal peptides were MAP-conjugated with a blocked N-terminus. Additional immunoreagents can also be generated by immunizing rabbits with the bacterially expressed GST-fusion proteins containing the cytoplasmic domains of each novel PTK or STK.

[0799] The various immune sera are first tested for reactivity and selectivity to recombinant protein, prior to testing for endogenous sources.

[0800] Western Blots

[0801] Proteins in SDS PAGE are transferred to immobilon membrane. The washing buffer is PBST (standard phosphate-buffered saline pH 7.4+0.1% Triton X-100). Blocking and antibody incubation buffer is PBST +5% milk. Antibody dilutions varied from 1:1000 to 1: 2000.

Example 7 Recombinant Expression and Biological Assays for Protein Kinases

[0802] Materials and Methods

[0803] Transient Expression of Kinases in Mammalian Cells

[0804] The pcDNA expression plasmids (10 μg DNA/100 mm plate) containing the kinase constructs are introduced into 293 cells with lipofectamine (Gibco BRL). After 72 hours, the cells are harvested in 0.5 mL solubilization buffer (20 mM HEPES, pH 7.35, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl₂, 1 mM EGTA, 2 mM phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin). Sample aliquots are resolved by SDS polyacrylamide gel electrophoresis (PAGE) on 6% acrylamide/0.5% bis-acrylamide gels and electrophoretically transferred to nitrocellulose. Non-specific binding is blocked by preincubating blots in Blotto (phosphate buffered saline containing 5% w/v non-fat dried milk and 0.2% v/v nonidet P-40 (Sigma)), and recombinant protein was detected using the various anti-peptide or anti-GST-fusion specific antisera.

[0805] In Vitro Kinase Assays

[0806] Three days after transfection with the kinase expression constructs, a 10 cm plate of 293 cells is washed with PBS and solubilized on ice with 2 mL PBSTDS containing phosphatase inhibitors (10 mM NaHPO₄, pH 7.25, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 0.2% sodium azide, 1 mM NaF, 1 mM EGTA, 4 mM sodium orthovanadate, 1% aprotinin, 5 μg/mL leupeptin). Cell debris was removed by centrifugation (12000×g, 15 min, 4° C.) and the lysate was precleared by two successive incubations with 50 μL of a 1:1 slurry of protein A sepharose for 1 hour each. One-half mL of the cleared supernatant was reacted with 10 μL of protein A purified kinase-specific antisera (generated from the GST fusion protein or antipeptide antisera) plus 50 μL of a 1:1 slurry of protein A-sepharose for 2 hr at 4° C. The beads were then washed 2 times in PBSTDS, and 2 times in HNTG (20 mM HEPES, pH 7.5/150 mM NaCl, 0,1% Triton X-100, 10% glycerol).

[0807] The immunopurified kinases on sepharose beads are resuspended in 20 μL HNTG plus 30 mM MgCl₂, 10 mM MnCl₂, and 20 μCi [α³²P]ATP (3000 Ci/mmol). The kinase reactions are run for 30 min at room temperature, and stopped by addition of HNTG supplemented with 50 mM EDTA. The samples are washed 6 times in HNTG, boiled 5 min in SDS sample buffer and analyzed by 6% SDS-PAGE followed by autoradiography. Phosphoamino acid analysis is performed by standard 2D methods on ³²P-labeled bands excised from the SDS-PAGE gel.

[0808] Similar assays are performed on bacterially expressed GST-fusion constructs of the kinases.

Example 8a Chromosomal Localization of Protein Kinases (Table 5)

[0809] Materials and Methods

[0810] Chromosomal location can identify candidate targets for a tumor amplicon or a tumor-suppressor locus. Summaries of prevalent tumor amplicons are available in the literature, and can identify tumor types to experimentally be confirmed to contain amplified copies of a kinase gene which localizes to an adjacent region. Several sources were used to find information about the chromosomal localization of each of the genes described in this patent. Materials and Methods

[0811] Several sources were used to find information about the chromosomal localization of each of the genes described in this patent. First, the Celera Browser was used to map the genes. A second source was through BLAT searching of the Human Genome using the University of California, Santa Cruz web tools (http //genome.ucsc.edu/). Alternatively, the accession number of a genomic contig (identified by BLAST against NRNA) was used to query the Entrez Genome Browser (http: //www.ncbi.nlm.nih.gov/PMGifs/Genomes/MapViewerHelp.html), and the cytogenetic localization was read from the NCBI data. References for association of the mapped sites with chromosomal amplifications found in human cancer can be found in: Knuutila, et al., Am J Pathol, 1998, 152: 1107-1123. Information on mapped positions was also obtained by searching published literature (at NCBI, bttp: //www.ncbi.nlm.nih.gov/entrez/query.fcgi) for documented association of the mapped position with human disease.

[0812] 1. Results

[0813] The chromosomal regions for mapped genes are listed Table 5, and are discussed in the section Nucleic Acids above. The chromosomal positions were cross-checked with the Online Mendelian Inheritance in Man database (OMIM, http: //www.ncbi.nlm.nih.gov/htbin-post/Omim)., which tracks genetic information for many human diseases, including cancer. References for association of the mapped sites with chromosomal abnormalities found in human cancer can be found in: Knuutila, et al., Am J Pathol, 1998, 152: 1107-1123. A third source of information on mapped positions was searching published literature (at NCBI, http: //www.ncbi.nlm.nih.gov/entrez/query.fcgi) for documented association of the mapped position with human disease.

[0814] Several sources were used to find information about the chromosomal localization of each of the genes described in this patent. First, cytogenetic map locations of these contigs were found in the title or text of their Genbank record, or by inspection through the NCBI human genome map viewer (http: //www.ncbi.nlm.nih.gov/cgi-bin/Entrez/hum_srch?).

[0815] Alternatively, the accession number of a genomic contig (identified by BLAST against NRNA) was used to query the Entrez Genome Browser (http: //www.ncbi.nlm.nih.gov/PMGifs/Genomes/MapViewerHelp.html), and the cytogenetic localization was read from the NCBI data. A thorough search of available literature for the cytogenetic region is also made using Medline (http: //www.ncbi.nlm.nih.gov/PubMed/medline.html). References for association of the mapped sites with chromosomal amplifications found in human cancer can be found in: Knuutila, et al., Am J Pathol, 1998, 152: 1107-1123.

[0816] Alternatively, the accession number for the nucleic acid sequence is used to query the Unigene database. The site containing the Unigene search engine is: http: //www.ncbi.nlm.nih.gov/UniGene/Hs.Home.html. Information on map position within the Unigene database is imported from several sources, including the Online Mendelian Inheritance in Man (OMIM, http: //www.ncbi.nlm.nih.gov/Omim/searchomim.html), The Genome Database (http: //gdb.infobiogen.fr/gdb/simpleSearch.html), and the Whitehead Institute human physical map (http: //carbon.wi.mit.edu: 8000/cgi-bin/contig/stsinfo?database=release).

[0817] Once a cytogenetic region has been identified bygone of these approaches, disease association can be established by searching OMIM with the cytogenetic location. OMIM maintains a searchable catalog of cytogenetic map locations organized by disease. A thorough search of available literature for the cytogenetic region is also made using Medline (http: //www.ncbi.nlm.nih.gov/PubMed/medline.html). As noted above, feferences for association of the mapped sites with chromosomal abnormalities found in human cancer can be found in: Knuutila, et al., Am J Pathol, 1998, 152: 1107-1123.

Example 8b Candidate Single Nucleotide Polymorphisms (SNPs) (Table 3)

[0818] Materials and Methods

[0819] The most common variations in human DNA are single nucleotide polymorphisms (SNPs), which occur approximately once every 100 to 300 bases. Because SNPs are expected to facilitate large-scale association genetics studies, there has recently been great interest in SNP discovery and detection. Candidate SNPs for the genes in this patent were identified by blastn searching the nucleic acid sequences against the public database of sequences containing documented SNPs (dbSNP: sequence files were downloaded from ftp: //ncbi.nlm.nih.gov/SNP/human/rs-fasta/and ftp: //ncbi.nlm.nih.gov/SNP/human/ss-fasta/and used to create a blast database). dbSNP accession numbers for the SNP-containing sequences are given. SNPs were also identified by comparing several databases of expressed genes (dbEST, NRNA) and genomic sequence (i.e., NRNA) for single basepair mismatches. The results are shown in Table 3. These are candidate SNPs—their actual frequency in the human population was not determined. The code below is standard for representing DNA sequence:

[0820] G=Guanosine

[0821] A=Adenosine

[0822] T=Thymidine

[0823] C=Cytidine

[0824] R=G or A, puRine

[0825] Y=C or T, pyrimidine

[0826] K=G or T, Keto

[0827] W=A or T, Weak (2 H-bonds)

[0828] S=C or G, Strong (3 H-bonds)

[0829] M=A or C, aMino

[0830] B=C, G or T (i.e., not A)

[0831] D=A, G or T (i.e., not C)

[0832] H=A, C or T (i.e., not G)

[0833] V=A, C or G (i.e., not T)

[0834] N=A, C, G or T, aNy

[0835] X=A, C, G or T complementary G A T C R Y W S K M B V D H N X DNA +−+−+−+−+−+−+−+−+−+−+−+−+−+−+−+−+ strands C T A G Y R S W M K V B H D N X

[0836] For example, if two versions of a gene exist, one with a “C” at a given position, and a second one with a “T: at the same position, then that position is represented as a Y, which means C or T.

[0837] Results

[0838] A single nucleotide polymorphism in CRIK, SEQ ID NO: 1, SEQ ID NO: 67, occurs at nucleotide position 2924. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 958. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “T.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1337340_allelePos=258.

[0839] A single nucleotide polymorphism in CRIK, SEQ ID NO: 1, SEQ ID NO: 67, occurs at nucleotide position 3377. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 1109. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1631893_allelePos=310.

[0840] A single nucleotide polymorphism in CRIK, SEQ ID NO: 1, SEQ ID NO: 67, occurs at nucleotide position 4085. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 1345. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1631886_allelePos=605.

[0841] A single nucleotide polymorphism in DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, occurs at nucleotide position 5050. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1752530_allelePos=201.

[0842] A single nucleotide polymorphism in DMPK2, SEQ ID NO: 2, SEQ ID NO: 68, occurs at nucleotide position 1139. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 358. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “G.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1754079_allelePos=201.

[0843] A single nucleotide polymorphism in MAST3, SEQ ID NO: 3, SEQ ID NO: 69, occurs at nucleotide position 2900. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 955. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “D.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1846926_allelePos=432.

[0844] A single nucleotide polymorphism in MAST3, SEQ ID NO: 3, SEQ ID NO: 69, occurs at nucleotide position 623. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 196. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “H.” The dbSNP accession number for this SNP is gn1|dbSNP|ss88979_allelePos=67.

[0845] A single nucleotide polymorphism in MAST205, SEQ ID NO: 4, SEQ ID NO: 70, occurs at nucleotide position 2739. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 913. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1363030_allelePos=144.

[0846] A single nucleotide polymorphism in MAST205, SEQ ID NO: 4, SEQ ID NO: 70, occurs at nucleotide position 25. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 9. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): R/stop. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss133576_allelePos=22.

[0847] A single nucleotide polymorphism in MAST205, SEQ ID NO: 4, SEQ ID NO: 70, occurs at nucleotide position 5303. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 1768. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): S/F. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1529170_allelePos=51.

[0848] A single nucleotide polymorphism in MAST205, SEQ ID NO: 4, SEQ ID NO: 70, occurs at nucleotide position 4652. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 1551. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): D/G. The amino acid at this position in the patent sequence is “D.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1529101_allelePos=5.

[0849] A single nucleotide polymorphism in MAST205, SEQ ID NO: 4, SEQ ID NO: 70, occurs at nucleotide position 3590. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 1197. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): K/R. The amino acid at this position in the patent sequence is “K.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1529096_allelePos=51.

[0850] A single nucleotide polymorphism in MAST205, SEQ ID NO: 4, SEQ ID NO: 70, occurs at nucleotide position 156. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 52. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1608593_allelePos=756.

[0851] A single nucleotide polymorphism in MAST205, SEQ ID NO: 4, SEQ ID NO: 70, occurs at nucleotide position 162. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 54. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “P.” The dbSNP accession number for this SNP is gn1|dbSNP|ss497486allelePos=201.

[0852] A single nucleotide polymorphism in MASTL, SEQ ID NO: 5, SEQ ID NO: 71, occurs at nucleotide position 3831. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1363_allelePos=40.

[0853] A single nucleotide polymorphism in PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, occurs at nucleotide position 1840. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 558. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “N.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1000395_allelePos=101.

[0854] A single nucleotide polymorphism in PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, occurs at nucleotide position 1239. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 358. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): T/I. The amino acid at this position in the patent sequence is “I.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1472906_allelePos=327.

[0855] A single nucleotide polymorphism in PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, occurs at nucleotide position 2288. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1548761_allelePos=51.

[0856] A single nucleotide polymorphism in PKC_eta, SEQ ID NO: 6, SEQ ID NO: 72, occurs at nucleotide position 681. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 172. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): H/G. The amino acid at this position in the patent sequence is “H.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1509877_allelePos=51.

[0857] A single nucleotide polymorphism in MSK1, SEQ ID NO: 8, SEQ ID NO: 74, occurs at nucleotide position 3186. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2025310_allelePos=201.

[0858] A single nucleotide polymorphism in MSK1, SEQ ID NO: 8, SEQ ID NO: 74, occurs at nucleotide position 3658. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1530678_allelePos=5.

[0859] A single nucleotide polymorphism in MSK1, SEQ ID NO: 8, SEQ ID NO: 74, occurs at nucleotide position 3769. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1530679_allelePos=51.

[0860] A single nucleotide polymorphism in MSK1, SEQ ID NO: 8, SEQ ID NO: 74, occurs at nucleotide position 3432. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1530677_allelePos=51.

[0861] A single nucleotide polymorphism in MSK1, SEQ ID NO: 8, SEQ ID NO: 74, occurs at nucleotide position 3779. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1530680_allelePos=51.

[0862] A single nucleotide polymorphism in YANK3, SEQ ID NO: 9, SEQ ID NO: 75, occurs at nucleotide position 1852. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss18125_allelePos=101.

[0863] A single nucleotide polymorphism in YANK3, SEQ ID NO: 9, SEQ ID NO: 75, occurs at nucleotide position 1895. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1517863_allelePos=5.

[0864] A single nucleotide polymorphism in YANK3, SEQ ID NO: 9, SEQ ID NO: 75, occurs at nucleotide position 2021. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1517886_allelePos=51.

[0865] A single nucleotide polymorphism in MARK2, SEQ ID NO: 10, SEQ ID NO: 76, occurs at nucleotide position 2570. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 724. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1121403_allelePos=101.

[0866] A single nucleotide polymorphism in MARK2, SEQ ID NO: 10, SEQ ID NO: 76, occurs at nucleotide position 2615. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 739. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “P.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1121404_allelePos=101.

[0867] A single nucleotide polymorphism in MARK2, SEQ ID NO: 10, SEQ ID NO: 76, occurs at nucleotide position 1641. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 415. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): P/A. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1537647_allelePos=51.

[0868] A single nucleotide polymorphism in MARK2, SEQ ID NO: 10, SEQ ID NO: 76, occurs at nucleotide position 1547. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 383. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|rs1057176_allelePos=51.

[0869] A single nucleotide polymorphism in NuaK2, SEQ ID NO: 11, SEQ iID NO: 77, occurs at nucleotide position 1670. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 538. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1295001_allelePos=93.

[0870] A single nucleotide polymorphism in NuaK2, SEQ ID NO: 11, SEQ IID NO: 77, occurs at nucleotide position 1727. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 557. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1295000_allelePos=36.

[0871] A single nucleotide polymorphism in MARK4, SEQ ID NO: 13, SEQ ID NO: 79, occurs at nucleotide position 2916. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1967699_allelePos=201.

[0872] A single nucleotide polymorphism in MARK4, SEQ ID NO: 13, SEQ ID NO: 79, occurs at nucleotide position 3032. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1967700_allelePos=242.

[0873] A single nucleotide polymorphism in MARK4, SEQ ID NO: 13, SEQ ID NO: 79, occurs at nucleotide position 1699. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 561. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1967693_allelePos=201.

[0874] A single nucleotide polymorphism in MARK4, SEQ ID NO: 13, SEQ ID NO: 79, occurs at nucleotide position 3092. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1512875_allelePos=51.

[0875] A single nucleotide polymorphism in PIM2, SEQ ID NO: 15, SEQ ID NO: 81, occurs at nucleotide position 630. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 210. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “E.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525746_allelePos=5.

[0876] A single nucleotide polymorphism in PIM2, SEQ ID NO: 15, SEQ ID NO: 81, occurs at nucleotide position 1749. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1525747_allelePos=51.

[0877] A single nucleotide polymorphism in PIM2, SEQ ID NO: 15, SEQ ID NO: 81, occurs at nucleotide position 1990. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1525754_allelePos=51.

[0878] A single nucleotide polymorphism in PIM3, SEQ ID NO: 16, SEQ ID NO: 82, occurs at nucleotide position 2057. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1548948_allelePos=51.

[0879] A single nucleotide polymorphism in PIM3, SEQ ID NO: 16, SEQ ID NO: 82, occurs at nucleotide position 1269. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 278. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “P.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1511148_allelePos=51.

[0880] A single nucleotide polymorphism in PIM3, SEQ ID NO: 16, SEQ ID NO: 82, occurs at nucleotide position 2362. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1511284_allelePos=51.

[0881] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 1203. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 196. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Q/R. The amino acid at this position in the patent sequence is “Q.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1975997_allelePos=201.

[0882] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 152. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1588747_allelePos=749.

[0883] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 141. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1588746_allelePos=738.

[0884] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 238. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1211997_allelePos=524.

[0885] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 84. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss934600_allelePos=307.

[0886] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 281. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1747635_allelePos=2506.

[0887] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 236. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1747634_allelePos=2461.

[0888] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 136. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2056655_allelePos=355.

[0889] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 22. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss45790_allelePos=479.

[0890] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 243. The polymorphism results in the following SN?: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2061784_allelePos=1157.

[0891] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 226. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2061783_allelePos=1140.

[0892] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 47. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1990388_allelePos=1229.

[0893] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 158. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1911350_allelePos=370.

[0894] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 77. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1909793_allelePos=506.

[0895] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 137. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1908525_allelePos=1475.

[0896] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 44. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1897673_allelePos=1677.

[0897] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 11. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1857878_allelePos=1145.

[0898] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 223. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1816570_allelePos=267.

[0899] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 85. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1799649_allelePos=306.

[0900] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 280. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1732367_allelePos=496.

[0901] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 97. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1729216_allelePos=408.

[0902] A single nucleotide polymorphism in TSSK4, SEQ ID NO: 17, SEQ ID NO: 83, occurs at nucleotide position 148. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1684407_allelePos=417.

[0903] A single nucleotide polymorphism in CKIL2, SEQ ID NO: 18, SEQ ID NO: 84, occurs at nucleotide position 3889. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 1208. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): H/D. The amino acid at this position in the patent sequence is “H.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1551913_allelePos=51.

[0904] A single nucleotide polymorphism in CKIIar, SEQ ID NO: 22, SEQ ID NO: 88, occurs at nucleotide position 1103. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 318. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1537202_allelePos=51.

[0905] A single nucleotide polymorphism in CKIIar, SEQ ID NO: 22, SEQ ID NO: 88, occurs at nucleotide position 1008. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 287. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): S/R. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1537192_allelePos=51.

[0906] A single nucleotide polymorphism in CKIIar, SEQ ID NO: 22, SEQ ID NO: 88, occurs at nucleotide position 663. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 172. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): R/stop. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1537165_allelePos=51.

[0907] A single nucleotide polymorphism in CKIIar, SEQ ID NO: 22, SEQ ID NO: 88, occurs at nucleotide position 1428. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1537238_allelePos=51.

[0908] A single nucleotide polymorphism in CKIIar, SEQ ID NO: 22, SEQ ID NO: 88, occurs at nucleotide position 194. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 15. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “V.” The dbSNP accession number for this SNP is gn1|dbSNP|ss5453_allelePos=51.

[0909] A single nucleotide polymorphism in CKIIar, SEQ ID NO: 22, SEQ ID NO: 88, occurs at nucleotide position 1200. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 351. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): M/V. The amino acid at this position in the patent sequence is “V.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1537218_allelePos=5.

[0910] A single nucleotide polymorphism in CKIIar, SEQ ID NO: 22, SEQ ID NO: 88, occurs at nucleotide position 1181. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 344. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “T.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1537216_allelePos=51.

[0911] A single nucleotide polymorphism in CKIIar, SEQ ID NO: 22, SEQ ID NO: 88, occurs at nucleotide position 1104. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 319. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): M/L. The amino acid at this position in the patent sequence is “M.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1537203_allelePos=51.

[0912] A single nucleotide polymorphism in DYRK4, SEQ ID NO: 23, SEQ ID NO: 89, occurs at nucleotide position 269. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 90. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): R/H. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss88136_allelePos=155.

[0913] A single nucleotide polymorphism in HIPK1, SEQ ID NO: 24, SEQ ID NO: 90, occurs at nucleotide position 4114. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss12250_allelePos=101.

[0914] A single nucleotide polymorphism in BIKE, SEQ ID NO: 26, SEQ ID NO: 92, occurs at nucleotide position 1606. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 468. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “Q.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1509438_allelePos=51.

[0915] A single nucleotide polymorphism in NEKlO, SEQ ID NO: 27, SEQ ID NO: 93, occurs at nucleotide position 1149. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 325. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): T/S. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss727804_allelePos=20.

[0916] A single nucleotide polymorphism in NEK10, SEQ ID NO: 27, SEQ ID NO: 93, occurs at nucleotide position 1849. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 558. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “G.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1891242_allelePos=201.

[0917] A single nucleotide polymorphism in NEK10, SEQ ID NO: 27, SEQ ID NO: 93, occurs at nucleotide position 2967. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 931. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): N/S. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1325417_allelePos=338.

[0918] A single nucleotide polymorphism in NEK1, SEQ ID NO: 29, SEQ ID NO: 95, occurs at nucleotide position 5063. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1520330_allelePos=51.

[0919] A single nucleotide polymorphism in NEK1, SEQ ID NO: 29, SEQ ID NO: 95, occurs at nucleotide position 4848. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1520329_allelePos=51.

[0920] A single nucleotide polymorphism in NEK3, SEQ ID NO: 30, SEQ ID NO: 96, occurs at nucleotide position 1854. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss3403_allelePos=2.

[0921] A single nucleotide polymorphism in SGK069, SEQ ID NO: 31, SEQ ID NO: 97, occurs at nucleotide position 1001. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 298. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): P/A. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1317629_allelePos=393.

[0922] A single nucleotide polymorphism in SGK069, SEQ ID NO: 31, SEQ ID NO: 97, occurs at nucleotide position 323. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 72. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): R/C. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1688815_allelePos=201.

[0923] A single nucleotide polymorphism in SGK110, SEQ ID NO: 32, SEQ ID NO: 98, occurs at nucleotide position 299. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 1. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): M/L. The amino acid at this position in the patent sequence is “M.” The dbSNP accession number for this SNP is gn1|dbSNP|ss767141_allelePos=201.

[0924] A single nucleotide polymorphism in SGK110, SEQ ID NO: 32, SEQ ID NO: 98, occurs at nucleotide position 985. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 229. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “P.” The dbSNP accession number for this SNP is gn1|dbSNP|ss827468_allelePos=20.

[0925] A single nucleotide polymorphism in SGK110, SEQ ID NO: 32, SEQ ID NO: 98, occurs at nucleotide position 640. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 114. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss661406_allelePos=201.

[0926] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2219. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 681. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): L/F. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525084_allelePos=51.

[0927] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2047. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 623. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “F.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525076_allelePos=51.

[0928] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2040. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 621. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Q/R. The anino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525074_allelePos=51.

[0929] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2035. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 619. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “Y.” The dbSNP accession number for this SNP is gn1|dbSNP|rs1050422_allelePos=51.

[0930] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2021. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 615. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): I/L. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525069_allelePos=51.

[0931] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2014. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 612. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Q/H. The amino acid at this position in the patent sequence is “H.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525066_allelePos=51.

[0932] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2029. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 617. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “G.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525072_allelePos=51.

[0933] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2017. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 613. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “F.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525068_allelePos=51.

[0934] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2016. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 613. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Y/F. The amino acid at this position in the patent sequence is “F.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525067_allelePos=51.

[0935] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2001. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 608. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): N/S. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525064_allelePos=51.

[0936] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 1999. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 607. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “G.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525063_allelePos=51.

[0937] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 1996. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 606. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525062_allelePos=51.

[0938] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 1969. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 597. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “D.” The dbSNP accession number for this SNP is gn1|dbSNP|ss152506 _allelePos=51.

[0939] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2044. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 622. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “E.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525075_allelePos=51.

[0940] A single nucleotide polymorphism in SRPK2, SEQ ID NO: 36, SEQ ID NO: 102, occurs at nucleotide position 2023. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 615. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525072_allelePos=51.

[0941] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 2174. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 646. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): V/D. The amino acid at this position in the patent sequence is “D.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515391_allelePos=51.

[0942] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 2489. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 751. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): N/S. The amino acid at this position in the patent sequence is “N.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515399_allelePos=51.

[0943] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 2515. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 760. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515400_allelePos=51.

[0944] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 2358. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 707. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “E.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515395_allelePos=51.

[0945] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 2294. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 686. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Y/F. The amino acid at this position in the patent sequence is “F.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515394_allelePos=51.

[0946] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 2229. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 664. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “V.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515393_allelePos=51.

[0947] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 2014. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 593. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515384_allelePos=51.

[0948] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 1137. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 300. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “I.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515380_allelePos=51.

[0949] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 3279. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1515413_allelePos=51.

[0950] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 3142. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1515412_allelePos=51.

[0951] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 2488. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 751. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): N/Y. The amino acid at this position in the patent sequence is “N.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515398_allelePos=51.

[0952] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 1711. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 492. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): D/Y. The amino acid at this position in the patent sequence is “Y.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515382_allelePos=51.

[0953] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 1730. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 498. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): S/Y. The amino acid at this position in the patent sequence is “Y.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515383_allelePos=51.

[0954] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 1083. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 282. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): E/D. The amino acid at this position in the patent sequence is “E.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515377_allelePos=51.

[0955] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 1647. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 470. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “H.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515381_allelePos=51.

[0956] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 1092. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 285. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “K.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515379_allelePos=51.

[0957] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 1035. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 266. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515376_allelePos=51.

[0958] A single nucleotide polymorphism in TLK1, SEQ ID NO: 37, SEQ ID NO: 103, occurs at nucleotide position 951. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 238. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “T.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1515375_allelePos=51.

[0959] A single nucleotide polymorphism in Wnk2, SEQ ID NO: 42, SEQ ID NO: 108, occurs at nucleotide position 7079. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2899_allelePos=78.

[0960] A single nucleotide polymorphism in MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, occurs at nucleotide position 2716. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 906. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): I/V. The amino acid at this position in the patent sequence is “I.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1317910allelePos=285.

[0961] A single nucleotide polymorphism in MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, occurs at nucleotide position 6227. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1146242_allelePos=109.

[0962] A single nucleotide polymorphism in MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, occurs at nucleotide position 5560. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1286358_allelePos=101.

[0963] A single nucleotide polymorphism in MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, occurs at nucleotide position 3187. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 1063. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1146312_allelePos=101.

[0964] A single nucleotide polymorphism in MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, occurs at nucleotide position 6015. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1146243_allelePos=101.

[0965] A single nucleotide polymorphism in MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, occurs at nucleotide position 2416. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 806. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): N/D. The amino acid at this position in the patent sequence is “N.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1146310_allelePos=101.

[0966] A single nucleotide polymorphism in MAP3K1, SEQ ID NO: 43, SEQ ID NO: 109, occurs at nucleotide position 1284. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 428. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “T.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1146300_allelePos=101.

[0967] A single nucleotide polymorphism in MAP3K8, SEQ ID NO: 44, SEQ ID NO: 110, occurs at nucleotide position 247. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 83. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Q/E. The amino acid at this position in the patent sequence is “E.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1394913_allelePos=101.

[0968] A single nucleotide polymorphism in MAP3K8, SEQ ID NO: 44, SEQ ID NO: 110, occurs at nucleotide position 2485. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1617_allelePos=49.

[0969] A single nucleotide polymorphism in MAP3K8, SEQ ID NO: 44, SEQ ID NO: 110, occurs at nucleotide position 2298. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1547718_allelePos=51.

[0970] A single nucleotide polymorphism in STLK6r, SEQ ID NO: 46 SEQ ID NO: 112, occurs at nucleotide position 487. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 82. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “T.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1483412_allelePos=100.

[0971] A single nucleotide polymorphism in Map2K2, SEQ ID NO: 47 SEQ ID NO: 113, occurs at nucleotide position 904. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 219. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “I.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1937135_allelePos=201.

[0972] A single nucleotide polymorphism in CCK4, SEQ ID NO: 48 SEQ ID NO: 114, occurs at nucleotide position 3636. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1527472_allelePos=51.

[0973] A single nucleotide polymorphism in RYK, SEQ ID NO: 50 SEQ ID NO: 116, occurs at nucleotide position 2875. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss16914_allelePos=101.

[0974] A single nucleotide polymorphism in RYK, SEQ ID NO: 50 SEQ ID NO: 116, occurs at nucleotide position 2496. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1525573_allelePos=51.

[0975] A single nucleotide polymorphism in RYK, SEQ ID NO: 50 SEQ ID NO: 116, occurs at nucleotide position 851. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 254. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): N/S. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525514_allelePos=51.

[0976] A single nucleotide polymorphism in RYK, SEQ ID NO: 50 SEQ ID NO: 116, occurs at nucleotide position 386. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 99. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): N/S. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1525513_allelePos=51.

[0977] A single nucleotide polymorphism in RYK, SEQ ID NO: 50 SEQ ID NO: 116, occurs at nucleotide position 2764. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss16913_allelePos=31.

[0978] A single nucleotide polymorphism in LRRK2, SEQ ID NO: 51 SEQ ID NO: 117, occurs at nucleotide position 5425. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 1598. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): E/V. The amino acid at this position in the patent sequence is “V.” The dbSNP accession number for this SNP is gn1|dbSNP|ss63276_allelePos=97.

[0979] A single nucleotide polymorphism in pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, occurs at nucleotide position 3597. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2057123_allelePos=323.

[0980] A single nucleotide polymorphism in pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, occurs at nucleotide position 3914. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2057120_allelePos=201.

[0981] A single nucleotide polymorphism in pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, occurs at nucleotide position 3668. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2057122_allelePos=288.

[0982] A single nucleotide polymorphism in pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, occurs at nucleotide position 3800. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2057121_allelePos=22.

[0983] A single nucleotide polymorphism in pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, occurs at nucleotide position 2580. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 773. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1411720_allelePos=519.

[0984] A single nucleotide polymorphism in pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, occurs at nucleotide position 2611. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 784. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): G/C. The amino acid at this position in the patent sequence is “C.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1411719_allelePos=488.

[0985] A single nucleotide polymorphism in pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, occurs at nucleotide position 4193. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2057119_allelePos=201.

[0986] A single nucleotide polymorphism in pMLK4, SEQ ID NO: 52 SEQ ID NO: 118, occurs at nucleotide position 4309. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2057118_allelePos=201.

[0987] A single nucleotide polymorphism in KSR, SEQ ID NO: 53 SEQ ID NO: 119, occurs at nucleotide position 4096. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss100899_allelePos=172.

[0988] A single nucleotide polymorphism in KSR2, SEQ ID NO: 54 SEQ ID NO: 120, occurs at nucleotide position 612. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 204. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “T.” The dbSNP accession number for this SNP is gn1|dbSNP|ss2005786_allelePos=201.

[0989] A single nucleotide polymorphism in KIAA1646, SEQ ID NO: 55 SEQ ID NO: 121, occurs at nucleotide position 3769. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2052346_allelePos=499.

[0990] A single nucleotide polymorphism in KIAA1646, SEQ ID NO: 55 SEQ ID NO: 121, occurs at nucleotide position 3020. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2052345_allelePos=201.

[0991] A single nucleotide polymorphism in KIAA1646, SEQ ID NO: 55 SEQ ID NO: 121, occurs at nucleotide position 2577. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2052344_allelePos=201.

[0992] A single nucleotide polymorphism in KLAA1646, SEQ ID NO: 55 SEQ ID NO: 121, occurs at nucleotide position 2391. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2052344_allelePos=201.

[0993] A single nucleotide polymorphism in KIAA1646, SEQ ID NO: 55 SEQ ID NO: 121, occurs at nucleotide position 4272. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss2052347_allelePos=201.

[0994] A single nucleotide polymorphism in IP6K1, SEQ ID NO: 57 SEQ ID NO: 123, occurs at nucleotide position 3669. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1522850_allelePos=51.

[0995] A single nucleotide polymorphism in IP6K1, SEQ ID NO: 57 SEQ ID NO: 123, occurs at nucleotide position 2851. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1522846_allelePos=51.

[0996] A single nucleotide polymorphism in YAB1, SEQ ID NO: 58 SEQ ID NO: 124, occurs at nucleotide position 2506. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1305707_allelePos=99.

[0997] A single nucleotide polymorphism in YAB1, SEQ ID NO: 58 SEQ ID NO: 124, occurs at nucleotide position 1538. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 480. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “F.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1529336_allelePos=51.

[0998] A single nucleotide polymorphism in SGK493, SEQ ID NO: 61 SEQ ID NO: 127, occurs at nucleotide position 1094. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 349. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): R/G. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1826551_allelePos=201.

[0999] A single nucleotide polymorphism in SGK493, SEQ ID NO: 61 SEQ ID NO: 127, occurs at nucleotide position 1690. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 547. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1826528_allelePos=201.

[1000] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 920. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1425392_allelePos=324.

[1001] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 1794. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 31. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “K.” The dbSNP accession number for this SNP is gn1|dbSNP|ss686785_allelePos=201.

[1002] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 3510. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 603. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|rs516535_allelePos=201.

[1003] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 2413. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 238. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): L/F. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1973307_allelePos=201.

[1004] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 3199. The polymorphism results in the following SNP: K (G/T). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 500. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): E/stop. The amino acid at this position in the patent sequence is “E.” The dbSNP accession number for this SNP is gn1|dbSNP|ss15121_allelePos=101.

[1005] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 3333. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 544. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “K.” The dbSNP accession number for this SNP is gn1|dbSNP|ss13218_allelepos=101.

[1006] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 4348. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR.—The dbSNP accession number for this SNP is gn1|dbSNP|ss12998_allelePos=101.

[1007] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 3411. The polymorphism results in the following. SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 570. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “D.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1550506_allelePos=51.

[1008] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 1344. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1550446_allelePos=51.

[1009] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 4416. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1550446_allelePos=51.

[1010] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 4219. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1523158_allelePos=51.

[1011] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 3342. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 547. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “R.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1523069_allelePos=51.

[1012] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 811. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 5′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1522874_allelePos=51.

[1013] A single nucleotide polymorphism in BRD2, SEQ ID NO: 62 SEQ ID NO: 128, occurs at nucleotide position 2379. The polymorphism results in the following SNP: S (C/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 226. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss18333_allelePos=31.

[1014] A single nucleotide polymorphism in BRD3, SEQ ID NO: 63, SEQ ID NO: 129, occurs at nucleotide position 2405. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss575919_allelePos=201.

[1015] A single nucleotide polymorphism in BRD3, SEQ ID NO: 63, SEQ ID NO: 129, occurs at nucleotide position 1075. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 312. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “L.” The dbSNP accession number for this SNP is gn1|dbSNP|ss630265_allelePos=201.

[1016] A single nucleotide polymorphism in BRD3, SEQ ID NO: 63, SEQ ID NO: 129, occurs at nucleotide position 1975. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 612. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “D.” The dbSNP accession number for this SNP is gn1|dbSNP|ss601346_allelePos=201.

[1017] A single nucleotide polymorphism in BRD3, SEQ ID NO: 63, SEQ ID NO: 129, occurs at nucleotide position 1423. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 428. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “P.” The dbSNP accession number for this SNP is gn1|dbSNP|ss634964_allelePos=201.

[1018] A single nucleotide polymorphism in BRD3, SEQ ID NO: 63, SEQ ID NO: 129, occurs at nucleotide position 2934. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss17101_allelePos=101.

[1019] A single nucleotide polymorphism in BRD3, SEQ ID NO: 63, SEQ ID NO: 129, occurs at nucleotide position 2796. The polymorphism results in the following SNP: Y (C/T). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1527035_allelePos=51.

[1020] A single nucleotide polymorphism in BRD4, SEQ ID NO: 64, SEQ ID NO: 130, occurs at nucleotide position 1846. The polymorphism results in the following SNP: R (A/G). The nucleotide in the patent sequence is “G.” The SNP occurs within the following region (UTR or amino acid number): 542. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): N/D. The amino acid at this position in the patent sequence is “D.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1512910_allelePos=51.

[1021] A single nucleotide polymorphism in BRDT, SEQ ID NO: 65, SEQ ID NO: 131, occurs at nucleotide position 821. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “A.” The SNP occurs within the following region (UTR or amino acid number): 238. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): K/N. The amino acid at this position in the patent sequence is “K.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1559581_allelePos=482.

[1022] A single nucleotide polymorphism in BRDT, SEQ ID NO: 65, SEQ ID NO: 131, occurs at nucleotide position 2976. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 3′ UTR. The dbSNP accession number for this SNP is gn1|dbSNP|ss1553268_allelePos=51.

[1023] A single nucleotide polymorphism in BRDT, SEQ ID NO: 65, SEQ ID NO: 131, occurs at nucleotide position 2785. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 893. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Q/P. The amino acid at this position in the patent sequence is “P.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1553264_allelePos=51.

[1024] A single nucleotide polymorphism in BRDT, SEQ ID NO: 65, SEQ ID NO: 131, occurs at nucleotide position 1114. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 336. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): stop/S. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1553262_allelePos=51.

[1025] A single nucleotide polymorphism in BRDT, SEQ ID NO: 65, SEQ ID NO: 131, occurs at nucleotide position 1113. The polymorphism results in the following SNP: W (A/T). The nucleotide in the patent sequence is “T.” The SNP occurs within the following region (UTR or amino acid number): 336. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Y/S. The amino acid at this position in the patent sequence is “S.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1553261_allelePos=51.

[1026] A single nucleotide polymorphism in BRDT, SEQ ID NO: 65, SEQ ID NO: 131, occurs at nucleotide position 2882. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 925. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1553267_allelePos=51.

[1027] A single nucleotide polymorphism in BRDT, SEQ ID NO: 65, SEQ ID NO: 131, occurs at nucleotide position 2851. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 915. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): Q/P. The amino acid at this position in the patent sequence is “P.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1553266_allelePos=51.

[1028] A single nucleotide polymorphism in BRDT, SEQ ID NO: 65, SEQ ID NO: 131, occurs at nucleotide position 2846. The polymorphism results in the following SNP: M (A/C). The nucleotide in the patent sequence is “C.” The SNP occurs within the following region (UTR or amino acid number): 913. The SNP has the following effect on the coding sequence of the gene (amino acid change or silent): silent. The amino acid at this position in the patent sequence is “A.” The dbSNP accession number for this SNP is gn1|dbSNP|ss1553265_allelePos=51.

Example 9 Demonstration of Gene Amplification By Southern Blotting

[1029] Materials and Methods

[1030] Nylon membranes are purchased from Boehringer Mannheim. Denaturing solution contains 0.4 M NaOH and 0.6 M NaCl. Neutralization solution contains 0.5 M Tris-HCL, pH 7.5 and 1.5 M NaCl. Hybridization solution contains 50% formamide, 6×SSPE, 2.5× Denhardt's solution, 0.2 mg/mL denatured salmon DNA, 0.1 mg/mL yeast tRNA, and 0.2% sodium dodecyl sulfate. Restriction enzymes are purchased from Boehringer Mannheim. Radiolabeled probes are prepared using the Prime-it II kit by Stratagene. The beta actin DNA fragment used for a probe template is purchased from Clontech.

[1031] Genomic DNA is isolated from a variety of tumor cell lines (such as MCF-7, MDA-MB-231, Calu-6, A549, HCT-15, HT-29, Colo 205, LS-180, DLD-1, HCT-116, PC3, CAPAN-2, MIA-PaCa-2, PANC-1, AsPc-1, BxPC-3, OVCAR-3, SKOV3, SW 626 and PA-1, and from two normal cell lines.

[1032] A 10 μg aliquot of each genomic DNA sample is digested with EcoR I restriction enzyme and a separate 10 μg sample is digested with Hind III restriction enzyme. The restriction-digested DNA samples are loaded onto a 0.7% agarose gel and, following electrophoretic separation, the DNA is capillary-transferred to a nylon membrane by standard methods (Sambrook, J. et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory).

Example 10 Detection of Protein-Protein Interaction Through Phage Display

[1033] Materials And Methods

[1034] Phage display provides a method for isolating molecular interactions based on affinity for a desired bait. cDNA fragments cloned as fusions to phage coat proteins are displayed on the surface of the phage. Phage(s) interacting with a bait are enriched by affinity purification and the insert DNA from individual clones is analyzed.

[1035] T7 Phage Display Libraries

[1036] All libraries were constructed in the T7Select1-1b vector (Novagen) according to the manufacturer's directions.

[1037] Bait Presentation

[1038] Protein domains to be used as baits are generated as C-terminal fusions to GST and expressed in E. coli. Peptides are chemically synthesized and biotinylated at the N-terminus using a long chain spacer biotin reagent.

[1039] Selection

[1040] Aliquots of refreshed libraries (10¹⁰-10¹² pfu) supplemented with PanMix and a cocktail of E. coli inhibitors (Sigma P-8465) are incubated for 1-2 hrs at room temperature with the immobilized baits. Unbound phage is extensively washed (at least 4 times) with wash buffer.

[1041] After 3-4 rounds of selection, bound phage is eluted in 100 μL of 1% SDS and plated on agarose plates to obtain single plaques.

[1042] Identification of insert DNAs

[1043] Individual plaques are picked into 25 μL of 10 mM EDTA and the phage is disrupted by heating at 70° C. for 10 min. 2 μL of the disrupted phage are added to 50 μL PCR reaction mix. The insert DNA is amplified by 35 rounds of thermal cycling (94° C., 50 sec; 50° C., 1 min; 72° C., 1 min).

[1044] Composition of Buffer

[1045] 10× PanMix

[1046] 5% Triton X-100

[1047]10% non-fat dry milk (Carnation)

[1048] 10 mM EGTA

[1049] 250 mM NaF

[1050] 250 μg/mL Heparin (sigma)

[1051] 250 μg/mL sheared, boiled salmon sperm DNA (sigma)

[1052] 0.05% Na azide

[1053] Prepared in PBS Wash Buffer PBS supplemented with: 0.5% NP-40 25 μl g/mL heparin PCR reaction mix 1.0 mL 10× PCR buffer (Perkin-Elmer, with 15 mM Mg) 0.2 mL each dNTPs (10 mM stock) 0.1 mL T7UP primer (15 pmol/μL) GGAGCTGTCGTATTCCAGTC 0.1 mL T7DN primer (15 pmol/μL) AACCCCTCAAGACCCGTTTAG 0.2 mL 25 mM MgCl₂ or MgSO₄ to compensate for EDTA Q.S. to 10 mL with distilled water Add 1 unit of Taq polymerase per 50 μL reaction LIBRARY: T7 Select1-H441

Example 26 HUV-EC-C Assay

[1054] The following protocol may also be used to measure a compound's activity against PDGF-R, FGF-R, VEGF, aFGF or Flk-1/KDR, all of which are naturally expressed by HUV-EC cells.

[1055] DAY 0

[1056] 1. Wash and trypsinize HUV-EC-C cells (human umbilical vein endothelial cells, (American Type Culture Collection; catalogue no. 1730 CRL). Wash with Dulbecco's phosphate-buffered saline (D-PBS; obtained from Gibco BRL; catalogue no. 14190-029) 2 times at about 1 mV/10 cm² of tissue culture flask. Trypsinize with 0.05% trypsin-EDTA in non-enzymatic cell dissociation solution (Sigma Chemical Company; catalogue no. C-1544). The 0.05% trypsin was made by diluting 0.25% trypsin/1 mM EDTA (Gibco; catalogue no. 25200-049) in the cell dissociation solution. Trypsinize with about 1 ml/25-30 cm² of tissue culture flask for about 5 minutes at 37° C. After cells have detached from the flask, add an equal volume of assay medium and transfer to a 50 ml sterile centrifuge tube (Fisher Scientific; catalogue no. 05-539-6).

[1057] 2. Wash the cells with about 35 ml assay medium in the 50 ml sterile centrifuge tube by adding the assay medium, centrifuge for 10 minutes at approximately 200 g, aspirate the supernatant, and resuspend with 35 ml D-PBS. Repeat the wash two more times with D-PBS, resuspend the cells in about 1 ml assay medium/15 cm² of tissue culture flask. Assay medium consists of F12K medium (Gibco BRL; catalogue no. 21127-014)+0.5% heat-inactivated fetal bovine serum. Count the cells with a Coulter Counter™ Coulter Electronics, Inc.) and add assay medium to the cells to obtain a concentration of 0.8-1.0×105 cells/ml.

[1058] 3. Add cells to 96-well flat-bottom plates at 100 μl/well or 0.8-1.0×10⁴ cells/well; incubate ˜24 h at 37° C., 5% CO2.

[1059] DAY 1

[1060] 1. Make up two-fold drug titrations in separate 96-well plates, generally 50 μM on down to 0 μM. Use the same assay medium as mentioned in day 0, step 2, above. Titrations are made by adding 90 μl/well of drug at 200 μM (4× the final well concentration) to the top well of a particular plate column. Since the stock drug concentration is usually 20 mM in DMSO, the 200 μM drug concentration contains 2% DMSO.

[1061] Therefore, diluent made up to 2% DMSO in assay medium (Fl2K+0.5% fetal bovine serum) is used as diluent for the drug titrations in order to dilute the drug but keep the DMSO concentration constant. Add this diluent to the remaining wells in the column at 60 μl/well. Take 60 μl from the 120 μl of 200 μM drug dilution in the top well of the column and mix with the 60 μl in the second well of the column. Take 60 μl from this well and mix with the 60 μl in the third well of the column, and so on until two-fold titrations are completed. When the next-to-the-last well is mixed, take 60 μl of the 120 μl in this well and discard it. Leave the last well with 60 μl of DMSO/media diluent as a non-drug-containing control. Make 9 columns of titrated drug, enough for triplicate wells each for 1) VEGF (obtained from Pepro Tech Inc., catalogue no. 100-200, 2) endothelial cell growth factor (ECGF) (also known as acidic fibroblast growth factor, or aFGF) (obtained from Boehringer Mannheim Biochemica, catalogue no. 1439 600); or, 3) human PDGF B/B (1276-956, Boehringer Mannheim, Germany) and assay media control. ECGF comes as a preparation with sodium heparin.

[1062] 2. Transfer 50 μl/well of the drug dilutions to the 96-well assay plates containing the 0.8-1.0×10⁴ cells/100 μl/well of the HUV-EC-C cells from day 0 and incubate ˜2 h at 37° C., 5% CO₂.

[1063] 3. In triplicate, add 50 μl/well of 80 μg/ml VEGF, 20 ng/ml ECGF, or media control to each drug condition. As with the drugs, the growth factor concentrations are 4× the desired final concentration. Use the assay media from day 0, step 2, to make the concentrations of growth factors. Incubate approximately 24 hours at 37° C., 5% CO₂. Each well will have 50 μl drug dilution, 50 μl growth factor or media, and 100 μl cells,=200 μl/well total. Thus the 4× concentrations of drugs and growth factors become 1× once everything has been added to the wells.

[1064] DAY 2

[1065] 1. Add ³H-thymidine (Amersham; catalogue no. TRK-686) at 1 μCi/well (10 μl/well of 100 μCi/ml solution made up in RPMI media+10% heat-inactivated fetal bovine serum) and incubate ˜24 h at 37° C., 5% CO₂. Note: ³H-thymidine is made up in RPMI media because all of the other applications for which we use the ³H-thymidine involve experiments done in RPMI. The media difference at this step is probably not significant. RPMI was obtained from Gibco BRL, catalogue no. 11875-051.

[1066] DAY 3

[1067] 1. Freeze plates overnight at ˜20° C.

[1068] DAY4

[1069] 1. Thaw plates and harvest with a 96-well plate harvester (Tomtec Harvester 96^((R))) onto filter mats (Wallac; catalogue no. 1205-401); read counts on a Wallac Betaplate™ liquid scintillation counter.

CONCLUSION

[1070] One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

[1071] All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

[1072] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising,” “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[1073] In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.

[1074] In view of the degeneracy of the genetic code, other combinations of nucleic acids also encode the claimed peptides and proteins of the invention. For example, all four nucleic acid sequences GCT, GCC, GCC, and GCG encode the amino acid alanine. Therefore, if for an amino acid there exists an average of three codons, a polypeptide of 100 amino acids in length will, on average, be encoded by 3100, or 5×1047, nucleic acid sequences. Thus, a nucleic acid sequence can be modified to form a second nucleic acid sequence, encoding the same polypeptide as encoded by the first nucleic acid sequences, using routine procedures and without undue experimentation. Thus, all possible nucleic acids that encode the claimed peptides and proteins are also fully described herein, as if all were written out in full taking into account the codon usage, especially that preferred in humans. Furthermore, changes in the amino acid sequences of polypeptides, or in the corresponding nucleic acid sequence encoding such polypeptide, may be designed or selected to take place in an area of the sequence where the significant activity of the polypeptide remains unchanged. For example, an amino acid change may take place within a β-turn, away from the active site of the polypeptide. Also changes such as deletions (e.g. removal of a segment of the polypeptide, or in the corresponding nucleic acid sequence encoding such polypeptide, which does not affect the active site) and additions (e.g. addition of more amino acids to the polypeptide sequence without affecting the function of the active site, such as the formation of GST-fusion proteins, or additions in the corresponding nucleic acid sequence encoding such polypeptide without affecting the function of the active site) are also within the scope of the present invention. Such changes to the polypeptides can be performed by those with ordinary skill in the art using routine procedures and without undue experimentation. Thus, all possible nucleic and/or amino acid sequences that can readily be determined not to affect a significant activity of the peptide or protein of the invention are also fully described herein.

[1075] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. TABLE 1 Description of Open Reading Frames ORF ORF Physical Gene NAME Sp ID#na ID#aa Super-family Group Family NA_length AA_length Start ORF End Length Status CRIK H 1 67 Protein Kinase AGC DMPK 8656 2055 51 6218 6168 FL DMPK2 H 2 68 Protein Kinase AGC DMPK 5438 1572 66 4784 4719 Partial MAST3 H 3 69 Protein Kinase AGC MAST 5990 1332 36 4031 3996 Partial MAST205 H 4 70 Protein Kinase AGC MAST 5516 1798 1 5397 5397 Partial MASTL H 5 71 Protein Kinase AGC MAST 3882 878 967 3603 2637 FL PKC_eta H 6 72 Protein Kinase AGC PKC 2392 683 407 2458 2052 FL H19102 H 7 73 Protein Kinase AGC RSK 1564 449 188 1537 1350 Partial MSK1 H 8 74 Protein Kinase AGC RSK 3813 802 159 2567 2409 FL YANK3 H 9 75 Protein Kinase AGC YANK 2051 486 70 1530 1461 FL MARK2 H 10 76 Protein Kinase CAMK CAMKL 3063 787 399 2762 2364 Partial NuaK2 H 11 77 Protein Kinase CAMK CAMKL 3463 672 57 2075 2019 FL BRSK2 H 12 78 Protein Kinase CAMK CAMKL 3831 674 25 2049 2025 Partial MARK4 H 13 79 Protein Kinase CAMK CAMKL 3249 752 17 2275 2259 Partial DCAMKL2 H 14 80 Protein Kinase CAMK DCAMKL 2827 766 350 2650 2301 FL PIM2 H 15 81 Protein Kinase CAMK PIM 2186 435 1 1305 1305 Partial PIM3 H 16 82 Protein Kinase CAMK PIM 2405 326 436 1416 981 FL TSSK4 H 17 83 Protein Kinase CAMK TSSK 1710 328 617 1603 987 FL CKIL2 H 18 84 Protein Kinase CKI CKIL 5946 1244 368 4102 3735 FL PCTAIRE3 H 19 85 Protein Kinase CMGC CDK 3229 505 303 1817 1515 FL PFTAIRE2 H 20 86 Protein Kinase CMGC CDK 2250 435 45 1352 1308 FL ERK7 H 21 87 Protein Kinase CMGC MAPK 1906 563 19 1710 1692 FL CKIIa·rs H 22 88 Protein Kinase Other CKII 1494 391 150 1325 1176 Partial DYRK4 H 23 89 Protein Kinase CMGC DYRK 2886 921 1 2766 2766 FL HIPK1 H 24 90 Protein Kinase CMGC DYRK 8212 1210 286 3918 3633 FL HIPK4 H 25 91 Protein Kinase CMGC DYRK 3142 616 977 2827 1851 FL BIKE H 26 92 Protein Kinase Other NAK 3895 1161 203 3688 3486 FL NEK10 H 27 93 Protein Kinase Other NEK 3912 1125 176 3553 3378 FL pNEK5 H 28 94 Protein Kinase Other NEK 2816 889 147 2816 2670 FL NEK1 H 29 95 Protein Kinase Other NEK 5583 1286 493 4353 3861 Partial NEK3 H 30 96 Protein Kinase Other NEK 2326 506 296 1816 1521 Partial SGK069 H 31 97 Protein Kinase Other NKF1 1156 348 110 1156 1047 FL SGK110 H 32 98 Protein Kinase Other NKF1 1853 414 299 1543 1245 FL NRBP2 H 33 99 Protein Kinase Other NRBP 3765 507 282 1805 1524 FL CNK H 34 100 Protein Kinase Other PLK 2535 646 534 2474 1941 Partial SCYL2 H 35 101 Protein Kinase Other SCY1 5525 933 173 2974 2802 Partial SRPK2 H 36 102 Protein Kinase CMGC SRPK 3715 688 179 2245 2067 FL TLK1 H 37 103 Protein Kinase Other TLK 4321 787 238 2601 2364 Partial SGK071 H 38 104 Protein Kinase Other Unique 2285 632 195 2093 1899 FL SK516 H 39 105 Protein Kinase Other Unique 7364 929 180 2969 2790 Partial H85389 H 40 106 Protein Kinase Other ULK 1971 401 134 1339 1206 FL Weelb H 41 107 Protein Kinase Other WEE 1704 567 1 1704 1704 Partial Wnk2 H 42 108 Protein Kinase Other Wnk 7981 2245 67 6804 6738 Partial MAP3K1 H 43 109 Protein Kinase STE STE11 7026 1511 1 4536 4536 Partial MAP3K8 H 44 110 Protein Kinase STE STE11 2571 735 1 2208 2208 Partial Pak4_m M 45 111 Protein Kinase STE STE20 1782 593 1 1782 1782 Partial STLK6·rs H 46 112 Protein Kinase STE STE20 2171 418 242 1498 1257 Partial MAP2K2 H 47 113 Protein Kinase STE STE7 1724 380 248 1390 1143 FL CCK4 H 48 114 Protein Kinase TK CCK4 4232 1070 191 3403 3213 FL LMR1 H 49 115 Protein Kinase TK Lmr 5313 1374 85 4209 4125 FL RYK H 50 116 Protein Kinase TK Ryk 3663 607 91 1914 1824 Partial LRRK2 H 51 117 Protein Kinase TKL LRRK 9753 2534 633 8237 7605 Partial pMLK4 H 52 118 Protein Kinase TKL MLK 4667 1036 262 3372 3111 FL KSR H 53 119 Protein Kinase TKL RAF 5913 901 165 2870 2706 Partial KSR2 H 54 120 Protein Kinase TKL RAF 2994 982 1 2949 2949 FL KIAA1646 H 55 121 Lipid Kinase DAG kin DAG kin 4429 537 92 1705 1614 Partial DGK·beta H 56 122 Lipid Kinase DAG kin DAG kin 4297 804 372 2786 2415 FL IP6K1 H 57 123 Lipid Kinase Inositol kinase IP6K 4461 441 309 1634 1326 Partial YAB1 H 58 124 Atypical PK Atypical ABC1 2508 647 99 2042 1944 FL AF052122 H 59 125 Atypical PK Atypical ABC1 5237 591 1 1776 1776 FL AAF23326 H 60 126 Atypical PK Atypical ABC1 1368 455 1 1368 1368 FL SGK493 H 61 127 Atypical PK Atypical RIO1 1832 552 50 1708 1659 FL BRD2 H 62 128 Atypical PK BRD BRD 4693 801 1702 4107 2406 Partial BRD3 H 63 129 Atypical PK BRD BRD 3085 726 140 2320 2181 Partial BRD4 H 64 130 Atypical PK BRD BRD 3149 722 223 2391 2169 Partial BRDT H 65 131 Atypical PK BRD BRD 3106 947 108 2951 2844 Partial ZC1 H 66 132 Protein Kinase STE STE20 7986 1392 366 4544 4179 FL

[1076] TABLE 2A Smith-Waterman Comparison with NCBI Non-redundant Proteins Page 1 of 2 for Smith-Waterman Gene_NAME Sp ID#na ID#aa Super-family Group Family AA length PSCORE MATCHES CRIK H 1 67 Protein Kinase AGC DMPK 2055 0 1975 DMPK2 H 2 68 Protein Kinase AGC DMPK 1572 2.20E−211 731 MAST3 H 3 69 Protein Kinase AGC MAST 1331 0 1287 MAST205 H 4 70 Protein Kinase AGC MAST 1798 0 1664 MASTL H 5 71 Protein Kinase AGC MAST 878 0 876 PKC_eta H 6 72 Protein Kinase AGC PKC 663 0 679 H19102 H 7 73 Protein Kinase AGC RSK 449 1.00E−124 269 MSK1 H 8 74 Protein Kinase AGC RSK 802 3.50E−304 787 YANK3 H 9 75 Protein Kinase AGC YANK 486   8.9e−311 444 MARK2 H 10 76 Protein Kinase CAMK CAMKL 787 2.60E−299 752 NuaK2 H 11 77 Protein Kinase CAMK CAMKL 672 5.10E−269 628 BRSK2 H 12 76 Protein Kinase CAMK CAMKL 674 4.20E−175 602 MARK4 H 13 79 Protein Kinase CAMK CAMKL 752 4.30E−296 751 DCAMKL2 H 14 80 Protein Kinase CAMK DCAMKL 766 8.10E−159 513 PIM2 H 15 81 Protein Kinase CAMK PIM 434 1.40E−145 334 PIM3 H 16 82 Protein Kinase CAMK PIM 326 9.90E−174 311 TSSK4 H 17 83 Protein Kinase CAMK TSSK 328 1.60E−69 261 CKIL2 H 18 84 Protein Kinase CKI CKIL 1244 1.50E−298 645 PCTAIRE3 H 19 85 Protein Kinase CMGC CDK 504 1.50E−220 471 PFTAIRE2 H 20 86 Protein Kinase CMGC CDK 435 8.40E−100 225 ERK7 H 21 87 Protein Kinase CMGC MAPK 563 1.90E−128 384 CKIIa·rs H 22 88 Protein Kinase Other CKII 391 9.60E−195 390 DYRK4 H 23 89 Protein Kinase CMGC DYRK 921 1.20E−304 526 HIPK1 H 24 90 Protein Kinase CMGC DYRK 1210 0 1181 HIPK4 H 25 91 Protein Kinase CMGC DYRK 616 0 598 BIKE H 28 92 Protein Kinase Other NAK 1161 7.60E−244 960 NEK10 H 27 93 Protein Kinase Other NEK 1125 9.80E−185 428 pNEK5 H 28 94 Protein Kinase Other NEK 889 1.60E−78 160 NEK1 H 29 95 Protein Kinase Other NEK 1288 0 1258 NEK3 H 30 96 Protein Kinase Other NEK 508 1.80E−202 458 SGK069 H 31 97 Protein Kinase Other NKF1 343 7.40E−48 122 SGK110 H 32 96 Protein Kinase Other NKF1 414 4.00E−35 110 NRBP2 H 33 99 Protein Kinase Other NRBP 507 3.20E−158 300 CNK H 34 100 Protein Kinase Other PLK 646 8.60E−236 645 SCYL2 H 35 101 Protein Kinase Other SCY1 933 0 791 SRPK2 H 36 102 Protein Kinase CMGC SRPK 686 7.80E−183 684 TLK1 H 37 103 Protein Kinase Other TLK 787 0 777 SGK071 H 38 104 Protein Kinase Other Unique 632 0.000001 63 SK516 H 39 105 Protein Kinase Other Unique 929 5.70E−180 335 H85389 H 40 106 Protein Kinase Other ULK 401 2.40E−162 400 Wee1b H 41 107 Protein Kinase Other WEE 567 2.00E−287 541 Wnk2 H 42 108 Protein Kinase Other Wnk 2245 0 1385 MAP3K1 H 43 109 Protein Kinase STE STE11 1511 0 1459 MAP3K8 H 44 110 Protein Kinase STE STE11 735 2.80E−82 166 PAK4_m M 45 111 Protein Kinase STE STE20 593 2.70E−130 650 STLK6·rs H 46 112 Protein Kinase STE STE20 418 5.90E−222 407 MAP2K2 H 47 113 Protein Kinase STE STE7 381 4.80E−156 353 CCK4 H 48 114 Protein Kinase TK CCK4 1070 0 1069 LMR1 H 49 115 Protein Kinase TK Lmr 1374 0 1207 RYK H 50 116 Protein Kinase TK Ryk 607 3.60E−287 603 LRRK2 H 51 117 Protein Kinase TKL LRRK 2534 7.90E−189 463 pMLK4 H 52 118 Protein Kinase TKL MLK 1038 0 1027 KSR H 53 119 Protein Kinase TKL RAF 901 3.30E−269 797 KSR2 H 54 120 Protein Kinase TKL RAF 962 9.60E−119 452 KIAA1646 H 55 121 Lipid Kinase DAG kin DAG kin 537 0 481 DGK·beta H 58 122 Lipid Kinase DAG kin DAG kin 804 0 804 IP6K1 H 57 123 Lipid Kinase Inositol kinase IP6K 441 1.60E−257 441 YAB1 H 58 124 Atypical PK Atypical ABC1 647 3.80E−244 368 AF052122 H 59 125 Atypical PK Atypical ABC1 591 1.20E−248 335 AAF23326 H 60 126 Atypical PK Atypical ABC1 455 1.40E−304 455 SGK493 H 61 127 Atypical PK Atypical R1O1 552 0 552 BRD2 H 62 128 Atypical PK BRD BRD 801 2.60E−256 801 BRD3 H 63 129 Atypical PK BRD BRD 726 2.20E−243 726 BRD4 H 64 130 Atypical PK BRD BRD 722 2.60E−232 722 BRDT H 65 131 Atypical PK BRD BRD 947 0 947 ZC1 H 66 132 Protein Kinase STE STE20 1392 0 1202 Gene_NAME % Identity % Similar ACCESSION DESCRIPTION CRIK 96 98 AAC72823 Rho/rac-interacting citron kinase [Mus musculus] DMPK2 45 63 NP_446109 STK related to the myotonic dystrophy PK [Rattus norvegicus] MAST3 99 99 BAA25487 (AB011133) KIAA0561 protein [Homo sapiens] MAST205 99 99 NP_055927 KIAA0807 protein [Homo sapiens] MASTL 99 99 NP_116233 Hypothetical protein FLJ14813 [Homo sapiens] PKC_eta 99 99 NP_006246 (NM_06255) protein kinase C, eta [Homo sapiens] H19102 99 99 BAB71555 Unnamed protein product [Homo sapiens] MSK1 98 98 NP_004746 Ribosomal protein S6 kinase polypeptide 5 [Homo sapiens] YANK3 91 94 AAH26457 Hypothetical serine/threonine protein kinase [Mus musculus] MARK2 99 99 AAH08771 (BC008771) Similar to ELKL motif kinase [Homo sapiens] NuaK2 100 100 NP_112214 (NM_030952) hypothetical protein DKFZp434J037 [Homo sapiens] BRSK2 99 99 CAA07196 Putative serine/threonine protein kinase [Homo sapiens] MARK4 99 99 AAL23683 MARK4 serine/threonine protein kinase [Homo sapiens] DCAMKL2 67 80 O15075 DCAMKL1 (doublecortin-like and CAMK-like 1) [Homo sapiens] PIM2 100 100 NP_006866 Pim-2 oncogene proto-oncogene Pim 2 [Homo sapiens] PIM3 95 97 AAH17621 Serine threonine kinase pim3 [Mus musculus] TSSK4 65 94 BAB30483 Putative [Mus musculus] CKIL2 100 100 BAA74870 KIAA0847 protein [Homo sapiens] PCTAIRE3 93 93 Q07002 Serine/threonine protein kinase PCTAIRE-3 [Homo sapiens] PFTAIRE2 68 81 NP_035204 (NM_011074) PFTAIRE protein kinase 1 [Mus musculus] ERK7 67 75 AAD12719.2 Extracellular signal-regulated kinase 7 ERK7 [Rattus norvegicus] CKIIa·rs 99 100 CAA49758 Casein kinase II alpha subunit [Homo sapiens] DYRK4 99 100 Q9NR20 DYRK4 4 [Homo sapiens] HIPK1 97 99 AAD41592 Myak-L [Mus musculus] HIPK4 97 98 BAB72080 Hypothetical protein [Macaca fascicularis] BIKE 82 89 NP_542439 (NM_080708) Bmp2 inducible kinase [Mus musculus] NEK10 90 90 BAB71395 (AK057247) unnamed protein product [Homo sapiens] pNEK5 85 32 P51954 STK NEK1 (NimA-related protein kinase 1) [Mus musculus] NEK1 97 97 BAB67794 KIAA1901 protein [Homo sapiens] NEK3 99 99 P51956 NEK3 (HSPK 36) [Homo sapiens] SGK069 42 59 AAK52420 Protein kinase Bsk146 [Danio rerio] SGK110 41 60 S71887 pk9.7 gastrula-specific [Xenopus laevis] NRBP2 61 75 NP_037524 Nuclear receptor binding protein [Homo sapiens] CNK 99 100 AAH13899 Unknown (protein for MGC 14852) [Homo sapiens] SCYL2 99 99 BAA92598 KIAA1360 protein [Homo sapiens] SRPK2 99 99 NP_003129 (NM_003138) SFRS protein kinase 2[Homo sapiens] TLK1 98 99 NP_036422 (NM_012290) tousled-like kinase 1[Homo sapiens] SGK071 30 50 NP_175853 Hypothetical protein [Arabidopsis thaliana] SK516 100 100 BAA32317 KIAA0472 protein [Homo sapiens] H85389 99 99 CAC10518.2 Novel protein kinase [Homo sapiens] Wee1b 98 96 AAD04726 Similar to wee1-like protein kinase [Homo sapiens] Wnk2 99 99 BAB21851 KIAA1760 protein [Homo sapiens] MAP3K1 97 97 Q13233 MEKK 1 [Homo sapiens] MAP3K8 100 100 XP_017343 Hypothetical protein fragment FLJ23074 [Homo sapiens] PAK4_m 92 96 NP_005875 p21 activated kinase 4, effector for Cdc42Hs [Homo sapiens] STLK6·rs 97 98 NP_061041.2 Amyotrophic lateral sclerosis 2 candidate 2 [Homo sapiens] MAP2K2 92 95 NP_109587 p45 (MAP kinase kinase 2) [Homo sapiens] CCK4 99 100 JC4593 RTK PTK7 precursor [Homo sapiens] LMR1 100 100 NP_004911 Apoptosis-associated tyrosine kinase [Homo sapiens] RYK 99 99 I37560 Protein-tyrosine kinase Ryk [Homo sapiens] LRRK2 84 92 NP_080006 RIKEN cDNA 4921513020 gene [Mus musculus] pMLK4 99 99 CAC84640 (AJ311798) mixed lineage kinase 4beta [Homo sapiens] KSR 88 92 NP_038599 (NM_013571) kinase suppressor of ras [Mus musculus] KSR2 43 62 NP_038599 (NM_013571) kinase suppressor of ras [Mus musculus] KIAA1646 100 100 BAB33316 KIAA1646 protein [Homo sapiens] DGK·beta 100 100 Q9Y6T7 Diacytglycerol kinase bets (DGK-BETA) [Homo sapiens] IP6K1 100 100 BAA13393.2 KIAA0263 protein [Homo sapiens] YAB1 100 100 NP_064632 Chaperone ABC1 activity of bc1 complex like [Homo sapiens] AF052122 99 100 AAH13114 Hypothetical protein [Homo sapiens] AAF23326 100 100 NP_065154 Hypothetical protein [Homo sapiens] SGK493 100 100 NP_060813 Hypothetical protein FLJ11159 [Homo sapiens] BRD2 100 100 NP_005095 Bromodomain-containing protein 2 [Homo sapiens] BRD3 100 100 NP_031397 Bromodomain-containing protein 3 [Homo sapiens] BRD4 100 100 NP_055114 Bromodomain-containing protein 4 [Homo sapiens] BRDT 100 100 NP_001717 Testis-specific bromodomain protein [Homo sapiens] ZC1 86 87 NP_032722 NCK interacting kinase HPK/GCK-like kinase [Mus musculus]

[1077] TABLE 2B Smith-Waterman Comparison with NCBI Non-redundant Proteins Page 2 of 2 for Smith-Waterman Gene_(—) Super- QUERY- QUERY- TARGET- TARGET- % % NAME Sp ID#na ID#aa family Group Family START END START END QUERY TARGET CRIK H 1 67 Protein AGC DMPK 1 2055 1 2055 96 96 Kinase DMPK2 H 2 68 Protein AGC DMPK 2 1462 4 1588 46 42 Kinase MAST3 H 3 69 Protein AGC MAST 39 1331 16 1308 96 98 Kinase MAST205 H 4 70 Protein AGC MAST 1 1687 1 1687 93 97 Kinase MASTL H 5 71 Protein AGC MAST 1 678 1 878 99 99 Kinase PKC_eta H 6 72 Protein AGC PKC 1 683 1 682 99 99 Kinase H19102 H 7 73 Protein AGC RSK 41 310 1 271 59 98 Kinase MSK1 H 8 74 Protein AGC RSK 1 800 1 800 98 97 Kinase YANK3 H 9 75 Protein AGC YANK 1 485 1 487 91 90 Kinase MARK2 H 10 76 Protein CAMK CAMKL 34 787 1 755 95 99 Kinase NuaK2 H 11 77 Protein CAMK CAMKL 45 672 1 628 93 100 Kinase BRSK2 H 12 78 Protein CAMK CAMKL 72 674 1 603 89 99 Kinase MARK4 H 13 79 Protein CAMK CAMKL 1 752 1 752 99 99 Kinase DCAMKL2 H 14 80 Protein CAMK DCAMKL 1 741 1 739 66 69 Kinase PIM2 H 15 81 Protein CAMK PIM 101 434 1 334 76 100 Kinase PIM3 H 16 82 Protein CAMK PIM 1 326 1 326 95 95 Kinase TSSK4 H 17 83 Protein CAMK TSSK 1 328 1 328 85 85 Kinase CKIL2 H 18 84 Protein CKI CKIL 600 1244 1 645 51 100 Kinase PCTAIRE3 H 19 85 Protein CMGC CDK 1 502 1 472 93 99 Kinase PFTAIRE2 H 20 86 Protein CMGC CDK 97 426 129 458 51 47 Kinase ERK7 H 21 87 Protein CMGC MAPK 1 560 1 544 68 70 Kinase CKIIa·rs H 22 88 Protein Other CKII 1 391 1 391 99 99 Kinase DYRK4 H 23 89 Protein CMGC DYRK 395 921 15 541 57 97 Kinase HIPK1 H 24 90 Protein CMGC DYRK 1 1210 1 1210 97 97 Kinase HIPK4 H 25 91 Protein CMGC DYRK 1 616 1 616 97 97 Kinase BIKE H 26 92 Protein Other NAK 1 1161 1 1138 82 84 Kinase NEK10 H 27 93 Protein Other NEK 698 1125 10 484 38 88 Kinase pNEK5 H 28 94 Protein Other NEK 58 333 1 275 20 23 Kinase NEK1 H 29 95 Protein Other NEK 1 1286 8 1265 97 99 Kinase NEK3 H 30 96 Protein Other NEK 48 506 1 459 90 99 Kinase SGK069 H 31 97 Protein Other NKF1 1 348 394 763 99 41 Kinase SGK110 H 32 98 Protein Other NKF1 96 359 9 272 26 30 Kinase NRBP2 H 33 99 Protein Other NRBP 17 502 44 518 59 56 Kinase CNK H 34 100 Protein Other PLK 1 646 1 646 99 99 Kinase SCYL2 H 35 101 Protein Other SCY1 140 933 3 796 84 99 Kinase SRPK2 H 36 102 Protein CMGC SRPK 1 688 1 686 99 99 Kinase TLK1 H 37 103 Protein Other TLK 1 787 1 787 98 98 Kinase SGK071 H 38 104 Protein Other Unique 25 228 1 197 9 10 Kinase SK516 H 39 105 Protein Other Unique 565 929 1 365 39 100 Kinase H85389 H 40 106 Protein Other ULK 1 401 118 517 99 77 Kinase Wee1b H 41 107 Protein Other WEE 1 559 1 541 95 100 Kinase Wnk2 H 42 108 Protein Other Wnk 860 2245 1 1386 61 99 Kinase MAP3K1 H 43 109 Protein STE STE11 21 1511 2 1495 96 97 Kinase MAP3K8 H 44 110 Protein STE STE11 547 714 1 168 22 100 Kinase Pak4_m M 45 111 Protein STE STE20 1 593 1 591 92 93 Kinase STLK6·rs H 46 112 Protein STE STE20 1 418 1 418 97 97 Kinase MAP2K2 H 47 113 Protein STE STE7 2 380 1 380 92 88 Kinase CCK4 H 48 114 Protein TK CCK4 1 1070 1 1070 99 99 Kinase LMR1 H 49 115 Protein TK Lmr 168 1374 1 1207 87 100 Kinase RYK H 50 116 Protein TK Ryk 1 607 1 607 99 99 Kinase LRRK2 H 51 117 Protein TKL LRRK 1990 2534 17 561 18 82 Kinase pMLK4 H 52 118 Protein TKL MLK 1 1036 1 1036 99 99 Kinase KSR H 53 119 Protein TKL RAF 1 901 1 873 88 91 Kinase KSR2 H 54 120 Protein TKL RAF 51 982 34 849 46 51 Kinase KIAA1646 H 55 121 Lipid DAG kin DAG kin 57 537 1 481 89 100 Kinase DGK·beta H 56 122 Lipid DAG kin DAG kin 1 804 1 804 100 100 Kinase IP6K1 H 57 123 Lipid Inositol IP6K 1 441 22 462 100 95 Kinase kinase YAB1 H 58 124 Atypical PK Atypical ABC1 280 647 1 368 56 100 AF052122 H 59 125 Atypical PK Atypical ABC1 206 591 1 386 65 99 AAF23327 H 60 126 Atypical PK Atypical ABC1 1 455 1 455 100 100 SGL403 H 61 127 Atypical PK Atypical RIO1 1 552 1 552 100 100 BRD2 H 62 128 Atypical PK BRD BRD 1 801 1 801 100 100 BRD3 H 63 129 Atypical PK BRD BRD 1 726 1 726 100 100 BRD4 H 64 130 Atypical PK BRD BRD 1 722 1 722 100 100 BRDT H 65 131 Atypical PK BRD BRD 1 947 1 947 100 100 ZC1 H 66 132 Protein STE STE20 1 1392 1 1233 87 98 Kinase

[1078] TABLE 3 Single Nucleotide Polymorphisms AA Nucleo- Nucleotide AA Silent/ Residue tide In patent Residue Residue in Gene ID#na ID#aa # Polymorphism sequence # Change Patent Accession# CRIK 1 67 7676 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss1631920_allelePos = 201 CRIK 1 67 2933 Y (C/T) T 961 E/A A gnl|dbSNP|ss1337341_allelePos = 267 CRIK 1 67 2924 R (A/G) A 958 silent T gnl|dbSNP|ss1337340_allelePos = 258 CRIK 1 67 3377 R (A/G) A 1109 silent R gnl|dbSNP|ss1631893_allelePos = 310 CRIK 1 67 4085 Y (C/T) C 1345 silent S gnl|dbSNP|ss1631886_allelePos = 605 DMPK2 2 68 5050 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss1752530_allelePos = 201 DMPK2 2 68 1139 R (A/G) G 358 silent G gnl|dbSNP|ss1754079_allelePos = 201 MAST3 3 69 2900 Y (C/T) C 955 silent D gnl|dbSNP|ss1846926_allelePos = 432 MAST3 3 69 623 Y (C/T) C 196 silent H gnl|dbSNP|ss88979_allelePos = 67 MAST205 4 70 2739 R (A/G) A 913 silent S gnl|dbSNP|ss1363030_allelePos = 144 MAST205 4 70 25 Y (C/T) C 9 R/stop R gnl|dbSNP|ss133576_allelePos = 22 MAST205 4 70 5303 Y (C/T) C 1768 S/F S gnl|dbSNP|ss1529170_allelePos = 51 MAST205 4 70 4652 R (A/G) A 1551 DIG D gnl|dbSNP|ss1529101_allelePos = 5 MAST205 4 70 3590 R (A/G) A 1197 K/R K gnl|dbSNP|ss1529096_allelePos = 51 MAST205 4 70 156 R (A/G) G 52 silent A gnl|dbSNP|ss1608593_allelePos = 756 MAST205 4 70 162 S (C/G) C 54 silent P gnl|dbSNP|ss497486_allelePos = 201 MASTL 5 71 3831 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss1363_allelePos = 40 PKC_eta 6 72 1840 Y (C/T) T 558 silent N gnl|dbSNP|ss1000395_allelePos = 101 PKC_eta 6 72 1239 Y (C/T) T 358 T/I I gnl|dbSNP|ss1472906_allelePos = 327 PKC_eta 6 72 2288 S (C/G) C 3′ UTR — — gnl|dbSNP|ss1548761_allelePos = 51 PKC_eta 6 72 681 R (A/G) A 172 H/G H gnl|dbSNP|ss1509877_allelePos = 51 H19102 7 73 None — — — — — — MSK1 8 74 3186 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss2025310_allelePos = 201 MSK1 8 74 3658 R (A/G) A 3′ UTR — — gnl|dbSNP|ss1530678_allelePos = 5 MSK1 8 74 3769 R (A/G) A 3′ UTR — — gnl|dbSNP|ss1530679_allelePos = 51 MSK1 8 74 3432 K (G/T) T 3′ UTR — — gnl|dbSNP|ss1530677_allelePos = 51 MSK1 8 74 3779 K (G/T) T 3′ UTR — — gnl|dbSNP|ss1530680_allelePos = 51 YANK3 9 75 1852 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss18125_allelePos = 101 YANK3 9 75 1895 R (A/G) A 3′ UTR — — gnl|dbSNP|ss1517863_allelePos = 5 YANK3 9 75 2021 M (A/C) A 3′ UTR — — gnl|dbSNP|ss1517886_allelePos = 51 MARK2 10 76 2570 Y (C/T) C 724 silent S gnl|dbSNP|ss1121403_allelePos = 101 MARK2 10 76 2615 R (A/G) G 739 silent P gnl|dbSNP|ss1121404_allelePos = 101 MARK2 10 76 1641 S (C/G) G 415 P/A A gnl|dbSNP|ss1537647_allelePos = 51 MARK2 10 76 1547 R (A/G) A 383 silent L gnl|dbSNP|rs1057176_allelePos = 51 NuaK2 11 77 1670 S (C/G) G 538 silent L gnl|dbSNP|ss1295001_allelePos = 93 NuaK2 11 77 1727 R (A/G) G 557 silent L gnl|dbSNP|ss1295000_allelePos = 36 BRSK2 12 78 None — MARK4 13 79 2916 R (A/G) G 3′ UTR — — gnl|dbSNP|ss1967699_allelePos = 201 MARK4 13 79 3032 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss1967700_allelePos = 242 MARK4 13 79 1699 Y (C/T) C 561 silent R gnl|dbSNP|ss1967693_allelePos = 201 MARK4 13 79 3092 R (A/G) G 3′ UTR — — gnl|dbSNP|ss1512875_allelePos = 51 DCAMKL2 14 80 None — — — — — — PIM2 15 81 630 R (A/G) A 210 silent E gnl|dbSNP|ss1525746_allelePos = 5 PIM2 15 81 1749 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss1525747_allelePos = 51 PIM2 15 81 1990 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss1S2S754_allelePos = 51 PIM3 16 82 2057 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss1S48948_allelePos = 51 PIM3 16 82 1269 Y (C/T) C 278 silent P gnl|dbSNP|ss1511148_allelePos = 51 PIM3 16 82 2362 R (A/G) G 3′ UTR — — gnl|dbSNP|ss1511284_allelePos = 51 TSSK4 17 83 1203 R (A/G) A 196 Q/R Q gnl|dbSNP|ss1975997_allelePos = 201 TSSK4 17 83 152 M (A/C) C 5′ UTR — — gnl|dbSNP|ss1588747_allelePos = 749 TSSK4 17 83 141 R (A/G) A 5′ UTR — — gnl|dbSNP|ss1588746_allelePos = 738 TSSK4 17 83 238 R (A/G) G 5′ UTR — — gnl|dbSNP|ss1211997_allelePos = 524 TSSK4 17 83 84 Y (C/T) T 5′ UTR — — gnl|dbSNP|ss934600_allelePos = 307 TSSK4 17 83 281 R (A/G) G 5′ UTR — — gnl|dbSNP|ss1747635_allelePos = 2506 TSSK4 17 83 236 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss1747634_allelePos = 2461 TSSK4 17 83 136 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss2056655_allelePos = 355 TSSK4 17 83 22 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss45790_allelePos = 479 TSSK4 17 83 243 R (A/G) G 5′ UTR — — gnl|dbSNP|ss2061784_allelePos = 1157 TSSK4 17 83 226 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss2061783_allelePos = 1140 TSSK4 17 83 47 R (A/G) A 5′ UTR — — gnl|dbSNP|ss1990388_allelePos = 1229 TSSK4 17 83 158 W (A/T) A 5′ UTR — — gnl|dbSNP|ss1911350_allelePos = 370 TSSK4 17 83 77 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss1909793_allelePos = 506 TSSK4 17 83 137 R (A/G) G 5′ UTR — — gnl|dbSNP|ss1908525_allelePos = 1475 TSSK4 17 83 44 Y (C/T) T 5′ UTR — — gnl|dbSNP|ss1897673_allelePos = 1677 TSSK4 17 83 11 R (A/G) A 5′ UTR — — gnl|dbSNP|ss1857878_allelePos = 1145 TSSK4 17 83 223 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss1816570_allelePos = 267 TSSK4 17 83 85 R (A/G) G 5′ UTR — — gnl|dbSNP|ss1799649_allelePos = 306 TSSK4 17 83 280 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss1732367_allelePos = 496 TSSK4 17 83 97 Y (C/T) T 5′ UTR — — gnl|dbSNP|ss1729216_allelePos = 408 TSSK4 17 83 148 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss1684407_allelePos = 417 CKIL2 18 84 3889 S (C/G) C 1208 H/D H gnl|dbSNP|ss1551913_allelePos = 51 PCTAIRE3 19 85 None — — — — — — PFTAIRE2 20 86 None — — — — — — ERK7 21 87 None — — — — — — CKIIar 22 88 1103 M (A/C) C 318 silent A gnl|dbSNP|ss1537202_allelePos = 51 CKIIar 22 88 1008 M (A/C) C 287 SIR R gnl|dbSNP|ss1537192_allelePos = 51 CKIIar 22 88 663 Y (C/T) C 172 R/stop R gnl|dbSNP|ss1537165_allelePos = 51 CKIIar 22 88 1428 M (A/C) A 3′ UTR — — gnl|dbSNP|ss1537238_allelePos = 51 CKIIar 22 88 194 Y (C/T) T 15 silent V gnl|dbSNP|ss5453_allelePos = 51 CKIIar 22 88 1200 R (A/G) G 351 M/V V gnl|dbSNP|ss1537218_allelePos = 5 CKIIar 22 88 1181 R (A/G) A 344 silent T gnl|dbSNP|ss1537216_allelePos = 51 CKIIar 22 88 1104 W (A/T) A 319 MIL M gnl|dbSNP|ss1537203_allelePos = 51 DYRK4 23 89 269 R (A/G) G 90 R/H R gnl|dbSNP|ssS8136_allelePos = 155 HIPK1 24 90 4114 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss12250_allelePos = 101 HIPK4 25 91 None — BIKE 26 92 1606 R (A/G) A 468 silent Q gnl|dbSNP|ss1509438_allelePos = 51 NEK10 27 93 1149 S (C/G) G 325 T/S S gnl|dbSNP|ss727804_allelePos = 20 NEK10 27 93 1849 R (A/G) G 558 silent G gnl|dbSNP|ss1891242_allelePos = 201 NEK10 27 93 2967 R (A/G) G 931 N/S S gnl|dbSNP|ss1325417_allelePos = 338 pNEK5 28 94 None — — — — — — NEK1 29 95 5063 R (A/G) A 3′ UTR — — gnl|dbSNP|ss1520330_allelePos = 51 NEK1 29 95 4848 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss1520329_allelePos = 51 NEK3 30 96 1854 S (C/G) C 3′ UTR — — grt|dbSNP|ss3403_allelePos = 2 SGK069 31 97 1001 S (C/G) G 298 P/A A gni|dbSNP|ss1317629_allelePos = 393 SGK069 31 97 323 Y (C/T) C 72 R/C R gnl|dbSNP|ss1688815_allelePos = 201 SGK110 32 98 299 W (A/T) A 1 M/L M gnl|dbSNP|ss767141_allelePos = 201 SGK110 32 98 985 R (A/G) A 229 silent P gnl|dbSNP|ss827468_allelePos = 20 SGK110 32 98 640 Y (C/T) C 114 silent L gnl|dbSNP|ss661406_allelePos = 201 NRBP2/ 33 99 None — — — — — — SGK034 CNK 34 100 None — — — — — — SCYL2/ 35 101 None — — — — — — AI05225 SRPK2 36 102 2219 Y (C/T) C 681 L/F L gnl|dbSNP|ss1525084_allelePos = 51 SRPK2 36 102 2047 Y (C/T) C 623 silent F gnl|dbSNP|ss1525076_allelePos = 51 SRPK2 36 102 2040 R (A/G) G 621 Q/R R gnl|dbSNP|ss1525074_allelePos = 51 SRPK2 36 102 2035 Y (C/T) T 619 silent Y gnl|dbSNP|rs1050422_allelePos = 51 SRPK2 36 102 2021 M (A/C) C 615 I/L L gnl|dbSNP|ss1525069_allelePos = 51 SRPK2 36 102 2014 M (A/C) C 612 Q/H H gnl|dbSNP|ss1525066_allelePos = 51 SRPK2 36 102 2029 R (A/G) A 617 silent G gnl|dbSNP|SS1525072_allelePos = 51 SRPK2 36 102 2017 Y (C/T) T 613 silent F gnl|dbSNP|ss1525068_allelePos = 51 SRPK2 36 102 2016 W (A/T) T 613 Y/F F gnl|dbSNP|ss1525067_allelePos = 51 SRPK2 36 102 2001 R (A/G) G 608 N/S S gnl|dbSNP|ss1525064_allelePos = 51 SRPK2 36 102 1999 S (C/G) C 607 silent G gnl|dbSNP|ss1525063_allelePos = 51 SRPK2 36 102 1996 R (A/G) A 606 silent A gnl|dbSNP|ss1525062_allelePos = 51 SRPK2 36 102 1969 Y (C/T) C 597 silent D gnl|dbSNP|ss1525061_allelePos = 51 SRPK2 36 102 2044 R (A/G) A 622 silent E gnl|dbSNP|ss1525075_allelePos = 51 SRPK2 36 102 2023 R (A/G) A 615 silent L gnl|dbSNP|ss1525072_allelePos = 51 TLK1 37 103 2174 W (A/T) A 646 V/D D gnl|dbSNP|ss1515391_allelePos = 51 TLK1 37 103 2489 R (A/G) A 751 N/S N gnl|dbSNP|ss1515399_allelePos = 51 TLK1 37 103 2515 M (A/C) A 760 silent R gnl|dbSNP|ss1515400_allelePos = 51 TLK1 37 103 2358 R (A/G) A 707 silent E gnl|dbSNP|ss1515395_allelePos = 51 TLK1 37 103 2294 W (A/T) T 686 Y/F F gnl|dbSNP|ss151S394_allelePos = 51 TLK1 37 103 2229 R (A/G) A 664 silent V gnl|dbSNP|ss1515393_allelePos = 51 TLK1 37 103 2014 Y (C/T) C 593 silent L gnl|dbSNP|ss1515364_allelePos = 51 TLK1 37 103 1137 W (A/T) T 300 silent I gnl|dbSNP|ss1515380_allelePos = 51 TLK1 37 103 3279 R (A/G) A 3′ UTR — — gnl|dbSNP|ss1515413_allelePos = 51 TLK1 37 103 3142 S (C/G) G 3′ UTR — — gnl|dbSNP|ss1515412_allelePos = 51 TLK1 37 103 2488 W (A/T) A 751 N/Y N gnl|dbSNP|ss1515398_allelePos = 51 TLK1 37 103 1711 K (G/T) T 492 D/Y Y gnl|dbSNP|ss1515382_allelePos = 51 TLK1 37 103 1730 M (A/C) A 498 S/Y Y gnl|dbSNP|ss1515383_allelePos = 51 TLK1 37 103 1083 M (A/C) A 282 E/D E gnl|dbSNP|ss1515377_allelePos = 51 TLK1 37 103 1647 Y (C/T) C 470 silent H gnl|dbSNP|ss1515381_allelePos = 51 TLK1 37 103 1092 R (A/G) A 285 silent K gnl|dbSNP|ss1515379_allelePos = 51 TLK1 37 103 1035 Y (C/T) T 266 silent A gnl|dbSNP|ss1515376_allelePos = 51 TLK1 37 103 951 R (A/G) A 238 silent T gnl|dbSNP|ss1515375_allelePos = 51 SGK071 38 104 None — — — — — — SK516 39 105 None — — — — — — H85389 40 106 None — — — — — — Wee1b/ 41 107 None — — — — — — SGK461 Wnk2 42 108 7079 K (G/T) T 3′ UTR — — gnl|dbSNP|ss2899_allelePos = 78 MAP3K1 43 109 2716 R (A/G) A 906 I/V I gnl|dbSNP|ss1317910_allelePos = 265 MAP3K1 43 109 6227 W (A/T) A 3′ UTR — — gnl|dbSNP|ss1146242_allelePos = 109 MAP3K1 43 109 5560 R (A/G) A 3′ UTR — — gnl|dbSNP|ss1286358_allelePos = 101 MAP3K1 43 109 3187 M (A/C) C 1063 silent R gnl|dbSNP|ss1146312_allelePos = 101 MAP3K1 43 109 6015 R (A/G) G 3′ UTR — — gnl|dbSNP|ss1146243_allelePos = 101 MAP3K1 43 109 2416 R (A/G) A 806 N/D N gnl|dbSNP|ss1146310_allelePos = 101 MAP3K1 43 109 1284 R (A/G) A 428 silent T gnl|dbSNP|ss1146300_allelePos = 101 MAP3K8 44 110 247 S (C/G) G 83 Q/E E gnl|dbSNP|ss1394913_allelePos = 101 MAP3K8 44 110 2485 K (G/T) T 3′ UTR — — gnl|dbSNP|ss1617_allelePos = 49 MAP3K8 44 110 2298 M (A/C) A 3′ UTR — — gnl|dbSNP|ss1547718_allelePos = 51 Pak4_m 45 111 None — — — — — — STLK6r 46 112 487 R (A/G) G 82 silent T gnl|dbSNP|ss1483412_allelePos = 100 Map2K2 47 113 904 M (A/C) C 219 silent I gnl|dbSNP|ss1937135_allelePos = 201 CCK4 48 114 3636 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss1527472_allelePos = 51 LMR1 49 115 None — — — — — — RYK 50 116 2875 R (A/G) G 3′ UTR — — gnl|dbSNP|ss16914_allelePos = 101 RYK 50 116 2496 W (A/T) A 3′ UTR — — gnl|dbSNP|ss1525573_allelePos = 51 RYK 50 116 851 R (A/G) G 254 N/S S gnl|dbSNP|ss1525514_allelePos = 51 RYK 50 116 386 R (A/G) G 99 N/S S gnl|dbSNP|ss1525513_allelePos = 51 RYK 50 116 2764 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss16913_allelePos = 31 LRRK2 51 117 5425 W (A/T) T 1598 E/V V gnl|dbSNP|ss63276_allelePos = 97 pMLK4 52 118 3597 R (A/G) A 3′ UTR — — gnl|dbSNP|ss2057123_allelePos = 323 pMLK4 52 118 3914 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss2057120_allelePos = 201 pMLK4 52 118 3668 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss2057122_allelePos = 288 pMLK4 52 118 3800 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss2057121_allelePos = 22 pMLK4 52 118 2580 Y (C/T) C 773 silent S gnl|dbSNP|ss1411720_allelePos = 519 pMLK4 52 118 2611 K (G/T) T 784 G/C C gnl|dbSNP|ss1411719_allelePos = 488 pMLK4 52 118 4193 R (A/G) A 3′ UTR — — gnl|dbSNP|ss2057119_allelePos = 201 pMLK4 52 118 4309 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss2057118_allelePos = 201 KSR 53 119 4096 S (C/G) C 3′ UTR — — gnl|dbSNP|ss100899_allelePos = 172 KSR2 54 120 612 S (C/G) C 204 silent T gnl|dbSNP|ss2005786_allelePos = 201 KIAA1646 55 121 3769 M (A/C) A 3′ UTR — — gnl|dbSNP|ss2052346_allelePos = 499 KIAA1646 55 121 3020 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss2052345_allelePos = 201 KIAA1646 55 121 2577 K (G/T) T 3′ UTR — — gnl|dbSNP|ss2052344_allelePos = 201 KIAA1646 55 121 2391 R (A/G) A 3′ UTR — — gnl|dbSNP|ss2052344_allelePos = 201 KIAA1646 55 121 4272 R (A/G) A 3′ UTR — — gnl|dbSNP|ss2052347_allelePos = 201 DGK-beta 56 122 None — — — — — — IP6K1 57 123 3669 Y (C/T) C 3′ UTR — — gnl|dbSNP|ss1522850_allelePos = 51 IP6K1 57 123 2851 R (A/G) G 3′ UTR — — gnl|dbSNP|ss1522846_allelePos = 51 YAB1 58 124 2506 R (A/G) G 3′ UTR — — gnl|dbSNP|ss1305707_allelePos = 99 YAB1 58 124 1538 Y (C/T) C 480 silent F gnl|dbSNP|ss1529336_allelePos = 51 AF052122 59 125 None — — — — — — AAF23326 60 126 None — — — — — — SGK493 61 127 1094 R (A/G) A 349 R/G R gnl|dbSNP|ss182655t_allelePos = 201 SGK493 61 127 1690 Y (C/T) T 547 silent A gnl|dbSNP|ss1826528_allelePos = 201 BRD2 62 128 920 K (G/T) T 5′ UTR — — gnl|dbSNP|ss1425392_allelePos = 324 BRD2 62 128 1794 R (A/G) A 31 silent K gnl|dbSNP|ss686785_allelePos = 201 BRD2 62 128 3510 Y (C/T) T 603 silent S gnl|dbSNP|rs516535_allelePos = 201 BRD2 62 128 2413 Y (C/T) C 238 L/F L gnl|dbSNP|ss1973307_allelePos = 201 BRD2 62 128 3199 K (G/T) G 500 E/stop E gnl|dbSNP|ss15121_allelePos = 101 BRD2 62 128 3333 R (A/G) G 544 silent K gnl|dbSNP|ss13218_allelePos = 101 BRD2 62 128 4348 M (A/C) C 5′ UTR 3′ UTR — gnl|dbSNP|ss12998_allelePos = 101 BRD2 62 128 3411 Y (C/T) T 570 silent D gnl|dbSNP|ss1550506_allelePos = 51 BRD2 62 128 1344 R (A/G) G 5′ UTR — — gnl|dbSNP|ss1550446_allelePos = 51 BRD2 62 128 4416 Y (C/T) T 5′ UTR — — gnl|dbSNP|ss1550446_allelePos = 51 BRD2 62 128 4219 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss1523158_allelePos = 51 BRD2 62 128 3342 R (A/G) G 547 silent R gnl|dbSNP|ss1523069_allelePos = 51 BRD2 62 128 811 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss1522874_allelePos = 51 BRD2 62 128 2379 S (C/G) G 226 silent L gnl|dbSNP|ss18333_allelePos = 31 BRD3 63 129 2405 Y (C/T) T 3′ UTR — — gnl|dbSNP|ss575919_allelePos = 201 BRD3 63 129 1075 R (A/G) G 312 silent L gnl|dbSNP|ss630265_allelePos = 201 BRD3 63 129 1975 Y (C/T) C 612 silent D gnl|dbSNP|ss601348_allelePos = 201 BRD3 63 129 1423 Y (C/T) C 428 silent P gnl|dbSNP|ss634964_allelePos = 201 BRD3 63 129 2934 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss17101_allelePos = 101 BRD3 63 129 2796 Y (C/T) C 5′ UTR — — gnl|dbSNP|ss1527035_allelePos = 51 BRD4 64 130 1846 R (A/G) G 542 N/D D gnl|dbSNP|ss1512910_allelePos = 51 BRDT 65 131 821 M (A/C) A 238 K/N K gnl|dbSNP|ss1559561_allelePos = 482 BRDT 65 131 2976 M (A/C) C 5′ UTR — — gnl|dbSNP|ss15S326e_allelePos = 51 BRDT 65 131 2785 M (A/C) C 893 Q/P P gnl|dbSNP|ss1553264_allelePos = 51 BRDT 65 131 1114 M (A/C) C 336 Stop/S S gnl|dbSNP|ss1553262_allelePos = 51 BRDT 65 131 1113 W (A/T) T 336 Y/S S gnl|dbSNP|ss1553261_allelePos = 51 BRDT 65 131 2882 M (A/C) C 925 silent A gnl|dbSNP|ss1553267_allelePos = 51 BRDT 65 131 2851 M (A/C) C 915 Q/P P gnl|dbSNP|ss1553266_allelePos = 51 BRDT 65 131 2846 M (A/C) C 913 silent A gnl|dbSNP|ss1553265_allelePos = 51 ZC1 66 132 1382 R (A/G) A 418 silent E gnl|dbSNP|rs1139583_allelePos = 51 ZC1 66 132 2684 S (C/G) G 852 silent S gnl|dbSNP|rs1042916_allelePos = 51

[1079] TABLE 4 Protein Domains Profile Domain Domain Profile Profile Profile Query Gene ID#na ID#aa Profile Description Accession Pscore Start End Start End Length Length CRIK 1 67 Protein kinase domain PF00069 9.20E−67 98 361 1 278 278 2055 CRIK 1 67 CNH domain PF00780 2.60E−115 1620 1917 1 378 378 2055 CRIK 1 67 PH domain PF00169 3.00E−16 1472 1591 1 85 85 2055 CRIK 1 67 Phorbol esters/diacylglycerol PF00130 1.00E−09 1391 1439 1 51 51 2055 binding domain (C1 domain) CRIK 1 67 Protein kinase C terminal PF00433 3.00E−08 362 391 1 32 70 2055 domain DMPK2 2 68 Protein kinase domain PF00069 2.10E−70 71 337 1 278 278 1572 DMPK2 2 68 Phorbol esters/diacylglycerol PF00130 3.10E−17 887 935 1 51 51 1572 binding domain (C1 domain) DMPK2 2 68 PH domain PF00169 1.70E−16 956 1074 1 85 85 1572 DMPK2 2 68 CNH domain PF00780 1.50E−12 1100 1380 1 378 378 1572 DMPK2 2 68 Protein kinase C terminal PF00433 2.00E−08 351 366 16 31 70 1572 domain MAST3 3 69 Protein kinase domain PF00069 5.50E−74 389 535 1 149 294 1331 MAST3 3 69 Protein kinase domain PF00069 5.50E−74 560 662 158 294 294 1331 MAST3 3 69 PDZ domain PF00595 3.70E−09 972 1054 1 79 84 1331 MAST205 4 70 Protein kinase domain PF00069 7.90E−80 512 785 1 278 278 1798 MAST205 4 70 PDZ domain (Also known as PF00595 2.20E−10 1104 1191 1 83 83 1798 DHR or GLGF). MASTL 5 71 Protein kinase domain PF00069 2.20E−73 35 310 1 278 278 878 MASTL 5 71 Protein kinase domain PF00069 2.20E−73 739 834 149 278 278 878 MASTL 5 71 Protein kinase C terminal PF00433 4.60E−07 835 863 1 31 70 878 domain PKC_eta 6 72 Protein kinase domain PF00069 3.60E−82 355 614 1 294 294 683 PKC_eta 6 72 Phorbol esters/diacylglycerol PF00130 4.40E−46 172 222 1 51 51 683 binding domain (C1 domain) PKC_eta 6 72 Phorbol esters/diacylglycerol PF00130 4.40E−46 246 295 1 51 51 683 binding domain (C1 domain) PKC_eta 6 72 Protein kinase C terminal PF00433 1.80E−41 615 681 1 70 70 683 domain H19102 7 73 Protein kinase domain PF00069 3.20E−64 146 398 1 278 278 449 MSK1 8 74 Protein kinase domain PF00069 1.60E−1B2 49 318 1 278 278 802 MSK1 8 74 Protein kinase domain PF00069 1.60E−182 427 687 2 278 278 802 MSK1 8 74 Protein kinase C terminal PF00433 2.40E−21 319 382 1 70 70 802 domain YANK3 9 75 Protein kinase domain PF00069 3.80E−71 93 345 1 287 294 486 MARK2 10 76 Protein kinase domain PF00069 1.30E−100 53 304 1 294 294 787 MARK2 10 76 Kinase associated domain 1 PF02149 3.00E−21 738 787 1 50 50 787 MARK2 10 76 UBA/TS-N domain PF00627 0.000003 324 363 1 45 45 787 NuaK2 11 77 Protein kinase domain PF00069 8.00E−94 97 347 1 294 294 672 BRSK2 12 78 Protein kinase domain PF00069 3.20E−97 19 270 1 278 278 674 MARK4 13 79 Protein kinase domain PF00069 7.70E−104 59 310 1 278 278 752 MARK4 13 79 Kinase associated domain 1 PF02149 1.30E−15 703 752 1 50 50 752 MARK4 13 79 UBA domain PF00627 6.30E−11 330 368 1 41 41 752 DCAMKL2 14 80 Protein kinase domain PF00069 1.70E−97 394 651 1 278 278 766 PIM2 15 81 Protein kinase domain PF00069 1.40E−71 132 386 1 294 294 434 PIM3 16 82 Protein kinase domain PF00069 9.90E−80 40 293 1 278 278 326 TSSK4 17 83 Protein kinase domain PF00069 1.10E−78 25 293 1 278 278 328 CKIL2 18 84 Protein kinase domain PF00069 8.50E−33 21 276 1 265 278 1244 PCTAIRE3 19 85 Protein kinase domain PF00069 1.20E−87 50 331 1 278 278 380 PFTAIRE2 20 86 Protein kinase domain PF00069 4.40E−80 103 387 1 278 278 435 ERK7 21 87 Protein kinase domain PF00069 4.80E−90 13 323 1 278 278 563 CKIIa·rs 22 88 Protein kinase domain PF00069 2.20E−89 39 324 1 278 278 391 DYRK4 23 89 Protein kinase domain PF00069 4.00E−64 506 802 1 278 278 921 HIPK1 24 90 Protein kinase domain PF00069 6.20E−58 190 518 1 278 278 1210 HIPK4 25 91 Protein kinase domain PF00069 1.10E−58 11 347 1 278 278 616 BIKE 26 92 Protein kinase domain PF00069 2.50E−38 51 314 1 294 294 1161 NEK10 27 93 Protein kinase domain PF00069 8.80E−70 519 783 1 294 294 1125 NEK10 27 93 Armadillo/beta-catenin-like PF00514 0.009707 198 238 1 40 40 1125 repeat NEK10 27 93 Armadillo/beta-catenin-like PF00514 0.009707 239 279 1 40 40 1125 repeat NEK10 27 93 Armadillo/beta-catenin-like PF00514 0.009707 280 320 1 40 40 1125 repeat pNEK5 28 94 Protein kinase domain PF00069 9.10E−87 61 316 1 294 294 889 NEK1 29 95 Protein kinase domain PF00069 2.50E−89 4 258 1 278 278 1286 NEK3 30 96 Protein kinase domain PF00069 5.60E−92 4 257 1 278 278 506 SGK069 31 97 Protein kinase domain PF00069 3.80E−40 62 325 1 263 278 348 SGK110 32 98 Protein kinase domain PF00069 1.70E−39 98 359 1 273 278 414 NRBP2 33 99 Protein kinase domain PF00069 2.00E−24 38 313 1 278 278 507 CNK 34 100 Protein kinase domain PF00069 1.60E−91 62 314 1 278 278 646 CNK 34 100 POLO box duplicated region. PF00659 9.70E−35 470 533 1 77 77 646 CNK 34 100 POLO box duplicated region. PF00659 9.70E−35 567 637 1 77 77 646 SCYL2 35 101 Protein kinase domain PF00069 8.00E−13 32 327 1 278 278 933 SRPK2 36 102 Protein kinase domain PF00069 7.40E−42 81 686 1 278 278 688 TLK1 37 103 Protein kinase domain PF00069 4.70E−71 477 755 1 278 278 787 SGK071 38 104 Protein kinase domain PF00069 7.60E−26 28 296 27 278 278 632 SK516 39 105 Protein kinase domain PF00069 2.50E−44 652 915 1 278 278 929 H85389 40 106 Protein kinase domain PF00069 3.90E−60 69 397 1 278 278 401 Wee1b 41 107 Protein kinase domain PF00069 1.10E−49 212 486 1 272 278 567 Wnk2 42 108 Protein kinase domain PF00069 6.60E−63 181 439 1 278 278 2245 MAP3K1 43 109 Protein kinase domain PF00069 1.00E−85 1242 1507 1 278 278 1511 MAP3KB 44 110 Protein kinase domain PF00069 2.10E−88 468 731 1 278 278 735 Pak4 45 111 Protein kinase domain PF00069 5.00E−86 323 574 1 278 278 593 Pak4 45 111 P21-Rho-binding domain PF00786 3.20E−12 11 69 1 64 64 593 STLK6-rs 46 112 Protein kinase domain PF00069 2.60E−33 58 369 14 278 278 418 MAP2K2 47 113 Protein kinase domain PF00069 3.20E−58 72 369 1 278 278 381 CCK4 48 114 Protein kinase domain PF00069 6.70E−63 796 1061 1 272 278 1070 CCK4 48 114 Immunoglobulin domain PF00047 1.00E−61 46 103 1 45 45 1070 CCK4 48 114 Immunoglobulin domain PF00047 1.00E−61 143 202 1 45 45 1070 CCK4 46 114 Immunoglobulin domain PF00047 1.00E−61 239 303 1 45 45 1070 CCK4 48 114 Immunoglobulin domain PF00047 1.00E−61 336 393 1 45 45 1070 CCK4 48 114 Immunoglobulin domain PF00047 1.00E−61 426 483 1 45 45 1070 CCK4 48 114 Immunoglobulin domain PF00047 1.00E−61 517 572 1 45 45 1070 CCK4 48 114 Immunoglobulin domain PF00047 1.00E−61 606 666 1 45 45 1070 LMR1 49 115 Protein kinase domain PF00069 1.10E−16 125 395 1 294 294 1374 RYK 50 116 Protein kinase domain PF00069 3.10E−81 330 596 1 276 278 607 RYK 50 115 WIF domain PF02019 3.30E−91 66 194 1 132 132 607 LRRK2 51 117 Protein kinase domain PF00069 1.00E−41 1886 2138 8 272 278 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 983 1004 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1012 1035 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1036 1058 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1084 1103 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1108 1129 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1130 1153 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1174 1196 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1197 1218 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1221 1244 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1246 1268 1 23 23 2534 LRRK2 51 117 Leucine Rich Repeat PF00560 2.10E−34 1269 1293 1 23 23 2534 pMLK4 52 118 Protein kinase domain PF00069 1.70E−87 124 398 1 292 294 1036 pMLK4 52 118 SH3 domain PF00018 2.00E−14 45 100 5 58 58 1036 KSR 53 119 Protein kinase domain PF00069 1.40E−31 591 731 1 147 294 901 KSR 53 119 Protein kinase domain PF00069 1.40E−31 753 792 163 195 294 901 KSR 53 119 Phorbol esters/diacylglycerol PF00130 0.008623 348 391 1 51 51 901 binding domain (C1 domain) KSR 53 119 MYND finger PF01753 1.311685 360 377 1 21 43 901 KSR2 54 120 Protein kinase domain PF00069 6.90E−40 698 957 1 289 294 982 KSR2 54 120 Phorbol esters/diacylglycerol PF00130 0.000127 445 488 1 51 51 982 binding domain (C1 domain) KIAA1646 55 121 Diacylglycerol kinase PF00781 2.50E−09 132 278 1 159 159 537 catalytic domain DGK-beta 56 122 Diacylglycerol kinase PF00609 3.30E−129 582 762 1 190 190 804 accessory domain DGK-beta 56 122 Diacylglycerol kinase PF00781 1.20E−71 438 562 1 159 159 804 catalytic domain DGK-beta 56 122 Phorbol esters/diacylglycerol PF00130 5.00E−28 245 294 1 51 51 804 binding domain (C1 domain) DGK-beta 56 122 Phorbol esters/diacylglycerol PF00130 5.00E−28 310 358 1 51 51 804 binding domain (C1 domain) DGK-beta 56 122 EF hand PF00036 4.10E−17 153 181 1 29 29 804 DGK-beta 56 122 EF hand PF00036 4.10E−17 198 226 1 29 29 804 IP6K1 57 123 No domain identified YAB1 58 124 ABC1 family PF03109 1.20E−42 318 434 1 124 124 647 AF052122 59 125 No domain identified AAF23326 60 126 No domain identified SGK493 61 127 No domain identified BRD2 62 128 Bromodomain PF00439 4.90E−91 79 168 1 92 92 801 BRD2 62 128 Bromodomain PF00439 4.90E−91 352 441 1 92 92 801 BRD3 63 129 Bromodomain PF00439 6.50E−87 39 128 1 92 92 726 BRD3 63 129 Bromodomain PF00439 6.50E−87 315 403 1 92 92 726 BRD4 64 130 Bromodomain PF00439 1.80E−90 63 152 1 92 92 722 BRD4 64 130 Bromodomain PF00439 1.80E−90 356 445 1 92 92 722 BRDT 65 131 Bromodomain PF00439 7.50E−86 32 121 1 92 92 947 BRDT 65 131 Bromodomain PF00439 7.50E−86 275 364 1 92 92 947 ZC1 66 132 CNH PF00780 9.20E−131 1066 1372 1 378 378 1392 ZC1 66 132 Protein kinase domain PF00069 1.40E−91 25 289 1 278 278 1392

[1080] TABLE 5 Chromosomal Data Cytogenetic Cancer Sp ID#na ID#aa position Amplicon Disease Locl CRIK H 1 67 12q24.31 DMPK2 H 2 68 11q12-q13.1 11q13-q14 Osteoarthritis OMIM 165720 MAST3 H 3 69 19p13.1 MAST205 H 4 70 1p34.1 MASTL H 5 71 10p11.2-p12.1 Schizophrenia, OMIM 181500 PKC_eta H 6 72 14q23.1 H19102 H 7 73 17q11.1 17q12-q21 MSK1 H 8 74 14q32.11 YANK3 H 9 75 10q26.3 MARK2 H 10 76 11q12-11q13 11q13-q14 Osteoarthritis OMIM 165720 NuaK2 H 11 77 1q31-q32.1 BRSK2 H 12 78 11p15.5 MARK4 H 13 79 19q13.2-q13.33 19cen-q13.3 DCAMKL2 H 14 80 4q31.3 PIM2 H 15 81 Xp11.23 Xp11.2-p21 PIM3 H 16 82 22q13 TSSK4 H 17 83 14q11.1 CKIL2 H 18 84 15q14-q15.3 Schizophrenia, 15q15, OMIM 181500 PCTAIRE3 H 19 85 1q32 PFTAIRE2 H 20 86 2q33.2-q34 2q31-q33 Pulmonary Hypertension, 2q33, OMIM 178600; Osteoarthritis, 2q34-q35, OMIM 140600 ERK7 H 21 87 8q24.3 CKIIa-rs H 22 88 11p15 DYRK4 H 23 89 12p13 Hypertension, essential, 12p13, OMIM 145500 HIPK1 H 24 90 1p11-p12 HIPK4 H 25 91 19q13.1 19cen-q13.3 BIKE H 26 92 4q13-q21.21 Osteoarthritis OMIM 165720 NEK10 H 27 93 3p21.33 pNEK5 H 28 94 13q14 13q14 NEK1 H 29 95 4q33-q34 NEK3 H 30 96 13q14.3 13q14 SGK069 H 31 97 19q13.43 SGK110 H 32 98 19q13.43 NRB02 H 33 99 8q24.3 CNK H 34 100 1p34.1 SCYL2 H 35 101 12q23-q24.1 SRPK2 H 36 102 7q22.3 7q21-q22 TLK1 H 37 103 2q31.1 Osteoarthritis OMIM 165720 SGK071 H 38 104 9q34 SK516 H 39 105 1q31-32.1 H85389 H 40 106 20p13 Wee1b H 41 107 7q34-36 Wnk2 H 42 108 9q22.31 MAP3K1 H 43 109 5q11.2-q13 Schizophrenia, 5q11-q13, OMIM 181500 MAP3K8 H 44 110 2q21.3 Pak4_m M 45 111 murine STLK6-rs H 46 112 1p33 MAP2K2 H 47 113 7q34 CCK4 H 48 114 6p21-p12 LMR1 H 49 115 17q25 RYK H 50 116 3q22 LRRK2 H 51 117 12q11-q12 pMLK4 H 52 118 1q42.2 KSR H 53 119 17q11.1 17q12-q21 KSR2 H 54 120 12q24.3 KIAA1646 H 55 121 22q13.31 DGK-beta H 56 122 7p21.3-p22 Osteoarthritis OMIM 165720 IP6K1 H 57 123 3p21.31 YAB1 H 58 124 1q42 Schizophrenia, 1q42.1, OMIM 181500 AF052122 H 59 125 19q13.1 19cen-q13.3 AAF23326 H 60 126 14q24.3-q32 SGK493 H 61 127 5q14 BRD2 H 62 128 6p21.2 BRD3 H 63 129 9q34 BRD4 H 64 130 19p13.2 BRDT H 65 131 1p21 ZC1 H 66 132 2q11.1-q11.2

[1081] TABLE 6 Human ESTs Rank Gene Human EST 1 CRIK_H_SEQID#NA_1 BQ070955.1 2 CRIK_H_SEQID#NA_1 BQ071141.1 3 CRIK_H_SEQID#NA_1 BQ228524.1 4 CRIK_H_SEQID#NA_1 BM545592.1 5 CRIK_H_SEQID#NA_1 BI253509.1 6 CRIK_H_SEQID#NA_1 BG912161.1 7 CRIK_H_SEQID#NA_1 BG252350.1 8 CRIK_H_SEQID#NA_1 BG120427.1 9 CRIK_H_SEQID#NA_1 BE875297.1 10 CRIK_H_SEQID#NA_1 BQ448184.1 1 DMPK2_H_SEQID#NA_2 BI793270.1 2 DMPK2_H_SEQID#NA_2 BI792977.1 3 DMPK2_H_SEQID#NA_2 BG752641.1 4 DMPK2_H_SEQID#NA_2 BG752641.1 5 DMPK2_H_SEQID#NA_2 AW516225.1 6 DMPK2_H_SEQID#NA_2 BG678034.1 7 DMPK2_H_SEQID#NA_2 AA809737.1 8 DMPK2_H_SEQID#NA_2 BE793390.1 9 DMPK2_H_SEQID#NA_2 BE793390.1 10 DMPK2_H_SEQID#NA_2 AW814108.1 1 MAST3_H_SEQID#NA_3 BG765138.1 2 MAST3_H_SEQID#NA_3 BG767919.1 3 MAST3_H_SEQID#NA_3 BF684640.1 4 MAST3_H_SEQID#NA_3 BF346524.1 5 MAST3_H_SEQID#NA_3 BE261265.1 6 MAST3_H_SEQID#NA_3 BF346384.1 7 MAST3_H_SEQID#NA_3 BG257232.1 8 MAST3_H_SEQID#NA_3 BF689544.1 9 MAST3_H_SEQID#NA_3 BI907332.1 10 MAST3_H_SEQID#NA_3 BM966751.1 1 MAST205_H_SEQID#NA_4 BQ231137.1 2 MAST205_H_SEQID#NA_4 BQ070626.1 3 MAST205_H_SEQID#NA_4 AL568230.1 4 MAST205_H_SEQID#NA_4 BQ050660.1 5 MAST205_H_SEQID#NA_4 BM471504.1 6 MAST205_H_SEQID#NA_4 BG831571.1 7 MAST205_H_SEQID#NA_4 AL540100.1 8 MAST205_H_SEQID#NA_4 BI771067.1 9 MAST205_H_SEQID#NA_4 BG762487.1 10 MAST205_H_SEQID#NA_4 BG676428.1 1 MASTL_H_SEQID#NA_5 AL541215.1 2 MASTL_H_SEQID#NA_5 AL520252.1 3 MASTL_H_SEQID#NA_5 BQ441178.1 4 MASTL_H_SEQID#NA_5 BM550518.1 5 MASTL_H_SEQID#NA_5 BQ224736.1 6 MASTL_H_SEQID#NA_5 BM721150.1 7 MASTL_H_SEQID#NA_5 AL712023.1 8 MASTL_H_SEQID#NA_5 BM679574.1 9 MASTL_H_SEQID#NA_5 BG027109.1 10 MASTL_H_SEQID#NA_5 BM748750.1 1 PKC_eta_H_SEQID#NA_6 BM920615.1 2 PKC_eta_H_SEQID#NA_6 BM457208.1 3 PKC_eta_H_SEQID#NA_6 BQ051772.1 4 PKC_eta_H_SEQID#NA_6 AU136862.1 5 PKC_eta_H_SEQID#NA_6 BI913495.1 6 PKC_eta_H_SEQID#NA_6 BG820252.1 7 PKC_eta_H_SEQID#NA_6 BM549890.1 8 PKC_eta_H_SEQID#NA_6 BE161764.1 9 PKC_eta_H_SEQID#NA_6 BG719560.1 10 PKC_eta_H_SEQID#NA_6 BQ006934.1 1 H19102_H_SEQID#NA_7 BI546006.1 2 H19102_H_SEQID#NA_7 BF954472.1 3 H19102_H_SEQID#NA_7 BQ363219.1 4 H19102_H_SEQID#NA_7 H19102.1 5 H19102_H_SEQID#NA_7 BF362477.1 6 H19102_H_SEQID#NA_7 BF362466.1 7 H19102_H_SEQID#NA_7 BF362458.1 8 H19102_H_SEQID#NA_7 AA808745.1 9 H19102_H_SEQID#NA_7 BE968821.1 10 H19102_H_SEQID#NA_7 BE968821.1 1 MSK1_H_SEQID#NA_8 BM556986.1 2 MSK1_H_SEQID#NA_8 BM453259.1 3 MSK1_H_SEQID#NA_8 BG684373.1 4 MSK1_H_SEQID#NA_8 BM968829.1 5 MSK1_H_SEQID#NA_8 BI088037.1 6 MSK1_H_SEQID#NA_8 BE410965.1 7 MSK1_H_SEQID#NA_8 BG699153.1 8 MSK1_H_SEQID#NA_8 AA314565.1 9 MSK1_H_SEQID#NA_8 BM475296.1 10 MSK1_H_SEQID#NA_8 BM690068.1 1 YANK3_H_SEQID#NA_9 BI917132.1 2 YANK3_H_SEQID#NA_9 BI257653.1 3 YANK3_H_SEQID#NA_9 BG824303.1 4 YANK3_H_SEQID#NA_9 BG282899.1 5 YANK3_H_SEQID#NA_9 BM702426.1 6 YANK3_H_SEQID#NA_9 AW245946.1 7 YANK3_H_SEQID#NA_9 AW245503.1 8 YANK3_H_SEQID#NA_9 BG719068.1 9 YANK3_H_SEQID#NA_9 BM666731.1 10 YANK3_H_SEQID#NA_9 BF446773.1 1 MARK2_H_SEQID#NA_10 BM550195.1 2 MARK2_H_SEQID#NA_10 BE795309.1 3 MARK2_H_SEQID#NA_10 BG825423.1 4 MARK2_H_SEQID#NA_10 BE798169.1 5 MARK2_H_SEQID#NA_10 BI521469.1 6 MARK2_H_SEQID#NA_10 AU133733.1 7 MARK2_H_SEQID#NA_10 BE397682.1 8 MARK2_H_SEQID#NA_10 BG822223.1 9 MARK2_H_SEQID#NA_10 BI911013.1 10 MARK2_H_SEQID#NA_10 BE280645.1 1 NuaK2_H_SEQID#NA_11 BM927376.1 2 NuaK2_H_SEQID#NA_11 BQ062868.1 3 NuaK2_H_SEQID#NA_11 BQ064231.1 4 NuaK2_H_SEQID#NA_11 BQ059508.1 5 NuaK2_H_SEQID#NA_11 BQ060729.1 6 NuaK2_H_SEQID#NA_11 BM909401.1 7 NuaK2_H_SEQID#NA_11 BQ056806.1 8 NuaK2_H_SEQID#NA_11 BQ065633.1 9 NuaK2_H_SEQID#NA_11 BQ064127.1 10 NuaK2_H_SEQID#NA_11 BQ056490.1 1 BRSK2_H_SEQID#NA_12 AL538014.1 2 BRSK2_H_SEQID#NA_12 BG395625.1 3 BRSK2_H_SEQID#NA_12 BI825755.1 4 BRSK2_H_SEQID#NA_12 BM677936.1 5 BRSK2_H_SEQID#NA_12 BG395884.1 6 BRSK2_H_SEQID#NA_12 BM805756.1 7 BRSK2_H_SEQID#NA_12 BE251924.1 8 BRSK2_H_SEQID#NA_12 BE550940.1 9 BRSK2_H_SEQID#NA_12 BF525960.1 10 BRSK2_H_SEQID#NA_12 BE259121.1 1 MARK4_H_SEQID#NA_13 BG745114.1 2 MARK4_H_SEQID#NA_13 BM543319.1 3 MARK4_H_SEQID#NA_13 BQ066239.1 4 MARK4_H_SEQID#NA_13 BG389721.1 5 MARK4_H_SEQID#NA_13 BF982422.1 6 MARK4_H_SEQID#NA_13 BM467107.1 7 MARK4_H_SEQID#NA_13 BG744466.1 8 MARK4_H_SEQID#NA_13 BG760697.1 9 MARK4_H_SEQID#NA_13 BF686388.1 10 MARK4_H_SEQID#NA_13 BM999847.1 1 DCAMKL2_H_SEQID#NA_14 BM467980.1 2 DCAMKL2_H_SEQID#NA_14 BI034992.1 3 DCAMKL2_H_SEQID#NA_14 BI035543.1 4 DCAMKL2_H_SEQID#NA_14 BF943256.1 5 DCAMKL2_H_SEQID#NA_14 BF943502.1 6 DCAMKL2_H_SEQID#NA_14 BF362270.1 7 DCAMKL2_H_SEQID#NA_14 BF963919.1 8 DCAMKL2_H_SEQID#NA_14 BF362283.1 9 DCAMKL2_H_SEQID#NA_14 BQ217828.1 10 DCAMKL2_H_SEQID#NA_14 BF886988.1 1 PIM2_H_SEQID#NA_15 BM457909.1 2 PIM2_H_SEQID#NA_15 BM459453.1 3 PIM2_H_SEQID#NA_15 BM464831.1 4 PIM2_H_SEQID#NA_15 AU124437.1 5 PIM2_H_SEQID#NA_15 BI908737.1 6 PIM2_H_SEQID#NA_15 BI546781.1 7 PIM2_H_SEQID#NA_15 AU125921.1 8 PIM2_H_SEQID#NA_15 BI253854.1 9 PIM2_H_SEQID#NA_15 BG705716.1 10 PIM2_H_SEQID#NA_15 BM008442.1 1 PIM3_H_SEQID#NA_16 AL525596.1 2 PIM3_H_SEQID#NA_16 AL549520.1 3 PIM3_H_SEQID#NA_16 AL570770.1 4 PIM3_H_SEQID#NA_16 AL523928.1 5 PIM3_H_SEQID#NA_16 AL570076.1 6 PIM3_H_SEQID#NA_16 BI753308.1 7 PIM3_H_SEQID#NA_16 AL519345.1 8 PIM3_H_SEQID#NA_16 AL543684.1 9 PIM3_H_SEQID#NA_16 BG744856.1 10 PIM3_H_SEQID#NA_16 AL562787.1 1 TSSK4_H_SEQID#NA_17 BE551971.1 2 TSSK4_H_SEQID#NA_17 AI075923.1 3 TSSK4_H_SEQID#NA_17 BI825382.1 4 TSSK4_H_SEQID#NA_17 H87255.1 5 TSSK4_H_SEQID#NA_17 BF510751.1 6 TSSK4_H_SEQID#NA_17 BF510751.1 7 TSSK4_H_SEQID#NA_17 AW296282.1 8 TSSK4_H_SEQID#NA_17 AI218614.1 9 TSSK4_H_SEQID#NA_17 AI218614.1 10 TSSK4_H_SEQID#NA_17 AI365148.1 1 CKIL2_H_SEQID#NA_18 AL530844.1 2 CKIL2_H_SEQID#NA_18 BQ439549.1 3 CKIL2_H_SEQID#NA_18 AL577840.1 4 CKIL2_H_SEQID#NA_18 AL555305.1 5 CKIL2_H_SEQID#NA_18 AL705762.1 6 CKIL2_H_SEQID#NA_18 BE548084.1 7 CKIL2_H_SEQID#NA_18 BF433088.1 8 CKIL2_H_SEQID#NA_18 BE222107.1 9 CKIL2_H_SEQID#NA_18 AW294686.1 10 CKIL2_H_SEQID#NA_18 BG718751.1 1 PCTAIRE3_H_SEQID#NA_19 AL520700.1 2 PCTAIRE3_H_SEQID#NA_19 AL528335.1 3 PCTAIRE3_H_SEQID#NA_19 AL520699.1 4 PCTAIRE3_H_SEQID#NA_19 BM457869.1 5 PCTAIRE3_H_SEQID#NA_19 BQ437828.1 6 PCTAIRE3_H_SEQID#NA_19 BM549437.1 7 PCTAIRE3_H_SEQID#NA_19 BM045832.1 8 PCTAIRE3_H_SEQID#NA_19 BG912679.1 9 PCTAIRE3_H_SEQID#NA_19 BE747807.1 10 PCTAIRE3_H_SEQID#NA_19 BF345421.1 1 PFTAIRE2_H_SEQID#NA_20 BI755983.1 2 PFTAIRE2_H_SEQID#NA_20 BE562611.1 3 PFTAIRE2_H_SEQID#NA_20 BG326162.1 4 PFTAIRE2_H_SEQID#NA_20 AA436054.1 5 PFTAIRE2_H_SEQID#NA_20 AA435956.1 6 PFTAIRE2_H_SEQID#NA_20 BG249066.1 7 PFTAIRE2_H_SEQID#NA_20 BG249066.1 8 PFTAIRE2_H_SEQID#NA_20 BG772738.1 9 PFTAIRE2_H_SEQID#NA_20 BG720115.1 10 PFTAIRE2_H_SEQID#NA_20 W03371.1 1 ERK7_H_SEQID#NA_21 AL537138.1 2 ERK7_H_SEQID#NA_21 AL537137.1 3 ERK7_H_SEQID#NA_21 BM553342.1 4 ERK7_H_SEQID#NA_21 BM553342.1 5 ERK7_H_SEQID#NA_21 BE464560.1 6 ERK7_H_SEQID#NA_21 AI049667.1 7 ERK7_H_SEQID#NA_21 AJ403115.1 8 ERK7_H_SEQID#NA_21 AI476756.1 9 ERK7_H_SEQID#NA_21 AI921266.1 10 ERK7_H_SEQID#NA_21 AI680380.1 1 CKIIa·rs_H_SEQID#NA_22 AL559846.1 2 CKIIa·rs_H_SEQID#NA_22 AL560958.1 3 CKIIa·rs_H_SEQID#NA_22 AU131772.1 4 CKIIa·rs_H_SEQID#NA_22 AU120646.1 5 CKIIa·rs_H_SEQID#NA_22 BI258630.1 6 CKIIa·rs_H_SEQID#NA_22 AU133318.1 7 CKIIa·rs_H_SEQID#NA_22 AU133037.1 8 CKIIa·rs_H_SEQID#NA_22 AU125134.1 9 CKIIa·rs_H_SEQID#NA_22 AL582368.1 10 CKIIa·rs_H_SEQID#NA_22 AU117006.1 1 DYRK4_H_SEQID#NA_23 AL561586.1 2 DYRK4_H_SEQID#NA_23 AL582755.1 3 DYRK4_H_SEQID#NA_23 BG721331.1 4 DYRK4_H_SEQID#NA_23 BM041899.1 5 DYRK4_H_SEQID#NA_23 BI559381.1 6 DYRK4_H_SEQID#NA_23 BM042712.1 7 DYRK4_H_SEQID#NA_23 BI459242.1 8 DYRK4_H_SEQID#NA_23 BI459242.1 9 DYRK4_H_SEQID#NA_23 BF431376.1 10 DYRK4_H_SEQID#NA_23 AI066522.1 1 HIPK1_H_SEQID#NA_24 BQ224060.1 2 HIPK1_H_SEQID#NA_24 BM476759.1 3 HIPK1_H_SEQID#NA_24 BM724085.1 4 HIPK1_H_SEQID#NA_24 BG742609.1 5 HIPK1_H_SEQID#NA_24 BG681186.1 6 HIPK1_H_SEQID#NA_24 BG676057.1 7 HIPK1_H_SEQID#NA_24 AW166113.1 8 HIPK1_H_SEQID#NA_24 BG498068.1 9 HIPK1_H_SEQID#NA_24 BG612475.1 10 HIPK1_H_SEQID#NA_24 BE877361.1 1 HIPK4_H_SEQID#NA_25 BM554291.1 2 HIPK4_H_SEQID#NA_25 BG772881.1 3 HIPK4_H_SEQID#NA_25 BI827147.1 4 HIPK4_H_SEQID#NA_25 BI561789.1 5 HIPK4_H_SEQID#NA_25 BG105231.1 6 HIPK4_H_SEQID#NA_25 BG771831.1 7 HIPK4_H_SEQID#NA_25 BG720082.1 8 HIPK4_H_SEQID#NA_25 AI806773.1 9 HIPK4_H_SEQID#NA_25 AI001807.1 10 HIPK4_H_SEQID#NA_25 M62294.1 1 BIKE_H_SEQID#NA_26 BI755383.1 2 BIKE_H_SEQID#NA_26 AW968082.1 3 BIKE_H_SEQID#NA_26 BG776990.1 4 BIKE_H_SEQID#NA_26 BG485573.1 5 BIKE_H_SEQID#NA_26 AW968084.1 6 BIKE_H_SEQID#NA_26 AI939552.1 7 BIKE_H_SEQID#NA_26 AL546234.1 8 BIKE_H_SEQID#NA_26 AW967339.1 9 BIKE_H_SEQID#NA_26 BI461241.1 10 BIKE_H_SEQID#NA_26 BI461241.1 1 NEK10_H_SEQID#NA_27 AI652681.1 2 NEK10_H_SEQID#NA_27 BM976126.1 3 NEK10_H_SEQID#NA_27 AI962584.1 4 NEK10_H_SEQID#NA_27 AA954906.1 5 NEK10_H_SEQID#NA 27 BG717420.1 6 NEK10_H_SEQID#NA_27 AA889152.1 7 NEK10_H_SEQID#NA_27 AA429606.1 8 NEK10_H_SEQID#NA_27 BM976173.1 9 NEK10_H_SEQID#NA_27 AA430250.1 10 NEK10_H_SEQID#NA_27 BI462787.1 1 pNEK5_H_SEQID#NA_28 AA398536.1 2 pNEK5_H_SEQID#NA_28 AA393108.1 3 pNEK5_H_SEQID#NA_28 AI627290.1 1 NEK1_H_SEQID#NA_29 AV700007.1 2 NEK1_H_SEQID#NA_29 AV700747.1 3 NEK1_H_SEQID#NA_29 AI936517.1 4 NEK1_H_SEQID#NA_29 AV699533.1 5 NEK1_H_SEQID#NA_29 BG290898.1 6 NEK1_H_SEQID#NA_29 AV700291.1 7 NEK1_H_SEQID#NA_29 AI816275.1 8 NEK1_H_SEQID#NA_29 AV699817.1 9 NEK1_H_SEQID#NA_29 BG706222.1 10 NEK1_H_SEQID#NA_29 AW976435.1 1 NEK3_H_SEQID#NA_30 BQ432111.1 2 NEK3_H_SEQID#NA_30 BI093553.1 3 NEK3_H_SEQID#NA_30 AI971454.1 4 NEK3_H_SEQID#NA_30 AI191920.1 5 NEK3_H_SEQID#NA_30 AI659549.1 6 NEK3_H_SEQID#NA_30 BI754945.1 7 NEK3_H_SEQID#NA_30 AW043698.1 8 NEK3_H_SEQID#NA_30 AI627473.1 9 NEK3_H_SEQID#NA_30 BM984985.1 10 NEK3_H_SEQID#NA_30 AA873814.1 1 SGK069_H_SEQID#NA_31 None 1 SGK110_H_SEQID#NA_32 None 1 NRBP2_H_SEQID#NA_33 AL564934.1 2 NRBP2_H_SEQID#NA_33 BG108500.1 3 NRBP2_H_SEQID#NA_33 BQ014431.1 4 NRBP2_H_SEQID#NA_33 BQ182709.1 5 NRBP2_H_SEQID#NA_33 BG913260.1 6 NRBP2_H_SEQID#NA_33 AW962453.1 7 NRBP2_H_SEQID#NA_33 BM709377.1 8 NRBP2_H_SEQID#NA_33 BF944679.1 9 NRBP2_H_SEQID#NA_33 BG571713.1 10 NRBP2_H_SEQID#NA_33 BG576689.1 1 CNK_H_SEQID#NA_34 BG675045.1 2 CNK_H_SEQID#NA_34 BM927202.1 3 CNK_H_SEQID#NA_34 BE250216.1 4 CNK_H_SEQID#NA_34 BQ065567.1 5 CNK_H_SEQID#NA_34 BE515113.1 6 CNK_H_SEQID#NA_34 BE783099.1 7 CNK_H_SEQID#NA_34 BQ228988.1 8 CNK_H_SEQID#NA_34 BF205939.1 9 CNK_H_SEQID#NA_34 AI951666.1 10 CNK_H_SEQID#NA_34 BQ066297.1 1 SCYL2_H_SEQID#NA_35 BM905696.1 2 SCYL2_H_SEQID#NA_35 AL563032.1 3 SCYL2_H_SEQID#NA_35 AL700123.1 4 SCYL2_H_SEQID#NA_35 AU130771.1 5 SCYL2_H_SEQID#NA_35 AL528010.1 6 SCYL2_H_SEQID#NA_35 AU120073.1 7 SCYL2_H_SEQID#NA_35 BE614405.1 8 SCYL2_H_SEQID#NA_35 BM459956.1 9 SCYL2_H_SEQID#NA_35 BM786779.1 10 SCYL2_H_SEQID#NA_35 BF982530.1 1 SRPK2_H_SEQID#NA_36 BM464185.1 2 SRPK2_H_SEQID#NA_36 BQ428104.1 3 SRPK2_H_SEQID#NA_36 AL521820.1 4 SRPK2_H_SEQID#NA_36 AL045362.1 5 SRPK2_H_SEQID#NA_36 AL521821.1 6 SRPK2_H_SEQID#NA_36 AU124931.1 7 SRPK2_H_SEQID#NA_36 BG200431.1 8 SRPK2_H_SEQID#NA_36 BG389934.1 9 SRPK2_H_SEQID#NA_36 BM979654.1 10 SRPK2_H_SEQID#NA_36 AI038250.1 1 TLK1_H_SEQID#NA_37 BM561353.1 2 TLK1_H_SEQID#NA_37 AL526362.1 3 TLK1_H_SEQID#NA_37 B1488932.1 4 TLK1_H_SEQID#NA_37 AU124094.1 5 TLK1_H_SEQID#NA_37 AU119119.1 6 TLK1_H_SEQID#NA_37 BM470340.1 7 TLK1_H_SEQID#NA_37 AU134085.1 8 TLK1_H_SEQID#NA_37 BG779394.1 9 TLK1_H_SEQID#NA_37 BM981774.1 10 TLK1_H_SEQID#NA_37 BM724955.1 1 SGK071_H_SEQID#NA_38 BI458908.1 2 SGK071_H_SEQID#NA_38 AL044935.1 3 SGK071_H_SEQID#NA_38 BQ184985.1 4 SGK071_H_SEQID#NA_38 AV763896.1 1 SK516_H_SEQID#NA_39 BM918041.1 2 SK516_H_SEQID#NA_39 BQ215537.1 3 SK516_H_SEQID#NA_39 BG479508.1 4 SK516_H_SEQID#NA_39 BG475168.1 5 SK516_H_SEQID#NA_39 BG473913.1 6 SK516_H_SEQID#NA_39 BG280828.1 7 SK516_H_SEQID#NA_39 BG763842.1 8 SK516_H_SEQID#NA_39 BQ279002.1 9 SK516_H_SEQID#NA_39 BI090323.1 10 SK516_H_SEQID#NA_39 BG033116.1 1 H85389_H_SEQID#NA_40 AW292935.1 2 H85389_H_SEQID#NA_40 BG875928.1 3 H85389_H_SEQID#NA_40 BG766602.1 4 H85389_H_SEQID#NA_40 BG766602.1 5 H85389_H_SEQID#NA_40 AW027321.1 6 H85389_H_SEQID#NA_40 AW027332.1 7 H85389_H_SEQID#NA_40 AL732079.1 8 H85389_H_SEQID#NA_40 BG875945.1 9 H85389_H_SEQID#NA_40 BG875933.1 1 Wee1b_H_SEQID#NA_41 BM790836.1 2 Wee1b_H_SEQID#NA_41 BG402079.1 1 Wnk2_H_SEQID#NA_42 BQ222235.1 2 Wnk2_H_SEQID#NA_42 AL534358.1 3 Wnk2_H_SEQID#NA_42 BM907282.1 4 Wnk2_H_SEQID#NA_42 BI546992.1 5 Wnk2_H_SEQID#NA_42 BI756222.1 6 Wnk2_H_SEQID#NA_42 BM678640.1 7 Wnk2_H_SEQID#NA_42 AW962621.1 8 Wnk2_H_SEQID#NA_42 BM689160.1 9 Wnk2_H_SEQID#NA_42 BF336877.1 10 Wnk2_H_SEQID#NA_42 AI637586.1 1 MAP3K1_H_SEQID#NA_43 AU132367.1 2 MAP3K1_H_SEQID#NA_43 AL133917.1 3 MAP3K1_H_SEQID#NA_43 BM928438.1 4 MAP3K1_H_SEQID#NA_43 BM928438.1 5 MAP3K1_H_SEQID#NA_43 AL042445.1 6 MAP3K1_H_SEQID#NA_43 AW499603.1 7 MAP3K1_H_SEQID#NA_43 BG119132.1 8 MAP3K1_H_SEQID#NA_43 BE162514.1 9 MAP3K1_H_SEQID#NA_43 BF216567.1 10 MAP3K1_H_SEQID#NA_43 BF216567.1 1 MAP3K8_H_SEQID#NA_44 BM969829.1 2 MAP3K8_H_SEQID#NA_44 BG484791.1 3 MAP3K8_H_SEQID#NA_44 BI832332.1 4 MAP3K8_H_SEQID#NA_44 N57475.1 5 MAP3K8_H_SEQID#NA_44 AI683447.1 6 MAP3K8_H_SEQID#NA_44 N47620.1 1 STLK6-rs_H_SEQID#NA_46 AL552387.1 2 STLK6-rs_H_SEQID#NA_46 AL515422.1 3 STLK6-rs_H_SEQID#NA_46 AL520217.1 4 STLK6-rs_H_SEQID#NA_46 AL520216.1 5 STLK6-rs_H_SEQID#NA_46 BM465416.1 6 STLK6-rs_H_SEQID#NA_46 BI825875.1 7 STLK6-rs_H_SEQID#NA_46 BI859101.1 8 STLK6-rs_H_SEQID#NA_46 AL558687.1 9 STLK6-rs_H_SEQID#NA_46 BI823806.1 10 STLK6-rs_H_SEQID#NA_46 BI765467.1 1 MAP2K2_H_SEQID#NA_47 BQ278839.1 2 MAP2K2_H_SEQID#NA_47 AL525264.1 3 MAP2K2_H_SEQID#NA_47 BM804931.1 4 MAP2K2_H_SEQID#NA_47 BM920109.1 5 MAP2K2_H_SEQID#NA_47 BI826639.1 6 MAP2K2_H_SEQID#NA_47 AL525439.1 7 MAP2K2_H_SEQID#NA_47 BG769213.1 8 MAP2K2_H_SEQID#NA_47 BE732844.1 9 MAP2K2_H_SEQID#NA_47 BG770148.1 10 MAP2K2_H_SEQID#NA_47 BG769998.1 1 CCK4_H_SEQID#NA_48 AL515621.1 2 CCK4_H_SEQID#NA_48 BM554494.1 3 CCK4_H_SEQID#NA_48 AL515620.1 4 CCK4_H_SEQID#NA_48 BM048660.1 5 CCK4_H_SEQID#NA_48 BM801688.1 6 CCK4_H_SEQID#NA_48 AL558185.1 7 CCK4_H_SEQID#NA_48 BI871758.1 8 CCK4_H_SEQID#NA_48 BM802337.1 9 CCK4_H_SEQID#NA_48 BG773310.1 10 CCK4_H_SEQID#NA_48 BF981652.1 1 LMR1_H_SEQID#NA_49 BI603257.1 2 LMR1_H_SEQID#NA_49 BF306070.1 3 LMR1_H_SEQID#NA_49 BM549649.1 4 LMR1_H_SEQID#NA_49 BG827921.1 5 LMR1_H_SEQID#NA_49 BI601257.1 6 LMR1_H_SEQID#NA_49 BM547656.1 7 LMR1_H_SEQID#NA_49 BG911396.1 8 LMR1_H_SEQID#NA_49 AL120105.1 9 LMR1_H_SEQID#NA_49 AV727368.1 10 LMR1_H_SEQID#NA_49 BI600711.1 1 RYK_H_SEQID#NA_50 BQ067310.1 2 RYK_H_SEQID#NA_50 BQ434679.1 3 RYK_H_SEQID#NA_50 BG740085.1 4 RYK_H_SEQID#NA_50 BG764027.1 5 RYK_H_SEQID#NA_50 AU130782.1 6 RYK_H_SEQID#NA_50 BI870859.1 7 RYK_H_SEQID#NA_50 BM450529.1 8 RYK_H_SEQID#NA_50 BG762507.1 9 RYK_H_SEQID#NA_50 AL038696.1 10 RYK_H_SEQID#NA_50 BG260940.1 1 LRRK2_H_SEQID#NA_51 BG189993.1 2 LRRK2_H_SEQID#NA_51 BM998398.1 3 LRRK2_H_SEQID#NA_51 AV705213.1 4 LRRK2_H_SEQID#NA_51 BF665089.1 5 LRRK2_H_SEQID#NA_51 AW958959.1 6 LRRK2_H_SEQID#NA_51 BF699250.1 7 LRRK2_H_SEQID#NA_51 BF669643.1 8 LRRK2_H_SEQID#NA_51 BF669643.1 9 LRRK2_H_SEQID#NA_51 BQ437477.1 10 LRRK2_H_SEQID#NA_51 BQ437477.1 1 pMLK4_H_SEQID#NA_52 BG824246.1 2 pMLK4_H_SEQID#NA_52 BI964128.1 3 pMLK4_H_SEQID#NA_52 BG540713.1 4 pMLK4_H_SEQID#NA_52 BI964177.1 5 pMLK4_H_SEQID#NA_52 BE867187.1 6 pMLK4_H_SEQID#NA_52 AW408639.1 7 pMLK4_H_SEQID#NA_52 BI963837.1 8 pMLK4_H_SEQID#NA_52 BF352800.1 9 pMLK4_H_SEQID#NA_52 BI963872.1 10 pMLK4_H_SEQID#NA_52 H67242.1 1 KSR_H_SEQID#NA_53 BI086433.1 2 KSR_H_SEQID#NA_53 BF528425.1 3 KSR_H_SEQID#NA_53 AI123553.1 4 KSR_H_SEQID#NA_53 BM989782.1 5 KSR_H_SEQID#NA_53 BI091489.1 6 KSR_H_SEQID#NA_53 AW963516.1 7 KSR_H_SEQID#NA_53 AI809969.1 8 KSR_H_SEQID#NA_53 AI458861.1 9 KSR_H_SEQID#NA_53 AI088028.1 10 KSR_H_SEQID#NA_53 AW166454.1 1 KSR2_H_SEQID#NA_54 BF948353.1 1 KIAA1646_H_SEQID#NA_55 BM479389.1 2 KIAA1646_H_SEQID#NA_55 BG754980.1 3 KIAA1646_H_SEQID#NA_55 BM453176.1 4 KIAA1646_H_SEQID#NA_55 BQ230294.1 5 KIAA1646_H_SEQID#NA_55 BQ054406.1 6 KIAA1646_H_SEQID#NA_55 BQ063738.1 7 KIAA1646_H_SEQID#NA_55 BG284450.1 8 KIAA1646_H_SEQID#NA_55 BQ057191.1 9 KIAA1646_H_SEQID#NA_55 BE898542.1 10 KIAA1646_H_SEQID#NA_55 BG750642.1 1 DGK·beta_H_SEQID#NA_56 BG912323.1 2 DGK·beta_H_SEQID#NA_56 BG201482.1 3 DGK·beta_H_SEQID#NA_56 BF949285.1 4 DGK·beta_H_SEQID#NA_56 BI032910.1 1 IP6K1_H_SEQID#NA_57 AL515350.1 2 IP6K1_H_SEQID#NA_57 AL537602.1 3 IP6K1_H_SEQID#NA_57 BM544669.1 4 IP6K1_H_SEQID#NA_57 BM546339.1 5 IP6K1_H_SEQID#NA_57 BQ232298.1 6 IP6K1_H_SEQID#NA_57 BQ053969.1 7 IP6K1_H_SEQID#NA_57 AL536739.1 8 IP6K1_H_SEQID#NA_57 BG468729.1 9 IP6K1_H_SEQID#NA_57 BG822723.1 10 IP6K1_H_SEQID#NA_57 BQ220938.1 1 YAB1_H_SEQID#NA_58 BM925217.1 2 YAB1_H_SEQID#NA_58 BI771908.1 3 YAB1_H_SEQID#NA_58 BM475528.1 4 YAB1_H_SEQID#NA_58 BM929585.1 5 YAB1_H_SEQID#NA_58 BQ067514.1 6 YAB1_H_SEQID#NA_58 AW964156.1 7 YAB1_H_SEQID#NA_58 BI829039.1 8 YAB1_H_SEQID#NA_58 BG541994.1 9 YAB1_H_SEQID#NA_58 BI871673.1 10 YAB1_H_SEQID#NA_58 BE797060.1 1 AF052122_H_SEQID#NA_59 BI833115.1 2 AF052122_H_SEQID#NA_59 BI227273.1 3 AF052122_H_SEQID#NA_59 BI226041.1 4 AF052122_H_SEQID#NA_59 BI226088.1 5 AF052122_H_SEQID#NA_59 BE562310.1 6 AF052122_H_SEQID#NA_59 BM458499.1 7 AF052122_H_SEQID#NA_59 BG324551.1 8 AF052122_H_SEQID#NA_59 BF057611.1 9 AF052122_H_SEQID#NA_59 BG779592.1 10 AF052122_H_SEQID#NA_59 BI117258.1 1 AAF23326_H_SEQID#NA_60 BI193027.1 2 AAF23326_H_SEQID#NA_60 BQ214713.1 3 AAF23326_H_SEQID#NA_60 AI907812.1 4 AAF23326_H_SEQID#NA_60 AA478358.1 5 AAF23326_H_SEQID#NA_60 AA459637.1 6 AAF23326_H_SEQID#NA_60 AA284562.1 7 AAF23326_H_SEQID#NA_60 AA401004.1 8 AAF23326_H_SEQID#NA_60 BM128250.1 9 AAF23326_H_SEQID#NA_60 BG219074.1 10 AAF23326_H_SEQID#NA_60 W88819.1 1 SGK493_H_SEQID#NA_61 BQ049234.1 2 SGK493_H_SEQID#NA_61 BM554462.1 3 SGK493_H_SEQID#NA_61 AL527674.1 4 SGK493_H_SEQID#NA_61 AL527675.1 5 SGK493_H_SEQID#NA_61 AU133075.1 6 SGK493_H_SEQID#NA_61 BI833907.1 7 SGK493_H_SEQID#NA_61 BI819237.1 8 SGK493_H_SEQID#NA_61 BM677568.1 9 SGK493_H_SEQID#NA_61 BI756523.1 10 SGK493_H_SEQID#NA_61 BG388681.1 1 BRD2_H_SEQID#NA_62 BQ222485.1 2 BRD2_H_SEQID#NA_62 BM800104.1 3 BRD2_H_SEQID#NA_62 BQ212470.1 4 BRD2_H_SEQID#NA_62 AU141190.1 5 BRD2_H_SEQID#NA_62 BQ054271.1 6 BRD2_H_SEQID#NA_62 AU143483.1 7 BRD2_H_SEQID#NA_62 BQ072172.1 8 BRD2_H_SEQID#NA_62 BI771111.1 9 BRD2_H_SEQID#NA_62 BI855660.1 10 BRD2_H_SEQID#NA_62 AU130987.1 1 BRD3_H_SEQID#NA_63 BQ072151.1 2 BRD3_H_SEQID#NA_63 BM807235.1 3 BRD3_H_SEQID#NA_63 BM799542.1 4 BRD3_H_SEQID#NA_63 AU131741.1 5 BRD3_H_SEQID#NA_63 BQ435244.1 6 BRD3_H_SEQID#NA_63 BM910839.1 7 BRD3_H_SEQID#NA_63 BM909939.1 8 BRD3_H_SEQID#NA_63 AU123823.1 9 BRD3_H_SEQID#NA_63 BI858783.1 10 BRD3_H_SEQID#NA_63 AU131644.1 1 BRD4_H_SEQID#NA_64 BG476527.1 2 BRD4_H_SEQID#NA_64 BM542719.1 3 BRD4_H_SEQID#NA_64 BQ218394.1 4 BRD4_H_SEQID#NA_64 BQ219777.1 5 BRD4_H_SEQID#NA_64 AU126004.1 6 BRD4_H_SEQID#NA_64 BG397005.1 7 BRD4_H_SEQID#NA_64 BM467005.1 8 BRD4_H_SEQID#NA_64 BG478389.1 9 BRD4_H_SEQID#NA_64 BQ214403.1 10 BRD4_H_SEQID#NA_64 BF314720.1 1 BRDT_H_SEQID#NA_65 BM552817.1 2 BRDT_H_SEQID#NA_65 BI830253.1 3 BRDT_H_SEQID#NA_65 BG150293.1 4 BRDT_H_SEQID#NA_65 BI827344.1 5 BRDT_H_SEQID#NA_65 BG718280.1 6 BRDT_H_SEQID#NA_65 BG717291.1 7 BRDT_H_SEQID#NA_65 BG718558.1 8 BRDT_H_SEQID#NA_65 AL705795.1 9 BRDT_H_SEQID#NA_65 BF057076.1 10 BRDT_H_SEQID#NA_65 AI656466.1 1 ZC1_H_SEQID#NA_66 BQ232312.1 2 ZC1_H_SEQID#NA_66 BQ221714.1 3 ZC1_H_SEQID#NA_66 BM927043.1 4 ZC1_H_SEQID#NA_66 BI915627.1 5 ZC1_H_SEQID#NA_66 BQ004320.1 6 ZC1_H_SEQID#NA_66 BI850450.1 7 ZC1_H_SEQID#NA_66 BQ014222.1 8 ZC1_H_SEQID#NA_66 BI224416.1 9 ZC1_H_SEQID#NA_66 BQ026964.1 10 ZC1_H_SEQID#NA_66 BG026496.1 

What is claimed is:
 1. An isolated, enriched or purified nucleic acid molecule encoding a kinase polypeptide, wherein said nucleic acid molecule comprises a nucleotide sequence that: (a) encodes a polypeptide having an amino acid selected from the group consisting of those set forth in SEQ ID NO: 67 though 132; (b) is the complement of the nucleotide sequence of (a); (c) hybridizes under stringent conditions to the nucleotide molecule of (a) and encodes a kinase polypeptide; (d) encodes a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, except that said polypeptide lacks one or more, but no; all, of an N-terminal domain, a C-terminal catalytic domain, a catalytic domain, a C-terminal domain, a coiled-coil structure region, a proline rich region, a spacer region and a C-terminal tail; or (e) is the complement of the nucleotide sequence of (d).
 2. The nucleic acid molecule of claim 1, further comprising a vector or promoter effective to initiate transcription in a host cell.
 3. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is isolated, enriched, or purified from a mammal.
 4. The nucleic acid molecule of claim 3, wherein said mammal is a human.
 5. The nucleic acid molecule of claim 1 comprising a nucleic acid having a nucleotide sequence which hybridizes under stringent conditions to a nucleotide sequence encoding a kinase polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through
 132. 6. An isolated, enriched, or purified kinase polypeptide, wherein said polypeptide comprises: (a) an amino acid sequence at least about 90% identical to a sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132; or (b) an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132, except that the polypeptide lacks one or more, but not all, of the domains selected from the group consisting of an N-terminal domain, a C-terminal catalytic domain, a catalytic domain, a C-terminal domain, a coiled-coil structure region, a proline- rich region, a spacer region-and a C-terminal tail.
 7. The kinase polypeptide of claim 6, wherein said polypeptide is isolated, purified, or enriched from a mammal.
 8. The kinase polypeptide of claim 7, wherein said mammal is a human.
 9. An antibody or antibody fragment having specific binding affinity to the kinase polypeptide of claim 6, or a domain thereof.
 10. A hybridoma which produces the antibody of claim
 9. 11. A kit comprising an antibody which binds to a polypeptide of claim 6 and a negative control antibody.
 12. A method for identifying a substance that modulates the activity of a kinase polypeptide comprising the steps of: (a) contacting a kinase polypeptide substantially identical to an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132 with a test substance; (b) measuring the activity of said polypeptide; and (c) determining whether said substance modulates the activity of said polypeptide.
 13. A method for identifying a substance that modulates the activity of a kinase polypeptide in a cell comprising the steps of: (a) expressing a kinase polypeptide having a sequence substantially identical to an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132; (b) adding a test substance to said cell; and (c) monitoring a change in cell phenotype or the interaction between said polypeptide and a natural binding partner.
 14. A method for treating a disease or disorder by administering to a patient in need of such treatment a substance that modulates activity of the kinase polypeptide according to claim
 6. 15. The method of claim 14, wherein said disease or disorder is selected from the group consisting of cancers, immune-related diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, metabolic disorders and inflammatory disorders.
 16. The method of claim 15, wherein said disease or disorder is selected from the group consisting of cancers of tissues; cancers of blood or hematopoietic origin; cancers of the breast, colon, lung, prostate, cervix, brain, ovaries, bladder or kidney.
 17. The method of claim 15, wherein said disease or disorder is selected from the group consisting of disorders of the central or peripheral nervous system; migraines; pain; sexual dysfunction; mood disorders; attention disorders; cognition disorders; hypotension; hypertension; psychotic disorders; neurological disorders and dyskinesias.
 18. The method of claim 15, wherein said disease or disorder is selected from the group consisting of inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity and organ transplant rejection.
 19. The method of claim 15, wherein said substance modulates kinase activity in vitro.
 20. The method of claim 19, wherein said substance is a kinase inhibitor.
 21. A method for detection of a kinase polypeptide in a sample as a diagnostic tool for a disease or disorder, wherein said method comprises: (a) contacting said sample with a nucleic acid probe which hybridizes under hybridization assay conditions to a nucleic acid target region of the nucleic acid molecule of claim 1; and (b) detecting the presence or amount of the target region:probe hybrid, as an indication of said disease or disorder.
 22. The method of claim 21, wherein said disease or disorder is selected from the group consisting of cancers, immune-related diseases and disorders, cardiovascular disease, brain or neuronal-associated diseases, metabolic disorders and inflammatory disorders.
 23. The method of claim 22, wherein said disease or disorder is selected from the group consisting of cancers of tissues; cancers of blood or hematopoietic origin; cancers of the breast, colon, lung, prostate, cervix, brain, ovary, bladder or kidney.
 24. The method of claim 22, wherein said disease or disorder is selected from the group consisting of central or peripheral nervious system disease, migraines, pain; sexual dysfunction; mood disorders; attention disorders; cognition disorders; hypotension; hypertension; psychotic disorders; neurological disorders and dyskinesias.
 25. The method of claim 22, wherein said disease or disorder is selected from the group consisting of inflammatory disorders including rheumatoid arthritis, chronic inflammatory bowel disease, chronic inflammatory pelvic disease, multiple sclerosis, asthma, osteoarthritis, psoriasis, atherosclerosis, rhinitis, autoimmunity, and organ transplant rejection.
 26. An isolated, enriched or purified nucleic acid probe consisting essentially of about 10-30 contiguous nucleotide bases of a nucleic acid sequence that encodes a polypeptide selected from the group consisting of SEQ ID NO: 67 through
 132. 27. The isolated, enriched or purified nucleic acid probe of claim 26 consisting essentially of about 10-30 contiguous nucleotide bases of a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through
 66. 28. A recombinant cell comprising the nucleic acid molecule of claim
 1. 29. A vector comprising the nucleic acid molecule of claim
 1. 30. A method for identification of a nucleic acid encoding a kinase polypeptide in a sample, wherein said method comprises: (a) contacting said sample with the nucleic acid probe of claim 26; and (b) isolating a nucleic acid that hybridizes to said probe, thereby identifying said nucleic acid encoding a kinase polypeptide.
 31. A transgenic mouse comprising a nucleic acid sequence that encodes a polypeptide substantially identical to an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO: 67 through 132; wherein said mouse exhibits a phenotype, relative to a wild-type phenotype, comprising modulation of kinase activity of said polypeptide.
 32. A cell or cell line obtained from the transgenic mouse of claim
 31. 33. A method for identifying a substance that modulates the activity of a kinase polypeptide, wherein said method comprises: (a) determining in a sample obtained from the transgenic mouse of claim 31 the presence and/or quantity of kinase activity attributable to the polypeptide encoded by the nucleic acid used to create said transgenic mouse; (b) administering a test substance to said transgenic mouse; and (c) determining whether said test substance modulates the kinase activity as determined in step (a).
 34. A method for identifying a substance that modulates the activity of a kinase polypeptide, wherein said method comprises: (a) determining in a cell line obtained from the transgenic mouse of claim 31 the presence and/or quantity of kinase activity attributable to the polypeptide encoded by the nucleic acid used to create said transgenic mouse; (b) contacting said cell line with a test substance; and (c) determining whether said test substance modulates the kinase activity as determined in step (a).
 35. A method for treating a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase identified by the method of claim
 33. 36. A method for treating a disease or disorder by administering to a patient in need of such treatment a substance that modulates the activity of a kinase identified by the method of claim
 34. 